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1. Zusammenfassung 
Rekombinante adeno-assoziierter Viren (rAAV) weisen aufgrund ihrer geringen Immunogenität, 
hohen Stabilität und langfristigen Genexpression in Zielzellen ein großes Potential für den Einsatz 
in der Gentherapie auf. Jedoch fehlt es bisher sowohl an effizienten als auch kostengünstigen rAAV 
Herstellungsverfahren, um eine Erweiterung der Verwendung von rAAVs auch auf weitere 
medizinische Indikationen, wie zum Beispiel die Tumortherapie zu ermöglichen da hier weitaus 
höhere rAAV Dosen benötigt werden. Zusätzlich sind durch den breiten Tropismus des AAV 
schädliche Auswirkungen in einer Tumorgentherapie mit einem letalen Transgen auch auf gesunde 
Zellen zu erwarten. Daher wurde in dieser Arbeit der Einsatz von tumorspezifischen Promotoren 
(TSP) und mikroRNA (miRNA) Zielsequenzen analysiert, um eine selektive Abtötung von 
Tumorzellen zu erreichen. Darüber hinaus wurden eine in diesem Labor erzeugte rAAV-
Produktionszelllinie, eine neue Affinitätschromatographie und die Möglichkeit der rAAV-
Produktion in Suspensionszellen analysiert. 
Eine neue Zelllinie mit integrierten adenoviralen Helfersequenzen wurde hinsichtlich effizienter 
Produktion analysiert. Ein Transfektionprotokoll wurde etabliert, mit dem es möglich wurde 
ausschließlich das RepCap- und ein ITR/Vektor-Plasmid in die Produktionszellen einzubringen, 
wodurch die während der Produktion benötigte Menge an DNA um die Hälfte reduziert werden 
konnte. Die biologischen Eigenschaften der so produzierten rAAV sowie die Ausbeute wurden 
analysiert und waren vergleichbar mit Ergebnissen des Dreiplasmid-Transfektionsprotokolls in der 
Standard HEK-293 Zelllinie. Demnach konnte gezeigt werden, dass die neue Zelllinie rAAVs in 
gleichbleibender Qualität und Ausbeute produziert bei gleichzeitiger Kosten- und Zeitersparnis 
durch den Wegfall der Bereitstellung der sonst benötigten-Helfer-Plasmid DNA. 
Die begrenzte Wachstumsfläche in dem auf adhärent wachsenden HEK-293 Zellen beruhendem 
Standardprozess erschwert die Bereitstellung großer Mengen an rAAV. Daher wurde in einer 
kommerziell erhältlichen, suspensionsadaptierten Zelllinie das für die rAAV Produktion benötigte 
Dreiplasmid-System etabliert und die Kultivierungsbedingungen vor und während der Transfektion 
optimiert, wodurch eine deutliche Erhöhung der rAAV Ausbeute verglichen zu dem 
Ursprungsprotokoll erzielt werden konnte. Generell konnte durch die Kultivierung der 
Suspensionszellen mit hoher Zelldichte eine höhere volumetrischen Ausbeute als das Verfahren 
auf Basis adhärent wachsender Zellen erzielt werden und eröffnet dabei die Möglichkeit den 
Produktionsmaßstab zu erhöhen. 
Die Aufreinigung von rAAV2 durch die Verwendung der polycystic kidney disease 2 (PKD2) 
Domäne des natürlichen AAV-Rezeptors (AAVR) als Affinitätsliganden wurde etabliert. Die 
Analyse verschiedener Trägermaterialien zur kovalenten Bindung des Liganden wurden getestet, 
wobei Cellulosepapier die einfachste Handhabung ermöglichte, sowie eine hohe Reinheit und 
zeitgleich eine hohe rAAV Ausbeute erzielt werden konnte. Die biologische Aktivität der so 
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aufgereinigten rAAVs war vergleichbar mit solchen die mittels Ultrazentrifugation (UZ) 
aufgereinigt wurden. Jedoch konnte mit der entwickelten Affinitätschromatographie eine deutlich 
höhere Reinheit der Endprobe bei gleichzeitiger Reduktion der Arbeitszeit von mehr als einem Tag 
für die UZ-Reinigung auf wenige Stunden für die Affinitätschromatographie erzielt werden, u.a. 
durch den Wegfall des der UZ vorgeschalteten Ankonzentrierungsschrittes. 
Die Vorteile von TSP und miRNA vermitteltem De-targeting in einer virusgesteuerten Enzym-
Prodrug-Therapie (VDEPT) wurden untersucht. Als Selbstmordgen wurde das Thymidinkinasegen 
(HSV-tk) des Herpes-Simplex-Virus verwendet und die Umwandlung des prodrugs Ganciclovir 
(GCV) in seinen toxischen Metaboliten indirekt durch einen Zytotoxizitätstest gemessen. Die 
Aktivität von drei zuvor als tumorspezifischen beschriebenen Promotoren (Survivin (SUR), 
Cyclooxygenase-2 (COX-2) und C-X-C-Motiv Chemokin-Rezeptor 4 (CXCR-4)) wurde mit der 
Aktivität des Cytomegalievirus immediate early promoters (CMV) in vier Tumor- und zwei 
gesunden Zelllinien verglichen. Für die SUR- und CMV-promotorgetriebene Expression des 
Suizidgens wurde zusätzlich die let-7a miRNA-Zielsequenz in die Transgenexpressionskassette 
integriert. Je nach betrachteter Zelllinie konnte eine Tumorspezifität der TSP nachgewiesen 
werden, wobei mit der vom CMV Promotor getriebene Genexpression in Kombination mit der 
let-7a miRNA-Zielsequenz eine hohe Tumorspezifität in allen untersuchten Krebszelllinien erreicht 
werden konnte. 
Die Ergebnisse dieser Studie bilden die Grundlage für weitere Verbesserungen des rAAV-
Produktionsprozesses und zeigen zusätzliche Strategien zur Erzielung einer Tumorspezifität in 
VDEPT-Ansätzen. So könnte in Zukunft eine Adaption der neuen rAAV-Produktionszelllinie an 
die Kultivierung in Suspension, sowie weitere Kombinationen von CMV-Promotor-gesteuerter 
Genexpression mit unterschiedlichen miRNA-Zielsequenzen getestet werden. Darüber hinaus 
sollte zusätzlich transkriptionelles Targeting und miRNA-vermitteltes De-Targeting mit 
Tumormarker-basiertem Re-Targeting kombiniert werden, um in Zukunft eine noch spezifischere 
Suizidgentherapie zu ermöglichen. 
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2. Abstract 
Recombinant adeno-associated viruses (rAAV) have gained an outstanding reputation in gene ther-
apy due to their low immunogenicity, high stability and long-term gene expression in target cells. 
However, there is a lack of efficient and cost-effective manufacturing processes to enable the ex-
pansion of AAVs into therapeutic indications such as tumor therapy where higher doses are needed. 
Additionally, in tumor therapy, the broad tropism of the AAV is problematic since harmful effects 
on healthy cells can be expected during cancer gene therapy with lethal transgenes. In this work, 
the use of tumor-specific promoters (TSPs) and microRNA (miRNA) target sequences have been 
analyzed to allow selective eradication of tumor cells. Moreover, the use of a rAAV production cell 
line generated in our laboratory, a new affinity chromatography and the possibility of rAAV pro-
duction in suspension cells have been analyzed. 
For efficient rAAV production, a new cell line with integrated adenoviral helper sequences was 
analyzed during this work. Providing a RepCap and an ITR/vector plasmid during transient trans-
fection was established, leading to a significant reduction in the amount of plasmid DNA required 
for production. Biological characteristics and the yield were analyzed and were comparable to those 
obtained with the triple transfection protocol in the HEK-293 standard cell line. This result demon-
strates that the new producer ensures constant quality of viral particles produced while reducing 
costs and time, as providing of the helper plasmid is no longer required. 
Upscaling of the production is very restricted due to the limited growth area in the standard adherent 
growing HEK-293 cells. Therefore, a triple transfection protocol for the rAAV production was 
established, in a commercially available suspension adapted cell line and the medium conditions 
for cell propagation and production were adjusted and resulted in a protocol with increased yields 
compared to the starting conditions. The high cell density cultivation in the suspension-based pro-
cess led to a higher volumetric yield than the process based on adherent growing cells and at the 
same time allows for up-scaling. 
The use of single domains of the natural AAV receptor (AAVR) as an affinity ligand for rAAV 
purification was established in this work. Different carrier materials for covalent binding were 
tested, with cellulose paper showing the best characteristics regarding the ease of handling as well 
as final purity and yield of the rAAV sample. The biological activity of rAAV purified by this 
affinity chromatography was comparable to those purified by the standard ultracentrifugation (UC) 
method but with a superior purity. Furthermore, the processing time was reduced from more than 
one day for UC purification to a few hours for the affinity chromatography, since the affinity chro-
matography was optimized for the application of directly capturing rAAVs from the crude cell 
extract contrary to UC purification where a concentrating step is necessary. 
The benefits of TSPs and miRNA mediated de-targeting in a virus-directed enzyme prodrug therapy 
(VDEPT) were investigated in this work. As a suicide gene, the herpes simplex virus thymidine 
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kinase (HSV-tk) was used, and the conversion of the prodrug Ganciclovir (GCV) to its toxic me-
tabolite was indirectly measured by a cytotoxicity assay. The activity of three tumor-specific pro-
moters (survivin (SUR), cyclooxygenase-2 (COX-2) and C-X-C motif chemokine receptor 4 
(CXCR-4)) was compared to the cytomegalovirus immediate early promoter (CMV) in four cancer 
and two healthy cell lines. For SUR and CMV promoter driven HSV-tk expression, a let-7a miRNA 
target sequence was included. Depending on the cell line investigated, tumor specificity was ena-
bled, with the CMV promoter driven gene expression in combination with the let-7a miRNA target 
sequence reaching, the highest tumor specificity in all investigated cancer cell lines. 
The results of this study provide a starting point for further improvements of the rAAV manufac-
turing process and strategies for de-targeting of healthy cells in VDEPT approaches. For example, 
an adaption of the new rAAV production cell line to suspension and combinations of CMV pro-
moter driven gene expression with distinct miRNA target sequences could be tested. In addition, 
combinations of transcriptional targeting and miRNA mediated de-targeting should be tested to-
gether with tumor marker-based re-targeting of rAAVs, which may enable more specific suicide 
gene therapy in the future. 
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3. Introduction 
3.1. Biology of adeno-associated viruses 
The adeno-associated virus is a single-stranded DNA virus and belongs to the family of parvovi-
ruses. Even though most humans show a high seroprevalence of neutralizing antibodies (NAb) for 
at least one serotype, AAV has not been associated with any human or animal disease.1,2 The 4.7 kb 
genome contains three open reading frames (ORFs) which are flanked by inverted terminal repeats 
(ITRs) (Figure 1). The T-shaped palindromic ITRs are 145 bases long and serve as origins for DNA 
replication. They are the only cis-acting elements and are required for packaging, integration and 
rescue of the AAV genome, while all other viral sequences are supplied in trans.3 The four Rep 
proteins (Rep78, Rep 68, Rep52, Rep40) responsible for replication, are located in the left ORF 
and are synthesized from mRNAs initiated from the p5 and p19 promoter. Rep78 and Rep68 are 
required for DNA replication, whereas Rep52 and Rep40 are necessary for packaging DNA into 
the AAV capsid.4–6  
 
Figure 1: Representation of the surface and of the AAV genomic structure.(A) Surface structure of AAV2 
based on the PDB-ID (Protein Data Bank Identity) 1LP3 using PyMOL. Amino-acids are colored by their 
relative distance to the center from dark blue in the center to cyan. The 5-fold axes are located in the 
center of the dark blue canyon. The cyan colored protrusions are surrounding the 3-fold axes in the center. 
(B) AAV genomic structure. The open reading frame for the four Rep proteins is colored in red. Expression 
is driven by the p5 promoter for Rep78, Rep68 and from p19 promoter for Rep52, Rep40.5,6 The open 
reading frame for the Cap proteins is colored in beige. The p40 promoter drives the expression of the 
mRNA which is then alternatively spliced and by this generating the three capsid proteins VP1, VP2 and 
VP3.7 A third ORF in the VP2/VP3 mRNA codes for the assembly activating protein (green) and the x 
protein (not shown).8,9 Asterisks marks the VP2 start codon and the AAP start codon. Inverted terminal 
repeats are highlighted in blue. Figure 1B adopted from Samulski, R. J.; Muzyczka, N., 2014.10 
 
The right ORF encodes the three capsid proteins VP1, VP2 and VP3 whose expression is initiated 
by the p40 promoter from one single gene. By alternative splicing, the VP1 and the VP2/VP3 con-
taining transcript arise.7,11 The shorter VP2/VP3 mRNA codes for VP3 from a conventional initia-
tion codon (AUG) and for VP2 by a weak noncanonical ACG start codon upstream of the VP3 
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start. As a result, VP1, VP2 and VP3 proteins have the same C-terminus and only differ from each 
other in their N-terminus with VP1 being the largest and VP3 the smallest protein.12 The additional 
N-terminal sequence of VP1 harbors phospholipase A2 (PLA2) activity and nuclear localization 
signals which are also located inVP2 N-terminus. These sequences are conserved among all AAV 
serotypes and are required for the translocation of the AAV genome to the nucleus.13,14 From a 
weak noncanonical CTG start codon in the VP2/VP3 mRNA, a third ORF is located, which codes 
for the assembly activating protein (AAP). AAP plays an essential role in the assembly of the viral 
capsid for some serotypes.8 In the same reading frame at the 3'-end of AAV2, the sequence of the 
x gene was found and the transcript is supposed to support AAV DNA replication.9  
To assemble the 25 nm sized icosahedral capsid shell, a total of 60 proteins are required. The stoi-
chiometry of V1, VP2 and VP3 in AAV particles of 1:1:10 is thought to be the consequence of the 
relative abundance of the proteins caused by splice product abundance and the efficiency of trans-
lation initiation at the different start codons.15 After capsid assembly, the AAV DNA is selectively 
encapsulated by protein-protein interactions between the pre-formed empty capsid and Rep78/ 
Rep68 which are complexed with the newly synthesized AAV DNA.16,17 The capsid shell is the 
main determinant of AAV tropism and transduction characteristics and several naturally occurring 
AAV variants were discovered.18 Depending on the capsid serotype, different cellular receptors and 
co-receptors are necessary for AAV transduction.  
In the past, AAV2 has been extensively studied and heparan sulfate proteoglycane (HSPG) was 
found to be the primary receptor for initial cell membrane binding.19 The basic amino acids R484, 
R487, K532, R585 and R588 (VP1 numbering) in the three-fold spike region  of the capsid interact 
through electrostatic interactions with the negatively charged sulfate and carboxyl groups of the 
abundantly expressed HSPG. In the multistep infectious entry pathway fibroblast growth factor 1 
(FGFR-1)20, hepatocyte growth factor (HGFR)21, 37/67 kDa laminin receptor (LamR)22 and integ-
rins (α5β1 and αvβ5)23,24 were identified as secondary receptors which stabilize virus attachment 
or participate during internalization.25 Further processes include receptor-mediated endocytosis via 
the formation of clathrin-coated pits and endosomal escape through a pH-dependent process by 
inducing a conformational change, leading to the exposure of PLA2.14,26 Upon entry into the nu-
cleus, AAVs can either follow the lytic or lysogenic pathway. In the absence of a helper virus, the 
AAV genome integrates specifically in human chromosome 19 designated as AAV safe-harbor 
locus (AAVS1).27,28 The integrated genome can then be rescued from the latent infection by super-
infection with helper virus which induces expression of AAV Rep and Cap genes in trans.29 
In 2016, a new cellular factor, the so-called AAVR was identified.30 In a haploid genetic screen, 
the KIAA0319L gene showed to be essential for multiple AAV serotypes for efficient transduction. 
KIAA0319L codes for a type I transmembrane protein containing a motif at N-terminus with eight 
cysteines (MANEC domain), five Ig-like poly-cystic kidney disease (PKD) domains, and a C6 re-
  3 Introduction 
7 
 
gion near the N-terminus (Figure 2A).31 The AAVR is a N-linked glycosylated protein, but glyco-
sylation is not required for AAV binding or functional transduction. Dominant interactions of cer-
tain domains with specific serotypes have been described. AAV2 interacts predominantly with the 
second PKD domain, whereas PKD1 promotes transduction for AAV5. For AAV1 and AAV8 a 
combination of PKD1 and PKD2 is necessary for optimal transduction.32 By cryogenic electron 
microscopy (cryo-EM) the interaction of AAV2 with the AAVR was shown and the interacting 
amino acids bound to the capsid were identified as belonging to AAVR PKD2. One AAVR PKD2 
interacts with the right edge of the spike which surrounds the icosahedral three-fold axis, making 
contact with two AAV2 capsid protomers (Figure 2B,C).33 For the other AAV serotypes, interaction 
with the AAVR has not been clarified so far. 
 
Figure 2: Schematic view of the AAVR domains and their interaction with the AAV2 capsid. (A) The do-
mains of the KIAA0319L protein. (B, C) Structure of trimeric AAV2 protomers in complex with AAVR from 
the side (B) and from the top (C). The protomers are shown blue, green and cyan, the AAVR is shown in 
red. The five-fold axes are indicated by pentagons and the triangle indicates the three-fold axis.  
SP, signal peptide; MANEC, motif with eight cysteines; TM, transmembrane. Figure 2A: modified from 
Pillay et al. 2016.30 Figure 2B, C: Adopted from Zhang et al. 2019.33 
 
3.2. Cancer gene therapy 
Cancer is one of the leading causes of death in the world. In 2018, 18.1 million new cases and 9.6 
million deaths worldwide were estimated.34,35 The clinical effectiveness of conventional chemo- 
and radiotherapy is limited due to a lack of tissue specificity, which causes serious side effects. 
Gene therapy offers the possibility to target a therapeutic transgene directly to tumor cells so that 
normal tissue toxicity might be avoided. So far, gene therapy has mainly referred to the transfer of 
1 2 3 54
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human normal genes or therapeutically interesting genes into human target cells, to correct gene 
defects.36 By now, gene therapy is also being researched for the treatment of a variety of other 
diseases including cancer, cardiovascular disease, and neurodegenerative diseases with cancer as 
the most frequent clinical trial representative.37 Regardless of the disease to be treated, the transport 
of a transgene into target cells is required. 
For this purpose, viral and non-viral vectors are available.38 Transfection of non-viral vectors into 
cells can be accomplished with physical methods like electroporation of naked DNA and chemical- 
mediated transfer for example with cationic liposomes.39,40 Their advantages of safety and modifi-
ability as well as simple large-scale production offset the disadvantages of low transfection effi-
ciency and low transgene expression. In contrast, viral vectors own the highly evolved mechanism 
of the parental viruses to efficiently transduce cells with prolonged gene expression and by this 
offer advantages over non-viral delivery systems. Despite challenges in the introduction of modi-
fications, the majority of clinical studies are conducted with viral vectors.37 Here, adenoviruses are 
the most commonly used vectors, followed by retrovirus, lentivirus and adeno-associated virus. 
Most of them trigger extensive immune responses to the vector, or randomly integrate into the host 
cell genome with the risk of insertional mutation.37,38 The adeno-associated virus emerged as an 
outstanding option for gene therapy. It provides long-term target gene expression, is not associated 
with any disease and is unable to replicate autonomously which results in a high safety profile. 
They transduce a wide range of dividing and non-dividing cells and are able to penetrate the stroma 
of solid tumors due to their small size, which ensures adequate distribution of the transgene 
throughout the tumor.41,42 Until today, seven gene therapies although not in the field of tumor ther-
apy, have received approval, with three based on AAV. The latest, onasemnogene abeparvovec-
xioi (Zolgensma) was approved in 2019 by the U.S. Food and Drug Administration (FDA) and is 
based on rAAV9. It delivers a functional variant of the survival motor neuron 1 (SMN1) gene and 
is used to treat children less than two years old with spinal muscular atrophy (SMA) with bi-allelic 
mutations. 
3.3. Capsid engineering of AAV in cancer gene therapy 
AAVs offer the potential to serve as a gene delivery vehicle for cancer gene therapy. Systemic 
application of AAV allows for targeting of the primary tumor and metastases but requires a strict 
control of gene expression to prevent harm to normal tissue.43 A number of natural AAV serotypes, 
which differ in their tropism, provide optimal transduction for particular cell types. Though, chal-
lenges in the use of AAV vectors remain. The use is limited by prior exposure of most people to 
natural AAVs and by this a reduction of vector delivery efficiency by anti-AAV neutralizing anti-
bodies, as well as poor vector bio distribution to important tissue targets and limited spread within 
those tissues. Therefore, great effort in the engineering of AAV capsids as well as the engineering 
of genetic cargos has been made.44  
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The amino acid sequence of the proteins that constitute the viral capsid determines the tropism of 
AAV vectors. Thus, engineering the capsid can generate novel AAV phenotypes with higher po-
tency and selective expression. Such vector engineering efforts can be grouped into two categories: 
directed evolution, and rational design of the capsid proteins.45  
Directed evolution offers the possibility to generate enhanced AAV variants, even without 
knowledge of viral structure function. Here, large libraries of AAV cap genes are created by meth-
ods like DNA shuffling, random point mutagenesis and random peptide insertions.46–48 In a suitable 
number of selection rounds, optimized AAV vectors with altered tissue tropism, enhanced tissue 
spread and infection of non-permissive cells are isolated.49,50 Directed evolution therefore poten-
tially enables the development of new AAV vectors for improved gene transfer. 
In cancer gene therapy, changes in the expression profile of degenerated cells and the associated 
presentation of tumor-specific antigens on the cell surface allows for a rational design of AAV 
capsid proteins.51,52 In 2008, Zhong et al. showed that mutations of surface exposed tyrosine resi-
dues on AAV2 capsids towards phenylalanine resulted in high-efficient transduction of cells.53 By 
site-directed mutagenesis of AAV2 serine, threonine and lysine residues Gabriel et al. were able to 
show optimized transduction efficiency and higher packaging titer.54 To obtain not only a general 
improvement in transduction efficiency but also increased tumor specificity, peptide motifs were 
introduced into the AAV capsid. By introducing an NGR peptide motif into the AAV2 capsid, 
Grifman et al. changed the tropism from HSPG to CD13, a membrane-bound enzyme strongly 
expressed in tumor tissue.55 Also RGD peptides have been successfully incorporated into surface-
exposed VP areas to target integrin expressing cancer cells.56. By insertions of larger binding pro-
teins e.g. designed ankyrin repeat proteins (DARPins), variants of known AAV serotypes have been 
produced to ensure greater cell specificity.57,58 Transcriptional control of transgene expression can 
further increase targeting efficiency. This can prevent toxicity to normal cells and will be an essen-
tial part of systemic cancer therapy.43,59 
3.4. Payload engineering for cancer-specific gene expression 
The key factors for successful application of gene therapy in the treatment of cancer lie within its 
targeting efficiency and safety. In addition to tissue specificity, AAV vectors may have regulatory 
elements which can be used to achieve a tumor-specific gene expression and by this reducing the 
damage to normal cells. One of these regulatory elements is the promoter, located near the tran-
scription start sites of genes, upstream on the DNA 5' region of a gene. Promoters are DNA se-
quences that direct accurate initiation of transcription by the RNA polymerase II machinery.60 Con-
ventionally, the CMV promoter is used to drive transgene expression. However, the CMV promoter 
but is ubiquitously active and by this of limited use to increase vector specificity, as it can cause 
serious side effects in normal human cells. In the past, genes have been identified which are turned 
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on or are upregulated in certain types of tumors and by this attracted attention in cancer gene ther-
apy. Promoters of such upregulated genes are ideal candidates for the use in tumor-specific gene 
expressions and were extensively studied in the past. Examples of previously studied promotors 
are shown in Table 1. 
Table 1: Promoters used in cancer gene therapy with their advantages and disadvantages. 
Promoter Target Advantages Disadvantages 
hTERT61,62 lung cancer, liver cancer, gastrointesti-
nal cancer, breast cancer, etc.  
suitable for a variety of 
cancer cells 
varying outcome 
KDR63,64 lung cancer, liver cancer, gastrointesti-
nal cancer, breast cancer, etc. 
Survivin65–67 liver cancer, gastrointestinal cancer, 
gallbladder cancer, etc. 
HER268,69 prostate cancer, breast cancer, pancre-
atic cancer, etc. 
COX-270–72 colorectal cancer, endometrial cancer, 
breast cancer, etc. 
CXCR-473,74 breast cancer, skin cancer 
CCKAR75,76 pancreatic cancer 
effect on specific tumor 
is relatively certain 
only for specific tu-
mors 
AFP77,78 liver cancer 
CEA79,80 gastrointestinal cancer 
AFP, alpha fetal protein; CCKAR, cholecystokinin type A receptor; CEA, carcinoma embryonic antigen; 
COX-2, cyclooxygenase 2; CXCR-4, C-X-C chemokine receptor 4; HER2, human epidermal growth factor 
receptor 2; hTERT, human telomerase reverse transcriptase; KDR, kinase insert domain receptor 
 
Depending on the type of cancer, different genes are overexpressed due to their upregulated pro-
moters. Thus, these promoters offer the possibility to increase specificity of transcriptional regula-
tion in therapy approaches. The telomerase reverse transcriptase (TERT) promoter serves as an 
example, approximately 90% of human cancers show TERT activity, which is considered to be a 
critical step in cancer progression due to its role in cellular immortalization.81 The hTERT promoter 
has therefore widely been used as a cancer-specific promoter but often showed weak transcriptional 
activity.82 
Next to promoters like CCKAR, AFP and CEA which are targeting specific tumor cells, there are 
also promoters that can be widely used for various tumors. One of these, is the promoter of survivin 
gene (BIRC5). Survivin belongs to the inhibitor of apoptosis (IAPs) family, which have an im-
portant role in the regulation of programmed cell death. Survivin is expressed during mitosis and 
is essential for the completion of various stages of cell division. Inhibition of the intrinsic (mito-
chondrial) pathway of apoptosis via interference with caspase-9 processing, allows survivin to con-
tribute to the inhibition of apoptosis.83,84 Compared to normal human tissue, the survivin expression 
is highly upregulated in several cancer types like breast, colorectal, melanoma, pancreatic and non-
small-cell lung cancer.85 Here it is involved in the critical determinants of tumor progression such 
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as cell proliferation, evasion of apoptosis, resistance to growth-inhibitory signals and angiogene-
sis.86 Transgene expression based on plasmid transfection or adenovirus transduction, had shown 
that the survivin promoter was predominantly achieved in tumor cells in vitro and in vivo.85,87,88  
Other promising promoters in the context of cancer gene therapy are the COX-2 and the CXCR-4 
promoter. The cyclooxygenase (COX) isoenzymes catalyze the metabolism of arachidonic acid 
(AA) to prostaglandin (PG).89 Three isoforms of Cyclooxygenases have been identified. COX-1 is 
constitutively expressed and plays a role in tissue homeostasis by modulating several cellular pro-
cesses. COX-2 expression is induced by growth factors and cytokines during inflammation and 
modulates cell proliferation, cell death, and tumor invasion in many types of cancer including co-
lon, breast, and lung, but it is rarely detected in most normal adult tissues.70 In 2009, Wang et al. 
showed that adenoviral expression of the HSV-tk gene under the transcriptional control of COX-2 
promoter induced a significant in vitro and in vivo growth inhibition of cancer cells.72 Furthermore, 
Yamamoto et al. demonstrated selective killing of COX-2 positive cells in the context of adenoviral 
transduction.71 CXCR-4 is a chemokine receptor which is highly expressed in cancer cells, but 
repressed in normal tissue. For example, in tumor cells from breast, prostate, pancreatic, lung and 
ovarian carcinomas, CXCR-4 overexpression was detected. Chemokines belong to the family of 
cytokine-like proteins, which play an important role in cytoskeletal rearrangement, adhesion to 
endothelial cells and directional migration.90 In tumor cells they regulate the growth of primary and 
metastatic tumors through chemokine gradients.91 In the context of AAV2 and adenoviral gene 
transfer, it had been shown that expression of the transgene was preferential achieved in tumor 
cells.73,74,92 
An additional layer of tumor specificity is advisable as residual activity of tumor-specific promoters 
in normal human cells was observed.93,94 Post-transcriptional repression of transgene expression 
has been an emerging approach to improve vector targeting. MicroRNAs (miRNAs) are single-
stranded, non-coding RNA molecules that anneal with complementary sequences in the 3'- UTR of 
target mRNAs triggering either translational repression or mRNA degradation.95 As depicted in 
Figure 3, the ~ 22 nucleotide (nt) long mature miRNAs are transcribed by RNA-polymerase II as 
long precursor RNAs (pri-miRNAs) which are then further processed in the nucleus and finally 
shortened in the cytoplasm by RNase III Endonuclease Dicer to give rise to mature miRNA. The 
miRNAs associate with mRNAs within a multiprotein complex of Argonaute (AGO2) proteins. 
This RNA-induced silencing complex (RISC) facilitates and stabilizes miRNA–mRNA interac-
tions.96 The sequence with which miRNAs bind their RNA targets is known as the ‘seed sequence’, 
which is typically 6–8 nt long, and is located at the 5′-end of the miRNA. The degree of comple-
mentarity determines whether RISC-mediates translational inhibition or target mRNA degrada-
tion.97  
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Figure 3: MicroRNA biogenesis and mechanism of action. RNA polymerase II (Pol II) generates a capped 
and polyadenylated transcript, the primary miRNA (pri-miRNA). The RNase III Drosha and DiGeorge 
syndrome critical region 8 (DGCR8)., cleaves the pri-miRNA to produce the precursor-miRNA (pre-
miRNA). The pre-miRNA is exported from the nucleus into the cytoplasm by Exportin5/RanGTP, where it 
is further cleaved by the RNase III enzyme Dicer, which yields in an imperfect miRNA–miRNA* duplex 
that is about 22 nucleotides in length. Finally, the 5' or 3' strand of the mature miRNA duplex is incorpo-
rated into the RNA-induced silencing complex (RISC). Association of a miRNA-RISC complex with its 
mRNA target results in translational repression as well as in degradation of the mRNA. 
m7G, 7-methylguanosine; ORF, open reading frame. Modified from van Rooij et al..98 
 
Lethal-7 (let-7) was one of the first miRNAs to be discovered. In humans, the let-7 family is com-
posed of nine mature let-7 miRNAs which generally function as tumor suppressors and promote 
differentiation during development. Reduced levels of let-7 were observed in lung, breast, gastric 
and colon cancer.99 This downregulation is possibly explained by a delayed or inhibited processing 
by Dicer and/or a failure at the Drosha-processing step.100 The downregulation of let-7 upregulates 
some cell cycle regulators such as cyclin A2, cyclin D1/2 as well as Aurora A and B kinases, which 
results in the activation of cell cycle and by this promotes unregulated tumor growth.101 In the past, 
incorporation of let-7 microRNA complementary sequences to-mediate post-transcriptional gene 
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silencing has proven to be an effective and tissue-specific approach to regulate gene expression. In 
suicide gene therapy, utilizing vesicular stomatitis virus (VSV) and adenovirus vectors, miRNA 
regulated gene expression prevented toxicity to normal tissue and by this can further increase the 
safety profile of AAV vectors in cancer gene therapy.102–104 
3.5. Suicide gene therapy in cancer 
By introducing a viral or bacterial suicide transgene to a tumor cell, activation of a non-toxic pro-
drug into a toxic metabolite by the expressed transgene is enabled and elimination of targeted cells 
is possible. The resulting cytotoxic substance can then expand into neighboring cells and creates a 
so called bystander effect (Figure 4).105  
 
Figure 4: Schematic illustration of suicide gene therapy. Upon transduction, the transgene that codes for 
a prodrug-converting enzyme is expressed. Cell death is induced by local or systematic delivery of the 
non-toxic prodrug and the conversion of the prodrug to a toxic metabolite. The activated drug expands 
from the tumor cell to neighboring cells in the so called bystander effect. Modified from McCormick.106 
 
For suicide gene therapy the gene for cytosine-deaminase (CD) from E. coli and the herpes simplex 
virus type 1 thymidine kinase (HSV-tk) are most commonly used. CD converts the non-toxic 5-
fluorocytosine (5-FC) to 5-fluorouracil (5-FU), whereas HSV-tk converts Ganciclovir (GCV) into 
the metabolite GCV-monophosphate.107 The elaborately studied HSV-tk gene/prodrug system re-
lies on the phosphorylation of GCV to GCV monophosphate (GCV-MP) by thymidine kinase ex-
pressed in transduced tumor cells. GCV-MP is further processed by cellular guanylate kinase 
(GMK) to the diphosphate and by guanosine diphosphate kinase to the toxic triphosphate (GCV-
TP) (Figure 5).108,109 GCV-TP is an analogue of deoxyguanosine triphosphate (dGTP), and once 
bound to the DNA polymerase, inhibition of the polymerase or incorporation into the DNA is caus-
ing chain termination, S-phase delay as well as G2-phase arrest and is finally leading to apopto-
sis.110–113 Limitations in the intracellular conversion pathway are located in the phosphorylation 
step of GCV-MP to GCV-DP by the guanosine monophosphate kinase, thus leading to the accu-
mulation of ineffective intermediate products.114 To overcome these limitations, a fusion protein 
was generated consisting of mouse guanylate kinase (mGMK) and HSV-TK30, which showed an 
improved turnover rate.115 Also HSV-tk mutants with increased activity were generated which en-
hanced cell sensitivity to GCV by a factor of 200.116,117  
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Figure 5: Structure and conversion of Ganciclovir (GCV) to GCV triphosphate (GCV-TP). HSV-tk con-
verts GCV to GCV-MP. Subsequently, GCV-MP is further processed by cellular guanylate kinase (GMK) 
to the diphosphate and by guanosine diphosphate kinase to the toxic GCV-TP. Adopted from Gynther et 
al., 2015.109 
 
The frequently observed bystander effect, where not only HSV-tk positive cells, but also neighbor-
ing cells are affected upon GCV treatment, is primarily based on cell-cell contacts. Toxic metabo-
lites are transported between nearby cells through gap junctions (GJIC) in a process called 'meta-
bolic cooperation'. These intercellular channels are composed of six connexin (Cx) protein subunits 
and form a central pore through which small molecules with a molecular weight (MW) up to 
1000 Da (GCV-TP MW: 495 Da) can pass to adjacent cells.118 Depending on cell type, other mech-
anisms, independent of GIJC, contribute to the bystander effect as well.119 
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4. Aim 
Recombinant adeno associated virus emerged as an outstanding option in the field of gene therapy. 
However, the prospective success of rAAV relies on efficient and cost-effective manufacturing 
processes. Thus, one aim of this thesis is to simplify and optimize current rAAV up- and down-
stream processes. 
To increase the yield and quality of viral preparations, a new rAAV producer cell line will be used 
for rAAV upstream processing. For this cell line, an improved rAAV production protocol will es-
tablished and biological characteristics of viral particles will be determined, to achieve a time and 
cost advantage over the standard HEK-293 producer cells.  
For further optimization of the upstream process, the production procedure will be converted to a 
suspension-based process to enable simple upscaling. To this end, the transfection protocol and the 
medium conditions will be analyzed in small batches before being transferred to a bioreactor culti-
vation. 
In rAAV downstream processing, purification strategies suitable for future up-scale requirements 
are needed. Thus, an affinity chromatography based on the AAV receptor will be established. Op-
timal formulation of the affinity resin, amount of affinity ligand and rAAV elution conditions will 
be examined in order to obtain sufficient purity and biological functionality in a one-step purifica-
tion process. 
Analyzing transcriptional and translational targeting strategies for rAAV based suicide gene ther-
apy will be another fundamental issue in this thesis. Different tumor-specific promoters will be 
examined for their ability of selective gene expression in cancerous cell lines. Additionally, a de-
targeting strategy by miRNA will be implemented. To analyze tumor selectivity, rAAV variants, 
delivering a transgene coding for a suicide gene, will be generated and upon transduction cell tox-
icity assays will be conducted. 
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5. Results and Discussion 
5.1. Transcriptional and translational targeting of cancer cells 
Results of this project were summarized in a manuscript with the title 'Comparison of viral mediated 
suicide gene therapy targeting by promoters and de-targeting by miRNA in tumor and primary 
cells'. The original manuscript is included in the appendix and a summary of the work is presented 
in the following chapter. 
The regulation of transgene expression after rAAV2 transduction was one of the main goals in this 
work. For this purpose, the HSV-tk/GCV system was selected as a reporter. To facilitate cell killing, 
a HSV-tk mutant (HSV-tk30) was used which shows higher kinase activity and by this an increased 
GCV sensitivity.117 
5.1.1. Choice of tumor-specific promoters, miRNA target sequence and cell 
lines 
The promoters of survivin (SUR), cyclooxygenase-2 (COX-2) and the C-X-C motif chemokine 
receptor 4 (CXCR-4) were chosen to drive transgene expression. Survivin was found to be ex-
pressed in a variety of human cancers like brain, breast and ovarian tumors and to be absent in most 
normal tissue.83,120 In this work, the DNA sequence related to the SUR promoter was chosen as a 
521-base-pair (bp) fragment (nucleotides 2283 to 2804, GenBank Accession number U75285.1). 
The second promoter sequence relies on the COX-2 expression which is upregulated during inflam-
mation and cancers like breast and colorectal cancer.72 For the COX-2 promoter, a 904 bp fragment 
(nucleotides 6249 to 7152, GenBank Accession Number AF044206.1) was selected. The third pro-
moter sequence is predicated on the overexpression of CXCR-4 gene which is typical observed in 
ovarian and breast cancer, as well as for human melanoma.90,92 For CXCR-4 a 936 bp (nucleotides 
1165 to 2100, GenBank Accession Number AY728138.1) fragment was designed during the master 
thesis of Claudia Curdt.121 The CMV promoter in contrast shows high expression levels in a variety 
of mammalian cells without tumor specificity and by this leads to off-target effects in normal hu-
man tissue. This promoter was chosen as a positive control for transfection efficiency as well as for 
comparison of achieved protection of non-tumor cells using tumor specific promoters (TSPs). All 
promoters were cloned in bicistronic vector constructs by Claudia Curdt and analyzed by transient 
transfection approaches. Nevertheless, low promoter activities and varying transfection efficiencies 
were observed. 
Within this work, promoters were equipped with a strong Kozak sequence in front of the start codon 
by overlap-extension PCR. The Kozak consensus sequence 5'-GCCRCCATGG-3' (R = purine A 
or G), is known to enhance the initiation of translation by improving the recognition of the AUG 
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start codon through the pre-initiation complex (PIC) and recruitment of the large ribosomal subu-
nit.122,123 By this, potentially low transcription rate of chosen promoters should be compensated by 
improved translation. 
To reduce unwanted AAV transgene expression in normal human tissue without affecting the ex-
pression in various cancer cell lines the let-7a target sequence 5'-ACTATACAACCTACTAC-
CTCA-3' was introduced into the 3' UTR of the CMV and SUR driven transgene expression cas-
settes. A schematic overview of the bicistronic vectors is shown in Figure 6. 
 
Figure 6: Vector plasmid for translational targeting of cancer cells, where transgene expression is driven 
by CMV (A) and SUR (B) promoter, respectively. In the 3'-UTR of the transgene, a let7a target sequence 
(let7-T) was introduced. 
 
The selective expression of the HSV-tk suicide gene was studied in two non-cancer (healthy) fibro-
blast cell lines HDFa (human dermal fibroblasts),124 and M1FS (GM22143, human fibroblasts from 
foreskin)125, as well as in four tumor cell lines. Fibrosarcoma cell line HT-1080 was chosen, be-
cause of the high amount of AAV2 primary receptor HSPG on the cell surface, allowing for high 
transduction efficiencies. For breast cancer cell lines MDA-MB231 and MDA-MB453 previous 
data suggested high survivin promoter activity,126,127 and for MDA-MB231 additionally, COX-2 
and CXCR-4 promoter activity was reported.90,120 In the future, a combined transcriptional target-
ing, miRNA mediated de-targeting and tumor marker-based re-targeting, is from particular interest. 
Therefore, the epidermoid carcinoma cell line A431 was included showing high amounts of the 
known tumor-marker epidermal growth factor receptor (EGFR) on the cell surface.128 Also for 
MDA-MB231 high EGF-receptor densities were reported, whereas for MDA-MB453 a low EGFR 
density was known.129,130 For HT-1080 no data were available for the EGF-receptor status. 
5.1.2. Determination of transduction efficiencies and prodrug toxicity 
By introducing a viral or bacterial suicide transgene to a tumor cell, activation of a non-toxic pro-
drug into a toxic metabolite by the expressed transgene is enabled and elimination of targeted cells 
is possible. This process is named VDEPT when a viral vector is utilized for gene transfer. In this 
work, the HSV-tk as a transgene and GCV as a prodrug were used. To correlate the effect of GCV 
on transduced cells with the transduction efficiency, the sequence of enhanced green fluorescent 
protein (eGFP) was introduced into the mGMK-TK30_T2A_eGFP bicistronic vector construct. To 
obtain two proteins from one promoter a T2A site was introduced in between the two genes (Figure 
8A). However, after transduction no eGFP fluorescence was detectable for the tumor specific pro-
moters and minimal fluorescence for the CMV promoter vector was seen (Figure 7A). 
CMVITR Kozak hGHpA ITRmGMK-TK30 T2A GFP
Let-7T
SURITR Kozak hGHpA ITRmGMK-TK30 T2A GFP
Let-7T
B
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Figure 7: Flow cytometry data for rAAV transduction of HT1080 cells in comparison the negative buffer 
control. (A) Cells were transduced with rAAV2_CMV_TK_eGFP at a multiplicity of infection (MOI) of 
10,000 and analyzed via flow cytometry after incubation in biological duplicates. (B) Cells were trans-
duced with rAAV2_CMV_mVenus at a MOI of 10,000 and analyzed via flow cytometry after incubation in 
biological duplicates. Data analysis was performed using FlowJo. A gate of 1% false positive cells was 
selected in the sample of the negative control. This gate is visualized in each diagram. 
 
By this, the eGFP fluorescence signal was not suitable for the determination of transduction effi-
ciency. The T2A site in the bicistronic vector should mediate 'cleavage' of polypeptides during 
translation. The underlying mechanism relies on a steric hindrance during translation and ribosome 
skipping leading to two 'cleaved' proteins. More 2A sites exist, but T2A was reported to show the 
highest level of protein expression at the second gene position.131 However, a decrease of up to 
70 % compared to the first gene in a bicistronic vector construct was observed.132 Additionally, it 
was found that cleavage efficiency differs widely between different cell lines.133 Therefore, a drop 
in eGFP expression was to be expected, although a decrease of the fluorescence signal below the 
detection limit was unpredictable. To determine the transduction efficiency of rAAV2 wt on the 
cell lines despite missing GFP fluorescence, cells were transduced with rAAV2-CMV-mVenus 
(Figure 8B). 
 
Successful transduction was detected by the expression of the delivered transgene mVenus using 
flow cytometry. rAAV2_mVenus was able to transduce all examined cell lines to varying degrees 
(Table 2).  
A B
HT1080 
rAAV2_CMV_TK_eGFP
HT1080 negative
HT1080 rAAV2_mVenus
HT1080 negative
 
Figure 8: Schematic view of transgene expression cassettes. (A) Vector plasmid for transcriptional tar-
geting of cancer cells, with promoter as placeholder for CMV, COX-2, SUR or CXCR-4 promoter, respec-
tively. (B) CMV_mVenus vector plasmid used as transduction control for the determination of transduction 
efficiency of rAAV2 and as negative control for the calculation of relative fluorescence.   
PromoterITR Kozak hGHpA ITRmGMK-TK30 T2A GFP
CMVITR hGHpA ITRmVenus
A
B
  5 Results and Discussion 
19 
 
Table 2:Transduction efficiencies of rAAV2 with CMV_mVenus as reporter for different cell lines transduced 
with a MOI of 10.000. Mean and standard deviation (SD) of two biological duplicates are shown. 
Cell line Transduction efficiency in % 
HDFa 58.1 ± 1.5 
M1FS 73.5 ± 1.4 
HT1080 97.0 ± 1.0 
MDA-MB231 64.5 ± 2.6 
MDA-MB453 59.3 ± 2.3 
A431 77.1 ± 2.3 
 
It was assumed, that this transduction ability should remain if the transgene is changed, since the 
capsid remains the same. Admittedly, it has been reported that about 10 % of undissolved polypep-
tides are produced by ribosome read-through.132 This effect was not taken into account in the fol-
lowing evaluations but should be aware, since individual activity of the two proteins in potentially 
present fusion proteins is unknown and may cause cells to show no thymidine kinase activity even 
though they were transduced.  
To determine the individual strength of TSPs by the conversion of GCV to its toxic metabolite by 
a cell viability assay the optimal working concentration of GCV had to be determined. Previous 
data suggested, that a GCV concentration of 1 mM showed the greatest effect on cell viability after 
transduction of HT1080 cells with viral particles containing the mGMK-TK30 transgene.134 Lower 
concentrations of GCV led to less reduction in cell viability at a constant MOI. However, higher 
concentrations were not tested in these previous experiments. To control whether even higher con-
centrations of ganciclovir were tolerated by the cells, a cytotoxicity assay was performed on 
HT1080 cells. In Figure 9A, a major drop in the fluorescence signal relative to non-incubated 
HT1080 cells (hereinafter referred to as (relative) cell viability),caused by the increasing GCV con-
centration was observed while cell viability remained relatively constant up to a concentration of 
1 mM. Since healthy cells should be studied, the high impact of GCV in the absence of thymidine-
kinase is untenable. Therefore, the concentration of 1 mM GCV was retained and the effect on all 
other cell lines used was investigated. The decline in cell viability relative to untreated cells was 
comparable between chosen cells lines with relative viability ranging from 80 % for MDA-MB231 
and 100 % for A431 (Figure 9B). 
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Figure 9: Effect of Ganciclovir on non-transduced cells. (A) Analysis of the effect of increasing GCV 
concentrations on the viability of HT1080 cells. Relative viability was determined to non-incubated 
HT1080 cells in biological duplicates and 6-fold technical replicates. For each spot, SD was calculated 
between biological samples. (B) Cytotoxicity assay to study the effect of 1 mM GCV on the cell viability of 
HDFa, M1FS, HT1080, MDA-MB231, MDA-MB453 and A431 cells. Relative viability was determined to 
non-incubated cells in biological duplicates and 6-fold technical replicates. For each column, SD was 
calculated between biological samples. 
 
In all subsequent analyses, the reference cells were also treated with 1 mM GCV as a precaution to 
exclude distortions caused by the influence of the prodrug on cell viability. Additionally, reference 
cells were transduced with rAAV2_mVenus, to exclude effects on cell viability resulting from 
transduction. 
5.1.3. Determination of de-targeting efficiencies by cell viability assays 
The effect of the prodrug conversion by thymidine kinase expressing cells was determined by a 
cytotoxicity assay (Alamar Blue assay). Here, the reduction of the non-fluorescent resazurin by 
metabolically active cells results in a pink fluorescent dye.135 This fluorescence can then be meas-
ured and was used to determine the cytotoxic effect of the prodrug GCV converted to its toxic 
metabolite GCV-TP.  
At first, cells were transduced with a multiplicity of infection (MOI) of 10'000 and after 24 h, 1 mM 
GCV was added for another 72 h and an Alamar Blue Assay was performed by adding resazurin 
and measuring the emerging fluorescence. In Figure 10, results of the Alamar Blue assays for the 
two non-cancer cell lines HDFa and M1FS are shown. Additionally, the number of non-transduced 
cells is displayed via a horizontal line (Figure 10A, C). For the calculation of relative fluorescence, 
the measured fluorescence for the different vector constructs was normalized to the fluorescence 
obtained from the rAAV-mVenus transduced reference (negative). The resulting relative fluores-
cence is hereinafter referred to as cell viability. By this, the cell viability of the total population was 
illustrated. Investigating the total cell population has the advantage to observe possible phenomena 
such as the bystander effect. A drop of the cell viability below the number of transduced cells 
(horizontal line) may provide an indication for this effect. However, this was not observed for 
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HDFa and M1FS cell lines. In previous in vitro studies, it was found that cell-cell contact is essen-
tial for most cell lines for an efficient bystander effect.136,137 In this study low plating densities were 
used in order to circumvent an overgrowing of the culture during the long cultivation in 96-well 
plates. This also suggests that no bystander effect was achieved. The conversion of GCV to its toxic 
metabolite was highest for the CXCR-4 promoter driven gene expression in HDFa (Figure 10A, 
sixth column) and CMV promoter in M1FS cells (Figure 10C, first column) indicated by the lowest 
cell viability. The addition of the let-7a miRNA target sequence (let-7aT) allowed for a strong 
protective effect for the CMV promoter construct, whereas the SUR promoter remained virtually 
unaffected by the translation control in both cell lines (Figure 10A, C columns with banded pattern).  
In Figure 10B, D only transduced cells were investigated and the proportion of dead cells in these 
populations were calculated from the relative fluorescence data. For HDFa and M1FS, the COX-2 
promoter led to the lowest number of dead cells in the transduced population if only transcriptional 
targeting is considered. Overall, CMV promoter driven gene expression in combination with let-
7aT, turned out to be the best combination for both non-cancer cell lines, and was able to rescue all 
transduced HDFa cells and only 12.8 % of M1FS cells died (Figure 10B, D second columns). In-
terestingly, even if the highest expression rate was achieved under the CMV-promoter, many of the 
transduced cells were still viable (~ 40 % HDFa, ~30 % M1FS). Since we observed doubling times 
of up to 48 h for both cell lines, a higher effect of GCV-treatment can probably be achieved by 
longer exposure times, as cytotoxicity of GCV-TP is induced by its incorporation into the DNA of 
replicating cells and by this inhibiting DNA synthesis.  
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Figure 10: Alamar Blue Assay for determination of thymidine kinase activity in the context of TSPs. The 
transcriptional activity of CMV, COX-2, SUR and CXCR-4 promoters, driving the transgene expression upon 
rAAV transduction, was measured in the two non-cancer cell lines HDFa (A, B) and M1FS (C, D). Cells 
were transduced with a MOI of 10ʹ000 and after 24 h treated with 1 mM GCV for another 72 h before per-
forming the Alamar blue assay. Negative reference cells were transduced with rAAV2_mVenus and treated 
with 1 mM GCV. (A, C) Calculation of relative fluorescence was performed by normalization of the fluores-
cence for the different viral vectors to the fluorescence obtained from the rAAV-mVenus transduced reference 
(negative). The number of non-transduced cells is given as a horizontal line. (B, D) The proportion of dead 
cells in the transduced population was calculated from the relative fluorescence data and the transduction 
efficiency determined by rAAV_mVenus transduction of the respective cells. The data shown are the means 
of two biological duplicates with six technical replicates, with error bars indicating the standard deviation. 
 
The results of the cytotoxicity assay for the four cancer cell lines were displayed in Figure 11. On 
the left hand side (Figure 11A, C, E, G) an overview of the total populations, and on the right hand 
side (Figure 11B, D, F, H) only the percentage of dead cells in the transduced fraction were shown. 
In the transduced population, for HT1080, MDA-MB231 and A431 almost all cells died under 
CMV promoter driven suicide gene expression (Figure 11B, D, H, first column). For MDA-MB453 
(Figure 11E), the high percentage of viable cells is expected to be a result of observed doubling 
times of approximately 48 h as before for HDFa and M1FS cells. Again, the data indicate that no 
bystander effect has been achieved as no drop of the relative fluorescence below the number of 
transduced cells (Figure 11A, C, E, G, horizontal line) was observed. HT1080 cells strongly re-
sponded to the treatment with ganciclovir regardless of the promoter and let-7aT and by this 
HT1080 were not well suited as a control cell line, since differences in targeting efficiency were 
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not discernible (Figure 11A, B). De-targeting with let-7aT led to an increase in the relative fluores-
cence for all tumor cells (Figure 11A, C, E, G; columns with banded pattern) indicating that let-7a 
target sequence may not be the best-possible sequence for selected cell lines. Aberrant miRNA 
expression is well known for cancer cells.138–140 However, a general statement about the expression 
profile cannot be made. For MDA-MB231 and MDA-MB453 cells a high let-7a expression level 
was detected in miRNA microarrays,139 which fits to obtained results, at least for the CMV pro-
moter construct. Though, for A431 and HT1080 no published data were found, but the experimental 
findings indicate that let-7a miRNA is also expressed in this both cell lines. To optimize the regu-
lation of protein translation, other miRNA target sequences are possible or even the use of different 
targets in one transgene expression cassette to de-target various cells.94  
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Figure 11: Alamar Blue Assay for determination of thymidine kinase activity in the context of TSPs. The 
transcriptional activity of CMV, COX-2, SUR and CXCR-4 promoters, driving the transgene expression upon 
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rAAV transduction, was measured in four cancer cell lines HT1080 (A, B), MDA-MB231 (C, D), MDA-
MB453 (E, F) and A431 (G, H). Cells were transduced with a MOI of 10ʹ000 and after 24 h treated with 
1 mM GCV for another 72 h before performing the Alamar blue assay. Negative reference cells were trans-
duced with rAAV2_mVenus and treated with 1 mM GCV. (A, C, E, G) Calculation of relative fluorescence 
was performed by normalization of the fluorescence for the different viral vectors to the fluorescence ob-
tained from the rAAV-mVenus transduced reference (negative). The number of non-transduced cells is given 
as a horizontal line. (B, D, F, H) The proportion of dead cells in the transduced population was calculated 
from the relative fluorescence data and the transduction efficiency determined by rAAV_mVenus transduc-
tion of the respective cells. The data shown are the means of two biological duplicates with six technical 
replicates, with error bars indicating the standard deviation. 
 
5.1.4. Calculation of individual tumor specificities 
To determine the individual tumor specificity of the promoters used alone, or in combination with 
the let-7aT, the percentage of dead cells for the given promoter in HDFa (Figure 12A) or M1FS 
(Figure 12B) cells was divided by the percentage of dead cells of the respective tumor cells with 
the corresponding promoters. By this a heat map was generated indicating a ratio of zero in green 
and a ratio of one and more in read. Combinations with a value close to zero or zero, show the 
highest tumor specificity. Here, no or low numbers of the non-cancer cells and high proportions of 
the cancer cells died. At a value of one and more at least the same proportion of dead cells was 
found in the cancer and non-cancer cell lines. 
 
Figure 12: Heat map of calculations of individual tumor specificities. The percentage of dead cells of the 
transduced cell populations for the given promoter in (A) HDFa or (B) M1FS cells was divided by the 
percentage of dead cells of the transduced cell population of respective tumor cells with the corresponding 
promoters. 
 
For both reference cell lines (HDFa, M1FS) the same pattern can be seen, with MDA-MB453 
showing the only exception for CMV_let-7a. Across all other cell lines, the highest tumor 
specificity was achieved with the combination of the CMV promoter with the let7a target sequence.  
HDFa A431 MDA-MB231 MDA-MB453 HT-1080
CMV 0.59 0.51 0.97 0.70
CMV_let7 0.00 0.00 2.65 0.00
COX2 0.67 0.55 0.40 0.24
SUR 0.84 0.69 4.46 0.58
SUR_let7 1.38 0.51 0.00 0.48
CXCR4 2.51 0.92 2.96 0.79
M1FS A431 MDA-MB231 MDA-MB453 HT-1080
CMV 0.71 0.61 1.17 0.84
CMV_let7 0.39 0.61 0.00 0.19
COX2 0.98 0.80 0.58 0.35
SUR 0.46 0.38 2.46 0.32
SUR_let7 1.32 0.48 0.00 0.46
CXCR4 1.47 0.54 1.73 0.46
A
B
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The CXCR-4 promoter showed low tumor specificity in the investigated cell lines. On the contrary, 
in A431 and MDA-MB453 even more non-tumor than tumor cells died. For breast cancer cell lines 
MDA-MB231 and MDA-MB453 previous data suggested high survivin promoter activity.126,127 At 
least for MDA-MB231 this was proven here as well. For MDA-MB453, both the COX-2 promoter 
and the SUR_let-7a combination achieve the highest tumor specificity.  
In summary these results suggest, that no general statement can be made about the functionality of 
the individual promoters. Also, for let-7a upregulation rather than downregulation of the miRNA 
was reported for several types of cancer.141 Regarding the bystander effect, higher plating densities  
could potentially lead to an increased killing and needs to be further evaluated. The most promising 
combination of the strong CMV promoter with the let-7a miRNA target sequence can serve as a 
good starting point for further optimization e.g. with other or even a combination of several miRNA 
target sequences in one transgene expression cassette. One optimal promoter and one miRNA target 
sequence for all types of cancer is unrealistic and a patient-specific adaptation of the transgene 
expression cassette is probably inevitable. 
5.2. Optimization of rAAV production in HEK-F suspension cells 
As the demand for high titer rAAV production with superior purity, which is likewise user friendly 
and cost-efficient increases, great effort was put into the generation of a suspension-based rAAV 
manufacturing process. 
5.2.1. Establishment of a transfection protocol for rAAV production 
The most widely used method for the production of rAAV is based on the multi-plasmid transfec-
tion of adherent growing HEK-293 cells.142 By this the possibility for a scalable rAAV manufac-
turing process is very restricted due to the limited growth area. A suspension-based production 
system in e.g. bioreactors allows for mammalian production to a scale of many thousands of li-
ters.143  
In the beginning a transfection protocol had to be established first in small scale. An attempt for 
the adaption of HEK-293 cells failed as the cells were found to grow not individually but as large 
grapes. Thus, rAAV2 production was optimized in commercially available Freestyle™ 293-F cells 
(HEK-F) (Thermo Fisher Scientific) which were derived from adherent growing HEK-293 cells 
and already adapted for high-density growth as a serum-free suspension culture. In a first step, the 
transfection protocol had to be adapted. Here, several aspects like the cultivation medium, the trans-
fection reagent, the amount of plasmid DNA and the ratio between the three plasmids must be 
considered. Good experience was already made with the HEK-TF medium (Xell AG) and an asso-
ciated standard protocol and served as a starting point. As a transfection reagent linear PEI 
(MW:25k Polysciences, Inc.) was utilized in the beginning and the DNA:PEI ratio, as well as the 
best DNA concentration were analyzed. For this reason, HEK-F cells were seeded in 6-well plates 
  5 Results and Discussion 
27 
 
and transfected with the ITR-containing plasmid coding for the transgene mVenus. In a first step, 
three different DNA amounts were combined with altered DNA:PEI ratios. Overall, a higher excess 
of PEI to DNA always achieved the best transfection efficiency for all DNA concentrations (Figure 
13A, third, sixth and ninth column). With 47.2 % the highest transfection efficiency was reached 
for 2 µg ml-1 plasmid DNA with the four-fold excess of linear PEI (Figure 13A, ninth bar) and was 
therefore maintained as the best conditions. In a second step the molar ratio between the 
pHelper:RepCap:ITR plasmids was evaluated. In literature, molar ratios ranging from 1:1:1,144 
2:1:1,145,146 2:1.6:1,147 1:1:2 148 and 1.5:2:1149 were frequently used. Transient transfection with be-
forehand optimized DNA amount of 2 µg ml-1 and DNA:PEI ratio of 1:4 was performed, and as the 
proportion of viral particles released into the medium during production was not known, DNase I 
resistant particles were determined from cell pellet and from spent medium by qPCR three days 
after transfection. As presented in Figure 13B, three molar ratios were selected for this purpose. 
Admittedly, the differences were not very pronounced. Overall, most of the vector genomes were 
found in the cell pellet, regardless of the molar ratio of the individual plasmids. For AAV2, this 
relationship was already known and is primarily related to the heparin affinity of the capsid, which 
negatively influences the release of the particles into the medium. It should be considered that dur-
ing production of other AAV serotypes this ratio could be shifted towards more rAAVs in the sol-
uble fraction. 
 
Figure 13: Evaluation of optimal transfection conditions. (A) HEK-F cells were seeded in a 6-well plate 
with 3∙106 cells ml-1 in a total volume of 3 ml. For transfection 1, 1.5 and 2 µg ml-1of the ITR containing 
plasmid DNA were incubated with linear PEI in two-, three- or four-fold the amount of the DNA. After 
three days, transfection efficiency was determined using the expression of the delivered transgene mVenus 
measured by flow cytometry of 10,000 cells in total. For each column, standard deviation was calculated 
from two biological duplicates. (B) HEK-F cells were seeded in a 6-well plate with 3∙106 cells ml-1 in a 
total volume of 4 ml. For transfection, 2 µg ml-1of pHelper:RepCap:ITR in a molar ratio of 1:1:1, 2:1.6:1 
or 2:1:1 where complexed  with four-fold amount of linear PEI. After three days, cells were pelleted and 
DNase I resistant particles were determined in the cell pellet after cell disruption in lysis buffer by three 
freeze-thaw cycles and in the spent medium. 
 
The molar plasmid ratio of 2:1:1 resulted in the highest genomic titer (Figure 13B, the two right 
columns) and all subsequent optimizations were continued on this basis. 
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5.2.2. Analysis of the optimal cultivation medium to improve rAAV yields 
In cooperation with Xell AG, an optimized manufacturing protocol, primarily regarding the culti-
vation medium, should be established. To evaluate the productivity of HEK-F cells in HEK-TF 
medium, an additional commercially available medium, FreeStyle™ F17 Expression Medium 
(F17) (Thermo Fisher Scientific), was to be used. Besides the transfection medium (HEK-TF) in 
which the HEK-F cells were propagated and transfected, further media from Xell AG were availa-
ble. On the one hand a growth medium (HEK-GM) and on the other hand a HEK feeding solution 
(FS). In Table 3 all tested combinations were summarized. 
Table 3: Overview of the different medium conditions tested for rAAV2 production. 
Batch number Growth medium Transfection medium Comments 
1.1/1.2 HEK-TF HEK-TF Fill up with HEK-TF 
2.1/2.2 HEK-GM HEK-TF Fill up with HEK-GM 
3.1/3.2 HEK-TF HEK-TF Fill up with HEK-GM 
4.1/4.2 HEK-TF HEK-TF Fill-up with FS 
5.1/5.2 HEK-TF HEK-TF Fill-up with HEK-TF+1x FS* 
6.1/6.2 HEK-TF HEK-TF Fill-up with HEK-TF+xx FS** 
7.1/7.2 F17 F17 HEK-TF optimized protocol 
8.1/8.2 F17 F17 F17 optimized protocol 
*simple feed pulse (3mL) 24 h after filling up; **daily feed pulse (500 µl) starting 24 h after filling up 
 
The focus of these experiments was to determine the best manufacturing process for the media as 
well as the required cultivation time for the highest possible titer. In the beginning, HEK-F cells 
were initially adapted to the respective growth medium for at least three passages. All transfection 
approaches were conducted in 50 ml TubeSpin® bioreactors with a transfection volume of 6 ml 
which was then filled up to the final volume of 12 ml 4 h after transfection with the appropriate 
medium. To determine the best manufacturing process, viable cell density, and viability were meas-
ured every day. Two days after transfection, transfection efficiency was further determined by flow 
cytometry analysis. Additionally, on day one, three and five samples were taken and stored at -80 
°C for later analysis of the genomic rAAV2 titer. As a transfection protocol, the beforehand opti-
mized conditions were chosen. For F17 medium, the HEK-TF optimized protocol was chosen (ap-
proaches 7.1/7.2) as well as a F17 specific protocol (approaches 8.1/8.2) published by Grieger et 
al..149 Here, an optimal cell density of 1∙106 cells ml-1, 1.5 µg ml-1 plasmid DNA and a DNA:PEI 
ratio of 1:2 is recommended. Furthermore, the suggested plasmid ratio of pHelper:RepCap:ITR of 
1.5:2:1 was adopted. 
The transfection efficiency, determined by flow cytometry analysis utilizing expression of the 
mVenus gene, ranged from 66 % for the best Batch 1 to 3.85 % for Batch 2 (Table 4). 
  5 Results and Discussion 
29 
 
Table 4: Transfection efficiency and maximum reached genomic rAAV2 titer for designated batches. Mean 
and standard deviation (SD) of two biological duplicates are shown for the transfection efficiency. 
Batch number Transfection efficiency Maximum total genomic titer 
1.1/1.2 66.61 ± 2.83 6.5∙109 
2.1/2.2 3.85 ± 2.03 1.16∙1010 
3.1/3.2 62.0 ± 1.63 1.47∙109 
4.1/4.2 39.96 ± 3.87 9.14∙108 
5.1/5.2 65.54 ± 4.11 1.08∙109 
6.1/6.2 64.15 ± 4.15 7.16∙109 
7.1/7.2 29.64 ± 5.48 2.15∙109 
8.1/8.2 20.59 ± 1.26 1.11∙1010 
 
Surprisingly, the transfection efficiency did not correlate with maximum total genomic titer. The 
previously optimized process conditions still resulted in the best transfection efficiency (Batch 
1.1/1.2) but not in the overall highest total genomic titer which was highest for Batch 2.1/2.2. There 
is no simple explanation for this phenomenon. It is possible that the fluorescence intensity in ap-
proach 2.1/2.2 was not intense enough, so that the transfection efficiency was underestimated. It is 
more likely, though that the low transfection efficiency for Batch 2.1/2.2 shows that a more rigorous 
washing process before transfection is required as media components of the GM medium appear to 
inhibit transfection. Possibly the number of transfected cells is sufficient for the titer achieved. In 
the context of the recorded growth curves, the different genomic titers obtained can be partially 
clarified. For Batch 1.1/1.2 and Batch 2.1/2.2 growth characteristics are comparable. As expected, 
the maximum viable cell density and the length of cultivation before the decline in viability was 
higher for Batch 2 (Figure 14B) than for Batch 1 (Figure 14A) as the GM medium should support 
stable cell growth, whereas the TF medium especially supports transfection.150,151 For both ap-
proaches, the highest total genomic titer was achieved on the third day. By using the growth me-
dium before and after transfection, with 1.2∙1010 twice as many total genomic copies as for HEK-
TF were yielded. Interestingly, if the HEK-GM medium was used only after transfection and not 
for cultivation before transfection, an extended cultivation time was also observed before viability 
fell below 50% (Figure 14C) in Batch 3.1/3.2, but the maximum yield decreased by a factor of 
about 50 compared to approach 2.1/2.2. Therefore, it seems that the supply of nutrients before 
transfection is more important than after transfection.  
When replenished with 100% FS after transfection (Figure 14D), viable cell density and viability 
already decreased within the first day, but the maximum genomic titer reached on day 5 was re-
duced by a factor of only 10 compared to the best batch of 2.1/2.2. This indicates that no cell growth 
is needed for rAAV2 production. Potentially, the nutrition supply was too high as the protocol 
recommends the addition up to a ratio of one tenth of the culture volume, which here was clearly 
exceeded with a ratio of 1:1.152 For glucose this means a final concentration of more than 100 mM 
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and thus far more than the physiological 3.9 - 7.8 mM found in human plasma.153 If productivity 
per cell is considered, the highest value is even achieved here.  
 
Figure 14: Viability, viable cell density and total genomic copies over the period of cultivation time. 
3.0∙106 ml-1 HEK-F cells were transfected, in a total volume of 6 ml, by triple transfection with a molar 
Ratio of 1:1:1 of pHelper:RepCap:ITR and viable cell density and viability were measured every 24 h. On 
day 1, 3 and 5 after transfection, produced genomic copies were determined by qPCR analysis from com-
bined spent media and from crude cell lysate after three freeze-thaw cycles. (A) For Batch 1.1/1.2, cells 
were cultivated in HEK-TF medium. Before transfection medium was exchanged to fresh HEK-TF. 4h 
after transfection, the cell suspension was filled up with 100 % HEK-TF. (B) For Batch 2.1/2.2, cells were 
cultivated in HEK-GM medium. Before transfection medium was exchanged to fresh HEK-TF medium. 4 
h after transfection, the cell suspension was filled up with 100 % HEK-GM. (C) For Batch 3.1/3.2, cells 
were cultivated in HEK-TF medium. Before transfection medium was exchanged to fresh HEK-TF. 4 h 
after transfection, the cell suspension was filled up with 100 % HEK-GM. (B) For Batch 4.1/4.2, cells 
were cultivated in HEK-TF medium. Before transfection medium was exchanged to fresh HEK-TF me-
dium. 4 h after transfection, the cell suspension was filled up with 100 % FS. 
 
In order to support the observation that a high nutrient supply after transfection does not improve 
the yield, two approaches were conducted in which the feed solution FS was given once in Batch 
5.1/5.2 (Figure 15A) or as a daily feed pulse in Batch 6.1/6.2 (Figure 15B). In either case, viability 
remained stable for a long time at over 90% and cultivation was stopped because of low culture 
volume instead of cell death. As before, a prolonged cultivation time did not lead to an increased 
productivity. For the single feed pulse Batch 5.1/5.2 the highest genomic titer was reached on day 
one but with a total of 1.1∙109 vector genomes, the yield was lower than for standard cultivation 
procedure in Batch 1.1/1.2 or for the variant were HEK-GM medium was used (Figure 14A, B, 
respectively). For Batch 6.1/6.2 very high cell densities of up to 2.5 ∙107 cells ml-1 were reached 
and the total genomic titer was highest on the third day of cultivation. With 7.2∙109 genomic copies 
the yield was comparable to those of the standard procedure. this confirmed the suspicion that a 
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supply of nutrients after transfection, i.e. during production, had no beneficial effect on productiv-
ity. A drop in total vector genomes in the end of the cultivation was observed in all cultivations to 
varying degrees. It should be noted that both the degradation of the rAAVs by enzymes released 
during cell death, but also an increased inhibition of qPCR by those same enzymes as well as other 
proteins can provide a possible explanation, since the qPCR was not carried out on purified sample. 
 
Figure 15: Viability, viable cell density and total genomic copies over the period of cultivation time. 
3.0∙106 ml-1 HEK-F cells were transfected, in a total volume of 6 ml, by triple transfection with a molar 
Ratio of 1:1:1 of pHelper:RepCap:ITR and viable cell density and viability were measured every 24 h. On 
day 1, 3, 5 11 and 14 after transfection, produced genomic copies were determined by qPCR analysis from 
combined spent media and from crude cell lysate after three freeze-thaw cycles. (A) For Batch 5.1/5.2, 
cells were cultivated in HEK-TF medium. Before transfection medium was exchanged to fresh HEK-TF. 4 
h after transfection, the cell suspension was filled up with 100 % HEK-TF. 24 h after transfection, 3 ml of 
FS were added once. (B) For Batch 6.1/6.2, cells were cultivated in HEK-TM medium. Before transfection 
medium was exchanged to fresh HEK-TF medium. 4 h after transfection, the cell suspension was filled up 
with 100 % HEK-TF. A daily feed pulse (500 µl) was added, starting 24 h after fill up. 
 
In the next step, the yield of the established protocol for HEK-TF medium was compared with 
rAAV2 production in F17 medium (Batch 7.1/7.2, Figure 16A). Here, similar productivity was 
obtained with the alternative medium. The F17 supported a high cell viability for only 3 days which 
indicates that the F17 medium did not support the initially high cell density, which was also ac-
companied by an early decline in viability, but this only played a minor role, as with 2.2∙109 total 
genomic copies, the highest genomic titer was reached within 24 hours. In Batch 8.1/8.2 (Figure 
16B) the F17 medium was used with the transfection protocol optimized for F17 medium from 
Grieger et al., using 1.5 µg ml-1 DNA, a DNA:PEI ratio of 1:2 with a plasmid ratio of pHelper:Rep-
Cap:ITR of 1.5:2:1with an initial cell density of 1∙106 cells ml-1.149 24 h after transfection, with 
2.9∙109, almost the same yield was achieved as with the HEK-TF protocol in Batch 7.1/7.2. How-
ever, for Batch 8.1/8.2 an increase in total vector yield was observed and by this 1.1∙1010 total 
genomic copies were reached on day 5 (Figure 16B, third column). When comparing those data to 
the data from Grieger et al., a 56 times lower yield per cell was achieved (3.7∙103 instead of 2.1∙105). 
This may to some extent be related to the determination of the genomic titer. Only in later experi-
ments proteinase K treatment was performed on crude cell extract samples which is used to release 
endonuclease resistant packaged viral genomes and to digest proteins that inhibit the qPCR reac-
tion.154 In addition, the reference standard curve should be performed in spent medium in order to 
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reasonably simulate the qPCR reaction conditions of the sample. Since these steps were not yet 
established at the time of data acquisition, a comparison with the reference is difficult. Also, not to 
be disregarded is the aspect that in the work of Grieger et al. a cell line optimized for rAAV pro-
duction was used.  
 
Figure 16: Viability, viable cell density and total genomic copies over the period of cultivation time. (A) 
For Batch 7.1/7.2, 3.0∙106 ml-1 HEK-F cells were cultivated in F17 medium and before transfection me-
dium was exchanged to fresh F17 medium. Cells were transfected, in a total volume of 6 ml, by triple 
transfection with a molar ratio of 1:1:1 of pHelper:RepCap:ITR. 4 h after transfection, the cell suspension 
was filled up with 100 % F17 and viable cell density and viability were measured every 24 h. On day 1, 3 
and 5 after transfection, produced genomic copies were determined by qPCR analysis from combined 
spent media and from crude cell lysate after three freeze-thaw cycles. (B) For Batch 8.1/8.2, 1.0∙106 ml-1 
HEK-F cells were cultivated in F17 medium and before transfection medium was exchanged to fresh F17 
medium. Cells were transfected in 12 ml F17 medium with 1.5 µg ml-1 plasmid DNA and a DNA:PEI ratio 
of 1:2 with a plasmid ratio of pHelper:RepCap:ITR of 1.5:2:1. Viable cell density and viability were meas-
ured every 24 h. On day 1, 3 and 5 after transfection, produced genomic copies were determined by qPCR 
analysis from combined spent media and from crude cell lysate after three freeze-thaw cycles. 
 
Overall, the different media strategies had only a limited influence on the rAAV2 yield. Within the 
cultivations, the yield for F17 is comparable with Batch 2.1/2.2, whereby the highest titer was al-
ready reached on the third day and not on day 5 (Figure 14B, Figure 16B, respectively. Therefore, 
the original approach in TF Medium seems to be the most appropriate (Batch 1.1/1.2). Batch 2.1/2.2 
is an alternative as it achieved twice the amount of genomic copies. In addition, it offers the possi-
bility to further increase the yield by optimizing the transfection. However, two different media are 
required here. The use of the F17 medium as an alternative should be carried out with the protocol 
adapted protocol from Grieger et al. as a higher yield is achieved. For later scaling up, this protocol 
in combination with the F17 medium also offers the advantage that no medium exchange is required 
at the beginning of the transfection. This not only means a lower amount of required medium, but 
also a reduction in the risk of contamination, as fewer steps are necessary in the preparation of the 
transfection. 
5.2.3. rAAV2 production in 2 L bioreactor 
From the optimized protocol, two 2 L batch processes in bioreactors were started. Here, the main 
problem regarding the transfection protocol established for HEK-TF came into focus. The medium 
exchange step by centrifugation before transfection is not easily realized. Therefore, one day before 
transfection, cells were seeded in HEK-TF medium in half of the transfection volume in a cell 
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density of 6∙106 cells ml-1. On day of transfection, they were diluted to the final 3∙106 cells ml-1 and 
the standard transfection protocol was used. After 4 h, the cell suspension was filled up either with 
100 % HEK-TF or with 100 % HEK-GM medium. Transfection efficiency, total cell density and 
rAAV2 yield were monitored over six days. The transfection efficiency of 49.63 % for HEK-TF 
and 55.5 % for HEK-GM was slightly lower than for SpinTube bioreactor cultivations  ((66.61 %) 
(Table 4)) possibly due to the modification of the transfection protocol. 
Figure 17: Total cell densities and total genomic copies of a rAAV production in a 2 l bioreactor. 3.0∙106 
ml-1 HEK-F cells were transfected, in a total final volume of 800 ml for HEK-TF and 900 ml for HEK-GM 
bioreactor, by triple transfection with a molar Ratio of 1:1:1 of pHelper:RepCap:ITR. After 4h HEK-TF 
bioreactor was filled up to a final volume of 1665 ml with HEK-TF and HEK-GM bioreactor was filled 
up to a final volume of 1833 ml with HEK-GM medium. Viable cell density and viability were measured 
every 24 h. On day 1 and 6 after transfection, produced genomic copies were determined by qPCR analysis 
from combined 1ml of combined spent media and from crude cell lysate after three freeze-thaw cycles. 
Error bars were calculated from the standard deviation of two technical duplicates. 
 
The total cell density (TCD) increased over time regardless of which medium was used for replen-
ishment, with TF Medium even reaching a slightly higher TCD. DNaseI-resistant particles were 
determined from raw cell lysates by qPCR. Considering the error bars, the rAAV2 yield was the 
same for both reactors and as seen before, prolonged cultivation times did not yield in higher ge-
nomic titers. With about 1∙105 genomic copies per cell, cell-specific productivity was much higher 
as seen before for TubeSpin cultivations (1.4∙103 for Batch 1.1/1.2). However, a representation of 
the total vector genomes per cell was deliberately omitted, as the productivity of the individual cell 
showed significant differences, but the overall process was to be examined for its yield. Although 
an increased productivity of the individual cell was found for the bioreactor runs, the overall yield 
of the process was nevertheless low due to low cell numbers, especially at the beginning of the 
cultivation where most of the rAAVs seem to be produced. 
The optimization of rAAV production in HEK-F suspension cells progressed in the master theses 
of Irina Schierbaum and Thilo Pohle. Until now, downstream processing with standard purification 
protocols, mainly iodixanol-based ultracentrifugation was not successful implemented which is 
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possibly related to media components interfering with the viral capsids. For this thesis, required 
AAVs were therefore mainly produced in adherent HEK-293 cells. 
5.3. Establishment of a novel rAAV production cell line 
Results for the generation of the rAAV producer cell were summarized in a manuscript with the 
title 'HEK293-KARE1, a cell line with stably integrated adenovirus helper sequences simplifies 
rAAV production”  and submitted to BMC Biotechnology. The original manuscript is included in 
the appendix. The data presented in the manuscript are the result of a shared authorship with Re-
becca Feiner. Rebecca Feiner performed the experiments to characterize the cell line. Here, only 
own results about optimization of the rAAV production were summarized. 
The standard process for rAAV production relies on the triple transfection of embryonic kidney 
293 (HEK-293) cells.155 These were originally immortalized by exposing the cells to the mechani-
cally sheared DNA of adenovirus type 5 (AD5). During this process, five to six copies of Ad5 early 
E1 gene were integrated into the genome including the chromosome region 19q 13.2. The 4-kbp 
adenoviral genome fragment encodes for the E1A/E1B proteins, which interfere with the cell cycle 
control pathways and counteract apoptosis.156,157 In the helper-free rAAV production system, the 
additionally lacking E2A and E4 and the non-coding RNA V need to be provided by a so called 
'helper plasmid'. This means the inconvenience of continuous production and co-transfection of 
invariant adenoviral helper genes of 9279 bp beside the RepCap and ITR plasmid during rAAV 
production. 
5.3.1. Integration of pHelper sequences into HEK-293 
In collaboration with Julian Teschner, a cell line was planned with stably integrated pHelper se-
quences. For selection of positive integration events, the gene of blasticidin deaminase (bsd) was 
cloned into the pHelper plasmid. The HEK-293 cells were transfected with the linearized plasmid 
and after three days, selective pressure was applied. After two weeks, a limiting dilution in 96 well 
plates was performed to select single cells. The four clones with the highest growth rate were cho-
sen for further characterization and named HEK-KARE1a-d. Because of decreased viability and 
transfection efficiency HEK-KARE1d was discarded at a later stage. For all clones, genomic inte-
gration of the helper genes was analyzed. Genomic DNA of all clones was isolated using a 
Chelex100 extraction. The presence of the bsd and the E2A gene was verified using PCR with two 
different sets of primers. The primers Bsd-for and Bsd-rev as well as Ad5-for and Ad5-rev anneal 
at different regions of the plasmid and, in the case of a successful complete integration, they amplify 
products with a size of 499 bp for E2A and 524 bp for bsd. Experimentally obtained fragments are 
shown in Figure 18A for all samples, demonstrating that both genes were integrated successfully 
into the genome of HEK-293. In microscopy analysis of clone KARE1c (Figure 18B) compared to 
the parental HEK-293 cells, (Figure 18C) no effect on the cell morphology by the integration of 
such a large fragment was detected. 
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Figure 18: Analysis of genomic DNA integration and cell morphology. (A) Agarose gel of the PCR analysis 
of pHelper-BSD integration. Genomic DNA of the four clones HEK293-KARE1a to HEK293-KARE1d 
probed by PCR using the primer pairs given above each lane. (B, C) Comparison of cell morphology in 
bright field images of (B) HEK293-KARE1c and (C) HEK293. The morphology of HEK293-KARE1c looks 
similar to the one of the parental HEK293 cell line. 
 
5.3.2. rAAV production in HEK293-KARE1 
In order to assess the rAAV production ability and their long-term productivity, three HEK293-
KARE1 clones were cultured similar to normal HEK-293 with the only difference of maintaining 
antibiotic selection at 5 µg BSD. First attempts for rAAV production started with adapting the 
three-plasmid co-transfection for high titer rAAV production in HEK-293 cells. Here, pHelper plas-
mid, Rep2Cap2587wt- and ITR-plasmid are transfected in a molar 1:1:1 ratio and a total plasmid 
DNA amount of 15 µg per 100 mm dish.  
First, a double transfection of the Rep2Cap2587wt and ITR plasmid in a ratio of 1:1 was performed, 
whereby only the pHelper plasmid was omitted, but the total plasmid DNA amount of 15 µg per 
100 mm dish was retained. These experiments were carried out with the three cell lines HEK293-
KARE1a to 1c after passage 3 and 9 and as a negative control with HEK293 cells and as a positive 
control with HEK-293 cells and triple plasmid transfection. Genomic titers, or more precisely of 
DNase I-resistant particles, were determined directly without further purification from the crude 
cell extract using qPCR with a set of ITR-plasmid specific primers. To get meaningful results, the 
standard curve used for determination of the genomic titer was set up in equal amounts of crude 
cell extract from untransfected cells. Resulting genomic titers of this experiment are presented in 
Figure 19A. 
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Figure 19: Analysis of rAAV2 production in HEK293-KARE1 and HEK-293 cells (A) HEK293-KARE1 
cells (1×100 mm dish) were transfected with ITR-plasmid and RepCap-plasmid, for HEK293 the pHelper 
was included. Three days after transfection rAAV yield was determined from crude cell lysate after three 
freeze-thaw cycles by qPCR. A molar ratio of 1:1 of the plasmids RepCap:ITR was used during this ex-
periment with a total of 15 µg plasmid DNA. For HEK2-93 cells experiments were performed also with a 
plasmid ratio of 1:1:1 for pHelper:RepCap:ITR. (B) HEK293-KARE1 and HEK293 cells (1×100 mm dish) 
were transfected with ITR-plasmid and RepCap-plasmid excluding the pHelper plasmid. Three days after 
transfection rAAV yield was determined from crude cell lysate after three freeze-thaw cycles by qPCR. A 
molar ratio of 1:1 of the plasmids RepCap:ITR was used during this experiment with a total of 15 µg or 
7.4 µg plasmid DNA. For each column, standard deviation was calculated from two biological duplicates. 
 
As expected, rAAV production was observed for HEK293-KARE1 clones when omitting the 
pHelper plasmid. HEK-293 cells transfected without addition of pHelper show a dramatic reduction 
in production capacity of viral particles. The relative high background may be related to residual 
plasmid DNA from the transfection. The rAAV yield for HEK293-KARE1 clones was in the range 
of 3.2×104 to 8.4×104 GC per cell (Figure 19A). For similar small-scale experiments with HEK-
293 cells, albeit in a commercial context, a value of 8.3×104 GC per cell has been reported.158 Other 
groups determined that the choice of primers and the reference material for qPCR (circular, linear 
DNA) have a tremendous effect on the genomic titers 159,160.Specifically, ITR primers compared to 
primers binding the gene of interest yielded up to ten times higher genomic copies when plasmids 
were used as reference. Here, primers binding the human growth hormone poly adenylation 
(hGHpA) region where used, whereas in literature primers binding the ITR region have been ap-
plied and both experiments used plasmid DNA as reference.158 After long-time cultivation for nine 
passages no reduction of rAAV titer was observed and cryopreservation did not alter production 
capacity as these experiments were conducted from biological duplicates that were independently 
thawed.  
5.3.3. Optimization of rAAV production in HEK293-KARE1c 
The high amount of DNA and the addition of the antibiotic during the production process might 
not be desired. Lowering the required plasmid dose and omitting the antibiotic would reduce pro-
duction costs and possible sources of product contaminations. Thus, a reduction of the total plasmid 
DNA amount from 15 µg to 7.4 µg was tested. This value corresponds to the total DNA amount of 
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Rep2Cap2587wt- and ITR-plasmid in the standard triple-transfection protocol with just omitting the 
pHelper plasmid DNA. However, the yield decreased dramatically as shown in Figure 19B. Simply 
reducing the amount of DNA did not lead to a satisfying result. The calcium-phosphate transfection 
method is based on DNA-calcium phosphate precipitation which is dependent on a specific DNA 
to calcium ion ratio.161 During transfection mix preparation a decreased turbidity of the transfection 
solution was observed, which indicated a deterioration of transfection efficiency and associated 
lower genomic titer.  
For further optimization only clone HEK293-KARE1c was used because the productivity of all 
clones had a yield in the same order of magnitude. The adaption of the transfection protocol for the 
reduced amount of DNA resulted in genomic titers comparable to the use of 15 µg total DNA per 
transfection (Figure 20, first and second bar). In a second optimization step, the need for the selec-
tive pressure during the production process was evaluated. As it is known that gene silencing might 
occur if selective pressure is not maintained, the use of the antibiotic should not be generally omit-
ted. Thus, only during the rAAV production no blasticidin was added. HEK293-KARE1c cells 
were seeded without addition of blasticidin and transfections was performed the day after. Com-
parison of genomic titers from crude cell extracts after 72 h proved rAAV production even without 
the addition of the antibiotic in comparable yields (Figure 20, third and fourth bar). The variations 
observed between separate biologic experiments (Figure 20, second and third bar) can be attributed 
to passaging and handling.  
 
Figure 20: Comparison of rAAV production in HEK293-KARE1c cells depending on 15 µg transfection 
protocol and the optimized 7.4 µg transfection protocol. rAAV2 yield was quantified in crude lysates by 
qPCR. In general, RepCap and ITR plasmid were transfected in a molar 1:1 ratio. For each column, 
standard deviation was calculated from two technical duplicates. 
 
5.3.4. Analysis of rAAV2 produced by HEK293-KARE1c 
After reducing the amount of DNA and the concentration of antibiotic, the quality of the produced 
viral particles was characterized. rAAV2 was produced in the favorite HEK293-KARE1c clone. 
Cells were seeded on ten 100 mm dishes the day before transfection. Transfections were carried 
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out using the previously adapted calcium-phosphate transfection protocol with a total plasmid DNA 
of 7.4 µg (2.5 pg per cell) and 1:1 molar ratio of Rep2Cap2587wt to ITR-plasmid. Viral particles 
were purified using a standard iodixanol-gradient ultracentrifugation protocol. The transducing titer 
was determined for a serial dilution of viral particles on HT1080 cells. The ITR-delivered gene of 
interest coded for the fluorescent protein mVenus under the control of a CMV promoter and thus 
successful transduction resulted in yellow fluorescent cells, which were analyzed by fluorescence 
microscopy and flow cytometry.  
 
Figure 21: Characterization of rAAV2. Viral particles were produced in the HEK293-KARE1c cell line 
seeded in ten 100 mm dishes and subsequently purified via iodixanol ultracentrifugation. (A) Determina-
tion of transduction ability of rAAV (1:200 diluted sample) on HT-1080 cells using expression of the mVe-
nus gene measured by flow cytometry of 10,000 cells in total. (B) The amount of DNase I-resistant parti-
cles was determined by qPCR from a standard curve of the ITR-plasmid. The total volume of the final viral 
sample was 2.5 ml. The transducing titer was determined based on percent of fluorescent cells as depicted 
in panel A (see methods). (C, D) rAAV were visualized by atomic force microscopy and resulting particle 
height profiles were determined. A mean diameter of 21.5 ± 1.8 nm was measured at half maximum height 
of 8 particles. 
 
To calculate the transducing titer from flow cytometry data, the lowest serial dilution was used 
(Figure 21A) and the genomic titer was determined via qPCR. Both titers are presented in Figure 
21B. The transducing titer is about 10-fold lower compared to the genomic titer which is in agree-
ment with the literature.162 The sample purified by ultracentrifugation was analyzed by atomic force 
microscopy (AFM) (Figure 21C). The calculated mean diameter of the marked particles is with 
21.5 nm in the expected range of 20 to 24 nm (Figure 21D).163 Hence, the quality of rAAVs pro-
duced using the novel cell line is equivalent. 
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A first attempt transferring the rAAV2 production platform towards serotypes 6 and 9 was success-
ful with total vector genomes from one 100 mm dish of 1.95∙108 for rAAV6 and 1.46∙109 for rAAV9 
which represents a 10 to 50 times lower yield compared to rAAV2 (9.29∙109 genomic copies per 
100 mm dish), but may be associated with observed poor transfection efficiency in this approach. 
In summary, by stably integrating the adenoviral helper genes VA RNA, E2A and E4orf6 into 
HEK-293 cells, the HEK293-KARE1 cell lines offer a simplified production platform for rAAV. 
The adaption of the transfection procedure towards a lower DNA amount does not only eliminate 
the time-consuming production and purification of the pHelper plasmid, but also reduces the high 
costs for the provision of sufficient plasmid DNA. This is even more important in the context of 
up-scaling. For this reason, an adaption to suspension should be considered in the future. 
5.4. Generation and characterization of a HEK-293 AAVR knock-out 
cell line 
After the discovery of the AAV receptor in 2016, the hypothesis arose that the productivity of HEK-
293 cells can be improved by a knock out of this receptor, which is known to be essential for 
transduction.30 We thereby hoped that rAAVs that were potentially released during production 
would not reinfect the production cell line and thereby increasing the yield. 
A CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated 
protein 9) approach based on the Pillay et al. publication was implemented to induce an indel mu-
tation in the HEK-293 AAVR gene. Two oligonucleotides were designed, hybridized and cloned 
into pSpCas9(BB)-2A-GFP from Zhang Lab.164 The target sequence introduced is located in exon 
3 of the AAVR receptor, directly adjacent to the protospacer adjacent motif (PAM). For AAVR 
knock-out, 3∙106 HEK-293 cells on one 100 mm dish were transfected by calcium-phosphate with 
15 µg of CRISPR plasmid DNA. After 2 days, successful transfection was detected by the expres-
sion of GFP from the CRISPR plasmid by fluorescence microscopy (Figure 22). Thereafter, cells 
were trypsinized and GFP-positive cells were sorted by fluorescence activated cell sorting (FACS). 
For this purpose, 1 ml of DMEM growth medium was added into a FACS vial and 100 of the cells 
marked as positive were sorted into the vial. From this cell suspension 10 µl each were seeded per 
well in a 96 well plate and filled up with 140 µl growth medium. Thus, statistically only one cell 
per well should be found. The sorting strategy is shown in Figure 22B, C. To determine a healthy 
cell population, only a small amount of cells was chosen based on a plot of sideward-scatter (SSC) 
against forward scatter (FSC) as marked in Figure 22B as a region of interest (ROI) with a green 
box. In a second step, only cells of this ROI were analyzed for their green fluorescence. Auto flu-
orescence of untransfected HEK-293 cells was determined to reach a signal strength of up to 101. 
Therefore, all cells that showed a signal beyond this were assessed as positive transfected. A posi-
tive population was determined with about a tenfold increase in signal-strength (Figure 22C, green 
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bar) and a super positive population with a 100 to 1000 fold increase in signal strength (Figure 22C, 
yellow bar). 
 
Figure 22: CRISPR-Cas9 knock-out of AAV receptor in adherent HEK-293 cells. 3∙106 HEK-293 cells 
were seeded on one 100 mm dish one day before transfection. For transfection by calcium-phosphate 
precipitation, 15 µg of CRISPR plasmid DNA were used. (A) Detection of GFP expression from the 
CRISPR-Cas9 plasmid by fluorescence microscopy of transfected HEK-293 cells 48 h after transfection. 
(B, C) FACS analysis of transfected HEK-293 cells. (B) Plot of sideward scatter against forward scatter 
to determine living cell population by defining a region of interest (ROI) (R1 in green) (C) Plot of cell 
count against fluorescence intensity in FL1 channel. Only cell from ROI were plotted. Two regions were 
defined for GFP positive (green) and GFP super positive (yellow) cells and 100 cells of the respective 
region were sorted into a FACS vial with 1 ml pre-added DMEM. 
 
After the cells had settled down, each individual well was screened to ensure that it contained only 
one cell at a time. Cells were cultivated for two weeks until they reached confluence. From the 
individual clones the genomic DNA was isolated by Chelex genomic DNA extraction and the re-
gion around the potential knock-out was amplified in a PCR. Theoretically. the primer pair should 
amplify a fragment with the size of 668 bp if genomic DNA extraction and PCR were successful 
(Figure 23A). As can be seen in Figure 23B, for all ten clones a fragment with the expected size 
was amplified and for all PCR reactions sequencing with Seq-AAVRko-for and Seq-AAVRko-rev 
was performed. 
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Figure 23: PCR analysis of HEK-293 AAVR knock-out clones. (A) Theoretical approach to amplify the 
area around the ko in exon 3 of the AAVR gene of 10 clones. A fragment with a size of 668 bp should be 
amplified if DNA extraction and PCR reaction were successful. (B) Agarose gel of the PCR analysis from 
amplification of the region surrounding the ko in AAVR gene. Genomic DNA of the ten clones HEK-293-
AAVRko1 to HEK-293-AAVRko1 was probed by PCR using the primer pair Seq-AAVRko-for and Seq-
AAVRko-rev. 
 
Interestingly, most of the clones from the super positive area did not expanded. Potentially high 
dose of the CRISPR plasmid led to cellular stress which resulted in increased cell death. The se-
quencing reactions revealed, that HEK-293 cells were triploid for chromosome 1p34-36 and there-
fore several sequences overlapped and made an evaluation impossible. In order to avoid this prob-
lem, the PCR reactions were cloned into a TOPO TA cloning vector so that all individual sequences 
could be covered by the delivery of several clones.165 Most of the clones possessed at least one 
chromosome where no indel mutation occurred (Figure 24A). These clones were suspected to be 
heterozygous and still express a certain amount of AAV receptor. For the most promising clone 
(Figure 24B), two chromosomes showed a deletion of 18 and 5 bp respectively. For the third chro-
mosome, an insertion of 1 bp was detected 
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Figure 24: Sequencing results using the primer pair Seq-AAVRko-for and Seq-AAVRko-rev of two clones 
after cloning of PCR products into TOPO TA cloning vector. (A) Sequencing reaction of a clone with two 
chromosomes showing a knock-out and one chromosome still possessing the original sequence. (B) Se-
quencing reaction of a clone with two chromosomes showing a knock-out and one chromosome showing 
an insertion of one nucleotide. 
 
This clone was further characterized by transduction experiments in a master thesis of Greta Bis-
chof but still transduction by rAAV2 was possible. Since 18 is a multiple of 3, a deletion of 6 amino 
acids in exon 3 is presumed to have occurred only, and not a shift in the reading frame, so that an 
AAV receptor can be formed that is still functional. Therefore, in the master thesis of Greta Bischof, 
this cell line was newly generated which possessed a 2 bp, 4 bp and a 14 bp deletion and by this on 
all chromosomes a frameshift should occur.166 
The assumption persisted that produced AAVs that are released from the production cell, for ex-
ample by cell death, could transduce other production cells thereby reducing the rAAV yield. To 
resolve this issue, the homozygous AAVR knock-out cell line was utilized for rAAV2 production 
by triple transfection. In parallel rAAV2 were produced in the standard HEK-293 cells and the 
  5 Results and Discussion 
43 
 
resulting genomic titer was determined. Transfection efficiency was determined by the expression 
of mVenus gene from the ITR containing plasmid and was comparable for both cell lines with 96 % 
for HEK-293 and 94 % for HEK-293 AAVR ko and by this no effect of different transfection 
efficiencies had to be taken into account when comparing total genomic copies. For both cell lines, 
total genomic copies were determined from crude cell lysate after 3 freeze-thaw cycles. Total ge-
nomic copies for HEK-293 was 3.3∙1012 and 2.8∙1012 for the AAVR knock-out cells. Therefore, no 
increase in yield was achieved through the AAVR knock-out. Thus, at least for rAAV2 the hypoth-
esis of reinfection and hence a reduction of the yield cannot be confirmed. However, as for rAAV2 
the majority of viral vectors were found in the cell pellet,167 the effect of reinfection is potentially 
not as pronounced as for other serotypes that are released more into the culture medium which 
should be studied in the future. 
5.5. Establishment of a novel rAAV affinity purification process 
Results for the generation of an affinity purification material were summarized in a manuscript with 
the title 'Generating a quick, easy and low-cost affinity purification method for rAAV based on 
adeno-associated virus receptor’s PKD domain'. Results on this have originated in cooperation with 
Julian Teschner and Monja Leppin. A summary of my part is presented in the following chapter. 
The original manuscript is included in the appendix and currently serves as a template for a patent.  
Standard processes for the purification of rAAV, relying on a cesium chloride (CsCl) or an iodixa-
nol gradient ultracentrifugation. However, they are restricted in their potential to scale up. Often, 
several chromatography steps are included into downstream processes like ion exchange, size ex-
clusion and heparin column chromatography. These procedures are not only time intensive but are 
accompanied by high costs and cumulative loss in yield. In this work a scalable affinity purification 
strategy, based on the natural AAV receptor AAVR was established. As an affinity ligand, PKD2 
was chosen in the first step, as Pillay et al. published that AAVR PKD2 is critical for the interaction 
of AAV2 with AAVR.32 As a supporting material, cellulose was elected as a cost-effective material 
with advantageous properties such as low unspecific binding and good physical and chemical re-
sistance under selected process conditions. In order to avoid the clogging of a packed chromatog-
raphy column by residues of the cell lysate, blotting paper was utilized, so that the incubation of 
cell lysate containing rAAV was carried out in batch mode and not in the usual flow process of a 
packed column. An overview of the rAAV purification strategy is given in Figure 25. 
In order to avoid time-consuming and elaborate steps in the purification procedure, the method has 
been designed to be performed directly from the crude cell extract as concentration steps with am-
monium sulfate or polyethylene glycol (PEG) precipitation interfere with upscaling due to the need 
for a centrifugation step.168 As depicted in Figure 25 section 3, in contrast to a packed column the 
chosen cellulose material in form of blotting paper allows for a batch process in where the rAAV 
containing suspension is either stirred or shaken with the PKD functionalized paper. Thereafter, the 
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column material can be transferred into a spin tube and by this, separation of the column material 
from the elution can easily be executed. As for commercial POROS CaptureSelect AAVX or AVB 
Sepharose High Performance, batch processes can also be conducted, but separation of the material 
from the sample is not easily realized as the small sized particles are sticking to the vessels. 
 
Figure 25: Schematic representation of recombinant adeno-associated virus (rAAV) manufacturing tech-
nology. (1) Adherent HEK-293 cells are seeded and transfected with the three-plasmid system and har-
vested after 72 h. rAAVs were released from the cells by three freeze-thaw cycles and cell debris is pelleted 
by centrifugation (2) E. coli BL21(DE3) cells expressing PKD-MBP are cultivated in shaker flask for 4 h 
after induction with IPTG. The cell pellets are resuspended and then lysed using a french press. Lysate is 
clarified and loaded onto a ÄKTA FPLC and purified using IMAC. Blotting paper (BP) is activated by 
divinyl sulfone (DVS) and functionalized with purified PKD overnight. (3) rAAV containing clear lysate is 
incubated with functionalized BP and rAAV are eluted by transferring the BP to a spin tube and covering 
it with elution buffer. The rAAV containing elution is then dialyzed into the final storage buffer. 
 
5.5.1. Expression and purification of PKD2-MBP in E. coli 
For the expression of PKD2 as an affinity ligand, it was subcloned into a pET-24b expression vector 
from KIAA0319L full cDNA clone by PCR amplification of amino acid 405 to 502, which included 
four amino acids to the left and to the right of the domain as proposed by Pillay et al. in order to 
ensure correct protein folding.30 To increase solubility the sequence of the maltose-binding protein 
(MBP) was subjoined separated by a short glycine-serine linker at the 3'-end of PKD2. Here, sub-
sequently a 6× His-tag was introduced to allow purification of the fusion protein from E. coli pro-
duction. A theoretical sequence of the fusion protein is given in Figure 26A. The success of purifi-
cation after immobilized metal affinity chromatography (IMAC) is shown in Figure 26B. PKD2 
can be produced in high concentrations and purity when fused to MBP and thus inexpensive supply 
of the affinity ligand is possible. 
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Figure 26: Construction and production of PKD2-MBP fusion protein. (A) Schematic representation of 
the basic components of the PKD2-MBP-fusion protein with its unique restriction sites for cloning and 
the position of GGSG linker sequences. (B) Coomassie-stained SDS PAGE protein analysis of PKD2-MBP 
purification steps. Cell extract, Ni-NTA column flow through and the wash fraction were diluted 1:2 in 
PBS buffer and elution fractions 1 to3 as well the combined and re buffered elution fraction was diluted 
1:10 with PBS before loading. 
 
5.5.2. Proof of binding of rAAV2 to PKD2-cellulose 
For covalent binding of PKD, divinyl sulfone (DVS) activation of the cellulose was chosen. Here, 
one of the vinyl groups reacts with a hydroxyl-group of the cellulose. The remaining vinyl group 
reacts with nucleophiles and by this covalently attaches biomolecules to the cellulose surface (Fig-
ure. 27).169  
 
Figure. 27: Activation of cellulose with divinyl sulfone and functionalization with nucleophile-bearing 
molecules (gray) as published by Yu et al..169 
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The binding of rAAV2 to PKD2 is known, but a negative influence of covalent coupling on PKD2 
functionality by steric hindrance or coupling to the cellulose resin with important amino acids could 
not be excluded. Therefore, the binding of rAAV2 to the PKD2-blotting paper (PKD2-BP) was 
proven prior to the optimization of the purification strategy. 30 µg PKD2-MBP were coupled to 
1 cm2 DVS activated blotting paper and subsequently incubated with 5.7∙108 virus genomes (vg) 
of ultracentrifuge (UC) purified rAAV2 for 20 min, followed by two wash steps. The supernatant, 
PKD2-BP before (BP-rAAV2) and after the wash step (BP-washed) and the wash fraction where 
analyzed by western blot analysis. As can be seen in Figure 28A, VP1, VP2 and VP3 were detected 
in the expected ratio on the PKD2-BP, with the washing procedure (BP-washed) had a low influ-
ence on signal strength. In the wash fraction no viral capsids were detected by western blot, which 
is in good accordance with qPCR data. These data further revealed that 78 % of rAAV2 were bound 
to the material, suggesting that the resin was saturated Figure 28B. 
 
Figure 28: Characterization of rAAV2 binding to the PKD2-BP resin. (A) Western blot analysis of binding 
of UC purified rAAV2 to the PKD2-BP resin. (B) qPCR analysis of DNase I-resistant particles remaining 
in the respective fractions. Percentages were calculated by setting the genomic titer of starting material 
as 100 %. For each column, standard deviation was calculated between two technical replicates. 
 
5.5.3. Optimization of PKD2 amount and elution conditions 
Previous western blot analysis confirmed, that covalent binding of the fusion protein to blotting 
paper by DVS activation did not impair the functionality of PKD2, so that the binding of rAAV2 
to the blotting paper was possible. 
Even if rAAV binding to the resin was proven, 22 % of the vector genomes were still found in the 
supernatant. Therefore, the amount of PKD2 applied for covalent coupling was varied in order to 
optimize the binding conditions. 5.7∙108 vg of UC purified rAAV2 were applied to 12 µg, 30 µg 
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and 120 µg PKD2 coupled to BP, and non-bound virus were detected by qPCR in the supernatant. 
As depicted in Table 5, no correlation between the amount of coupled PKD2 and rAAV2 in the 
supernatant was seen. Though, taking the excess of PKD2 towards rAAV2 into account no limita-
tion was expected. 
Table 5: Relationship between amount of applied PKD2 to the amount of rAAV2 vg in the supernatant and 
estimated functional PKD2 molecule number. 
Amount of PKD2 rAAV2 vg in supernatant in % PKD2 molecule number 
2 µM (12 µg) 7.8 ± 19.8 1.2∙1014 
5 µM (30 µg) 22.1 ± 0.98  3∙1014 
20 µM (120 µg) 6.0 ± 26.1  1.2∙1015 
 
The increase in the amount of PKD2 did not decrease the quantity of rAAV2 found in the superna-
tant. Potentially, even if the amount of PKD2 was raised, no more functional protein was covalently 
bound, as the method for coupling does not allow for quantification of bound protein as the blotting 
paper was just soaked with the protein without any protruding solution. After protein coupling SDS-
PAGE analysis with subsequent determination of bound protein should be considered in the future. 
However, as the amount of affinity ligand exceeds applied viral capsids by far it can be speculated, 
that non bound rAAV2 may be in a structural conformation which does not allow for accurate 
binding. If this hypothesis could be confirmed, this method would primarily purify biologically 
relevant viruses and thus would have a substantial advantage over other systems. 
As there was no tendency for the most appropriate PKD2 concentration definable, further experi-
ments were carried out with 30 µg PKD2 and elution conditions were evaluated. Lowering the pH 
or increasing the ionic strength is well known for affinity purification procedures. Therefore, an 
elution buffer with 100 mM citric acid, pH 2.5 and a 2.5 M magnesium chloride (MgCl2) buffer, 
pH 7.0 were selected. Starting with UC-purified rAAV2, only 0.2 % of the starting material was 
found in the pH elution sample, whereas for the MgCl2 elution a 33.5 % yield was reached after 
buffer exchange. Subsequently, all following attempts were performed with 2.5 M MgCl2 50 mM 
Tris pH 7.0. The MgCl2 buffer did not only result in the highest amount of rAAV but also offers 
the advantage of a neutral pH as other methods relying on elution conditions within a pH range of 
pH 2.0 - 3.0. AAV undergoes autolytic proteolysis at low pH which results in a decrease in VP1 
and VP2 and in an increase in lower-molecular-mass bands.170 For AAV serotype 8, amino acid 
side chain conformational rearrangements were observed at low pH values.171 However, effects on 
viral preparation potency still need to be investigated. 
5.5.4. Description of the purification strategy from crude cell extract 
For purification of rAAV2, predetermined conditions were used with crude cell extract of rAAV2 
containing HEK-293 cells. rAAV2, which carried the mVenus fluorescent protein as a transgene, 
were produced in HEK-293 cells by triple plasmid transfection using calcium-phosphate. After 
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three days, rAAV2-mVenus were released by three cycles of freeze-thaw and the clarified super-
natant of one 10 cm dish was incubated for 20 min with PKD2-BP while rotating on a roll-tumble 
shaker. The resin was then washed rigorously with PBS-Tween until residual phenol red from the 
spent cell culture medium was undetectable. For elution, the resin was covered with 500 µl elution 
buffer in a spin tube for 5 min before centrifugation at 1000 × g for 2 min. After three cycles of 
elution, the fractions were combined and buffer exchange to HBSS was performed by ultra-centrif-
ugal filters units with a cut-off of 100´000 kDa. In qPCR, 41.5 % of vectors genomes were detected 
in the supernatant which was more than in previous trials with UC purified rAAV2. 24.6 % of total 
virus genomes were found in the combined elution fraction (Figure 29A). The discrepancy between 
bound and eluted rAAV2 and the total amount of vector genomes applied shows that not all viruses 
may have been eluted from the resin. However, it is also conceivable that some viral capsids may 
be destroyed during elution, creating the gap between the applied and rescued rAAV2 vector ge-
nomes. In addition, artefacts of genomic titer determination are possible. On the one hand, the 
qPCR reaction reacts sensitively to buffer conditions, which differ greatly between the cell extract 
and the rebuffered elution fraction.172 On the other hand, the genomic titer is potentially overesti-
mated in the beginning as the DNase I is potentially inhibited during the digestion process of non-
encapsulated DNA before genomic titer determination as regularly observed by us. 
 
Figure 29: Characterization of rAAV2 binding to PKD2-BP from HEK-293 crude cell extract. (A) Distri-
bution of DNase I resistant particles in the respective fractions. Percentages were calculated by setting 
the genomic titer of starting material as 100 %. Genomic titer was quantified in crude cell extract after 
three freeze-thaw cycles for start value and for supernatant value after incubation with PKD2-BP by 
qPCR. For each column, standard deviation was calculated between two technical replicates. (B) Silver-
stained SDS PAGE analysis of rAAV2 sample purity after purification with PKD2-BP, POROS AAVX or 
UC. Viral particles were produced in HEK-293 cells seeded in two 100 mm dishes for each purification 
method and subsequently purified via PKD2-BP, POROS AAVX or iodixanol ultracentrifugation. 
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To compare the conventional UC method with a commercial affinity purification and the new 
PKD2 resin, two 10 cm dishes were purified either by PKD2, POROS CaptureSelect AAVX affin-
ity resin (POROS AAVX) or UC, and the elution fractions were analyzed by qPCR (Table 6). 
Table 6: Comparison of recovery rate for different purification approaches. 
 vg loaded in total vg recovered total Recovery rate in % 
PKD2 8.32∙1011 1.46∙1011 17.5 % 
POROS AAVX 8.32∙1011 1.12∙1011 13.4 % 
UC 8.32∙1011 3.2∙1011 38.0 % 
 
For UC-purified rAAV2 the highest recovery rate was reached, whereas for PKD2 and POROS 
AAVX with 17.5 % and 13.4 %, respectively a similar yield was obtained. In a SDS-PAGE using 
silver nitrate staining (Figure 29B), many protein contaminants were observed for UC-purified 
samples and, to a lower extent also for the POROS AAVX column material. Interestingly, the im-
purities in the POROS AAVX sample showed the same pattern as observed for the PKD2 sample. 
The most prominent contaminant was detected with a molecular weight of approximately 60 kDa, 
which may potentially be residual BSA or VP3. For the PKD2-BP resin, some other proteins were 
bound to the material, indicating that a more rigid wash procedure may be necessary to diminish 
these.  
5.5.5. Biological characteristics of PKD2 purified rAAV2 
To analyze the biological activity of PKD2-purified rAAV2, a transducing titer assay on HT1080, 
as well as a capsid ELISA (enzyme-linked immunosorbent assay) for the determination of empty 
capsids was performed and compared to UC-purified rAAV2. Additionally, a sample after POROS 
AAVX purification was used in order to have a comparison to another affinity purification system. 
Here, 500 µl of slurry were used to purify rAAV2 from the clarified supernatant of a 10 cm dish, 
analogous to PKD2.  
For the determination of the ratio of full to empty capsids, a new capsid ELISA was established. 
While the standard capsid ELISA from Progen utilizes the A20 monoclonal antibody (mAB) to 
capture fully assembled AAV capsids, PKD2 was coupled to the surface of a microtiter plate. For 
detection of captured viral capsids, a recombinant A20 single-chain variant (A20 scFv-Fc) was 
cloned by Julian Teschner and produced during this work in HEK-F suspension cells.  
The conversion of the substrate ABTS (2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) by 
the horseradish peroxidase coupled to the secondary antibody in ELISA was compared to the stand-
ard A20 antibody from Progen. The signal strength reached was higher for A20-scFv-Fc as for A20 
antibody, and by this has the advantage of giving higher signal to noise ratio in the case of low 
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signals due to low concentrations (Figure 30A). Whether this is a result of more A20-scFv-Fc mol-
ecules bound to the surface of rAAV2 or due to the different secondary antibody (anti-human HRP 
vs. anti-mouse HRP) does not emerge from this.  
 
Figure 30: Analysis of A20-scFv-Fc functionality. (A) The AAV capsid ELISA was performed with PKD2 
as the primary molecule to bind rAAV2. For detection A20-scFv-Fc or commercial A20 were used with 
the same final protein concentration (50 µg/ml). These were finally bound either by anti-human HRP or 
anti-mouse HRP antibody, respectively. Error bars are calculated from the standard deviation of three 
technical replicates. (B) Standard curve for the determination of capsid titer with PKD2 for capturing and 
A20-scFv-Fc for detection. The kit control from AAV2 titration ELISA (Progen) was diluted as recom-
mended in the kit instruction. The particle titer was calculated by a 4-parameter logistic fit with OriginPro 
2018 software. The equation was: 𝑦 = 𝐴2 + (𝐴1 − 𝐴2)/(1 + (
𝑥
𝑥0
))^𝑝) with A1: 1.368; A2: 6.752; x0: 
5.102 and p: 1.631. 
 
In order to determine the capsid concentration of the individual purified samples, a standard curve 
based on a known capsid titer was prepared (Figure 30B). This curve showed the expected loga-
rithmic progression as it is also known for the commercially available capsid ELISA. Therefore, 
results of this newly developed capsid ELISA are to be regarded as reliable. Using this method, the 
highest ratio of full to empty capsids was determined, for UC-purified rAAV2 with 0.27, whereas 
for PKD2 and POROS AAVX the ratio is roughly the same. 
Table 7: Biological characteristics of PKD2, POROS-AAVX and UC purified rAAV2 samples. 
 TU/ml Capsids/gc full to empty ratio 
PKD2-BP 1.6∙108 7.07 0.14 
POROS AAVX n.D. 5.89 0.17 
UC 1.9∙108 3.63 0.27 
 
As empty capsids may cause serious side effects in patients, also for UC-purified sample another 
polishing step is normally applied and by this, UC offers only a slight advantage when used as a 
one-step purification strategy in the context of research, when the high purity of vector preparation 
is not needed. 
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5.5.6. Purification of in suspension produced rAAV2 by PKD2 
For an efficient rAAV manufacturing process, a transfer of the purification strategy for the adherent 
produced rAAV towards serum-free, suspension-based produced rAAVs is desirable. Suspension-
based rAAV production in HEK-F cells has already been established in the working group. How-
ever, several attempts for the purification of rAAV from the cell extract, using the standard ultra-
centrifuge protocol, have not yet been successfully completed. Since regular flocculation could be 
observed during cell disruption, which cannot be eliminated during the subsequent centrifugation 
step, we assume that medium components react with the viral capsid, thus preventing efficient pu-
rification by ultracentrifugation. In order to determine whether purification of rAAV from HEK-F 
using the PKD affinity resin is possible, HEK-F suspension cells were cultivated in HEK-TF (TF) 
medium and rAAV2 were produced by PEI-mediated triple transfection. After three days, viral 
particles were released from the cells by three freeze-thaw cycles and 1 ml of the clarified super-
natant was incubated with PKD2-BP (Figure 31A). With 41.5 % a huge amount of rAAV2 vector 
genomes were found in the supernatant. For the elution fraction a comparable yield of 21.1 % of 
the initially used vector genomes was achieved as seen before for the rAAV2 purification from 
adherent HEK-293 cells (Figure 30A). Even though the yield was relatively low, it served as a good 
starting point for further optimizations.  
In order to exclude that the chosen column material has a decisive influence on the yield, a com-
mercial column material was additionally tested for the immobilization of PKD2. The chosen 
AminoLink™ Plus Coupling Resin (Thermo Scientific) is an aldehyde-activated beaded agarose, 
where proteins can be covalently attached through primary amines. As recommended by the man-
ufacturer, 300 µg of PKD2 were coupled to 200 µl (400 µL slurry) of the AminoLink (AL) resin.172 
As before, 1 ml of the same clarified cell lysate was incubated with the AL resin, leaving all sub-
sequent steps unchanged. As can be seen in Figure 31B the yield in the elution fraction was com-
parable to those of the PKD2-BP resin and by this the AL-material showed no advantage over the 
much cheaper cellulose material. On the contrary, the agarose beads were difficult to handle in the 
intended batch process and, moreover, the amount of PKD used was disproportionately much 
higher (300 µg for AL instead of 30 µg for BP). 
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Figure 31: Purification of rAAV2 by PKD2 affinity chromatography from HEK-F suspension cells. (A) 
Distribution of DNase I resistant particles in the respective fractions after purification with PKD2-BP. 
(B) Distribution of DNase I resistant particles in the respective fractions after purification with PKD2-
AL. Percentages were calculated by setting the genomic titer of starting material as 100 %. Genomic titer 
was quantified in crude cell extract after three freeze-thaw cycles for start value from 1 ml culture, and 
for supernatant value after incubation with PKD2-BP by qPCR. For each column, standard deviation was 
calculated between two technical replicates. 
 
Since no improvement of the yield was achieved by changing the carrier material, variants of the 
TF medium used were tested in cooperation with Xell AG for the high-titer production of rAAV2 
and for the improvement of affinity purification. For this reason, HEK-F cells were adapted for 
three passages in the respective medium variants and rAAV2 was produced by PEI-mediated triple 
transfection in a total volume of 10 ml as before. As demonstrated in Figure 32A, the genomic titer, 
determined by qPCR from the cell lysate after three-freeze thaw cycles, varied between the different 
media with a factor of about 10 for the worst variant V5 and the two best variants V1 and TF. As 
the yield was low for variant 3 to 5 no purification was attempted. For variant V1, V2 and TF the 
POROS-AAVX material was chosen for purification to investigate whether affinity chromatog-
raphy with PKD2 yields similar results with the selected suspension medium to those obtained with 
a commercial variant. As presented in Figure 32B, only V2 resulted in a comparable yield with 
23.8 % of total vg in the elution fraction. For TF and V3 medium, with 11.6 % and 11.9 %, total 
vg, respectively in the elution fraction the yield was even lower as with PKD2-based purification.  
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Figure 32: Analysis of different HEK-TF medium variants for rAAV2 production. (A) qPCR analysis of 
rAAV2 production in HEK-F suspension cells in HEK-TF medium and variant 1 to variant 5 in cleared 
crude cell extract after three freeze-thaw cycles. rAAV2 was produced by PEI-mediated triple transfection 
in a total volume of 10 ml. (B) Purification of rAAV2 from HEK-F suspension cell production in HEK-TF 
medium and the medium variant V1 and V2 from the cell pellet after freeze-thaw of a 10 ml production 
with POROS AAVX. 
 
Since the yield for rAAV produced in adherent as well as suspension cells is still low, further opti-
mizations need to be made here. However, the results showed that a cellulose-based column mate-
rial had advantages over an agarose-based material in the planned batch process. The yield achieved 
is comparable to the commercial POROS AAVX. Further optimization in the field of cell disruption 
to avoid flocculation and to improve elution conditions must be considered as future steps. 
As the affinity chromatography in general was successfully implemented for AAV serotype 2, 
Monja Leppin transferred the conditions to the other serotypes commonly used in our lab during 
her master thesis. Combinations of the PKD domains 1 to 5 with AAV serotype 6 and 9 with sub-
sequent elution and qPCR analysis revealed a high affinity of rAAV6 to PKD3 and for rAAV9 
towards PKD2 and PKD5. SDS PAGE analysis showed the high purity of the vector preparations. 
This gives rise to the assumption that a transfer of the method will be possible for other AAV 
serotypes and needs to be evaluated in the future. 
5.6. Extension of the existing plasmid system for the production of mo-
saic rAAV 
Detailed studies on the modifiability of the rAAV2 capsid with regard to its stability and plasticity 
were carried out in this working group.  
Results for this topic were summarized in a manuscript with the title ' rAAV engineering for capsid-
protein enzyme insertions and mosaicism reveals resilience to mutational, structural and thermal 
perturbations ' and submitted to the International Journal of Molecular Sciences. Data presented in 
the manuscript are the result of a collaborative effort. Only the results generated in this work are 
summarized here and the original manuscript is included in the appendix.  
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In this work, rAAV production was primarily conducted by triple transfection of HEK-293 cells 
with the so-called Helper-free plasmid system. Here, rep and cap genes are provided in trans on a 
RepCap plasmid whereas the packaged transgene is provided between the ITRs on the ITR plasmid. 
Required helper functions are delivered by a pHelper plasmid. In the beginning of this thesis, the 
plasmids used in this work were created during an iGEM competition.173 In the context of iGEM 
the BioBrick RFC[10] based cloning strategy was introduced into the plasmids. However, there 
was the issue that as soon as a part within the plasmid was to be replaced, it had to be reassembled 
from the individual components from the beginning. The ITR sequences are very prone to muta-
tions during plasmid propagation in E. coli and frequent cloning should be avoided. Thus, a new 
ITR plasmid (pZMB0522_ITR_EXS_CMV_mVenus_hGHpA) was constructed. In this plasmid 
the ITR sequences were part of a pUC19-based backbone where EcoRI, XbaI as prefix and SpeI as 
suffix sites were integrated by hybridized oligonucleotides. As before, this plasmid can be modu-
larly assembled using biobricks but without the need for cloning of the ITRs. rAAV2 produced 
with this ITR plasmid showed the same characteristics regarding rAAV yield and quality as a com-
mercial plasmid (pAAV-RC, GenBank: AF369963.1). 
For the RepCap plasmid (pZMB0216_Rep_VP123_453_587wt_ p5tataless) unique restriction sites 
exist, allowing for easy modification of the loop region 453 and 587. Integration of DNA sequences 
into these loop regions results in the expression of the corresponding amino acids in all VP proteins 
which implies a total of 60 modifications on the virus surface. The iGEM plasmid system also 
allowed for the fusion of proteins to the VP2 N-terminus and by this generation of mosaic viruses.58 
In this approach the start codon of VP2 was mutated in the RepCap plasmid 
(pZMB0600_Rep_VP13_453_587wt_p5tataless) and a fourth plasmid provides in trans modified 
VP2 and VP3. VP3 is always a part of the VP2 gene since both are encoded by the same mRNA 
and are differently expressed only by a leaky scanning mechanism at the VP2 start.174 In N-terminal 
fusion, the expression of VP3 is unproblematic, since VP3 only has the same C-terminus and not 
the same N-terminus. In case sequences are to be inserted into the loop regions, the expression of 
VP3 must be suppressed to ensure the presentation of only five modified VP2 proteins as the loop 
regions lies within the coding sequence of VP2 and VP3. In order to ensure solely VP2 expression, 
in a first step the VP3 start codon ATG was mutated towards ATC changing the amino acid methi-
onine to isoleucine as it also contains a hydrophobic side chain. The general cloning procedure is 
shown in Figure 33. Two PCR reactions were performed on plasmid 
pZMB0160_CMV_VP2/3_HSPGko to generate two fragments with overlapping ends containing 
the nucleotide change. In a third PCR, these fragments were combined and amplified with NgoMIV 
for and SalI rev primer. The resulting fragment was digested with NgoMIV and SalI and religated 
into the originating pZMB0160 vector which was stored as pZMB0297_CMV_VP2_HSPGko and 
nucleotide exchange was confirmed by sanger sequencing. Mutating the VP3 start codon was pub-
lished before,175 but no western blot was shown, suggesting that a maintained expression of VP3 
might have been present. 
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Figure 33: Cloning strategy to introduce a single point mutation into the VP3 coding sequence. Two PCR 
reactions were conducted with oligonucleotides NgoMIV for and Met-> Ile rev or rather Met->Ile for and 
Sal1 rev on plasmid pZMB0160_CMV_VP2/3_HSPGko. These fragments were fused by their complemen-
tary sequences on the 3' in a subsequent PCR reaction. This PCR product was digested with NgoMIV and 
SalI and introduced in the likewise opened originating vector, resulting in plasmid 
pZMB0297_CMV_VP2_HSPGko. Nucleotide exchange was confirmed by sanger sequencing. 
 
To examine if the VP3 protein expression was eliminated by the nucleotide exchange in the VP3 
start codon a western blot analysis was performed. 3.5 ml of HEK-F cells with a cell density of 
3∙106 ml-1 were transfected with the CMV_VP2/VP3 or the CMV_VP2 plasmid by PEI-mediated 
transfection. After three days, cells were pelleted, resuspended in lysis buffer and analyzed by SDS 
PAGE and subsequent Western blot analysis. Expression of VP2 and VP3 was still observed for 
both approaches (Figure 34A), indicating, that the leaky scanning mechanism is still active. When 
analyzing the DNA sequence (Figure 34B), it becomes clear that only 24 bp after the first start 
codon another start codon follows, which is in the correct reading frame and thus a slightly short-
ened VP3 variant is created (59.39 kDa instead of 60.045 kDa). 
. 
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Figure 34: Analysis of VP3 protein expression. (A) Analysis of cap protein expression after transient 
transfection of HEK-F cells by western blot analysis of crude cell lysates. In lane 1, untransfected HEK-
F cell lysate was applied as a control. In lane 2, the VP2/VP3 expression from plasmid CMV_VP23, and 
in lane 3 the expression from plasmid with VP3 start codon removal CMV_VP2 was applied and VP pro-
teins were detected by B1 antibody. (B) View of the DNA sequence at the beginning of VP3 coding se-
quence. Expression of VP3 after removal of the start codon can be explained with a second start codon, 
marked with a red box, 24 bp downstream of the original start codon. 
 
In order to prevent leaky scanning, a strong Kozak consensus sequence (GCC AAC) upstream of 
the VP2 start codon was introduced. Leaky scanning is based in ribosomes which bypasses the 
initial start codon because of weak a Kozak sequence and by this continue scanning until the next 
AUG.176 For this reason, two oligonucleotides were designed introducing the Kozak sequence in a 
PCR reaction as an overhang into the amplified fragment, which was then recloned by digestion of 
the PCR product and the plasmid CMV-VP2 by XbaI and NgoMIV. As before this plasmid was 
used for expression of VP2 in HEK-F cells, and the cell lysate was analyzed by western blot. Fi-
nally, only the expression of VP2 was detected (Figure 35A). A scheme of the final plasmid 
CMV_Kozak_VP2_453_587(ΔVP3) is given in Figure 35B. 
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Figure 35: Analysis of VP2/VP3 expression from plasmid CMV_Kozak_VP2_453_587 (ΔVP3). (A) West-
ern Blot analysis of protein expression in HEK F cells after transient transfection. The expected molecular 
weight for VP2 is 66.6 kDa. Western Blot was performed by Rebecca Feiner (B) Scheme of the final plas-
mid. From the plasmid DNA a mRNA (meandering line) is transcribed which contains the modified codon 
AUC instead of AUG. The combination of strong Kozak sequence and mutated VP3 start codon prevents 
VP3 protein expression. 
 
In the following this plasmid formed the basis for a mosaic virus with the stabilized β-lactamase 
variant 14FM and Julian Teschner was able to show that rAAV2-VP2_587_bla was produced with 
comparable titers to those of wild-type preparations. In a nitrocefin enzyme assay the number of 
active ß-lactamases was calculated to be 5.6 which was in good agreement to the expected number 
of modified VP2 proteins, as five of the 60 capsid-forming proteins should be VP2. 
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6. Conclusion and Outlook 
AAV cancer gene therapy offers the potential to overcome the lack of specificity of conventional 
non-invasive therapies. Analyzing the targeting efficiency of rAAV in suicide gene therapy, using 
tumor specific promoters and miRNA regulated gene expression, was therefore a focus of this work. 
In order to achieve high titer rAAV preparations for this project, in the beginning great effort was 
put in the optimization of the rAAV manufacturing process. To facilitate rAAV production, the 
HEK-293-KARE1 cell line with stably integrated adenoviral elements was generated which allows 
for the reduction of plasmid DNA necessary during production and thus offers a significant time 
and cost advantage. For further optimization, adaptation of this cell line to suspension cultivation 
would be advisable as it potentially allows for up-scaling in of the production process in the future. 
In this context, upscaling experiments were performed with the commercial 293-F suspension cell 
line, and rAAV production was analyzed under varying cultivation conditions in order to optimize 
the process conditions. A standard suspension-based production protocol was established but cell-
specific productivity was still lower compared to the standard adherent cell culture protocol indi-
cating more room for improvement in the future. 
Increasing the quality of AAV preparations was a fundamental question of this work, which was 
answered by a novel affinity chromatography procedure based on the natural cellular receptor 
AAVR. Covalent coupling of single PKD domains to cellulose allowed for rAAV purification from 
raw cell extract. Samples showed high purity and comparable potency as vectors purified with the 
standard ultracentrifugation. Direct capturing of rAAVs from crude cell extract allows for reduced 
costs and processing times of only few hours instead of more than one day. Nevertheless, a more 
detailed characterization of storage conditions, the amount of PKD required and the recyclability 
of the column material is still necessary. Also, an expansion of the PKD affinity chromatography 
to other AAV serotypes is conceivable for the future. 
Next to optimization of the rAAV manufacturing process, analysis of HSV-tk gene expression by 
tumor-specific promoters in four cancerous and two normal cell lines was the focus of this work. 
As low promoter activities were detected previously, Kozak sequences were introduced in front of 
the HSV-tk start codons and for all promoters, activity was detected by a cytotoxicity assay upon 
GCV treatment. Overall, non-tumor specific CMV promoter led to the highest decline in cell via-
bility in cancer and non-cancer cell lines. However, by introducing a second layer of tumor speci-
ficity by the introduction of the let-7 miRNA target sequences in the 3'-UTR of the CMV- and 
survivin promoter driven expression cassette, at least for the CMV promoter-driven gene expres-
sion a high protective effect on the cell viability was achieved. Therefore, a combination of a strong 
viral promoter in combination with de-targeting by miRNA, appears to be the preferable strategy 
to protect healthy cells from damage in suicide gene therapy.  
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7. Materials 
7.1. Technical equipment 
Table 8: Technical equipment used during this work. 
Device Supplier 
Äkta start chromatography system GE Healthcare Life Science 
Analytical camera system Fusion Fx7 Vilber 
Atomic force microscope Bruker 
Autoclave FVS 2 Integra Bioscience 
Autoclave GE6612 Getinge 
Automated cell counter LUNA Logos Biosystems 
BD FACSCalibur Becton Dickinson 
Blue light table Serva Electrophoresis GmbH 
Camera EOS 600D Canon 
Camera system FusionFx7 Vilber 
Centrifuge Pico17 Thermo Fisher Scientific 
Chemical duty pump WP6122050 Merck Millipore 
Clean bench LaminAir HB 2448 Heraeus Instruments 
Clean bench LaminAir Model 1.2 Holten 
CO2 Incubator CB E6 Binder GmbH 
Fluorescence microscope DMI 6000 SD Leica Microsystems 
Freezer (-150 °C) MDF2156VAN Panasonic 
Freezer (-20 °C) Liebherr 
Freezer (-80 °C) KM-DU 73Y1 Panasonic 
French press SLM AMINCO SLM Instruments 
French Pressure Cell (FA-032 (max 40’000 PSI, 35 
ml max)) 
Thermo Fisher Scientific 
Fridge (4 °C) Bosch 
Ice machine UBE 50-35 Ziegra Eismaschinen 
Incubator B 6120 Heraeus 
Light micsoscope Axiovert 25 Zeiss 
Magnetic stirrer RCT Ikamag 
Megafuge 1.0 Heraeus Instruments 
Microplate Spectrophotometer PowerWave HT BioTek 
Microwave HF 22043 Siemens 
Milli-Q water system Millipore 
Mixing Block MB-102 (with orbital shaking 
function) 
BIOER 
Orbital shaker ES-X Kühner 
pH electrode InLab Expert Pt1000 Mettler Toledo 
pH meter Seven compact S220 Mettler Toledo 
Pipette aid Pipetboy Comfort Integra 
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Device Supplier 
Pipette Research plus Eppendorf 
Power supply EV231 Consort 
Precision scale CP 224 S Sartorius 
Precision scale XA205 DualRange Mettler Toledo 
Real time PCR system Lightcycler 480 II Roche 
Refrigerated centrifuge Multifuge X1R Thermo Scientific 
Refrigerated centrifuge RC5C (SS-34 and GS-3 
rotors) 
Sorvall Instruments 
Refrigerated centrifuge5424R (FA-45-24-11 rotor) Eppendorf 
Rocking shaker Duo Max 1030 Star Lab 
Scale BP 2100 S Sartorius 
SDS PAGE chamber SE260 Hoefer 
SDS PAGE gel caster Hoefer 
Semi-dry blotter (V20-SDB) Scie Plas 
Shaking incubator SI-600 R (deflection: 40 mm) Lab. Companion 
Shaking platform Sky Line ELMI 
Spectrophotometer NanoDrop 2000c UV/Vis Thermo Fisher Scientific 
Thermoblock TB1 Biometra 
Thermocycler Peqstar 96x Universal gradient Peqlab 
Tube Roller N2400-7010 Sartorius 
Ultra centrifuge Ultra Pro 80 (T-880 rotor) Sorvall 
Vacuum Manifold QIAvac 24 Plus Qiagen 
Vortex Genie 2 Scientific Instruments 
Water bath GFL 
White light table LED, (LP-400N) Universal Electronics Industries 
 
7.2. Software and web services 
Table 9: List of Software and web services. 
Software Developer Version number 
Cell Quest BD Biosciences 8-1996 
Flowing Software 
Perttu Terho, Turku Centre for 
Biotechnology – University of Turku, 
Finland 
2.5.1 
FlowJo  BD Biosciences V10 
FUSION-CAPT Vilber - 
GeneArt online tool Thermo Fisher Scientific Inc. - 
Geneious Biomatters Ltd. 9.1.8 
Gwyddion David Nečas and Petr Klapetek 2.48 
KC4 BioTek 3.3 
LightCycler 480 Software Roche 1.5 
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Software Developer Version number 
Mendeley Desktop Mendeley Ltd. 1.19.4 
NanoDrop 2000/2000c 
Operating Software 
Thermo Fisher Scientific Inc. 1.5 
Office 2016 Microsoft  
OriginPro 2019 OriginLab Corporation 9.6.0.172 
paint.net dotPDN LLC 4.2.4 
Tm Calculator New England Biolabs 1.9.13 
PyMOL Schrödinger 2.3 
Unicorn start GE Healthcare Life Science 1.0 
 
7.3. E. coli strains 
Table 10: E. coli strains used during this work. 
Strain Source 
BL21(DE3) AG Fermentationstechnik 
DH5α AG Fermentationstechnik 
TOP10 (DH10β) Invitrogen 
 
For plasmid production and cloning work, E. coli DH5α or E. coli TOP10 were used, whereas for 
recombinant protein expression E. coli BL21(DE3) was used. 
7.4. Eukaryotic cell lines 
Table 11: Eukaryotic cell lines used during this work. 
Name Source 
HEK-293 DSMZ 
FreeStyle 293-F Thermo Fisher Scientific 
HT-1080 DSMZ 
A431 DSMZ 
MDA-MB231 DSMZ 
MDA-MB453 DSMZ 
HDFa Thermo Fisher Scientific 
M1FS Herz-und Diabeteszentrum NRW 
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7.5. Reagents 
7.5.1. Chemicals 
Table 12: Chemicals used during this work. 
Name Supplier 
ABTS AppliChem 
Acetic acide Chemical storage University Bielefeld 
Acrylamid-Bisacrylamid 30 % solution (29:1) AppliChem 
Agar-Agar Sigma Aldrich 
Agarose AppliChem 
Ammonium sulphate Sigma Aldrich 
APS AppliChem 
ATP NEB 
Brilliant Blue R-250 Sigma Aldrich 
Bromphenol blue AppliChem 
BSA Sigma Aldrich 
CaCl2 Merck 
CHAPS Carl Roth 
Citric acid Carl Roth 
Divinyl sulfone Sigma Aldrich 
DMSO Carl Roth 
DTT Thermo Scientific 
EDTA Carl Roth 
Ethanol (absolute) VWR 
Ethanol (denatured) Chemical storage University Bielefeld 
FCS (LOT number: BCBT0730) Sigma Aldrich 
Formaldehyd 37 % (v/v) Chemical storage University Bielefeld 
Glutamine solution (cell culture) Sigma Aldrich 
Glycerol Carl Roth 
Glycine Carl Roth 
H3PO4 Chemical storage University Bielefeld 
HBSS buffer Sigma Aldrich 
HCl VWR 
HEPES Carl Roth 
HiTrap Protein A HP GE Healthcare 
Imidazole Sigma Aldrich 
IPTG Carl Roth 
KCl VWR 
KH2PO4 Fluka 
MgCl2 Carl Roth 
MgSO4 Fluka 
Na2CO3 Carl Roth 
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Name Supplier 
Na2S2O3∙5 H2O Carl Roth 
NaCl VWR 
NaCNBH3 Sigma Aldrich 
NaH2PO4 VWR 
NaOH VWR 
Non-fat milk powder AppliChem 
OptiPrep Progen 
PEImax Polysciences, Inc 
Phenolred Sigma Aldrich 
POROS CaptureSelect AAVX Affinity Resin Thermo Fisher Scientific 
Protino Ni-NTA Agarose Macherey-Nagel 
Roti-GelStain Carl Roth 
SDS Carl Roth 
Silica 60 (0.04 – 0.063 mm) Merck Millipore 
Sodium citrate Carl Roth 
Sucrose Sigma Aldrich 
TEMED Sigma Aldrich 
Tris Carl Roth 
Tris-HCl Carl Roth 
Trypan blue solution Sigma Aldrich 
Trypsin/EDTA solution Sigma Aldrich 
Tryptone/Peptone Carl Roth 
Tween 20 Carl Roth 
Xylen cyanol FF Sigma Aldrich 
Yeast extract Carl Roth 
 
7.5.2. Buffers and Solutions 
Table 13: List of Buffers and Solutions. 
Name Composition 
ABTS buffer with ABTS 
3.25 mM BH2NaO4, 
40 mM citric acid, 
60 mM Na2HPO4, 
pH 4.5, 
1 g∙l-1 ABTS (added directly before use) 
Agarose gel solution with Roti-GelStain 
1 % (w/v) Agarose, 
0.005 % (v/v) Roti-GelStain, 
in TAE buffer 
APS solution (1.5 %) 1.5 % (w/v) APS 
Blocking buffer (rAAV2 capsid ELISA) 
0.8 % (w/v) BSA, 
in PBS 
CaCl2 solution (100 mM) 100 mM CaCl2 
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Name Composition 
CaCl2 solution (85 mM) with glycerol 85 mM CaCl2, 
15 % (v/v) Glycerol 
CaCl2 solution (for HEK-293 transfection) 0.3 M CaCl2 
CHAPS stock solution 10 % (w/v) CHAPS (make directly before use) 
Coomassie staining solution 
0.1 % (w/v) Brilliant Blue R-250, 
40 % (v/v) Ethanol, 
10 % (v/v) Acetic acid 
Coupling buffer pH 10 
0.1 M Sodium citrate, 
0.05 M Sodium carbonate, 
pH 10 
Coupling buffer pH 7.2 
0.1 M Sodium phosphate 
0.15 M NaCl, 
pH 7.2 
Cyanoborohydride solution 5 M NaCNBH3 in 1M NaOH 
Destaining solution (for Coomassie) 10 % (v/v) Acetic acid 
DNA loading buffer (10×) 
10 mM Tris-HCl, 
50 % (v/v) Glycerol, 
0.2 % (w/v) Bromphenol blue, 
0.2 % (w/v) Xylen cyanol FF, 
pH 7.5 
DNaseI buffer (10×) 
100 mM Tris-HCl, 
25 mM MgCl2, 
5 mM CaCl2, 
pH 7.6 
DVS buffer 
10 % (v/v) Divinyl sulfone, 
0.1 M Na2CO3, 
pH 11.0 
Elution buffer (for POROS) 
100 mM Sodium citrate 
pH 2.5 
HBS buffer (2×) 
50 mM HEPES, 
1.5 mM NaH2PO4, 
280 mM NaCl, 
pH 7.05 
IMAC elution buffer 
50 mM NaH2PO4, 
300 mM NaCl, 
250 mM Imidazole, 
pH 8.0 
IMAC equilibration buffer 
50 mM NaH2PO4, 
300 mM NaCl, 
10 mM Imidazole, 
pH 8.0 
IMAC wash buffer 
50 mM NaH2PO4, 
300 mM NaCl, 
20 mM Imidazole, 
pH 8.0 
IPTG stock solution 1 M IPTG 
Lysis buffer 
50 mM Tris, 
150 mM NaCl, 
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Name Composition 
2 mM MgCl2, 
pH 7.5 – 8.0 
MgCl2 solution (100 mM) 100 mM MgCl2 
Neutralization buffer (for POROS) 
1 M Tris, 
pH 9.0 
PBS buffer (1×) 
500 mM NaCl, 
100 mM KCl, 
10 mM Na2HPO4, 
10 mM KH2PO4, 
pH 7.5 
PBS buffer (10×) 
5 M NaCl, 
1 M KCl, 
100 mM Na2HPO4, 
100 mM KH2PO4, 
pH 7.5 
PBS-MK (10×) 
10 mM MgCl2, 
25 mM KCl, 
in 10×PBS 
PBS-MK + 2 M NaCl (1×) 
2 M NaCl, 
in PBS-MK 
PBST 
0.05 % (v/v) Tween-20, 
in PBS 
PEImax stock solution 1 g∙l-1 PEImax 
PKD2 elution buffer 
2.5 M MgCl2,  
50 mM Tris, 
pH 7.0 
Protein A elution buffer 
100 mM Citric acid, 
pH 3.0 
Protein A equilibration buffer 
20 mM NaH2PO4, 
pH 7.0 
Protein A neutralization buffer 
1 M Tris-HCl, 
pH 9.0 
SDS loading buffer (5×) 
0.05 % (w/v) Bromophenol blue, 
20 % (v/v) Glycerol, 
10 % (w/v) SDS, 
0.2 M Tris-HCl, 
250 mM DTT 
(DTT is added fresh prior to use) 
SDS solution (10 %) 10 % (w/v) SDS 
SDS-running buffer (1×) 
200 mM Glycerol, 
25 mM Tris, 
0.1 % (w/v) SDS 
Semi-dry transfer buffer 
25 mM Tris-HCl, 
192 mM Glycine, 
20 % (v/v) Ethanol, 
pH 8.2 
Separating gel buffer 
1.5 M Tris, 
pH 8.8 
Stacking gel buffer 500 mM Tris, 
7 Materials 
66 
 
Name Composition 
pH 6.8 
TAE buffer (1×) 
40 mM Tris, 
1 mM EDTA, 
20 mM Acetic acid, 
pH 8.0 
TBS blocking buffer 
10 % (w/v) Non-fat milk powder, 
in TBS buffer 
TBS buffer 
50 mM Tris-HCl, 
150 mM NaCl 
pH 7.6 
TBST buffer 
0.05 % (v/v) Tween 20, 
in TBS buffer 
Wash buffer (rAAV2 capsid ELISA) 
0.8 % (w/v) BSA 
in PBST 
 
7.5.3. Antibiotics 
Table 14:Antibiotics used during this work. 
Antibiotics Working concentration Stock concentration Supplier 
Ampicillin sodium salt 100 µg ml-1 1000×in water Carl Roth 
Blasticidin S hydrochloride 5 µg ml-1 1000×in water Carl Roth 
Chloramphenicol 
20 µg ml-1 1000×in absolute 
ethanol 
Carl Roth 
Kanamycin 50 µg ml-1 1000×in water Carl Roth 
Penicillin/Streptomycin 
solution  
1 % 100 % 
Sigma Aldrich 
 
7.5.4. Media 
7.5.4.1. Bacterial cell culture media 
Table 15: Bacterial cell culture media used during this work. 
Medium Composition 
LB medium (Lennox) 
5 g yeast extract  
10 g tryptone  
5 g NaCl  
LB agar plates LB, 
1.5 % agar agar 
SOC  5 g yeast extract, 
20 g tryptone, 
0.6 g NaCl, 
0.2 g KCl, 
10 mL 1 M MgCl2, 
10 mL 1 M MgSO4, 
20 ml 1 M Glucose  
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7.5.4.2. Mammalian cell culture media 
Table 16: Mammalian cell culture media used during this work. 
Medium Composition 
DMEM  
DMEM (Sigma Aldrich), 
10 % FCS, 
1 % P/S 
Freestyle F17 Expression Medium Freestyle F17 (Thermo Fisher Scientific) 
8 mM Glutamine 
HEK-TF 
HEK-TF (Xell AG) 
8 mM Glutamine 
HEK-GM 
HEK-TF (Xell AG) 
8 mM Glutamine 
HEK-FS 
HEK-TF (Xell AG) 
8 mM Glutamine 
RPMI 1640 RPMI 1640 (Thermo Fisher Scientific) 
10 % FCS, 
1 % P/S 
 
7.5.5. Kits 
Table 17: Kits used during this work. 
Kit Supplier 
GoTaq qPCR Master Mix Promega 
NucleoSpin Gel and PCR Clean-up Machery-Nagel 
NucleoSpin Plasmid Macherey-Nagel 
NucleoBond Xtra Midi Macherey-Nagel 
TOPO-TA cloning kit Thermo Fisher Scientific 
 
7.5.6. Antibodies 
Table 18: Antibodies used during this work. 
Antibody Dilution Supplier 
Tetra-His Antibody, BSA-free, mouse anti-(H)4 1:2000 Qiagen  
anti-AAV VP1/VP2/VP3 mouse monoclonal, B1 1:100 Progen  
anti-AAV2 (intact particle) mouse monoclonal, A20 1:250  Progen 
Goat anti-Mouse IgG (H+L) 
Secondary Antibody, HRP conjugate 
1:5000 Thermo Fisher Scientific 
Anti-Human IgG1 (gamma 1 chain specific), mouse 
antibody, HRP 
1:2500 Acris-antibodies 
 
7.5.7. Enzymes 
Table 19: Enzymes used during this work. 
Enzyme Supplier 
Antarctic Phosphatase NEB 
Benzonase nuclease Sigma Aldrich 
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Enzyme Supplier 
DNaseI NEB 
DNaseI AppliChem 
Phusion High-Fidelity DNA Polymerase NEB 
Taq DNA Polymerase NEB 
T4 DNA Ligase Thermo Fisher Scientific 
T4 Polynucleotide Kinase NEB 
Proteinase K Sigma Aldrich 
Restriction enzymes NEB 
 
7.5.8. Protein and DNA standards 
 
Figure 36: Protein and DNA ladder used during this work. (Color Prestained Protein Standard, Broad 
Range (11-245 kDa), NEB.177 (B) GeneRuler 1 kb DNA-Ladder, Thermo Scientific.178 
 
7.5.9. Oligonucleotides 
Oligonucleotides were purchased at Sigma Aldrich and delivered dry in desalt purity. Oligonucle-
otide names were chosen to represent the name of a vector and if appropriate restriction sites which 
are in the sequence. 
Table 20: List of oligonucleotides used during this work. 
Name Sequence (5'→3') 
SEQ-pHelper-1-neu GTCGCAACCA GGAACAGCTC 
SEQ-pHelper-2 GTAGCTGCCT TCCCAAAAAG 
SEQ-pHelper-3-neu GGTACTTGTC CATCAACGCG 
SEQ-pHelper-4 GTTTCGCGCT GCTCCTCTTC 
SEQ-pHelper-5 ATATCGCCTC GCTCGACGAA 
A B
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Name Sequence (5'→3') 
SEQ-pHelper-6 CGACTGCGTT TACTTATTTC 
SEQ-pHelper-7 GTTGAAACTC ACTCCGGG 
SEQ-pHelper-8 GCAACATCTC CTTCGCCC 
SEQ-pHelper-9 GACTTGCGGC TGGAGCTG 
SEQ-pHelper-10 CTGGTAAGGC TGACTGTTAT 
SEQ-pHelper-11 TATCGCCGCC CATGCAACAA 
SEQ-pHelper-12 TCCCGTGTGT GACTCGCAG 
SEQ-pHelper-13 GTCATTGTTC CAGTCCCG 
SEQ-pHelper-14 ATCACTGATG AGCGTTTGG 
SEQ-pHelper-15 GTCTTGCATG ACGGGGAGG 
SEQ-pHelper-16 CATCGGCATA GTATATCGGC 
SEQ-pHelper-17 GGCCAGGAA CCGTAAAAAG 
SEQ-pHelper-18 GCAAGCAGC AGATTACGC 
SEQ-pHelper-19 CAAGGCGAGT TACATGATCC 
SEQ-pHelper-20 GCCACCTAAA TTGTAAGCGT 
Bsd-for AAGCCTTTGT CTCAAGAAGA ATCC 
Bsd-rev TTAGCCCTCC CACACATAAC CA 
Ad5-for CAACTCCATG CTTAACAGTC CCCA 
Ad5-rev TCCAGTGCTG CAACCCTGTG TATC 
NgoMIV for GAAATTACTA GATGGCCGGC GC 
Met->Ile for CTAATACGAT CGCTACAGGC AGTGGC 
Met->Ile rev CCTGTAGCGA TCGTATTAGT TCCCAGAC 
SalI rev CGGCCTGAGA AAACTGAAGT CG 
AAVRko CRISPR Target for CACCGTATAG GTGTAACTAC GTCAC 
AAVRko CRISPR Target rev AAACGTGACG TAGTTACACC TATAC 
Seq-AAVRko-for GACACACTCC TCCAATTCCA TG 
Seq-AAVRko-rev GACTGTAACC ACATCAATCA ACTG 
XbaI-CMV-for CTTCTAGAGC GATGTACGGG 
CMV_Kozak_NgoMIV-rev ATAATGCCGG CCATGGTGGC CTAGTAATTT CGATAAGCCA 
GTAAG 
mGMK-TK30_RFC10_for_new TGGAATTCTT CTAGATGGCC GGCGCAGGAC CTA 
mGMK-TK30_2A_rev CCTCTGCCCT CTCCACTGCC ACCGGTGTTA GCCTCCCCCA T 
T2A_eGFP_for_ new GGCAGTGGAG AGGGCAGAGG AAGTCTGCTA ACATGCGGTG 
ACGTCGAGGA GAATCCTGGC CCAATGGTGT CCAAGGGCGA 
GG 
eGFP_RFC10_rev_new GGCATGGACG AGCTGTACAA GTAATACTAG TAGCGGCCGC 
TGCAGAAA 
Pr-for_CMV_MluI CCAGATATAC GCGTTGACAT TG 
Pr-rev_Kozak_CMV GGTGGCCTAG TAATTTCGAT AAGCCAGTAA GC 
Pr-for_CMV_Kozak GAAATTACTA GGCCACCATG GCCGGCGCAG G 
Pr-rev_TK30_SalI CCTTGTAGGT CGACATCTAG CAC 
COX-2-MfeI_Kozak-AvrII_for AATTGTCATA CTAGAGCCAC CATGGCCGGC GCAGGAC 
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Name Sequence (5'→3') 
COX-2-MfeI_Kozak-AvrII_rev CTAGGTCCTG CGCCGGCCAT GGTGGCTCTA GTATGAC 
Pr-for_Sur_MluI CTGCACGCGT TCTTTGAAA 
Pr-rev_Sur_Kozak GGTGGCCTAG TAGCCGCCAC CTCTG 
Pr-for_Sur_Kozak GCGGCTACTA GGCCACCATG GCCGGCGCAGG 
Pr-rev_TK30_SalI CCTTGTAGGT CGACATCTAG CAC 
Pr-for_MluI_CXCR-4 CACAGAGAGA CGCGTTCCTA G 
Pr-rev_CXCR-4_Kozak GGTGGCCTAG TAGACAAAGC AGGTTGAAAC TG 
Pr-for_CXCR-4_Kozak CTTTGTCTAC TAGGCCACCA TGGCCGGCGC AGG 
Pr-rev_TK30_SalI CCTTGTAGGT CGACATCTAG CAC 
eGFP_ENX_for AAAGAATTCG CGGCCCTTCT AGATGGTGTC CAAGGGCGAG 
eGFP_let-7a_SNP_rev AAACTGCAGC GGCCGCTACT AGTATGAGGT AGTAGGTTGT 
ATAGTTTACT TGTACAGCTC GTCCATGCC 
NdeI-PKD2-for AAAAACATAT GAATCGGCCC CCCATTGCTAT TG 
BamHI-PKD2-rev TTTTTGGTAC CACCGCCTGA ACCACCACCA GAGCCACCAC 
CGGATCCGGG GTAATCCACA GCTTTGTTCA C 
BamHI-linker-MBP-for AAAAAGGATC CGGTGGTGGC TCTGGTGGTG GTTCAGGCGG 
TAAAATCGAA GAAGGTAAAC TGG 
KpnI-linker-MBP-rev TTTTTGGTAC CACCGCTACC GCCACCTGAA CCACCACCGC 
TACCAGTCTG CGCGTCTTTC AG 
KpnI-His6-tag-XhoI-for ACCCATCATC ACCATCATCA TTAACTCGA 
XhoI-His6-tag-KpnI-rev GTTAATGATG ATGGTGATGA TGG 
 
7.5.10. Plasmids 
Table 21:List of generated and used plasmids. 
Number Name Source 
pzMB0088 pHelper Agilent 
pZMB0135 pSB1C3_hGHpA iGEM 
pZMB0216 pSB1C3_001_Rep_VP123_453_587wt_p5tataless JTE 
pZMB0259 pHelperBsd MRA 
pZMB0300 pSpCas9(BB)-2A-GFP (PX458) Addgene 
pZMB0301 pSpCas9(BB)-2A-GFP-AAVRko Exon3-CRISPR-Target (PX458) This work 
pZMB0307 pSB1C3_001_pCMV_Kozak_VP23_453_587wt This work 
pZMB0382 pcDNA5/FRT IgG-SigP-A20scFv-hFc-His JTE 
pZMB0398 pSB1C3_001_eGFP GBI 
pZMB0442 pSB1C3_CMV_mGMK-TK30_T2A_eGFP_hGHpA CCU 
pZMB0443 pSB1C3_COX-2_mGMK-TK30_T2A_eGFP_hGHpA CCU 
pZMB0444 pSB1C3_Suv_mGMK-TK30_T2A_eGFP_hGHpA CCU 
pZMB0474 pSB1C3_CXCR-4_mGMK-TK30_T2A_eGFP_hGHpA CCU 
pZMB0504 Rep2Cap9 RFE 
pZMB0522 pUC19bb_ ITR_EXS_pCMV_mVenus_hGHpolyA PBO 
pZMB0575 pSB1C3_002_RepCap6_VP123_453_587wt_p5tataless RFE 
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Number Name Source 
pZMB0584 pSB1C3_CMV_Kozak_mGMK-TK30_T2A_eGFP_hGHpA This work 
pZMB0585 pSB1C3_COX-2_Kozak_mGMK-TK30_T2A_eGFP_hGHpA This work 
pZMB0586 pSB1C3_Suv_Kozak_mGMK-TK30_T2A_eGFP_hGHpA This work 
pZMB0587 pSB1C3_CXCR-4_Kozak_mGMK-TK30_T2A_eGFP_hGHpA This work 
pZMB0588 pUC19bb_ITR_EXS_CMV_Kozak_mGMK-TK30_T2A_eGFP_hGHpA This work 
pZMB0589 pUC19bb_ITR_EXS_COX-2_Kozak_mGMK-TK30_T2A_eGFP_hGHpA This work 
pZMB0590 pUC19bb_ITR_EXS_Suv_Kozak_mGMK-TK30_T2A_eGFP_hGHpA This work 
pZMB0591 pUC19bb_ITR_EXS_CXCR-4_Kozak_mGMK-
TK30_T2A_eGFP_hGHpA 
This work 
pZMB0616 pet-24b_AAVR_PKD2-MBP-His6 JTE 
pZMB0639 pUC19bb_ ITR_EXS_CMV_Kozak_mGMK-
TK30_T2A_eGFP1xlet7a_hGHpA 
This work 
pZMB0640 pUC19bb_ ITR_EXS_Suv_Kozak_mGMK-
TK30_T2A_eGFP_1xlet7a_hGHpA 
This work 
 
7.6. Consumables  
Table 22: List of cunsumables. 
Name Specification Manufacturer 
Adhesive film for real-time PCR-
Plates 
Ultra-clear (A26979) GeneOn 
Bijou sample containers 7 ml, with screw cap, sterile, PS Sci Labware Limited 
Blotting Paper Thickness 0.35 mm Carl Roth 
Canula needle 21G, 0.6x80 mm B. Braun 
Cell scraper 25 cm Sarstedt 
Centrifugal filter units 
Amicon Ultra-4 100K centrifugal 
filter units 
Merck Millipore 
Cryogenic plastic vessel 2.0 ml Star Lab 
Cryogenic plastic vessel (cell 
culture) 
1.8 ml, Internal thread, silicone 
seal in lid 
Star Lab 
Empty lab column 5 ml (S10131) MoBiTec 
Lightcycler Plate 96-well, white Sarstedt 
LUNA Cell Counting Slide Two chamber slides Logos Biosystems 
MaxiSorp plate 96-well, flat-bottom plate Nunc 
Mica for AFM (50x76 mm, 0.2 mm thick) PLANO 
Multipette Combitips 5 ml Eppendorf 
Multi-well plates 
6-, 12-, 96-well, standard TC for 
adherent cells, flat base, sterile 
Sarstedt 
Nitrocellulose membrane 0.45 micron Thermo Scientific 
Petri dishes 92x16 mm, with ventilation cams Sarstedt 
Petri dishes (cell culture) Diameter 100 mm Sarstedt 
pH test strips MColorpHast, pH 5.0 – 10.0 Merk 
Pipette tips 10 µl, 100 µl, 1000 µl, 5000 µl Star Lab 
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Name Specification Manufacturer 
Pipette tips (cell culture) 
TipOne Filter Tips (10/20 µl, 200 
µl, 1000µl, sterile, graduated) 
Star Lab 
Reaction tube 15 ml, PP Sarstedt 
Reaction tube 50 ml, PP Sarstedt 
Reaction tube 50 ml, plug style caps, 25k×g VWR 
Reaction vessels 0.5 ml, 1.5 ml, 2.0 ml Sarstedt 
Reaction vessels (for PCR) 0.2 ml, flat cap, thin wall Star Lab 
Scalpel blades S123 Hartenstein 
Shaker flask 250 ml, 500 ml,  Sarsted 
Sterile filter 0.2 µm, 0.45 µm, PTFE Sarstedt/Sartorius 
Syringe 1.0 ml, 5 ml, 10 ml, 50 ml B. Braun 
T-flask 25 cm2, 75 cm2, 150 cm2,  Sarstedt 
Tube Spin bioreactors 50 ml TPP 
Ultracentrifuge tubes Open-top, PA, 16x76 mm Science Service 
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8. Methods 
8.1. Microbiology methods 
8.1.1. Cultivation and storage of E. coli cells 
E. coli cells were cultivated using different liquid or solid media supplemented with the appropriate 
antibiotic suitable to the resistance mediated by the respective plasmid for the selective growth. 
Cultures were stored at 4 °C for short-time storage on agar plates and for long-time storage, 1 ml 
of liquid cultures were mixed with 0.5 ml of a sterile glycerol solution and stored at -80 °C. 
8.1.2. Preparation and heat shock transformation of chemical competent 
E. coli cells 
Generation of chemical competent E. coli cells was performed using a standard CaCl2 protocol.179 
For heat shock transformation, 50 µl aliquots of competent cells were mixed with 5 µl of a ligation 
mixture or 1 µl of plasmid DNA and stored on ice for 30 min. After a heat shock for 45 s at 42°C 
and a regeneration for 4 min on ice, 1 ml of SOC medium was added and the cells were cultivated 
in a 1.5 ml plastic reaction vessel at 37 °C and 200 rpm on a shaking incubator. Cultivation time 
depended on the plasmid mediated resistance and was 30 min for ampicillin, and 45 min for chlo-
ramphenicol and kanamycin resistance. 100 µl of the transformation were plated on LB agar plates 
supplemented with the respective antibiotic and cultivated at 37 °C overnight. 
8.2. Molecular biological methods 
8.2.1. Isolation of plasmid DNA 
Plasmid-DNA was isolated from E. coli cells with the 'NucleoSpin Plasmid' kit from Macherey-
Nagel for small scale preparations, primarily in cloning procedures. Here, 4 ml of E. coli overnight 
cultures served as starting material and elution was performed with autoclaved MilliQ water.  
For larger amounts of plasmid DNA, e.g. for transient transfections, the 'NucleoBond Xtra Midi' 
kit from Macherey-Nagel was used. Plasmid DNA was extracted from 200 ml of an overnight 
grown E. coli culture according to the manufacturers protocol and eluted with autoclaved MilliQ 
water and stored at -20 °C. 
8.2.2. Isolation of genomic DNA 
For genomic DNA isolation from mammalian cells, Chelex 100 (Bio-Rad) extraction was applied. 
2.5×106 cells were pelleted in a 1.5 ml plastic reaction tube (1 min 10ʹ000×g) and washed with 
PBS. The pellet was resuspended in 100 µl Chelex suspension (5 % w/v), incubated for 30 min at 
56 °C, vortexed for 10 s and incubated for 8 min at 100 °C. The solution was centrifuged briefly at 
approx. 15,000×g for 2 min and the genomic DNA containing supernatant was transferred to a new 
tube. The DNA was stored at -20°C or was directly used for PCR reactions.  
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8.2.3. Determination of DNA and protein concentrations 
The NanoDrop 2000c UV/Vis spectrophotometer from Thermo Fisher Scientific was used for the 
determination of DNA and protein preparations. For DNA concentration, absorption was measured 
at 260 nm for protein concentrations a wavelength of 280 nm in combination with the molar ex-
tinction coefficient and the molecular weight was used. Calculation of the respective protein con-
centrations was performed on the basis of the Beer-Lambert law: 𝑐 =
𝐴
𝜀 × 𝑙
 with A: absorptivity, ε: 
molar attenuation coefficient and l: optical path length. 
8.2.4. Polymerase chain reaction 
The amplification of DNA fragments for cloning procedures was performed with Phusion High 
fidelity polymerase (NEB). It possesses a 3' → 5' exonuclease activity and by this a lower error rate 
compared to the Taq polymerase (NEB) which was used during this work for detection of DNA 
fragments in the context of genomic DNA integration. 
In the following the optimized composition of the standard protocol for Phusion (Table 23) and 
Taq Polymerase PCR reaction (Table 24) are given. 
Table 23: Composition of a standard Phusion Polymerase PCR reaction. 
Components Volume in µl 
5× GC buffer 10 
10 mM dNTPs 1 
Primer for 2.5 
Primer rev 2.5 
DMSO 1.5 
MgCl2 2 
Phusion Polymerase 0.5 
Plasmid DNA (< 10 ng recommended) variable 
Water To 50 µl 
 
Table 24: Composition of a standard Taq Polymerase PCR reaction. 
Components Volume in µl 
10× Thermopol buffer 2 
10 mM dNTPs 0.5 
Primer for 0.5 
Primer rev 0.5 
Taq Polymerase 0.15 
Genomic DNA 5 (from Chelex DNA extraction) 
Water 16.35 
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The thermocycling conditions were adapted to the annealing temperature of oligonucleotides used, 
and the length of the final PCR product according to the manufacturer's specifications. In subse-
quent gel electrophoresis (8.2.5), the success of DNA amplification was confirmed and in case of 
cloning procedures, the product with the desired size in was excised out and purified from remain-
ing gel by the NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel). 
8.2.5. Agarose gel electrophoresis 
For agarose gel electrophoresis, 1 % w/v agarose gels in TAE buffer were used. For detection of 
DNA, 0.5 µl of Roti-GelStain per 10 ml gel solution were added and electrophoresis was conducted 
at 120 V for about 50 min. Visualization of separated DNA fragments was performed by a LED 
blue light table and a camera with an orange light filter. The size of the fragments was estimated 
using a DNA length marker (7.5.8). 
8.2.6. Restriction endonuclease treatment 
Restriction digestion was used to generate DNA fragments with compatible ends for subsequent 
ligation. In general, type II restriction enzymes from NEB were used. For plasmid DNA approxi-
mately 1 µg and for PCR products the total reaction was digested in the following set-up. 
Table 25: Composition of a restriction endonuclease digest. 
Components Volume in µl 
Restriction Endonucleases 0.4 (per enzyme) 
DNA variable 
CutSmart Buffer (10×) 2 
Water To 20 µl 
 
Digestion was performed for 1 h at 37 °C and, if possible, enzymes were inactivated by heat inac-
tivation for 20 min at the temperature specified by the manufacturer. 
8.2.7. Addition and removal of 5' phosphates 
The ligation of DNA fragments requires the presence of 5' phosphate residues, therefore the re-
moval of the 5 'phosphate group is a proven method to avoid religation of a vector opened by 
restriction endonuclease treatment and thus was performed in parallel by adding Antarctic Phos-
phatase (NEB) directly to the restriction digest. For this purpose, 1 µl Antarctic Phosphatase and 
2 µl 10× Antarctic Phosphatase buffer were added to the restriction digest (8.2.6). Inactivation of 
the enzyme reaction was performed at 80 °C for 2 min. 
In the contrary oligonucleotides do not possess a 5' phosphate residue and in case of oligonucleotide 
hybridization (8.2.1), where no PCR or restriction digest is performed, leading to the introduction 
of a 5' phosphate residue, the T4 Polynucleotide Kinase (NEB) treatment in the presence of dATP 
was performed. The composition for the 5' phosphorylation of oligonucleotides is given in Table 
26. 
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Table 26: Composition of a T4 Polynucleotide Kinase reaction. 
Components Volume in µl 
Oligonucleotide 1 (100 mM) 1  
Oligonucleotide 2 (100 mM) 1 
T4 Ligase Buffer (10×) 1 
T4 Polynucleotide Kinase 0.5 
Water 6.5 
 
The reaction was performed for 30 min at 37 °C and then the enzyme was heat inactivated at 65 °C 
for 20 min. 
8.2.1. Oligonucleotide hybridization 
Complementary oligonucleotides were designed with overlapping ends that, when hybridized, 
match the overhangs generated during a restriction digest of the target vector. Hybridization was 
usually performed subsequently after the addition of 5' phosphates residues during T4 Polynucleo-
tide Kinase treatment (8.2.7). In order to ensure correct hybridization of two oligonucleotides a 
temperature gradient starting from 95 °C, decreasing to 25 °C with 5 °C per min was carried out. 
The hybridized oligonucleotides were finally used in ligation reactions as 1:200 dilutions in water. 
8.2.2. DNA ligation 
To form a phosphodiester bond two compatible DNA fragments, the T4 DNA Ligase (NEB) was 
used. Ligation reactions were usually composed as follows. 
Table 27: Composition of a T4 DNA Ligase reaction. 
Components Volume in µl 
T4 DNA Ligase Buffer (10×) 2 
Linearized Vector DNA variable (50 ng to 250 ng) 
Insert DNA/ hybridized oligonucleotides variable (5-fold molar ratio of vector DNA)/ 1  
T4 DNA Ligase (5 U∙µl-1) T4 DNA Ligase (5 U∙µl-1) 
Water To 20  
 
Ligation reactions were carried out at RT for at least 1 hour and the mixture could then be used 
directly for the transformation of competent E. coli cells (8.1.2). 
8.2.3. DNA sequencing 
The success of cloning work was analyzed by sequencing reactions. These were carried out by 
members of the 'AG für Genomforschung” at the 'Sequencing Core Facility” of the 'CeBiTec” at 
the University of Bielefeld. Sequencing primers are indicated by the abbreviation SEQ in the name 
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(Table 20) and 10 µl of primers with a concentration of 10 µM were required per reaction. Se-
quences were stored as FASTA-, PHERO- and AB1- files and evaluated by local alignments with 
the Geneious (version 9.1.8) software. 
8.3. Protein biochemistry methods 
8.3.1. Recombinant protein expression 
Recombinant protein expression was either conducted in E. coli BL21(DE3) cells using the IPTG 
inducible T7 expression system based on the pET vector or by mammalian expression using the 
strong CMV promoter on pcDNA5/FRT vector. 
For prokaryotic expression of the PKD-MBP fusion protein, a 50 ml preculture of E. coli 
BL21(DE3) strain carrying the respective pET expression plasmid was grown at 37 °C, 180 rpm 
overnight to inoculate 500 ml culture with an OD600 of 0.1 in LB medium with kanamycin 
(50µg∙ml-1). Cultivation was performed at 37 °C and 180 rpm. Once the OD600 reached a value of 
0.6, isopropyl-β-D-thiogalactopyranoside (IPTG) with a final concentration of 1 mM was added to 
induce protein expression and cultivation was continued for another 4 h. Afterwards, cells were 
harvested by centrifugation (6000×g, 15 min, 4 °C) and the cell pellet was stored at -20 °C or di-
rectly processed by French Press (8.3.2.1). 
For mammalian protein expression of the A20-scFv-Fc, HEK-F cells (Thermo Fisher Scientific) 
were cultivated in HEK-TF medium (Xell AG). One day before transfection, cells were seeded in 
a cell density of 1.5∙106 cells ml-1 in a 125 ml Erlenmeyer cell culture flask. Before transient trans-
fection, cells were counted, centrifuged at 150×g for 5 min and resuspended in fresh HEK-TF me-
dium with a cell density of 3∙106 cells ml-1 in a volume of 30 ml. 60 µg DNA (2 µg ml-1, (0.67 pg 
DNA per cell)) were pre-complexed in 1/8 of the transfection volume in HEK-TF medium (3.75 
ml). For polyethylenimine (PEI) Max (Polysciences, Inc). the same procedure was followed with 
240 µg (8 µg ml-1) PEI. After 1 min both approaches were combined, rigorously vortexed and in-
cubated for 15 min before the DNA: PEI complex was added to the cells. After 4 h 37.5 ml fresh 
HEK-TF medium (100 % of the transfection volume) was added and cells were cultivated for 6 
days. Cells were pelleted at 2000×g for 5 min and the A20-scFv-Fc containing supernatant was 
sterile-filtered and stored at -20 °C or directly processed by Protein A chromatography (8.3.2.2). 
8.3.2. Protein purification 
8.3.2.1. Immobilized metal affinity chromatography  
As PKD2-MBP was equipped with a C-terminal His6-tag (polyhistidine-tag), purification using 
immobilized metal affinity chromatography (IMAC) on a Ni-NTA resin (Macherey-Nagel) was 
possible.  
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In a first step, the E. coli cell pellet from protein expression was thawed and resuspended in 30 ml 
equilibration buffer (50 mM Na2HPO4, 300 mM NaCl, 10 mM imidazole pH 8) and the cell mem-
brane of bacteria was disrupted in three repeated French press cycles (SLM AMINCO) at a pressure 
of 1000 psi. The cell debris was separated from soluble protein by centrifugation at 15.000×g for 
30 min at 4 °C. 10× DNase I buffer and 0.1 µl DNase I solution (min 3000 U∙ml-1) per milliliter 
were added, and incubated at 37 °C for 20 minutes, before the suspension was sterile filtered and 
applied to a 1 ml self-packed Ni-NTA column. All chromatography steps were performed on a 
ÄKTA start chromatography system with a flowrate of 1 ml min-1. The column was equilibrated 
with a total of 10 CV equilibration buffer before loading of the sample. After washing with 10 CV 
equilibration buffer containing 20 mM imidazole, the protein was eluted with 5 CV of an elution 
buffer containing 250 mM imidazole. The elution was collected in 500 µl fractions, and protein 
concentrations were determined by measuring the absorbance at 280 nm (8.2.3) and the protein 
containing fractions were combined and buffer was exchanged to PBS using an Amicon Ultra cen-
trifugal filter unit (MWCO 30 kDa). Protein samples were stored at -80 °C as 50 µl aliquots. 
8.3.2.2. Protein A column chromatography 
The human IgG1-Fc part of the A20-scFv allowed for purification using a Protein A column 
(HiTrap Protein A HP, GE Healthcare). All chromatography steps were performed on a ÄKTA 
start chromatography system with a flowrate of 1 ml min-1. The column was equilibrated with a 
total of 10 column volumes (CV) equilibration buffer before loading of the sample. The sample 
was mixed with 0.5 volumes of equilibration buffer before it was loaded on the column. After 
washing with 10 CV of equilibration buffer, elution was performed with 5 CV elution buffer pH 
3.5. The elution was collected in 500 µl fractions in 1.5 ml plastic reaction tubes containing 50 µl 
neutralization buffer each. Protein concentrations were determined by measuring the absorbance at 
280 nm (8.2.3). The protein containing fractions were combined and buffer was exchanged to PBS 
using an Amicon Ultra centrifugal filter unit (MWCO 30 kDa). Protein samples were stored 
at -80 °C as 20 µl aliquots. 
8.3.3. SDS PAGE 
SDS PAGE analysis was performed to detect proteins and determine their molecular weight. The 
composition of the regularly used 10 % separating gel and the 4 % stacking gel is given in Table 
28. 
Table 28: Composition of 10 % SDS gels (sufficient for 4 gels). 
Component 10 % separating gel 4 % stacking gel 
Water 16.33 ml 8.17 ml 
Separating gel buffer 12.5 ml - 
Stacking gel buffer - 3.78 ml 
10 % SDS solution 0.5 ml 0.15 ml 
Acrylamid-Bisacrylamid 30 % solution 
(29:1) 
16.65 ml 3.35 ml 
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TEMED 0.025 ml 0.015 ml 
1.5 % APS solution 4 0.9 ml 
 
Protein samples were mixed with 5× SDS loading buffer and boiled at 95 °C for 5 min before 
loading. To estimate the size of the proteins, additionally 5 µl of a protein standard were loaded 
(7.5.8). The Hoefer SE260 chamber was filled with 1× SDS running buffer and gel electrophoresis 
was performed at 100 V for 30 minutes and was then increased to 200 V for additional 90 min. 
Polyacrylamide gels were then either stained (8.3.4; 8.3.5) or used for western blot analysis (8.3.6). 
8.3.4. Coomassie-staining 
For detection of proteins, SDS Gels were rinsed with water and then stained for 1 min in Coomassie 
staining solution which was warmed up in a microwave (600 W). The gel was washed heated sev-
eral times with a Coomassie destaining solution before it was covered overnight with the destaining 
solution.  
8.3.5. Silver-staining 
If a higher sensitivity was desired SDS gels were silver stained. The protocol was adapted from 
Blum et al. 180. All steps were performed under constant shaking at 60 rpm on a rocking shaker. At 
first, the gel was covered for at least 1 h with a fixing solution. For lower background signals, a 
prolonged incubation time overnight can be chosen. After two wash steps, each 10 min with wash 
solution and once with water the gel was strongly shaken by hand for exactly 1 min with a thiosul-
fate (0.02 % (w/v)) solution before it was rinsed three times with water. The gel was the transferred 
into a new vessel and incubated with a silver nitrate solution for 20 min. After rinsing three times 
with water, the gel was transferred into the starting vessel, covered with developing solution and 
was strongly shaken by hand until protein bands were visible. The reaction was stopped by covering 
the gel with stop solution. 
8.3.6. Western Blot 
For verification of the presence of proteins as well as for the detection of low concentrated proteins 
western blot analysis was performed. After separation of proteins by SDS-PAGE (8.3.3), transfer 
was performed onto a 0.45 µm nitrocellulose membrane (Thermo Fisher Scientific) by a semi-dry 
electrophoretic transfer. A 35 min transfer time at 4 mA cm-2 was chosen and successful transfer 
was detected by reversible Ponceau S staining of the membrane. Then, the membrane was washed, 
and remaining protein binding sites were blocked for 1 h or overnight in TBS buffer with 10 % 
(w/v) non-fat milk (blocking buffer). The following primary antibody (Table 18) was diluted in 
blocking buffer and incubated for 1 h and was chosen according to the target proteins to be detected. 
After 2 wash steps, each 10 min, the membrane was incubated with a secondary anti-mouse IgG 
linked to a horseradish peroxidase for 1 h. After 3 wash steps, each 10 min, proteins were detected 
by luminescence by mixing equal parts of Detection Reagent 1 and 2 (Pierce ECL Western Blot 
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Substrate, Thermo Fisher Scientific) with a total volume of 125 µl per cm2 membrane and a variable 
exposure time from 30 s to 5 min. Detection was performed with a CCD camera system (Fusion 
Fx7). 
8.4. Cell culture methods 
8.4.1. Cultivation of mammalian cells 
Generally, cultivation took place in a CO2 incubator at a humidity of 90 %, 5 % CO2 and 37 °C. 
Adherent growing cells were cultivated in T-flasks (Sarstedt), whereas in suspension growing cells 
were cultivated in tube spin bioreactors (TPP) or Erlenmeyer cell culture flasks on an orbital shak-
ing platform (185 rpm, 5 cm amplitude). Depending on the cell line different medium was needed. 
For A431, MDA-MB231 and MDA-MB453 RPMI supplemented with 10 %FCS and 1 % penicil-
lin/streptomycin (P/S) and for HEK-293, HT1080, HDFa and M1FS DMEM, high glucose supple-
mented with 10 %FCS and 1 % penicillin/streptomycin was used. For HEK293-KARE1, blasti-
cidin in a final concentration of 5 µg ml-1 was additionally added. Cultivation of HEK-F cells was 
mainly performed in HEK-TF medium supplemented with 8 mM Glutamine. 
8.4.2. Thawing and cryopreservation 
For long-term storage, cells were cryopreserved at -150 °C in the respective growth medium (8.4.1) 
supplemented with 10 % dimethyl sulfoxide (DMSO). Therefore, cells were counted, pelleted 
(150×g, 5 min) and subsequently resuspended to a final density of 1∙107 cells ml-1. This suspension 
was aliquoted in cryogenic vials 1 ml each and cooled down slowly with a cooling rate of 1 °C per 
min in a freezing container in a -80 °C freezer overnight before transferring to the -150 °C freezer. 
For thawing, cryogenic vials were transferred into a 37 °C warm water bath and afterwards spun 
down (150×g, 5 min) in 20 ml PBS to remove remaining DMSO. For adherent cells, the cell pellet 
was suspended in 20 ml of the respective growth medium and transferred into a T75 flask. For 
suspension cells, cells were suspended in 10 ml growth medium and transferred into tube spin bio-
reactors.  
8.4.3. Counting and seeding 
To determine the number and viability of mammalian cells, the Luna Automated Cell Counter sys-
tem (Logos Biosystems) was used. During passaging, 10 µl of the cell suspension was mixed with 
10 µl of a trypan blue solution (Sigma Aldrich) and 10ml of this suspension was filled into a count-
ing slide and cell number and viability was determined. These allowed to calculate the required 
number of cells to be seeded in the respective growth medium and the desired culture vessel. 
8.4.4. Alamar Blue Assay 
The effect of incorporation of GCV-triphosphate into genomic DNA of transduced cells was meas-
ured by determining the cell viability by an Alamar Blue Assay.  
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10'000 cells with a cell density of 1'000 cells ml-1 of HFa, M1Fs, HT1080, MDA-MB231 and MDA-
MB453 cells were mixed with rAAV_promoter_mGMK-TK30_T2A_eGFP were the expression is 
driven by different promoters or rAAV_promoter_mGMK-TK30_T2A_eGFP_let7a where the let-
7a miRNA target sequence was included. CMV, COX-2, survivin and CXCR-4 promoters were 
chosen, and cells were transduced with a MOI of 10,000 in biological duplicates. After careful 
mixing, 100 µl of the cell suspension was dispensed in 6-fold replicates in a 96-well plate. After 24 
h, a final concentration of 1 mM ganciclovir (Sigma Aldrich) from a 20 mM stock solution was 
added for another 72 h. After the incubation period, 5 µl resazurin of a 1 g∙L-1 stock solution in PBS 
was added (final concentration of 0.05 g L-1). The plates were placed in an incubator at 37 °C, 5 % 
CO2 and fluorescence intensity were measured at regular intervals in a PowerWave HT (BioTek) 
plate reader with an excitation wavelength of 545/30 nm and an 590/20 emission filter. Fluores-
cence data were normalized to the fluorescence signal of cells transduced with rAAV2_mVenus 
with added ganciclovir. For the analysis of the effect of GCV on non-transduced cells, 1'000 
HT1080 cells in 100 µl growth medium were seeded in 6-fold replicates in a 96-well plate and 0, 
0.5, 1, 2 and 4 mM GCV was added. After 72 h Alamar Blue Assay was performed. The relative 
fluorescence of the samples was calculated by setting the fluorescence signal of cells without GCV 
as 100 % viable. For the other cell lines, only the working concentration of 1 mM GCV was tested 
as described.  
8.5. Virological methods 
8.5.1. rAAV production in adherent HEK-293 cells 
The production of rAAV was mainly conducted in adherent growing HEK-293 cells using the 
helper-free plasmid system.181 Transient transfection was based on calcium phosphate mediated 
transient transfection.182 One day before transfection, cells were counted (8.4.3) and a total of 3∙106 
(100 mm) or 9∙106 (150 mm) cells were seeded in 10 ml or 20 ml complete growth medium, re-
spectively (8.4.1). On the day of transfection, depending on the size of the dish, 15 µg or 45 µg 
plasmid DNA (5 pg DNA per cell) were mixed in a molar ratio of 1: 1: 1 of pHelper: pRepCap: 
ITR in 0.5 ml or 1 ml calcium chloride (CaCl2) buffer, respectively. This solution was rigorously 
vortexed and dropwise added to 0.5 ml or 1 ml 2×HBS buffer, respectively. The reaction mixture 
was vortexed, and 1 or 2 ml were added to a 100 mm or a 150 mm dish. Transfected cells were 
cultivated for 72 h and before harvest, the transfection efficiency was estimated by fluorescence 
microscopy by making use of the gene expression of the fluorescence reporter mVenus delivered 
by the ITR containing plasmid. Subsequently, cells were detached from the surface using a cell 
scraper and pelleted (2'000×g, 5 min) and cell pellet and spent medium were stored separately 
at -80 °C or directly purified by ultracentrifugation (8.5.4) or affinity chromatography (8.5.5). 
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8.5.2. rAAV production in HEK-F suspension cells 
One day before transfection, cells were seeded in a cell density of 1.5∙106 cells ml-1 in a 125 ml 
Erlenmeyer cell culture flask. Before transient transfection, cells were counted, centrifuged at 
150×g for 5 min and resuspended in fresh HEK-TF medium with a cell density of 3∙106 cells ml-1 
in a volume of 30 ml. 60 µg DNA (2 µg ml-1) in a molar ratio of 2: 1: 1 of pHelper: pRepCap: ITR 
were pre-complexed in 1/8 of the transfection volume in HEK-TF medium (3.75 ml). For polyeth-
ylenimine (PEI) Max (Polysciences, Inc). the same procedure was followed with 240 µg (8 µg ml-1) 
PEI. After 1 min both approaches were combined, rigorously vortexed and incubated for 15 min 
before the DNA: PEI complex was added to the cells. After 4 h, 37.5 ml fresh HEK-TF medium 
(100 % of the transfection volume) was added and cells were cultivated for 3 days. Cells were 
pelleted at 2'000×g for 5 min. The rAAV containing cell pellet was then stored at -80 °C or subse-
quently purified by affinity chromatography (8.5.5; 8.5.6) or genomic titers obtained were deter-
mined (8.5.8). 
8.5.3. Ammonium sulfate precipitation of rAAV  
Viral particles were released from the cell pellet obtained during rAAV production by three freeze-
thaw cycles of the pellet resuspended in 2 ml lysis buffer. For degradation of residual DNA and 
RNA contaminants, 0.8 µl benzonase nuclease (Sigma-Aldrich) were added and incubated at 37 °C 
for 1 h. Subsequently, 0.5 % (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
hydrate (CHAPS) was added and after an incubation time of 37 °C for 30 min, cell debris was 
pelleted at 3'000×g for 10 min and the virus containing supernatant was used to resuspend the am-
monium sulfate precipitate of the spent medium which was conducted as follows. Per 40 ml spent 
medium 12.52 g ammonium sulfate were dissolved and incubated for 30 min on ice. The superna-
tant after centrifugation at 8'300×g for 10 min at 4 °C was discarded and the rAAV-containing 
pellet was resolved with the supernatant from pellet preparation. This suspension was used for 
iodixanol density gradient ultracentrifugation (8.5.4) or POROS CaptureSelect AAVX affinity pu-
rification (8.5.6). 
8.5.4. Discontinuous iodixanol density gradient ultracentrifugation 
Iodixanol density gradient ultracentrifugation was used to remove contaminants from production 
and to enrich full capsids. In a first step, different iodixanol solutions were prepared (Table 29). 
Table 29: Composition of solutions for iodixanol ultracentrifugation sufficient for two samples. 
Proportion of iodixanol  Volume iodixanol solu-
tion  
Buffer Additionally 
60 % Stock solution  Add phenolred 
54 % 8 ml of stock solution 0.887 ml 10× PBS-MK  
40 % 4 ml of 54 % solution 1.4 ml 1× PBS-MK  
25 % 2.5 ml of 54 % solution 2.9 ml 1× PBS-MK Add phenolred 
15 % 1.5 ml of 54 % solution 1.2 ml 1× PBS-MK 2.7 ml 1× PBS-MK 
NaCl 
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The prepared iodixanol solutions were layered in an open top polyallomer 16 x 76 mm tube (Sci-
ence Services) with the volumes given in Table 30. 
Table 30: Volumes of the respective iodixanol solutions for iodixanol ultracentrifugation for one sample. 
Solution Volume in ml 
60 % 1.25  
40 % 1.25 
25 % 1.5 
15 % 2.25 
 
Finally, the sample was applied with a maximal volume of 4 ml. The tubes were sealed with cap 
assemblies and tared before centrifugation in a T-880 rotor (Sorvall) at 340,000×g for 2 h at 18 °C. 
To collect the rAAV containing fraction a syringe with a 21G × 1 1/2” injection needle was stabbed 
into the tube at the interphase between 60 % and 40 % iodixanol layer and a fraction with a size of 
500 µl was taken. Finally, the buffer was exchanged to 1× HBSS (Sigma Aldrich) via Amicon 
Ultra-4 100K centrifugal filter units (Merck pore) and when concentrated to a volume of about 
500 µl, 50 µl aliquots were stored at -80 °C. A 10 µl aliquot was stored separately for subsequent 
determination of the rAAV genomic titer 8.5.8). 
8.5.5. PKD affinity purification  
In a first step, the PKD affinity resin needs to be prepared. Blotting paper (Rotilabo® Blotting 
Papers, Thickness 0.35 mm; Carl Roth) was cutted into 1 cm2 large pieces and incubated in 2 ml 
DVS buffer (0.1 M Na2CO3, pH11) with 10 % DVS (Sigma Aldrich) for 2 h. Then, the blotting 
paper was washed five times with 10 ml MilliQ and dried for at least 2 h. Each blotting paper was 
incubated with 100 µl 5 µM PKD in PBS overnight in a water-saturated atmosphere. The remaining 
surface was blocked with 2 ml of PBS-T for 1 h before it was washed three times with PBS. After-
wards the material could be used for affinity purification or stored in PBS buffer at -20 °C. 
For PKD affinity purification from crude cell lysate, one 1 cm2 of prepared PKD-blotting paper 
was added to the virus containing lysate for 30 min in a suitable vessel under constant shaking on 
a roll-tumble shaker. Afterwards the supernatant was removed, and the resin was washed with PBS 
until no phenol red residues from the medium were seen (usually five to six wash steps with 10 ml 
PBS). Elution was performed by transferring the PKD-blotting paper into an empty spin column 
and adding 500 µl of MgCl2 elution buffer. After 2 min incubation, elution was performed by cen-
trifugation (1000×g, 2 min). The elution fractions were combined, and the buffer was exchanged 
to 1× HBSS (Sigma Aldrich) via Amicon Ultra-4 100K centrifugal filter units (Merck Millipore).  
8.5.6. POROS CaptureSelect AAVX affinity purification 
For affinity purification with the POROS CaptureSelect AAVX affinity material, a 5 ml empty lab 
column with Luer-lock connections (MoBiTec S10131) was filled with 500 µl of the slurry and 
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once the material was settled, equilibrated with 10 column volumes of PBS. The rAAV containing 
crude cell extract either from adherent or suspension growing cells, was loaded with 1 ml per min 
with a syringe pump. After washing with 10 CV with PBS-T rAAV2 were eluted three times with 
250 µl 100 mM citric acid buffer pH 2.5 and neutralized with Tris-HCl pH 9.0 (80 µl per 250 µl). 
8.5.7. PKD-AminoLink Plus affinity purification 
At first, PKD was coupled to the AminoLink Plus Coupling Resin, which was mainly performed 
according to the manufacturer's instructions.183 400 µl of the AminoLink slurry were settled in a 
2 ml plastic reaction tube at 1'000×g for 1min and equilibrated with 600 µl Coupling buffer pH 10. 
Afterwards, the settled resin was mixed with 300 µg PKD2 diluted in 300 µl Coupling buffer pH 10 
and incubated on a roll-tumble-shaker for 4 h. The resin was washed with 600 µl Coupling buffer 
pH 7.2 and PKD2 was immobilized by adding 200 µl coupling buffer pH 7.2 and 4 µl cyanoboro-
hydride (NaCNBH3) solution for 4 h at RT or overnight at 4 °C and constant shaking on a roll-
tumble shaker. The resin was then washed with 400 µl Quenching buffer and remaining protein 
binding sites were blocked by adding 200 µl Quenching buffer and 4 µl of NaCNBH3 solution for 
30 min under constant shaking. The column was washed with 1 ml wash solution and stored at 4 °C 
or used directly for affinity purification from HEK-F crude cell lysate. Here, 1 ml of the clarified 
supernatant, after cell disruption by three freeze-thaw cycles, was incubated for 30 min with the 
generated affinity resin, washed 6 times with 2 ml PBS-T and viral particles were eluted 3 times 
with 0.5 ml MgCl2 elution buffer. The elution fractions were combined, and the buffer was ex-
changed to 1× HBSS (Sigma Aldrich) via Amicon Ultra-4 100K centrifugal filter units (Merck 
Millipore). 
8.5.8. Determination of rAAV genomic titer 
To determine the genomic titer of a sample by a qPCR, residual DNA from transfection was re-
moved by a DNaseI digestion. Samples were treated with 10 U DNase I (NEB) in 10× DNaseI 
buffer in a final volume of 50 µl at 37 °C for 30 min before heat inactivation of the DNase I at 
75 °C for 20 min. Crude lysate samples were additionally incubated with 0.8 U Proteinase K (New 
England Biolabs) for 50 min at 37 °C before heat inactivation at 95 °C for 10 min. A 50-fold dilu-
tion with nuclease-free water was used as a template in the following qPCR reaction. 5 µl of the 
diluted sample was mixed with 2.5 µl of qPCR-hGH-for (5'-CTCCCCAGTG CCTCTCCT-3') and 
2.5 µl qPCR-hGH-rev (5´-ACTTGCCCCT TGCTCCATAC-3´) primers, with a stock concentra-
tion of 4µM each. Additionally, 10 µl of 2× GoTaq qPCR Mastermix (Promega) was added and 
the qPCR reaction was carried out as described in Table 31; using a LightCycler 480 II (Roche).  
Table 31: Thermocycling conditions for qPCR reactions. 
Step Temperature in °C Time in s Cycles 
Initial Denaturation 95 600 1 
Denaturation 95 15 40 
Annealing + Elongation 60 30  
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To calculate the genomic titer a standard curve of 10 to 106 copies of the ITR plasmid (pZMB0522) 
was generated with an efficiency between 90-110% and an R value less than 0.1 and saved as a 
reference. In qPCR reaction a copy number of 104 or 105 was included as internal control. To de-
termine the genomic titer in crude lysates a standard curve mixed with the same amount of a non-
transfected cell lysate was generated. Based on the crossing point (Cp) value of the internal refer-
ence, compared to the sample, the genomic titer was calculated by the LightCycler 480 II software. 
Afterwards, a dilution factor of 50 and a factor of 2, because of the double stranded plasmid DNA, 
was taken into account. 
8.5.9. Determination of transducing titer 
Determination of the transducing titer of a rAAV sample was performed on HT1080 cells. 10'000 
cells per well were seeded in 500 µl of the corresponding media on a 12-well plate and settled for 
1 h before application of dilutions of rAAV preparations in PBS. Based on genomic titers deter-
mined by qPCR (8.5.8) a MOI of 10 to 105 was chosen. After 12 h incubation 500 µl of fresh me-
dium was added to the cells. Cells were incubated at 37 °C for further 72 h before detaching with 
0.25 % Trypsin/EDTA, resuspension in PBS and analysis of 10'000 events using a FACSCalibur. 
All experiments were performed as biological duplicates. Data sets were analyzed using FlowJo 
V10. Positive cells were gated above the 99 % interval of the negative control. For calculation of 
the transducing titer, dilutions with a transduction efficiency less than 30 % were used in order to 
avoid multiple transduction events per cell and by this leads to an underestimation of the transduc-
ing titer. Calculation was based on following formula: 𝑇𝑈 =
𝑛∙𝐹𝑝∙𝑑
𝑉
 with TU: Transducing Units 
(ml-1); n: number of cells in transduction batch; Fp: Amount of positive fluorescent cells; d: dilution 
factor of rAAV sample; V: volume of transduction batch (ml). 
8.5.10. rAAV2 capsid ELISA 
For the determination of viral capsid titer, a 96-well cell culture plate was incubated overnight at 
4 °C with purified PKD2 (200 ng in 100 µL per well) in carbonate buffer. Afterwards, the plate 
was washed three times with PBS-T (wash buffer) and remaining sites were blocked with 200 µl 
blocking buffer (0.8 % BSA in PBS) per well for 1 h at RT. After three wash steps with wash buffer 
the A20 scFv was added with 100 ng per well in blocking buffer for 1 h at RT. The wash step was 
repeated, and the plate was incubated with an anti-human IgG1 HRP antibody (AM08151HR-N, 
mouse monoclonal, 1:2'000 in wash buffer with 0.8 % BSA, Acris antibodies) for 1 h. The detection 
was started, after three wash steps with wash buffer, with 150 µl ABTS buffer with 1 g L-1 ABTS 
(2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid). The absorbance was measured at 405 nm 
with a microplate spectrophotometer (PowerWave HT, BioTek) after 30 min. Calculation of cap-
sids was performed by a standard curve of a serial dilution of a known capsid concentration (Kit 
control/Standard, Progen). The particle titer was calculated by a standard curve of a serial dilution 
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of a known capsid concentration (Kit control/Standard, Progen) by using a 4-parameter logistic fit 
with OriginPro 2018 software. The equation was: 𝑦 = 𝐴2 + (𝐴1 − 𝐴2)/(1 + (
𝑥
𝑥0
))^𝑝). 
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Abstract: Recombinant adeno-associated viruses (rAAV) provide outstanding options for cus-
tomization and superior capabilities for gene therapy. To access their full potential, facile genetic 
manipulation is pivotal, including capsid loop modifications. Therefore, we assessed capsid tol-
erance to modifications of the VP proteins in terms of stability and plasticity. Flexible glycine-
serine linkers of increasing sizes were, at the genetic level, introduced into the 587 loop region of 
the VP proteins of serotype 2, the best studied AAV representative. Analyses of biological func-
tion and thermal stability with respect to genome release of viral particles revealed structural 
plasticity. In addition, insertion of the 29 kDa enzyme β-lactamase into the loop region was tested 
with a complete or a mosaic modification setting. For the mosaic approach, investigation of VP2 
trans expression revealed that a Kozak sequence was required to prevent leaky scanning. Surpris-
ingly, even the full capsid modification with β-lactamase allowed for the assembly of capsids with 
a concomitant increase in size. Enzyme activity assays revealed lactamase functionality for both 
rAAV variants, which demonstrates the structural robustness of this platform technology.  
Keywords: Adeno-associated-virus; β-lactamase; inverted terminal repeat (ITR); loop modifica-
tion; capsid stability 
 
 
 
 
Introduction 
Recombinant adeno-associated viruses (rAAV) are frequently used as a basic research tool 
and are emerging as therapeutic agents. For example, the US FDA recently approved voretigene 
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neparvovec (Luxturna), which is based on rAAV serotype 2 (rAAV2) and delivers a gene to sup-
plement biallelic RPE65 mutation-associated retinal dystrophy [237]. In addition, products based 
on AAV1 (Alipogene tiparvovec / Glybera) and very recently AAV9 (Onasemnogene abeparvovec 
/ Zolgensma) obtained approval in Europe or the United States. The increasing impact of rAAV on 
gene therapy relies on a high safety profile resulting from the inability to replicate autonomously 
and on long-term target gene expression [118]. Wild-type AAVs have a non-enveloped, icosahedral 
capsid formed by 60 subunits of VP1, VP2 and VP3 proteins in an approximate molar ratio of 1:1:10 
[7, 238]. In the AAV wild-type setting, the single-stranded DNA genome of about 4.7 kb includes 
two main reading frames (Rep and Cap) and is flanked by inverted terminal-repeat (ITR) se-
quences, which provide the encapsidation signal. Genetic engineering enables decoupling of the 
capsid coding genes from the encapsidated DNA. In the recombinant setting, rep and cap genes are 
provided in trans on a RepCap plasmid whereas a transgene expression cassette, frequently named 
gene of interest (GOI), is provided between the ITRs on the ITR plasmid. AAV needs additional 
‘helper’ functionality from other viruses for production, which is provided on a separate pHelper 
plasmid [239, 240]. For this reason, a three-plasmid system is often used, wherein the pHelper de-
livers the essential adenoviral elements E2A, E4 and the non-coding RNA VA. As host, HEK293 
cells provide further adenoviral elements (E1A, E1B) and allow for high-titer production[239, 240]. 
Alternative versions are also used such as a two-plasmid system combining the genetic information 
of the adenoviral helper sequences with AAV serotype specific rep and cap genes [113]. 
For diverse applications, e.g. virus-directed enzyme prodrug therapy (VDEPT) [241], viral tar-
geting of specific cells is desired. AAV serotypes differ in their tropism and thus provide a first 
choice to achieve target specificity [242]. Deeper control over the target tropism requires genetic 
intervention. For this purpose, directed randomization and selection or rational engineering have 
been applied. Chimeric rAAV capsids are composed of proteins, which originate from different 
serotypes, and are often identified by evolutionary methods [243]. On the rational side, N-terminal 
fusions to e.g. the VP2 protein in rAAV2 have been studied [76, 107, 244]. In these cases, the addi-
tion of larger proteins, e.g. GFP and DARPins was compatible with capsid assembly and targeting. 
A further and early adopted rational approach, which is extended in this publication, is the 
integration of motifs in previously identified loop positions of the VP proteins. Two groups demon-
strated that capsid formation and gene packaging are only slightly influenced by integration of 
peptide sequences in VP proteins at various residue positions [245, 246]. Insertions in these posi-
tions has also been used for biorthogonal labelling of capsids [247, 248]. Capsid accommodation 
capacity was shown for the integration of larger moieties such as the minimal Fc-binding motif 
Z34C (34 amino acids) into the 587 loop region [249]. Production of such a Z34C rAAV2 with sub-
sequent binding of an antibody was shown and transduction of target cells was observed. For vac-
cination via viral particle display, peptides up to 35 or 31 amino acids were integrated in the 453 
or 587 position, respectively [250]. To our knowledge, the largest reported insertion to date is the 
fluorescent protein mCherry, which was functionally included in variable region IV at the 453 po-
sition of VP1, and allowed for the production of mosaic particles [251]. 
Our aim was to expand the loop modification strategy in combination with a systematic anal-
ysis of the engineering capacity of rAAV. For the construction of viruses, we extended an existing 
plasmid toolbox for rAAV2 manipulation and production [76, 252]. Insertion of peptides in capsid 
proteins was studied with regard to rAAV productivity and transduction capability. The impact of 
capsid protein modifications on thermal stability has, to our knowledge, not been investigated. 
Thus, we first tested rAAV stability with glycine-serine insertions of varying length at residue po-
sition 587. These experiments confirmed that larger insertions are tolerated and we opted to insert 
the enzyme β-lactamase. As the introduction of an entire protein could interfere with capsid as-
sembly, we tested partial insertions only in VP2 proteins. This required adaptation of the plasmid 
system for the production of mosaic rAAVs exclusively bearing VP2 loop modifications. Resulting 
mosaic particles were found to tolerate the insertion of a full-length β-lactamase in VP2 proteins. 
Finally, we set up a complete β-lactamase modification of all VP proteins. Production of these fully 
decorated rAAVs was possible and allowed for further characterization. In summary, our analyses 
demonstrated resilience of the virus to modifications at the genetic and protein level. We believe 
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that the plasmid system combines facile genetic manipulation with a broad range of rAAV capsid 
engineering options. 
 
 
Results 
 Modifications of ITR and RepCap plasmids are compatible with rAAV production. 
Despite the availability of different ITR and RepCap plasmids for rAAV2 production, options 
for facile loop capsid modification are sparse. In this work, previously modularized versions of the 
RepCap and ITR plasmids were used, which are largely compatible with the BioBrick RFC[10] 
cloning strategy (SI Figure 1) [252]. The RepCap plasmid (pZMB0216_Rep_VP123_453_587wt_ 
p5tataless) was retained but the ITR plasmid was redesigned to reduce cloning steps and serve 
user expectations outside the synthetic biology community. The new ITR plasmid 
(pZMB0522_ITR_EXS_ CMV_mVenus_hGHpA) contains the viral ITRs as part of a pUC19-based 
backbone, provides restriction sites for insertions based on BioBrick RFC[10] flanking the fluores-
cent reporter mVenus, and serves as a final destination plasmid. Plasmid generations are described 
in SI Method 1, final constructs used during this work are given in Table 1 and selected plasmids 
of the plasmid toolbox are given in SI table 1.  
For sequence analysis of the ITRs, which commonly defy Sanger cycle sequencing, we cleaved 
the ITR DNA with BsaHI, generating two halves that are amenable to standard sequencing proto-
cols (SI Figure 2, SI Method 2). Our plasmid pZMB0522 carries one complete ITR (in this plasmid 
notation referred to as 5´-ITR) and an ITR shortened by 11 bp (Figure 1).  
Table 1. Overview of plasmids submitted to Addgene including a short description of their fea-
tures. Information on the cloning of the plasmids is available in the supplementary information. 
Plasmid name with description Length Backbone 
pZMB0522_ITR_EXS_CMV_mVenus_hGHpA 
AAV2 ITR flanking a CMV promoter expressing the fluorescent protein 
mVenus 
4014 bp pUC19 
pZMB0216_Rep_VP123_453_587wt_p5tataless 
expression of VP1/2/3 of AAV2 with cloning ready 453 and 587 loop re-
gions, arginines in 587 loop region are intact, p5 promoter at end of ex-
pression cassette 
5455 bp pSB1C3_001 
pZMB0600_Rep_VP13_453_587wt_p5tataless 
expression of VP1 and VP3 with cloning ready 453 and 587 loop regions 
Arg in 587 loop region are intact 
6455 bp pSB1C3_001 
pZMB0315_CMV_Kozak_VP2_453_587wtHis 
expression of VP2 with Kozak sequence to prevent leaky scanning and 
VP3 start knock out, cloning ready 453 and 587 loop regions, Arg in 587 
intact, His-tag in 587 loop 
4705 bp pSB1C3_001 
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Figure 1. Overview of the ITR sequences of rAAV2. (a) Scheme of ITR plasmid components. The 
ITRs are enlarged compared to the interchangeable GOI (CMV promoter, mVenus fluorescent pro-
tein gene and hGHpolyA sequence). The deleted 11 bp sequence is highlighted in the right ITR 
adjacent to the pUC ori. (b) Structure of one ITR computed by Mfold webserver (150 mM NaCl, 5 
mM MaCl2, 37°C) [253]. Standard Sanger DNA-sequencing of ITRs was enabled by digestion with 
BsaHI whose recognition site is highlighted. (c) Results of Sanger-DNA sequencing aligned to orig-
inal ITR sequences. Fragments were sequenced with oligonucleotides given in SI Method 2. The 3‘-
part of rITR shows a deletion of 11 bp (5‘-TTTGCCCGGGC-3‘). Sequencing results of the remaining 
ITR fragments are shown in SI Figure 2 c, d. 
Production of DNaseI-resistant particles and thus functionality of the ITR plasmid 
(pZMB0522) in combination with either the RepCap plasmid (pZMB0216) or a commercially avail-
able counterpart (pAAV-RC, GenBank: AF369963.1) was assayed using small-scale transfections 
and quantitative real-time PCR (qPCR). Genomic titers in crude lysates with both plasmids showed 
no significant differences (Figure 2a). A larger preparation (pZMB0522, pZMB0216) was purified 
by precipitation [254] and imaged by transmission electron microscopy. Capsid diameter measure-
ments resulted in an average of 23.7 ± 1.2 nm (SI Figure 3), which is in good agreement with the 
expected value of 25 nm [255]. Manually counting over 500 particles yielded a fraction of filled 
capsid between 60% and 80% (Figure 2b, SI Figure 3). 
 
Figure 2. Production of rAAVs packaging the fluorescent reporter mVenus gene with plasmids 
pZMB0522 and pZMB0216. (a) Production yields of rAAV samples determined by qPCR from 
crude cell lysate from one 100 mm cell culture dish. Comparable values were obtained either using 
the new RepCap plasmid (left bar) or the commercial pAAV-RC plasmid (right bar). Standard de-
viations of three biological and two technical replicates were calculated for each sample type. (b) 
Transmission electron microscopy image analysis of precipitation-purified viral samples at 39,000-
fold magnification revealed viral particles with a size of about 24 nm. (c) Comparison of viral ge-
nomic and transducing titers. Genomic titers were determined via qPCR from three technical rep-
licates of ultracentrifugation-purified viral samples. Transducing titers were analyzed by mVenus 
expression from biological and technical duplicates after flow cytometry analysis of HT1080 cells. 
(d) Transduction of different cell lines. Cells were incubated with a MOI of 10,000. Biological du-
plicates at two time points were analyzed by flow cytometry, measuring mVenus fluorescence and 
counting 10,000 events. Histograms of flow cytometry analysis can be found in SI Figure 4. 
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To obtain higher purity samples, all further preparations were purified by iodixanol gradient 
ultracentrifugation. For unmodified rAAV2 wt (pZMB0522, pZMB0216) genomic titers were deter-
mined by qPCR (Figure 2c). Using a comparable setup but depending on culture conditions and 
transfection efficiencies, titers between 1×1010 to 1×1012 vg/ml have been obtained. 
Functionality of gene delivery was investigated with transduction assays. As common for 
AAV2, HT1080 cells were used, which express high levels of the rAAV2 primary receptor heparan 
sulfate proteoglycane (HSPG). Successful transduction was detected by the expression of the de-
livered transgene mVenus using flow cytometry. Based on a dilution series, the transducing titer 
was calculated. Genomes to infectious units yielded a specific infectivity of 16:1 (Figure 2c). This is 
in agreement with previous values, since for wild-type AAV2 a ratio of 1:1 and for rAAV2 ratios 
between 55:1 and 124:1 have been observed [256]. In addition, also transduction of the cancer cell 
lines A431, HeLa, MCF7, MDA-MB-231 and normal adult human dermal fibroblasts (HDFa) was 
tested with a multiplicity of infection (MOI) of 10,000. Flow cytometry analysis (Figure 2d) revealed 
that the rAAV2 wt preparation was able to transduce a variety of different cells with high efficien-
cies. In agreement with previous reports, only the breast cancer cell line MCF7 showed low trans-
duction [257]. These results demonstrated production and function of the rAAV plasmid system 
and provided the basis for further investigations regarding the tolerance of the viral capsid to in-
sertions in the 587 loop region. 
 
Systematic variation of loop modifications shows a complex pattern of stability and transduction effi-
ciency.  
Previous experiments showed that, VP proteins tolerate peptide insertions at residue positions 
453 and 587 [245, 246]. We aimed at systematically analyzing the impact of increasing insertion 
length on rAAV thermal stability and biological function. Since a protein had already been inserted 
in the 453 loop region [251] and the 587 loop region is even more frequently used for modification, 
we opted to integrate linkers with increasing size at residue position 587 and investigated produc-
tion and function of the resulting rAAVs. Glycine-serine linkers were chosen because of their flex-
ibility and solubility, resulting in incremental changes correlating with length. Specifically, amino-
acid linkers with the sequences GG, GGSG, (GGSG)2 and (GGSG)4 were integrated at the genetic 
level in all VP proteins to yield homogeneously decorated viral particles as presented in a sche-
matic overview in Figure 3a.  
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Figure 3. Comparison of different 587 loop variants and results of thermal stability assays. (a) Sche-
matic overview on the coding sequence of the rAAV wt VP sequence. Restrictions site positions 
enabling the introduction of motifs flanking the 587 position (triangle) are indicated and amino-
acid sequences of inserted linkers are shown. For β-lactamase only the first and the last amino acids 
are given. (b) Transduction efficiencies of different serine-glycine linker rAAV variants. Histo-
grams of flow cytometry analysis can be found in SI Figure 7. Statistical analysis was performed as 
described in the Material and Methods section. (c-g) Thermal stability assays of rAAV particles 
measured in PBS. The percentage of qPCR detected genomic copies is plotted against the incuba-
tion temperature. Each point represents a technical duplicate with the standard deviation. Fitted 
curves (red) were calculated using a logistic function to determine the disintegration temperature 
for all rAAV variants. Table 2 lists the Td values. (h) Disintegration kinetics of rAAV2 wt samples 
incubated at Td = 56.1°C for different time periods. A dashed line indicates the point where 50% of 
genomic copies were released from the capsid.  
Cloning was facilitated by the unique restriction sites of RepCap plasmid pZMB0216 flanking 
the loop region (SI Figure 1). Genomic titers of iodixanol-purified preparations demonstrated that 
all genetic constructs lead to rAAV production and that integration of flexible linkers only affected 
the titer for large integrations (Table 2). rAAV transduction ability was determined based on mVe-
nus expression in HT1080 cells incubated with a MOI of 50,000 viral genomes. Increasing linker 
length impeded transduction (Table 2), but not in a linear fashion. The integration of only two 
amino acids resulted in a decrease of transduction ability from 97% (rAAV2 wt) to 31% 
(rAAV_587_GG) in the given experiment. Interestingly, increasing the linker length to four amino 
acids (GGSG) resulted in a further decrease of transduction to 20%, but rAAV with an insertion of 
eight amino acids ((GGSG)2) showed a relatively improved transduction of 28% followed by a fur-
ther drop in transduction to 11% for 16 amino acids (Figure 3b).  
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Table 2. Overview of plasmids submitted to Addgene including a short description of their fea-
tures. Information on the cloning of the plasmids is available in the supplementary information. 
Sample Titer in 
vg ml-1 a 
Transduction 
ability in % b 
Td, 5 min in °Cc 
rAAV2 wt 3.1×1010 96.7 ± 0.1 56.1 ± 0.5 
rAAV2_587_GG 7.1×109 31.3 ± 0.1 56.4 ± 0.8 
rAAV2_587_GGSG 4.0×1010 20.4 ± 0.6 54.7 ± 0.5 
rAAV2_587_(GGSG)2 2.4×1010 28.0 ± 0.9 53.8 ± 0.8 
rAAV2_587_(GGSG)4 4.7×109 10.9 ± 0.2 50.7 ± 0.7 
rAAV2_587_bla 1.3×1010 1.2 ± 0.1 55.6 ± 0.4 
rAAV2_VP2_587_bla 6.3×1010 57.0 ± 2 n.d. 
a Genomic titers are given in viral genomes (vg) per ml as determined by qPCR. Each value corresponds to a 
production with 10× 10 cm cell culture dishes and a final purified volume of 0.5 ml. 
b Transduction ability was assayed with flow cytometry of HT1080 cells using a MOI of 50,000 and is given as 
percentage of mVenus expressing cells. The error is based on biological triplicates from one viral preparation. 
c Disintegration temperatures Td were determined in the qPCR-based stability assay. 
Thermal stability of AAV capsids is an interesting biological and biophysical parameter and 
various methods to assess capsid stability have been described, such as differential scanning calo-
rimetry (DSC), differential scanning fluorimetry (DSF) and electron microscopy[198], all of which 
monitor capsid breakdown but do not detect DNA release. We propose that the point of DNA 
release during heat treatment is a biological relevant event to describe capsid stability and that 
rAAV capsid integrity can be monitored by the DNase accessibility of the encapsidated DNA. Con-
sequently, we repurposed the standard assay for genomic copy number determination and incu-
bated rAAV samples at different temperatures before the treatment with DNase I. Subsequent 
analysis via qPCR yielded genomic copies of the rAAV sample plotted against the incubation tem-
perature (Figure 3c-g). The disintegration temperature after a five-minute incubation (Td, 5 min) was 
determined as the temperature at which 50% of rAAVs have released their DNA. The term disin-
tegration temperature Td was chosen to distinguish the value from the melting temperature (Tm) 
reported by other methods (e.g. DSF, DSC). The results for all glycine-serine linker variants are 
listed in Table 2. With an increase in linker size Td decreases slightly, showing that the capsid is 
destabilized by large insertions, but also that despite significant structural intervention, stability is 
maintained at physiological temperatures. 
To estimate the influence of the incubation time and the decay kinetics in our thermal release 
assay, rAAV2 wt was isothermally incubated at the previously determined Td (56.1 °C) for different 
time points. The percentage of intact genomic copies decreased in a hyperbolic fashion albeit dis-
playing different phases (Figure 3h).  
 
Mosaic rAAVs with a 29 kDa β-lactamase at position 578 in VP2 require a Kozak consensus sequence.  
To illuminate the possibly even larger insertion capacity of rAAV capsids, we chose the well-
studied TEM β-lactamase [206] as a protein with a small distance between the N- and C-terminus, 
which approximately matches the distance of the β-hairpin residues in the variable region of the 
VP protein. The protein was inserted at the genetic level at residue position 587 of the VP proteins. 
Lactamase offers the possibility to easily measure enzyme activity. In order to avoid maximum 
interference with capsid assembly, β-lactamase was in this experiment incorporated only into the 
587 loop of solely VP2. 
The modular rAAV plasmid system, which we used as a starting point, had been deployed to 
produce N-terminal VP2 protein fusions and the respective modified rAAV particles [76]. A muta-
tion in the RepCap plasmid eliminated the VP2 start codon 
(pZMB0600_Rep_VP13_453_587wt_p5tataless) and a fourth plasmid expressing VP2 and VP3 (here 
named shortly CMV_VP23 plasmid) was provided in trans. The regulatory mechanisms for expres-
sion of the three VP proteins is complex [12, 258]. Briefly, splicing results in two mRNA transcripts 
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that code for VP1 or for VP2/3, respectively. VP2 and VP3 are coded by the same mRNA and ex-
pression is controlled by a leaky-scanning mechanism at the VP2 start, thus the VP3 sequence is 
always part of a VP2 gene. For the previous modifications leaky scanning did not pose a problem, 
because they were located at the unique N-terminus (SI Figure 1c). However, since the 587 loop 
region lies within the coding sequence of both VP2 and VP3 proteins, loop modifications desired 
for VP2 only require suppression of concomitant expression of a likewise modified VP3. 
In order to understand and insure the sole expression of VP2, we conducted an expression and 
mutation analysis starting with the RepCap and the CMV_VP23 plasmid. Transient transfection of 
HEK293 cells with this plasmid and subsequent Western blot analysis of VP expression was per-
formed. Expression of all three VP proteins after transfection with the unmodified RepCap plasmid 
showed approximately the expected molar ratio between the three VP proteins (1:1:10) (Figure 4a, 
lane 1). A strong expression of both VP2 and VP3 proteins was observed for the CMV_VP23 plas-
mid (Figure 4a, lane 2). Apparently the leaky scanning mechanism is still active in the context of 
the CMV promoter and the cloning context (iGEM RFC[10]). To prevent undesired VP3 expression, 
a new plasmid abbreviated as CMV_VP2 was constructed, in which the VP3 start codon was re-
moved by an exchange from ATG to ATC (Ile) (Figure 4b). As seen in the third lane of Figure 4a, 
expression of VP3 is unexpectedly still observed, which might be due to a second start codon lo-
cated 24 bp downstream. To suppress leaky scanning, a strong Kozak sequence (GCC ACC) was 
introduced upstream of the VP2 start codon resulting in plasmid CMV_Kozak_VP2 (pZMB0315). 
Finally, solely the expression of VP2 (Figure 4a, lane 4) was detected with an expected increase in 
chemiluminescence intensity, indicating a higher level of expression. 
 
Figure 4. Establishment of mosaic 587 rAAV production using a modified four-plasmid system. (a) 
Analysis of cap protein expression after transient transfection in Western blots of crude cell lysates. 
Transfection of pZM0216_RepCap showed the expected ratio of 1:1:10 for VP1, VP2 and VP3 (lane 
1). Three plasmid versions for VP2 expression were analyzed containing i) the VP2 and VP3 cassette 
(lane 2, CMV_VP23, pZMB0160), ii) the cassette with VP3 start codon removal (lane 3, CMV_VP2, 
pZMB0298), and iii) the cassette with an upstream Kozak sequence and VP3 start knock out (lane 
4, CMV_Kozak_VP2 (pZMB0315). Expression of VP3 after removal of the start codon can be ex-
plained with a second start codon 24 bp downstream and persistent leaky scanning. SI Figure 5 
shows full length images. (b) Scheme of the final expression construct. (c) Nitrocefin assay probing 
rAAV2_VP2_587_bla mosaic viral particles in different concentrations for lactamase activity. Slopes 
of linear regressions of the first 300 s were used to calculate the concentration of active β-lactamases. 
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(d) Theoretical structure of the mosaic particle (UCSF Chimera [259]) composed of the AAV2 wt 
structure (purple, PDB: 1LP3) and five copies of β-lactamase (blue, PDB: 3DTM). 
The gene of the stabilized β-lactamase variant 14FM was cloned into plasmid 
CMV_Kozak_VP2. The resulting plasmid (pZMB0577_pSB1C3_001_CMV_Kozak_VP2 
_453_587wtbla) was used for rAAV production in combination with Rep_VP13 plasmid 
(pZMB0600), the mVenus bearing ITR plasmid (pZMB0522) and pHelper. The molar ratio of these 
plasmids, particularly of the VP expressing plasmids, needed to be controlled in order to provide 
the right amounts of each VP protein (1:1:10 for VP1:VP2:VP3) for desired capsid assembly and 
relative amount of modified VP protein. The AAV promoter p40 is weaker compared to CMV and 
the Kozak sequence additionally enhances expression. Two molar plasmid ratios of 5:5:1:4 and 
5:5:4:1 (pHelper : ITR : Rep_VP13 : CMV_VP2_587_bla) were tested for protein expression and pro-
duction. The ratio of 5:5:1:4 (higher amount of modified plasmid) was associated with a high pro-
portion of VP2 protein (SI Figure 6), which potentially leads to a higher portion of modified VP2 in 
the assembled capsid compared to the wild-type ratio. Next to Western blot, crude cell lysate sam-
ples from one 100 mm cell culture dish were analyzed regarding their genomic titers. The sample 
with the lower plasmid dose of the modified VP2_587_bla protein resulted in roughly three times 
higher amounts of viral particles (2.48×1010 vg/ml for a 1:4 VP13 : VP2_587_bla ratio compared to 
7.98×1010 vg/ml for a 4:1 VP13 : VP2_587_bla (pZMB0600:pZMB0577)). 
Based on the higher particle yield, mosaic rAAV2-VP2_587_bla particles were subsequently 
produced using the 5:5:4:1 ratio. A genomic titer of iodixanol-purified particles of 6.3×109 vg was 
obtained per 100 mm dish. Thus, production using the four-plasmid system yielded rAAVs in the 
same range as the triple transfection production (Table 2). Incubation of HT1080 cells with a MOI 
of 50,000 resulted in about 57 ± 2% mVenus-positive cells (Table 2, SI Figure 7h). Comparison with 
transduction values of rAAV2 wt shows a reduction of transduction ability for the enzyme-bearing 
particles (SI Figure 7b). However, it should be noted that fully modified glycine-serine linker vari-
ants showed a much stronger reduction of the transduction ability. 
We were interested if the enzymes presented on the capsid surface retained activity and thus, 
a colorimetric nitrocefin assay was performed. Enzymatic activity was evaluated from the linear 
correlation of absorbance against incubation time (Figure 4c). From this data we were able to esti-
mate the number of active β-lactamases on the capsid surface. The β-lactamase variant 14FM which 
we used is a semi-rational combination of mutations described in literature (Hecky, Baumann un-
published data)[211]. Characteristics of this enzyme are presented in SI Table 2. Combining the 
genomic copy number and the known turnover number of the free lactamase kcat allows for the 
estimation of the total number of active lactamases in the sample. In this experiment a β-lactamase 
concentration of 1.73×10-11 mol l-1 was calculated. This value is equivalent to 5.6 enzymes per 
DNaseI-resistant particle. Such particles with five β-lactamases might look as illustrated in Figure 
4d. In conclusion, mosaic rAAV2s (rAAV2-VP2_587_bla) with an incorporated full-length protein 
were produced with unaltered efficiency - thus capsid assembly was not posing a problem. Func-
tionality for β-lactamase was proven for enzymes presented on the viral particle surface.  
 
Fully-lactamase decorated rAAV capsids can be produced and show enzyme activity.  
As a limit for the integration of motives into the capsid was not found in the mosaic experi-
ment, we aimed at the production of rAAV with all VP proteins modified with a lactamase named 
rAAV2_587_bla. The β-lactamase gene was thus cloned in the RepCap plasmid (pZMB0216) at the 
587 position (yielding pZMB0221_Rep_VP123_453_587bla_p5tataless). A fully modified capsid 
model is depicted in Figure 5a. The genomic titer after ultracentrifugation was comparable to those 
of glycine-serine linker insertions (Table 2). To our surprise, the insertion with the size of approxi-
mately 29 kDa in every VP protein did not abrogate capsid assembly.  
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Figure 5. Comparison of rAAV2 wt and rAAV2_587_bla with respect to structure and β-lactamase 
activity. (a) Theoretical structure of rAAV2_587_bla constructed from the AAV2 wt structure (pur-
ple, PDB: 1LP3) and 60 copies of β-lactamase (blue, PDB: 3DTM). (b, c) AFM micrographs and par-
ticle size analysis of rAAV2 wt and rAAV2_587_bla. The calculated mean diameter of rAAV2 wt is 
20 nm and 29 nm for rAAV_587_bla. SI Figure 8 gives AFM raw data. (d) Results of thermal stability 
assay based on qPCR data for rAAV_587_bla. Each point represents the standard deviation of a 
technical duplicate. Td,5 min was calculated with 55.6 ± 0.4 °C. (e) Nitrocefin assay, probing the β-
lactamase activity of rAAV2_587_bla in different dilutions. (f) Images of a bacterial growth assay 
on LB Agar plates for β-lactamase activity. Samples with rAAV2_587_bla show a β-lactamase ac-
tivity up to 1:3 dilutions, whereas for rAAV2 wt and PBS no colony growth was observed. 
We were interested to see how the 60 insertions would affect the overall size of the capsid. 
Measuring the particle width by atomic force microscopy (Figure 5b) a diameter of approx. 20 nm 
for rAAV2 wt was found. Note that the 5 nm deviation in particle size compared to the TEM meas-
urements can be attributed to the type of method used and sample preparation. In contrast, a sig-
nificantly higher viral particle diameter of approx. 29 nm was found for rAAV2_587_bla (Figure 
5d). From the capsid model in Figure 5a a diameter of 35 nm was estimated for a fully enzyme-
modified rAAV and estimations for the wild-type capsid resulted in an average of 25 nm, which 
agrees with the observation. 
When rAAV2_587_bla samples were assayed for transduction ability on HT1080 cells, almost 
no transduction was measurable (Table 2). The thermal stability assay revealed a disintegration 
temperature Td for rAAV2_587_bla of 55.6 °C. Surprisingly, this value corresponds approximately 
to that of rAAV2 wt. (Figure 5d, Table 2). 
Besides testing the effect of the enzyme decoration on capsid integrity, functionality of the 
integrated β-lactamases was evaluated. From the nitrocefin assay a β-lactamase concentration of 
1.65×10-10 mol l-1 was calculated, equivalent to 26.9 lactamases per DNaseI-resistant particle (Fig-
ure 5e). Looking from a different angle and assuming all 60 β-lactamase are active, yields a catalytic 
rate of 20,056.2 s-1 per capsid and a kcat value of 334.3 s-1 for each β-lactamase. The presence of active 
enzyme was furthermore studied in a simplistic bacterial growth assay. E. coli cells lacking the 
corresponding resistance gene are not able to survive on agar plates supplemented with ampicillin. 
The presence of functional β-lactamase, however, leads to degradation of the antibiotic and thus 
bacterial growth is possible. Mixing samples of rAAV2 wt with E. coli does not allow for bacterial 
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growth, whereas for samples of rAAV2_587_bla growth of bacterial colonies was observed (Figure 
5f) - again indicating the presence of active enzyme in the viral particle preparation. 
 
 
3. Discussion 
At the outset of the project, which relies on modular RepCap and ITR plasmids that are largely 
compatible with the BioBrick cloning standard, we first constructed an ITR plasmid. In this context 
we reconsidered the very old problem, that the ITR sequences in plasmids are not stable during 
plasmid propagation in E. coli and that specifically one ITR is prone to deletions despite the sym-
metry of their sequences [202]. To our knowledge no explanation has been put forward. We hy-
pothesize that the mechanism of plasmid replication of the prevalently used pMB1-derived origin 
of replication, which works unidirectional with respect to RNA II elongation and result in a switch 
between PolI and PolIII about 200 bp downstream of the replication start contributes to this genetic 
instability (SI Figure 2) [204]. In several ITR plasmids including our version, the distance between 
ori-start (end of RNAII) and the ITR with the more frequent deletion is about 74 bp. PolI and the 
polymerase switch, which might take place around the observed deletion site, might be more prone 
to induce deletions compared to the PolIII mediated replication. Since the most often observed 
deletion of 11 bp is also present in commercial and Addgene plasmids (e.g. pAAV_MCS [203]) and 
since it has been reported that even larger ITR deletions reduce production but increase transgene 
expression [205], we maintained the deletion in one ITR and placed it strategically next to the ori. 
Due to the pUC numbering scheme and expected GOI orientation of our plasmid, the deletion is 
located in the right or 3´ ITR, respectively (Figure 2e). Future experiments with various ITR to ori 
distances with high throughput ITR sequencing will test our hypothesis. 
We were pleased to see that production of rAAV2 wt with the modified RepCap plasmid and 
the ITR plasmid (Table 2) enabled production in useful quantity and quality. Previous work has 
shown that insertion of motifs at various sites of VP proteins is possible [260, 261]. We investigated 
glycine-serine linkers incorporated at residue position 587 by assaying capsid assembly, function-
ality and thermal stability. Production yields equal to that of rAAV wt showed compatibility with 
capsid assembly. Regarding transduction, we observed a significant impact of increasing insertion 
size with a non-linear decrease. The insertion of eight amino acids (GGSG)2 showed a significantly 
higher transduction compared to four amino acids (GGSG). Variable region VIII harbors residues 
R585 and R588, which mediate the primary interaction of AAV2 with the cell via HSPG [20, 21]. 
Spatial separation of the two arginines is known to interfere with cell binding and internalization 
[22]. The insertion of small motifs presumably increases the tension within the β-hairpin and hence 
the distance between the arginines (Figure 6). Larger flexible insertions probably are compatible 
with the correct arginine positioning but with increasing size a shielding effect becomes more and 
more prevalent. 
 
Figure 6. Model of the 587 loop region, from left to right: Structural model of the wild-type 587 loop 
with residue R585 and R588 highlighted in yellow (PDB: 1LP3); schematic model of 587 wild-type 
loop region (pink), 587 loop region with GGSG linker (light green) insertion leading to an increased 
arginine-arginine-distance; 587 loop region with (GGSG)2 linker (light green) insertion leading to a 
regular arginine-arginine-distance but steric shielding of HSPG binding motif. 
Next, we analyzed thermal stability using a qPCR-based method. We propose that the tem-
perature of viral DNA release given by a disintegration temperature named Td is a physical value 
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that is on a par or even better corresponding to the biological activity of rAAV as values obtained 
by DSF or DSC experiments. It was hypothesized that viral particles transfer to a metastable state 
upon heating, which is defined by ejection of the encapsulated ssDNA [208, 209]. Further temper-
ature increases then completely rupture the capsid. DSC and DSF are more likely to capture the 
complete disassembly of the capsid, and thus are expected to result in higher Tm values compared 
to the Td values. This is in agreement with our data which yielded disintegration temperatures 
about 15 °C lower than the melting temperatures published so far [198, 210]. 
As seen in the time course of isothermal disintegration (Figure 3h), the particles are not in 
thermal equilibrium at elevated temperatures discouraging thermodynamic interpretations. Thus, 
the Td values obtained are sensitive to the incubation time, which is expected for the megadalton 
complex. Interestingly, Figure 2h reveals a multi-phase behavior, which could be either interpreted 
by different composition or structural states of the initial capsid ensemble or by two unfolding 
pathways. Longer incubation times (> 5 min) most likely result in even lower Td values. Since most 
experimentally determined thermal stability changes within variants are minor, one can conclude 
that the capsid proteins form a stable framework highly resilient to sequence insertions. 
Since peptide insertions of up to 16 amino acids were well tolerated, a β-lactamase was inte-
grated at residue position 587. In one experiment β-lactamase was to be integrated only within the 
VP2 protein and not the VP3, which results from the same reading frame. An expression analysis 
of our existing CMV_VP2 plasmid revealed VP3 expression despite the CMV promoter for VP2 
and even after deletion of the VP3 start codon. This can be explained by persistent leaky scanning 
and by a second AUG codon present 24 bp downstream of the mutated VP3 start. Mutating the 
first AUG of the VP3 protein was described before [262], but no Western blot was provided sug-
gesting that a retained expression of VP3 could have occurred. That the VP2/3 gene retains expres-
sion of two proteins even if taken out of context and after a start codon removal indicates a deeply 
engrailed resilience to mutations and points to high robustness of the complex viral genome. We 
found that an additional strong Kozak sequence in front of VP3 resulted in the expression of solely 
modified VP2 [263].  
Initial experiments of the mosaic lactamase approach indicated that the molar ratio (i.e. gene 
dose) of the transfected plasmids plays a crucial role for the amount of modified VP2 proteins in 
the final capsid. Optimizing the quadruple setting, mosaic viral particles displaying lactamases 
were obtained with titers only slightly lower than those of wild-type preparations. Transduction 
efficiency of mosaic β-lactamase particles was reduced, but not as dramatically as in case of the 16 
amino acids insertion into the homogenously modified rAAV_587_(GGSG)4. Most likely the lac-
tamases pose a steric hindrance to the interaction with the cell, but the wild-type capsid proteins 
can still engage with HSPG. To our knowledge, this presents the first example of a successful en-
zyme incorporation at position 587 in the AAV capsid.  
From a nitrocefin enzyme assay the number of active β-lactamases on the mosaic 
rAAV2_VP2_587bla capsid was estimated to be 5.6. Our calculations are based on the genomic titer 
and the proportion of empty capsids has not been taken into account. An alternative analysis of the 
full capsid titer using ELISA techniques is probably equally misleading as the modification of the 
capsid surface might interfere with antibody binding. Another uncertainty for the exact determi-
nation of the lactamase concentration lies within the assumption of a constant kcat value, which was 
experimentally determined for the enzyme in solution. Due to immobilization on the capsids sur-
face, the enzymes possess less degrees of freedom and substrate access is hindered, which might 
result in lower turnover numbers. Taken together, the true number of capsids is higher than esti-
mated by genomic titer, because of empty capsids, but the true kcat on the surface is lower than the 
one taken from solution measurements. It is conceivable that a heterogeneous mixture of active, 
partially active and inactive enzymes is presented, but due to the highly cooperative unfolding of 
lactamase this is less likely. Therefore, the deduced enzyme concentration should only be taken as 
an estimate. Still, the calculated number of 5.6 enzymes per viral capsid is very close to the expected 
number of modified VP2 proteins in the wild-type setting where five of the 60 capsid-forming pro-
teins would be VP2. In combination, the data for a rAAV2 mCherry modification in the VP1 453 
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position [251] and for a lactamase modification in the VP2 587 position support the conclusion of a 
high structural plasticity of the AAV2 capsid.  
In order to further explore the robustness of AAV assembly, the integration of β-lactamase 
was expanded to all VP proteins. We were intrigued to see that introduction of the enzyme into 
position 587 is possible while viral integrity and thermal stability are maintained. AFM measure-
ments showed an increase in capsid diameter of 10 nm, which corresponds well to our estimations. 
Genomic titers were in the same range compared to the one of rAAV2 wt, which is remarkable 
considering the size of the β-lactamase. This suggests that VP folding, core capsid assembly and 
DNA encapsidation are not significantly affected by bulky insertions. Like the originating β-lac-
tamase variants [211], the enzyme variant used herein is known to fold well and to possess high 
thermodynamic stability (Hecky, Baumann unpublished data), which might contribute to the ro-
bustness of the modified VP protein and the corresponding capsid assembly. The high thermal 
stability of the inserted enzyme might even protect the VP proteins from unfolding. In contrast, 
glycine-serine linkers are intrinsically disordered. As expected, they were found to destabilize the 
VP proteins and the overall capsid. Enzyme activity of the sterically confined β-lactamases was 
measured. Calculations on the basis of the genomic titer and the turnover number show that ap-
proximately the equivalent of 26.9 active enzymes are presented. As discussed above, enzyme ac-
tivity could be reduced and deduced numbers of active enzymes per intact capsid present only an 
estimation. 
In summary we provide plasmids for facile genetic manipulation of AAV2 capsids and illu-
minate the intriguing resilience of AAV2 to a breadth of genetic and structural modifications. 
 
 
Materials and Methods  
Construction of plasmids. 
All constructs were made by standard cloning techniques mainly using idempotent cloning 
strategies according to RFC[10] or RFC[25], respectively [264, 265]. AAV plasmids listed in Table 1 
and SI Table 1 were cloned as described in SI Method 1. ITR sequencing is described in SI Method 
2. The CMV and hGHpA containing plasmids are from the iGEM parts registry (parts.igem.org). 
Resulting vectors were analyzed for their correctness by Sanger DNA-sequencing (Sequencing 
Core Facility, CeBiTec, Bielefeld, Germany). 
Cell Culture. 
HDFa (Thermo Fisher Scientific), HEK293, HeLa, HT1080 (DSMZ) cells were cultured in Dul-
becco’s Modified Eagle Medium supplemented 10% (v/v) fetal calf serum and 1% (v/v) penicil-
lin/streptomycin (Sigma Aldrich). MCF7, A431 and MDA-MB-231 (DSMZ) were cultured in RPMI 
supplemented 10% (v/v) fetal calf serum and 1% (v/v) penicillin/streptomycin. Cells were main-
tained at 37 °C and 5% CO2.  
Viral particle production. 
HEK293 cells were seeded at a density of 3×106 cells per 100 mm dish the day before transfec-
tion. A total amount of 15 µg DNA per 100 mm dish was transfected using calcium phosphate. 
RepCap plasmid, ITR-containing plasmid and pHelper plasmid were used in a 1:1:1 molar ratio 
[266]. For mosaic viral particles four plasmids were used in a 5:5:4:1 molar ratio of 
pHelper:ITR:RepCap_VP13:CMV_VP2. After 72 h of incubation at 37 °C, cells were harvested and 
pelleted by centrifugation (2000×g, 5 min). 
Purification of viral particles. 
Cells were resuspended in lysis buffer (50 mM Tris, 150 mM NaCl, 2 mM MgCl2, pH 7.5) and 
viral particles were released from cells with three freeze-thaw cycles. Remaining DNA contamina-
tion was degraded by incubation with benzonase nuclease (final 100 U/ml, Sigma Aldrich) at 37 °C 
prior to addition of CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate, 0.5% 
w/v final). The crude lysate was cleared from cell debris by centrifugation (3,000×g, 10 min). This 
crude viral stock was further purified with a discontinuous iodixanol gradient[134]. Briefly, the 
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lysate was transferred onto a gradient of 60%, 40%, 25% and 15% iodixanol in an open top polyal-
lomer 16 x 76 mm tube (Science Services). Tubes were sealed and centrifuged in a T-880 rotor (Sor-
vall) at 340,000×g for 2 h at 18 °C. The rAAV containing fraction was collected with a 21G x 1 1/2” 
injection needle and the buffer was exchanged to 1× PBS (137 mM NaCl, 2.6 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.2) via Amicon Ultra-4 100K centrifugal filter units (Merck Milli-
pore). 
SDS-PAGE and Western blot analysis.  
Cell pellets from rAAV production (1× 100 mm dish) were resuspended in 100 µl PBS and 5× 
SDS loading buffer. Samples were incubated at 95 °C for 10 min, centrifuged and 20 µl per lane 
were loaded on a 10% SDS-polyacrylamide gel (Hoefer SE260). Samples were blotted onto a 0.45 
µm nitrocellulose membrane (Thermo Fisher Scientific) using semi-dry electrophoretic transfer 
(V20-SDB, Sci Plas). After blocking the membrane with 10% (w/v) non-fat milk in TBS, the mem-
brane was incubated simultaneously for 1.5 h with the B1 antibody (mouse monoclonal, superna-
tant, 1:100, Progen) and an anti β-Actin antibody (8H10D10, mouse monoclonal, 1:1000, Cell Sig-
naling Technology). After incubation with an anti-mouse IgG, HRP-linked antibody (1:5000, Cell 
Signaling Technology), blots were imaged by luminescence detection (Pierce ECL Western Blot 
Substrate, Thermo Fisher Scientific). 
Determination of genomic titers.  
Before determination of genomic titers via qPCR, samples were treated with 10 U DNase I 
(New England Biolabs) in 10× DNaseI buffer in a final volume of 50 µl at 37 °C for 30 min before 
heat inactivation of the DNase I (75 °C, 20 min). Crude lysate samples were additionally incubated 
with 0.8 U Proteinase K (New England Biolabs) for 50 min at 37 °C before heat inactivation (95 °C, 
10 min). Dilutions of the DNase I digest were used as template in the qPCR reaction. The sample 
was mixed with 2.5 µl primer qPCR-hGH-for (5'-CTCCCCAGTG CCTCTCCT-3') and 2.5 µl primer 
qPCR-hGH-rev (5´-ACTTGCCCCT TGCTCCATAC-3´), each at a stock concentration of 4 µM, and 
10 µl of 2× GoTaq qPCR Mastermix (Promega). The qPCR reaction was carried out as described in 
the manual (TM318 6/14, Promega) with an increased time interval for the first denaturation step 
(95 °C, 10 min) using a LightCycler 480 II (Roche). The genomic titer was calculated from a standard 
curve of 102 to 107 copies of the ITR plasmid (pZMB0522) with an efficiency between 90-110% and 
an R value less than 0.1. Genomic titers in crude lysates were estimated from a standard curve 
mixed with the same amount of a non-transfected cell lysate. 
Transducing titer assay.  
10,000 cells per well were seeded in 500 µl of the corresponding media on a 12-well plate, 
settled for 1 h at 37 °C and then ultracentrifugation-purified rAAV samples were added. After 12 
h incubation, 500 µl fresh medium was added. After further 72 h incubation, cells were detached 
with 0.25% Trypsin/EDTA, resuspended in PBS and analyzed using a FACSCalibur and counting 
10,000 events. All experiments were performed as biological duplicates from two independent 
rAAV preparations. 
Transmission electron microscopy.  
Carbon-coated copper grids, 200 mesh (Electron Microscopy Science) were treated with oxy-
gen plasma (Zepto, Diener electronic GmbH). After this, 3 µl of precipitation-purified rAAV sam-
ple [254] was applied to the grid and incubated for 2 min. Excess liquid was drained off, the grid 
was dried at room temperature and washed with three drops of distilled water. Negative staining 
was performed using 3 µl 2% (v/v) uranyl acetate replacement stain (Electron Microscopy Sciences) 
for 30 s. Excess liquid was drained off and grids were dried before channeling the sample into the 
microscope. rAAVs were visualized with a Philips CM100 (PW6021) instrument with an accelera-
tion voltage of 80 kV. Images were analyzed using the Soft Imaging Viewer (Olympus) and ImageJ 
[267]. 
Atomic force microscopy.  
AFM measurements of rAAV2 wt and rAAV2_587_bla were performed on a Multimode 8 
AFM (Bruker) with Tap300Al-G cantilevers (BudgetSensors) in tapping mode in air. 2 µl of sample 
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in PBS were spotted onto freshly cleaved mica and incubated for one minute. The mica was then 
briefly rinsed with water and dried under a gentle nitrogen flow. Data analysis was performed 
with Gwyddion 2.48. Obtained images were treated with offset and plane correction algorithms 
and the size of visualized particles was measured at half maximum particle height. Statistical anal-
ysis of size measurements was performed using Excel 2016. 
 
AAV stability assay.  
Thermal stability was analyzed using iodixanol-purified rAAV2 variants in two technical rep-
licates. rAAV2 samples were diluted to 1.5×109 vg ml-1 with PBS. 10 µL aliquots of rAAV2 samples 
were incubated at temperatures ranging from 37.5 °C to 75.0 °C in 2.5 °C steps for 5 min in a ther-
mocycler (peqSTAR 96 Universal Gradient, peqlab). To determine the disintegration time kinetics 
rAAV2 wt samples were incubated at 56.1 °C for different time points. Immediately after incuba-
tion, samples were stored on ice. Genomic titers of each sample (10 µl) were determined by qPCR 
as described above. Due to the conceptual identity to the qPCR titration method, sensitivity and 
reliability are from this point on well established. A complete digest of the not encapsidated DNA 
was assured by additional tests. We evaluated the minimum titer of the starting material for a suc-
cessful evaluation of vector particle stability. This needed to be higher than 1×109 genomic copies 
per ml in order to result in a data set that covers the sigmoidal-shaped disintegration curve. Our 
qPCR standard curve shows a linear correlation between 102 and 107 genomic copies per sample 
which represents the dynamic range. Note that our qPCR primers hybridize in the hGHpolyA re-
gion and that we detect completeness of this region. Probing of different parts or the whole genome 
is possible. Data analysis was performed using Origin2018. The total rAAV amount per reaction 
was normalized to 100% and a logistic regression 𝑦 = 𝐴𝑚𝑖𝑛 +
(𝐴𝑚𝑎𝑥−𝐴min)
(1+(
𝑥0
𝑥
)
ℎ
)
𝑠   was performed with Amin 
= 0, Amax = 100, no weighting). The disintegration temperature (Td) was determined as the temper-
ature at which 50% of rAAVs released its DNA. 
β-lactamase activity assays.  
Activity of β-lactamase presented on the rAAV capsid was determined using a nitrocefin and 
a bacterial assay. For the spectrophotometric nitrocefin assay 91 µl of rAAV sample containing 
either rAAV2_587_bla or rAAV2_VP2_587_bla (each 3.7×108 vg total) or PBS (negative control) 
were mixed with 9 µl of nitrocefin buffer (2 mM nitrocefin, 500 mM KH2PO4 and 5% (v/v) DMSO 
at pH 7.0) in a 96-well plate. Absorption at 486 nm was measured with a microplate spectropho-
tometer (PowerWave HT, BioTek) in 1 min intervals for 40 min at room temperature. Calculations 
are based on Lambert-Beer’ rule as given in the formula: 
∆𝐴
∆𝑡
=  ∆𝜀486 ∙ 𝑐𝑏𝑙𝑎 ∙ 𝑘𝑐𝑎𝑡𝑏𝑙𝑎with 
∆𝐴
∆𝑡
= slope of 
linear regression from nitrocefin assay; ∆𝜀486 = molar extinction coefficient of nitrocefin shift (here 
16000 l mol-1 cm-1); 𝑐𝑏𝑙𝑎 =  concentration of β-lactamase; 𝑘𝑐𝑎𝑡𝑏𝑙𝑎 = catalytic constant of β-lactamase; 
𝑑 = distance (here 0.267 cm). Either the turnover number (here 746 s-1) or the concentration of active 
lactamases was assumed to be known. 
In the bacterial assay an aliquot of about 200 µl of an E. coli DH5α culture transfected with 
plasmid pSB1C3_BBa_J04450 harboring a constitutively expressed chloramphenicol acetyltransfer-
ase and a red fluorescent protein was plated on LB agar supplemented with ampicillin (100 µg ml-
1 final) and chloramphenicol (20 µg ml-1 final). rAAV samples (3 µl) were spotted (rAAV2_587_bla 
undiluted, 1:2, 1:3 and rAAV2 wt undiluted). The dish was incubated at 37 °C overnight. Due to 
lacking ampicillin resistance, growth and colony formation of E. coli cells only occur, when ampi-
cillin is hydrolyzed by active β-lactamase of the rAAV sample. Growing E. coli colonies could be 
easily detected by eye via their red appearance.  
Statistical analysis and reproducibility.  
Standard deviation was calculated for all biological and technical replicates. To test whether 
differences were statistically significant based on a 0.05 significance level, data were checked for a 
normal distribution by a Shapiro-Wilk-test, then an independent Student’s t-test was performed 
and p-values are given according to: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. Variation of transduction 
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efficiency determination was exemplarily tested in fully independent experiments with independ-
ent viral rAAV2 wt preparations by two authors. These data agree nicely with 95.7% (Figure 2d, SI 
Figure 4a) and 96.7% (Table 2, SI Figure 7b). Variation in the qPCR stability assay was tested with 
two independent viral preparations in two settings as shown in Figure 3c and 3h. In both assays 
50% of genomic copies are detected after 5 min incubation. 
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rAAV engineering for capsid-protein enzyme insertions and 
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1   Methods 
1.1   SI Method 1. Plasmid construction 
1.1.1   Plasmids constructed in this work 
pZMB0522_ITR_EXS_CMV_mVenus_hGHpA. This is the streamlined version of the rAAV ITR plasmid. To 
allow BioBrick compatible integration of expression casettes into the ITR plasmid, the region in-between the 
ITRs of vector pGolden-AAV (Addgene plasmid # 51424 was a gift from Yonglun Luo [47]) was changed 
and EcoRI, XbaI as prefix and SpeI as suffix sites were integrated by hybridized oligonucleotides through 
the unique BsmFI and AgeI sites. The backbone of this new generated RFC[10]-compatible ITR plasmid was 
digested with PstI and ligated with PCR-amplified pUC19 backbone (pUC19_PstI_for 5´-CTGCAGAAAA 
GGCCAGCAAA AGGC and pUC19_PstI_rev 5´-CTGCAGGCAC TTTTCGGGGA AATG) yielding 
pUC19_ITR_EXS. In the last step, the previously assembled BioBrick CMV_mVenus_hGHpA was cloned 
via EcoRI and SpeI into pUC19_ITR_EXS to generate pZMB0522_ITR_EXS_CMV_mVenus_hGHpA. 
This plasmid can be used to test GOI expression and at the same time allows integration of other genes. Note 
that XbaI and SpeI generate compatible cohesive ends. Facilitating new assemblies, a BioBrick CMV pro-
moter (pZMB0143-CMV) and BioBrick hGHpA (pZMB0135_hGHpA) are also available.  
pZMB0315_CMV_Kozak_VP2_453_587wtHis. This vector was constructed in two steps starting from 
pZMB0156_VP23_453_587wt. After RFC[10] integration of the CMV promoter, the VP3 initiation codon 
was mutated from ATG (Met) to ATC (Ile) using site-directed mutagenesis primers SDM_VP3ko_for 5´-
CTAATACGAT CGCTACAGGC AGTGGC and SDM_VP3ko_rev 5´-CCTGTAGCGA TCGTATTAGT 
TCCCAGAC. In the second step, a strong Kozak sequence was introduced via PCR primers XbaI_CMV-for 
5´-CTTCTAGAGC GATGTACGGG and CMV_Kozak_NgoMIV-rev 5´-ATAATGCCGG 
CCATGGTGGC CTAGTAATTT CGATAAGCCA GTAAG and recloning of the fragment. The HisTag in 
587 position was integrated by hybridization of oligonucleotide as described in SI Figure 11.  
Rep_VP123_453_587wtGG_p5tataless. This plasmid was constructed based on 
pZMB0216_Rep_VP123_453_587wt_p5tataless. A sequence coding for a Gly-Gly linker was integrated in 
position 587 by hybridization of oligonucleotides as described in SI Figure 11 upon digestion with BamHI 
and PvuII. The cloning strategy for other GGSG linker constructs is similar to this one. 
Rep_VP123_453_587wtbla_p5tataless. This plasmid was constructed based on iGEM plasmid 
BBa_K404250. Amongst others BBa_K404250 codes for a thermostabilised variant of β-lactamase which 
was amplified by PCR using BamHI_wt_bla-for 5´- AAAGGATCCG TATCTACCAA CCTCCAGAGA 
GGCAACCACC CAGAAACGCT GGCGAAAG and PvuII_wt_bla-rev 5´- AAACAGCTGT 
AGCTGCTTGT CTCCAATGCT TAATCAGTGA GGCACC primers. The BamHI and PvuII digested PCR 
product was inserted in 587 position of pZMB0216_Rep_VP123_453_587wt_p5tataless by standard cloning 
techniques. 
 
1.1.2   Plasmids previously generated and deposited  
pZMB0216_Rep_VP123_453_587wt_p5tataless. Base pair numbering given here refers to the start codon 
of the RepCap coding region. Starting with the pAAV-RC plasmid (GenBank: AF369963.1) silent mutations 
of two PstI restriction sites (nucleotide substitutions G177C and G3940C) in the Rep coding region were 
introduced by site-directed mutagenesis (QuikChange II Site-Directed Mutagenesis Kit, Agilent Technolo-
gies). Two EcoRI sites (substitutions A1449G and T1668C) and a PstI site (substitution C1641T) were re-
moved by cloning a synthesized DNA fragment (GeneArt, Darmstadt, Germany) into rep via BstEII/SwaI. 
To enable restriction-based modification of the 453 or 587 loop coding sequences, the unique restriction sites 
SspI/SalI (G3202A, C3205T, C3206T; T3254A, C3255G, A3256T, A3257C, G3259A) and BamHI/PvuII 
(T3613A, T3616C; C3658A, A3661T) were introduced adjacent to the 453 and 587 loop of the viral capsid 
protein (VP), respectively. This was achieved by cloning a second synthesized DNA fragment (GeneArt) into 
the respective region via XcmI and BsiWI. BamHI (C729T) and SalI (C1110G) within the Rep coding region 
were removed by silent site-directed mutagenesis. The final RepCap construct was cloned in pSB1C3_001 
via PCR using the primer Prefix_Rep68_78-ex (5´-GGAATTCGCG GCCGCTTCTA GATGGCGGGG 
TTTTACGAGA TTGTGATTAA G) and Suffix VP123ex RFC_25 5´-GCTACTAGTA TTAACCGGTG 
  10 Appendix: Publications 
125 
 
TAGTTAATGA TTAACCCGCC ATGCTACTTA TC) yielding pSB1C3_001_Rep_VP123_453_ 587wt. 
The promoter p5 TATA-less was converted into a BioBrick using p5_primer_for 5´-GCTCTAGAGG 
GAGGGGTGGA GTCGTGACGT G and p5_primer_rev 5´-TTCTGCAGCGG CCGCTACTAG TAG-
TTCAAAC CTCCCGCTTC AAAATGG and was cloned into pSB1C3_001_Rep_VP123_453_587wt via 
RFC[10] to generate the final construct pZMB0216_Rep_VP123_453_587wt_p5tataless. 
pZMB0600_Rep_VP13_453_587ko_p5tataless. This plasmid was obtained by silent site-directed mutagen-
esis of the ACG initiation codon of VP2 in pZMB0216_Rep_VP123_453_587wt_p5tataless with the primers: 
VP2-ko_for 5´-GGTTGAGGAACCTGTTAAGACCGCTCCGGGAAAAAAGAGG and VP2-ko_rev 5´-
CCTCTTTTTTCCCGGAGCGGTCTTAACAGGTTCCTCAACC to ACC. 
pZMB0091_CMV_DARPinE01_mli_VP23 _453_587koHis. This vector is the product of two BioBrick cloning 
steps. First DARPinE01 with a GGSGGGSG linker sequence was cloned via RFC[25] into 
pZMB0156_VP23_453_587wt and then the CMV promoter from pZMB0143_CMV was added via RFC[10]. 
The HSPGko and the His-tag were integrated into the 587 loop region via hybridization of oligonucleotides 
as described in SI Figure 11. 
pZMB0246_CMV_VP1up_NLS_mVenus_VP23_453_587koHis. This plasmid was generated by integrating 
the mVenus gene in pZMB0156_VP23_453_587wt fusing the VP1up_NLS part from 
pZMB0503_VP1up_NLS using the RFC[25] standard and adding the CMV promoter of pZMB0143_CMV. 
Finally, the 587 loop region was modified by hybridization of oligonucleotide coding for a His-Tag and the 
HSPGko as described in SI Figure 11.  
pZMB0156_VP23_453_587wt. This vector is a BioBrick plasmid for subcloning purposes and was con-
structed by PCR amplification of the cap part from pZMB0216_Rep_VP123_453_587wt_p5tataless with the 
primers Prefix_VP2ex 5‘-ATGGCCGGCG CTCCGGGAAA AAAGAGGCCG and Suf-
fix_VP123ex_RFC_25 5´-GCTACTAGT ATTAACCGGT GTAGTTAATG ATTAACCCGC CATGC-
TACTT ATC followed by cloning the product into pSB1C3_001 via RFC[10] to generate 
pZMB0156_VP23_453_587wt. This plasmid serves for further N-terminal modifications. Thus, the VP3 in-
itiation codon was not mutated. R585 and R588 (587ko) was introduced by hybridization of oligonucleotide 
as described in SI Figure 11. 
pZMB0503_VP1up_NLS. A fragment of VP1 named VP1up was converted to a RFC[25] Biobrick by PCR 
amplification from pAAV-RC using the primers Prefix_VP1ex 5´-ATGGCCGGCG CTGCCGATGG 
TTATCTTCCA G and VP1up_Suffix_rev 5´-GGACTAGTA TTAACCGGTC GCCTTAACAG 
GTTCCTCAAC CAGG and cloning into pSB1C3. The NLS was generated in RFC[25] standard with the 
oligonucleotides NLS_for 5´-AATTCGCGGC CGCTTCTAGA TGGCCGGCCC TGCAAGAAAA 
AGATTGAATA CCGGTTAATA CTAGTAGCGG CCGCTGCA and NLS_rev 5´-GCGGCCGCT 
ACTAGTATTA ACCGGTATTC AATCTTTTTC TTGCAGGGCC GGCCATCTAG AAGCGGCCGC G 
and cloned downstream of the VP1up sequence. 
pZMB0143_CMV. The CMV promoter was kindly provided by the iGEM team Ljubljana 2007 
(BBa_I712004). A sequence alignment of this BioBrick with the CMV promoter used in pAAV-MCS shows 
slight differences.  
pZMB0135_hGHpA. The human growth hormone polyadenylation signal (hGHpA) was converted into 
RFC[10] by PCR using pAAV-MCS as template and hGH_primer_for 5´-GCTCTAGACG GGTGGCATCC 
CTGTGAC and hGH_primer_rev 5´-GAACTGCAGC GGCCGCTACT AGTAAGGACAG 
GGAAGGGAGC AG and cloning the fragment in a pSB1C3 backbone.  
 
1.2   SI Method 2. Determination of ITR sequences using Sanger sequencing 
About 60 µg of ITR plasmid pZMB0522 were digested with 120 U MlyI in a total volume of 240 µl at 37 °C 
for 1.5 h and separated on an agarose gel. lITR and rITR fragments were isolated using NucleoSpin Gel and 
PCR Clean-up kit (MACHEREY-NAGEL). About 18 µg of each fragments were digested with 60 U BsaHI 
in a total volume of 120 µl at 37 °C for 2 h to split the sequence forming the major stem loop of the ITR 
sequence in half. Resulting fragments were separated on an agarose gel and 5´- and 3´-parts of the lITR and 
rITR were isolated. Sufficient material for several sequencing reactions was recovered. The obtained four 
DNA fragments were analysed by Sanger DNA-sequencing (Sequencing Core Facility, CeBiTec, Bielefeld, 
Germany). The sequencing primers were SEQ-lITR-5: 5´-GAAATGTTGA ATACTCATAC TCTTCC, 
SEQ-lITR-3: 5´-ATGAACTAAT GACCCCGTAA TTG, SEQ-rITR-5: 5´-CCTAATCTCA 
GGTGATCTACC and SEQ-rITR-3: 5´-AACGCCTGGT ATCTTTATAG TCC. Results are shown in SI 
Figure 2.  
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2   Supplementary Information Figures 
2.1   SI Figure 1 
 
 
No.  Position Site Action 
1 180 PstI removed 
2 726 BamHI removed 
3 1109 SalI removed 
4 1448 EcoRI removed 
5 1643 PstI removed 
6 1666 EcoRI removed 
7 3204 SspI introduced 
7 3244 KpnI introduced 
7 3256 SalI introduced 
8 3612 BamHI introduced 
8 3660 PvuII introduced 
9 3943 PstI removed 
 
  
 
SI Figure 1. Construction of the AAV2 RepCap plasmid (pZMB0216_Rep_VP123_453_587wt_p5tataless) 
and schematic overview of the rAAV plasmid production system. a) Rep and cap genes were integrated into 
the pSB1C3_001 backbone. Restriction sites not compatible with the RFC[10] standard were eliminated. 
Removal of restriction sites is marked with numbers and explained in the inset. For easy modification of 453 
and 587 loop regions, the recognition sequences of SspI and SalI, as well as BamHI and PvuII were intro-
duced. These allow for easy modification of the loop regions. Promoters are marked as green arrows. b) A 
forth plasmid allows for the production of mosaic rAAVs with e.g. modified 453 or 587 loop regions (green, 
e.g. His-tag) of the virion. Expressing a modified VP2 from a separate plasmid reduces the number of motifs 
on the capsid surface. c) Displaying proteins (grey, e.g. DARPinE01) on the capsid surface is also possible 
using a N-terminal fusion to VP2. d) Assembly of fusion proteins is carried out using the RFC[25] standard. 
The RFC[25] compatible multiple cloning site is visualized here.   
Rep genes
Cap genes
Promoter
453 loop region
587 loop region
rep
motif
(VP13)
CMV VP2
b
rep
VP2DARPinE01
(VP13)
CMV
c
d
5' - GAATTC GCGGCCGC T TCTAGA TG GCCGGC...[part]... ACCGGT TAAT ACTAGT A GCGGCCG CTGCAG - 3' 
EcoRI NotI XbaI NgoMIV AgeI SpeI NotI PstI
  10 Appendix: Publications 
127 
 
2.2   SI Figure 2 
 
SI Figure 2: Preparation of fragments suitable for sequencing of ITRs. a, b) Agarose gel electrophoresis 
using a 1 % gel at a voltage of 120 V for 90 min. a) The restriction digest of pZMB0522 with MlyI results in 
three fragments and both ITRs are separated on an agarose gel as highlighted in red. b) The larger fragments 
are further digested with BsaHI to break up the T-shaped stem loop and to enable Sanger DNA-sequencing. 
c, d) Results of Sanger-DNA sequencing aligned to original ITR sequences. Fragments were sequenced with 
oligonucleotides given in the methods. c) The left ITR is completely intact. d) The 3‘-part of rITR shows a 
deletion of 11 bp (5‘-TTTGCCCGGGC-3‘). e) Schematic overview of the ITR plasmid with used restriction 
sites. The 3‘ end of the ori is orientated towards the right ITR. f) Overview of the commercially available 
pAAV-MCS from Cell Biolabs with highlighted left and right ITR. The 3‘ end of the ori is oriented towards 
the left ITR which shows the 11 bp deletion. The distance between 3‘ end of the ori and the ITR with deletions 
is 74bp and 85 bp, respectively.  
We hypothesize that the distance of an ITR to the plasmid origin, the type of origin and the occurrence of 
Okazaki fragment processing sites may affect genetic ITR stability. In particular we assume that the E. coli 
PolI itself and the switch to PolII, which takes place shortly downstream of pMB1 type ori, contribute to the 
genetic instability.  
Note that the original modular ITR plasmid was numbered and presented as most ITR plasmids (panel f) and 
the deletion carrying ITR was the left or 5´ ITR. In the new ITR plasmid (pZMB0522) we kept the classical 
pUC numbering and thus the deletion is formally now in the right or 3´ ITR.  
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2.3   SI Figure 3 
 
SI Figure 3. Transmission electron microscopy micrographs to calculate the full to empty capsid ratio of 
rAAV particles. An overview of images used for calculations is shown. Samples were applied to carbon-
coated copper grids and stained with 2% uranyl acetate replacement stain (Science Services). rAAVs were 
visualized with a Philips CM100 (PW6021) with an acceleration voltage of 80 kV. Image analysis was per-
formed using Soft Imaging viewer (Olympus). Scale bars indicate 200 nm. The first image shows diameter 
measurements to verify the diameter of rAAV particles.  
  
200 nm 200 nm
200 nm200 nm 200 nm
200 nm
200 nm 200 nm 200 nm
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2.4   SI Figure 4 
 
SI Figure 4. Flow cytometry data for rAAV variants in comparison to the negative buffer control. Cells were 
transduced with rAAVs at a MOI of 10,000 and analyzed via flow cytometry after incubation. Data analysis 
was performed using FlowJo. In a first step a population of live cells was gated. In a second step a gate of 
1% false positive cells was selected in the sample of the negative control. This gate is visualized in each 
diagram.  
 
2.5   SI Figure 5 
 
SI Figure 5. Full length western blot images. a) Western blot of crude cell lysate after HEK293 triple-trans-
fection with pZMB0216, pZMB0522 and the pHelper plasmid. VP proteins were detected with the B1 anti-
body (Progen), a secondary HRP-coupled antibody and subsequent chemiluminescence imaging for 270 s. 
b) Western blot of crude cell lysate after transfection with the above mentioned plasmids. VP proteins were 
detected with the B1 antibody (Progen), a secondary HRP-coupled antibody and subsequent chemilumines-
cence imaging for 200 s. c) Western blot of a rAAV wt and rAAV bla from purified viral stocks. VP proteins 
were detected with the B1 antibody (Progen), a secondary HRP-coupled antibody and subsequent chemilu-
minescence imaging for 600 s.  
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2.6   SI Figure 6 
 
SI Figure 6. Western Blot analysis for rAAV2_mosaicVP2_587bla with respect to the gene dose of each 
plasmid. Crude cell lysate was applied to a 10 % SDS PAGE gel for electrophoresis. After semi-dry blotting 
onto a nitrocellulose membrane the VP proteins were detected with the B1 antibody (Progen). The plasmid 
ratio of the quadruple transfection was based on the ratio of the triple transfection. ITR, RC and pHelper 
plasmid have been used in a molar ratio of 1:1:1. To create a mosaic virus, CMV_Kozak_VP2_587bla and 
Rep2Cap2_VP13 have been transfected. The ratio of these plasmids was varied between 4:1 and 1:4.  
2.7   SI Figure 7 
 
SI Figure 7. Flow cytometry data for rAAV variants in comparison the negative buffer control. HT1080 cells 
were transduced with rAAVs at a MOI of 50,000 and analyzed via flow cytometry after incubation. Data 
analysis was performed using FlowJo. In a first step a population of live cells was gated (a). In a second step 
a gate of 1% false positive cells was selected in the sample of the negative control. This gate is visualized in 
each diagram. Overlay histograms for the wild-type rAAV2 b), all glycine-serine linker variants c-f) and both 
bla variants g-h) are shown. 
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2.8   SI Figure 8 
 
SI Figure 8. Atomic force micrographs of wild-type (wt) and fully β-lactamase modified rAAV (bla). The 
scale bars indicate 200 nm. Thin white lines with ticks show height profiles that were extracted to measure 
the individual particle diameter for particles that met a height threshold of 5 nm (wild-type capsids) and 6 
nm respectively. Particle width was determined at half maximum height. 
 
2.9   SI Figure 9 
 
SI Figure 9. Nitrocefin assay for determination of β-lactamase activity. a, b) Absorption measurements of 
rAAV2_587_bla and rAAV2_VP2_587_bla in different concentrations at 486 nm. Data points were meas-
ured in 1 min intervals. c) The first six data point were included in linear regression calculations. Resulting 
values are given in the table and correlate with dilution. Since very low concentrations were used, there are 
variations which can be explained in the pipetting the dilutions.  
 
 
 
 
wt wt
wt bla
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3   SI Tables 
3.1   SI Table 1 
 
SI Table 1. Overview of plasmids provided by the iGEM competition in 2010 including a short description 
of their features. 
Plasmid name with description Length Backbone 
pZMB0246_CMV_VP1up_NLS_mVenus_VP23_453_587koHis 
expression of VP1 with N-terminal mVenus as well as VP2 and VP3, R585 and R588 in 587 
loop regions are changed to Ala (HSPGko), His-tag in 587 loop 
5863 bp pSB1C3_001 
pZMB0091_CMV_DARPinE01_mli_VP23 _453_587koHis 
expression of VP2 with N-terminal DARPin E01 fusion, Arg in 587 loop changed to Ala 
(HSPGko) 
5191 bp pSB1C3_001 
pZMB0156_VP23_453_587wt 
construct for cloning, encodes VP2/3 with cloning ready loop regions, allows for the con-
struction of a N-terminal VP2 fusion 
4004 bp pSB1C3_001 
RFC[25] 
pZMB0503_VP1up_NLS 
construct for cloning, encodes the unique upstream region of VP1 (VP1up) and a nuclear 
localization sequence (NLS), precursor for assembly of surface exposed VP1 integrations 
2525 bp pSB1C3_001 
RFC[25] 
pZMB0143_CMV 
CMV promoter in RFC[10] for construction of N-terminal VP2 fusion vectors or ITR plas-
mid assembly 
2725 bp pSB1C3 
RFC[10] 
pZMB0135_hGHpA 
hGH polyadenylation signal in RFC[10] for assembling of the ITR plasmid.  
2550 bp pSB1C3  
RFC[10] 
 
3.2   SI Table 2 
 
SI Table 2. Characteristics of TEM β-lactamase variant 14FM. 
  β-lactamase 14FM 
Mutations compared to wild-type TEM-116 β-lactamase 
(GenBank ID: AY425988) 
V31A, A36L, L51I, R120G, E147G, H153R, V159T, M182T, 
L201P, I208M, E212K, A224V, A249V, T264M 
Melting temperature TM determined using far-UV circular 
dichroism in phosphate buffer 
71.6 °C (2 µM) 
72.7 °C (20 µM) 
Catalytic constant kcat for nitrocefin conversion in s-1 746 ± 76 s-1 
Source: T. Baumann, 2013, PhD thesis, University of Potsdam, Germany, “Stability and interconnected protein properties 
studied with TEM β-lactamase”  
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4   Cloning strategy 
4.1   Cloning of loop modifications in pZMB0216 
 
Residue 453 (position determined via Uniprot #P03135) 
For 5´-ATTTGTATTACTTGAGCAGAACAAACACTCCAAGTGGTNNN…NNNACCACCACGCAGAG-3´ 
Rev 5´-TAAACATAATGAACTCGTCTTGTTTGTGAGGTTCACCANNN…NNNTGGTGGTGCGTCTCAGCT-3´ 
 
Residue 587 WT 
For 5´-GATCCGTATCTACCAACCTCCAGAGAGGCAACNNN…NNNAGACAAGCAGCTACAG-3´ 
Rev 5´-GCATAGATGGTTGGAGGTCTCTCCGTTGNNN…NNNTCTGTTCGTCGATGTC-3´ 
 
Residue 587 KO 
For 5´-GATCCGTATCTACCAACCTCCAGGCTGGCAACNNN…NNNGCCCAAGCAGCTACAG-3´ 
Rev 5´-GCATAGATGGTTGGAGGTCCGACCGTTGNNN…NNNCGGGTTCGTCGATGTC-3´ 
 
Viral Brick 587ko-empty  
For 5´-GATCCGTATCTACCAACCTCCAGGCTGGCAACGCCCAAGCAGCTACAG-3´ 
Rev 5´-CTGTAGCTGCTTGGGCGTTGCCAGCCTGGAGGTTGGTAGATACG-3´ 
 
Viral Brick 587-GG  
For 5´-GATCCGTATCTACCAACCTCCAGAGAGGCAACGGAGGCAGACAAGCAGCTACAG-3´ 
Rev 5´-CTGTAGCTGCTTGTCTGCCTCCGTTGCCTCTCTGGAGGTTGGTAGATACG-3´ 
 
Viral Brick 587-GGSG  
For 5´-GATCCGTATCTACCAACCTCCAGAGAGGCAACGGAGGCTCTGGTAGACAAGCAGCTACAG-3´ 
Rev 5´-CTGTAGCTGCTTGTCTACCAGAGCCTCCGTTGCCTCTCTGGAGGTTGGTAGATACG-3´ 
 
Viral Brick 587-2x(GGSG)  
For 5´-GATCCGTATCTACCAACCTCCAGAGAGGCAACGGAGGCTCTGGTGGCGGTTCAGGAAGACAAGCAGCTACAG-3´ 
Rev 5´-CTGTAGCTGCTTGTCTTCCTGAACCGCCACCAGAGCCTCCGTTGCCTCTCTGGAGGTTGGTAGATACG-3´ 
 
Viral Brick 587-4x(GGSG)  
For 5´-GATCCGTATCTACCAACCTCCAGAGAGGCAACGGAGGCTCTGGTGGCGGTTCAGGAGGTG-
GAAGCGGCGGAGGTAGTGGCAGACAAGCAGCTACAG-3´ 
Rev 5´-CTGTAGCTGCTTGTCTGCCACTACCTCCGCCGCTTCCACCTCCTGAACCGCCACCAGAGCCTCCGTTGCCTCTCTGGAGGTTGGTAGATACG-3´ 
 
SI Figure 11: Cloning strategy for 453 and 587 loop regions. Sequences of oligonucleotides used for the 
generation of different loop modifications by hybridization are shown. The given oligonucleotides have been 
cloned via the above mentioned restriction enzymes. 
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4.2   Cloning of N-terminal VP2 modifications in rAAV2 
 
SI Figure 12: Cloning strategy for pZMB0091_CMV_GOI_mli_VP23 _453_587koHis. This plasmid was 
not used during this work but shows the potential assembly of N-terminal fusion proteins. Assembly of Bio-
Bricks can be performed as shown. The following abbreviations are used for the restriction enzymes and their 
recognition sites, respectively: E= EcoRI, X= XbaI, N= NgoMIV, A= AgeI, S= SpeI, P= PstI.  
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Abstract 
Background: Recombinant adeno-associated viruses (rAAV) bear great potential for gene therapy and their 
production with helper-free plasmid systems in HEK293 cells is well established. However, current ap-
proaches require the tedious preparation and co-transfection of the invariant adenoviral helper genes for 
each production cycle. Genomic integration of essential elements can simplify the manufacturing process. 
Results: We engineered a HEK293 cell line by stably integrating adenoviral elements E2A, E4 and the non-
coding VA RNA. After selection, single cell colonies were analyzed for sequence integration. Insert stability 
was maintained over more than four months of continuous culture. The novel HEK293-KARE1 cell line was 
characterized with regard to growth and cell cycle state demonstrating a very small influence of adenoviral 
genes. RNA Expression of E2A and E4 was verified using RT-PCR at a low level compared to already present 
E1A. Transduction and rAAV2 production in the new cell line by solely providing a RepCap and a ITR/vector 
plasmid was established with yields comparable to those obtained with the well-established three-plasmid 
system in the original HEK293 cells.  
Conclusions: The results show that HEK293-Ad-helper cell lines have the potential to reduce upstream time 
and cost while ensuring consistent and safe rAAV manufacturability. 
Keywords: AAV2, adenovirus, virus-like particle 
  10 Appendix: Publications 
137 
 
Background 
Recombinant adeno-associated virus (rAAV) approaches gained an outstanding reputation in gene therapy 
due to their beneficial characteristics. Among the numerous advantages over other virus-based gene ther-
apy approaches is the attainable long-term gene expression and the high safety profile resulting from the 
inability to autonomously replicate without additional genes from a wild type and a helper virus. AAVs tar-
get dividing and non-dividing cells, possess low immunogenicity and are produced at larger scale for clinical 
applications [1]. The AAV toolbox for gene therapy is large: currently 13 different serotypes are character-
ized and over 100 AAV variants are known [2]. Serotype 2 was studied intensively and was the first serotype 
to be produced in mammalian cells [3, 4]. Mammalian cells and insect cells are well established as host 
systems. The best studied and most widely used system relies on the human embryonic kidney cell line 293 
(HEK293) [5]. Formerly, a helper virus (e.g. adenovirus (Ad)) was used to facilitate production, but nowadays 
the biologically safer use of a plasmid system is the standard, in which the genes coding for supporting 
adenoviral proteins are encoded in trans [6]. The latter is named the helper-free plasmid system and han-
dling is in many countries regarded as biosafety level 1 work. The helper-free production was independently 
published by two research groups in 1998, demonstrating that the presence of the Ad genes E1A, E1B, E2A 
and E4 and the non-coding RNA VA are required for replication of AAV [7, 8]. The production cell line HEK293 
cell line was generated by transfection with fragments of mechanically sheared adenovirus 5 DNA and the 
presence of adenoviral E1A and E1B in chromosome 19 (19q13.2) was confirmed indicating random inte-
gration [9–11]. Besides their biological function for immortalization, transcripts from both genes were iden-
tified. The gene of E1A (early E1A protein) promotes host DNA synthesis and stabilizes the tumor suppressor 
p53 inducing apoptosis [12]. Two gene products generated from E1B (E1B19K and E1B55K) are able to pro-
tect cells from the cytotoxic effects of E1A [12]. In the helper-free system the remaining genes E2A and E4 
and the non-coding RNA VA are provided by plasmids called pVAE2AE4-5 or pXX6 [7, 8], which are collec-
tively referred to as ‘helper plasmids’. More specifically, pHelper GenBank AF369965.1 contains the VA 
RNAs, the E2A part coding for the 72 kDa single stranded DNA binding protein, and the coding region of 
E4orf6 [13]. Undesired adenovirus late genes were omitted from those helper plasmids eliminating the 
possibility of a wild-type adenovirus contamination. Expression of E1A and E1B induces expression of E2A 
and E4. E1A also acts on the AAV P5 promoter and induces expression of AAV Rep and Cap genes in trans 
[14]. E2A codes mainly for the Ad single-stranded DNA binding protein (DBP), which is besides several other 
functions involved in augmentation of rAAV circular intermediate formations [15]. The gene E4 codes for 
several proteins but during rAAV production mainly E4orf6 is of importance. E4orf6 is able to associate to 
E1B55K and regulates p53 stability promoting apoptosis [16, 17]. The last important feature required for 
helper-free rAAV production is VA I RNA. VA I RNA generates a small RNA transcript, that regulates gene 
expression at the level of translation in transfected cells [18]. In presence of DBP it enhances AAV cytosolic 
mRNA by stabilization [19].  
For rAAV production, the two commonly used helper-free plasmid systems either employ a two- or a three-
plasmid system [20, 21]. By distributing the genetic information of rAAV on different plasmids the likelihood 
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of the emergence of a replicative competent virus becomes extremely low. The three-plasmid system con-
sists of the pHelper plasmid coding for the required Ad5 genes, a RepCap plasmid and an ITR-containing 
plasmid often named vector plasmid. The RepCap plasmid provides the information for the four nonstruc-
tural proteins Rep 78, 68, 52, 40 and the three proteins VP1, VP2, VP3 forming the icosahedral capsid struc-
ture. Furthermore, the Cap open reading cassette codes, in an alternative reading frame, for the assembly 
activating protein (AAP) as well the X protein, which influences replication and vision production [22–25]. 
The third plasmid needed is the ITR-containing plasmid, which harbors the gene of interest flanked on both 
sites by an inverted terminal repeat (ITR) sequence. ITRs mediate DNA replication and function as packaging 
signal for the single-stranded DNA into the capsid shell [26]. The two-plasmid system, which was devised 
by Grimm et al. in 2003, combines the genetic information of the adenoviral helper sequences E2A, E4 and 
VA with AAV serotype specific rep and cap genes on the pDG plasmid [20]. This approach has been further 
optimized by the use of minicircle DNA [27]. 
The widely adopted helper-free plasmid systems are reliable, but pose the inconvenience of the continuous 
production and co-transfection of the invariant adenoviral helper genes of 9279 bp. So far, even in cellular 
optimized processes for clinical rAAV production developed by leading research groups, the three-plasmid 
system is deployed [1]. 
Several groups have tried to establish production cell lines harboring either single parts of the adenoviral 
elements or combinations of different elements. First trials to create a production cell line started with 
genomic integration of rAAV RepCap and ITR parts into HeLa cells [28]. rAAV production starts upon infec-
tion with adenovirus and, thus does not need DNA transfection. Next, groups started with integration of 
RepCap and ITR parts into a E1A and E1B inducible cell line and went on by further introducing adenoviral 
elements E2, E4 and VA [29]. Nonetheless, integration of all necessary elements resulted in less stable cell 
lines with decreasing yields of viral particles. Other attempts to create AAV production cell lines relied on 
genomic integration of adenoviral elements or RepCap parts but also resulted in cell lines where either 
transfection of invariant plasmids or the use of the adenovirus are required [30, 31].  
In order to ease and improve rAAV production, we generated a HEK293-Ad-helper cell line, that stably pro-
vides the Ad5 genes necessary for rAAV formation. As known from previous work, high levels of early ade-
noviral gene products can have toxic effects to cells [32]. Until now, the most effective gene dose for high-
titer rAAV production is not known, which provides the opportunity that cells producing a non-toxic level 
of proteins are able to produce viral particles without addition of a helper plasmid. Such an engineered cell 
line was generated and named HEK293-KARE1. The integration of helper genes was verified in three clones. 
rAAV2 virus-particle production was monitored and the transfection protocol was optimized with regard to 
the amount of required DNA and the potential need for selection pressure for genomic integration. Fur-
thermore, genomic and transducing titers were determined and compared to the common three-plasmid 
production system. The presented methodology simplifies the well-established AAV production process and 
reduces the risks of undesired DNA packaging of pHelper DNA [33]. 
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Results  
Integration of pHelper sequences into HEK293 
As introduced above, pHelper plasmid (GenBank Accession number: AF369965.1) harbors the three adeno-
viral elements E2A, E4 and VA and a BLAST comparison confirms 100 % sequence coverage with the corre-
sponding parts of the genome of adenovirus 2 (GenBank: J01917.1). Integration of the entire pHelper plas-
mid into the genome of HEK293 was facilitated by introduction of a selectable marker into the pHelper 
plasmid. The gene for blasticidin S deaminase from Aspergillus terreus was amplified and cloned into 
pHelper via two unique restriction sites (NdeI, SalI) yielding pHelper-BSD (Figure 1). This plasmid was line-
arized, dephosphorylated and transfected in HEK293 cells. Three days post transfection selective pressure 
was applied and cell death of putatively non-transfected cells was observed after further incubation for two 
days. Medium was exchanged every second day and after two weeks dividing cells were observable, that 
potentially carried the desired construct. Consequently, a limiting dilution in 96-well plates was used to 
select single cells for further cultivation and characterization. Cells growing as monoclonal colonies were 
identified by microscopy and, after reaching confluence, four monoclonal cultures were transferred in a 6-
well plate and named HEK293-KARE1a to HEK293-KARE1d. These clones were chosen, because they showed 
the highest growth rates. The growth of all clones was comparable to that of the parental HEK293 cell line, 
while maintaining the blasticidin concentration. Cells were passaged regularly, and since HEK293-KARE1d 
showed decreased viability and transfection efficiency this clone was discarded. For cell lines HEK293-
KARE1a to 1c characteristic HEK293-like growth in monolayers, adherence and viability were confirmed 
beyond 30 passages. During subculturing no changes in morphology were seen in bright field microscopy at 
40-fold magnification as exemplified by HEK293-KARE1c after 20 passages (Figure 2A) in comparison to the 
parental HEK293 (Figure 2B). Growth behavior of HEK293 and HEK293-KARE1a to 1c was analyzed for 72 h 
after passage three and is depicted in Figure 2C. Experimental results were fitted with an exponential func-
tion to determine the population doubling times. Clones HEK293-KARE1a and 1c showed a doubling time 
comparable to that of HEK293 cells. For HEK293-KARE1b a slower growth rate was calculated. 
Verifying genomic integration of pHelper sequences 
After isolation of monoclonal cultures and detection of normal cell growth, genomic integration of the 
helper genes was analyzed. Genomic DNA of the three clones was isolated using a Chelex100 extraction. 
The presence of the bsd and the E2A gene was verified using PCR with two different sets of primers. As seen 
in Figure 1 primers Bsd-for and Bsd-rev as well as Ad5-for and Ad5-rev anneal at different regions of the 
plasmid and, in the case of a successful complete integration, amplification products with a size of 499 bp 
and 524 bp respectively for E2A and bsd should emerge. Experimentally obtained fragments are shown in 
Figure 2D for all samples, demonstrating that both genes were integrated successfully into the genome of 
HEK293. Genetic integration of the plasmid sequence might not automatically result in successful gene ex-
pression. In a next step, the presence of the gene products was verified. 
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Gene expression of adenoviral E2A and E4 does not interfere with cell growth and cell cycle progression 
The resistance of monoclonal cells to blasticidin indicated that integrated genes are not silenced and gene 
expression is likely. To verify the presence and expression of the integrated elements E2A and E4 the mRNA 
level was determined. RNA from HEK293 and HEK293-KARE1 cells was extracted and subsequently cDNA 
was generated. A qPCR was carried out with three different sets of primers for E1A, E2A and E4. Oligonu-
cleotide sequences to amplify E2A were selected to bind in the coding sequences for the DNA-binding pro-
tein of human adenovirus type 2 (GenBank: AAA92217.1). The primer pair used to amplify E4 was selected 
to anneal at open reading frame 6 coding for E4 34k, mainly involved in the AAV production process [34]. 
Calculation of ΔΔCt values showed an elevated relative expression level of both adenoviral early genes in 
HEK293-KARE1 clones compared to HEK293 (Figure 3A). These calculations were based on E1A as a normal-
izing gene which is present in the parental and the novel HEK293 cell line. Since expression of E2A and E4 
might influence the expression of E1A, we evaluated three independent RNA isolations and qRT-PCR reac-
tion to show that cycle thresholds for E1A were constant during the experiments and E1A expression is not 
altered (SI Table 1). The expression level of E2A was higher compared to the E4 expression. Analysis of the 
PCR products on an agarose gel (Figure 3B) revealed the correct sizes with 68 bp, 65 bp and 143 bp for E1A, 
E2A and E4 respectively. Previously published work showed that expression of adenoviral parts in HEK293 
cells can have a strong impact on cell growth and cell cycle. Integration of E4 in an inducible system showed 
that the progression through the cell cycle can be altered [35]. Furthermore, it is known that high levels of 
E2A and E4 in the presence of E1 gene products are toxic to cells [32]. To gain a deeper insight in the newly 
developed cell line, cell cycle progression was determined.  
In literature, it was proposed that expression of the E4 ORF6 protein leads to an accumulation of the cells 
in the S-phase of the cell cycle [35]. To this end, we investigated the effect of adenoviral elements on the 
cell cycle under general AAV production conditions. A delay in the S-phase was not observed as seen in 
Figure 3C and D. Cells were seeded at the same high density as typically done for AAV production (3×106 
per 100 mm dish), and thus, cell growth was limited. The observed distribution of cell cycle states over the 
typical production time of 72 h of the cultivation is expected. There is no significant difference between the 
HEK293 cell lines and the newly developed HEK293-KARE1 cell lines. As a control for adenoviral element 
expression, a rAAV producing HEK293 sample was used. This showed a high accumulation in G1 phase right 
after the transfection, which was reversed as the cells adapted to the conditions of the transfection. These 
experiments suggest that production of rAAVs in HEK293-KARE1 cells is possible, because necessary pro-
teins are expressed and cell proliferation is largely unaltered upon genetic intervention. 
 
rAAV production was confirmed for HEK293-KARE1  
In order to assess the rAAV production ability and their long-term productivity, three HEK293-KARE1 clones 
were cultured similar to normal HEK293 with the only difference of maintaining antibiotic selection. First 
attempts for rAAV production started with adapting the three-plasmid co-transfection for high titer rAAV 
production in HEK293 cells. Here, pHelper plasmid, Rep2Cap2587wt- and ITR-plasmid are transfected in a 
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molar 1:1:1 ratio and a total plasmid DNA amount of 15 µg per 100 mm dish. We started with a double-
transfection of the Rep2Cap2587wt - and ITR-plasmid in a 1:1 ratio omitting the pHelper plasmid but keeping 
the total plasmid DNA amount of 15 µg per 100 mm dish. These experiments were carried out with the 
three cell lines HEK293-KARE1a to 1c after passage 3 and 9 and as a negative control with HEK293 cells and 
as a positive control with HEK293 cells and triple plasmid transfection. Genomic titers, or more precisely of 
DNase I-resistant particles, were determined directly without further purification from the crude cell extract 
using qPCR with a set of ITR-plasmid specific primers. To get meaningful results, the standard curve used 
for determination of the genomic titer was set up in equal amounts of crude cell extract from untransfected 
cells. Resulting genomic titers of this experiment are presented in Figure 4A. As expected, rAAV production 
was observed for HEK293-KARE1 clones when omitting the pHelper plasmid. HEK293 cells transfected with-
out addition of pHelper show a dramatic reduction in production capacity of viral particles. Note that this 
background may be related to small impurities of transfected plasmid. Productivity of all clones is compa-
rable to the parental HEK293 cell line after the well-known triple transfection. Optimization of the rAAV 
production process was performed only with clone HEK293-KARE1c which yielded in the highest genomic 
titer (4.6x1010 vg per ml) in crude cell extract. Furthermore, no reduction of rAAV titer was observed when 
cells were cultivated for nine passages. Cryopreservation did not alter production capacity as these experi-
ments were conducted from biological duplicates that were independently thawed. We additionally opti-
mized the production process as the high DNA amount and addition of the antibiotic might not be desired 
during the production process. Lowering the required plasmid dose and omitting the antibiotic would re-
duce production costs and possible sources of product contaminations. We hypothesized that reduction of 
the total DNA amount is compatible with rAAV production. Thus, a reduction of the total plasmid DNA 
amount from 15 µg to 7.4 µg was tested. This value corresponds to the total DNA amount of Rep2Cap2587wt- 
and ITR-plasmid in the standard triple-transfection protocol with just omitting the pHelper plasmid DNA. 
Previous attempts using the standard calcium-phosphate transfection protocol indicated a deterioration of 
transfection efficiency and associated lower genomic titer (data not shown). The calcium-phosphate trans-
fection method is based on DNA-calcium phosphate precipitation which is dependent on a specific DNA to 
calcium ion ratio [36]. Simply reducing the DNA amount did not lead to satisfying precipitation, which was 
observed by a decreased turbidity of the transfection solution. We adapted the transfection protocol for a 
reduced amount of DNA which resulted in genomic titers comparable to the use of 15 µg total DNA per 
transfection (Figure 4B, first and second bar). In a second optimization step we evaluated the need for the 
selective pressure during the production process. We did not want to generally omit the use of the antibiotic 
as it is known that gene silencing might occur if the selective pressure is not maintained. We seeded cells 
for rAAV production without addition of blasticidin and performed transfections the day after. Comparison 
of genomic titers from crude cell extracts after 72 h proved rAAV production even without the addition of 
the antibiotic in comparable yields (Figure 4B, third and fourth bar). The variations observed between sep-
arate biologic experiments (Figure 4B, second and third bar) can be attributed to passaging and handling. 
These differences might seem high but it should be considered that experiments were conducted in the 
course of cell line characterization. 
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rAAV2 was successfully produced in HEK293-KARE1c, purified and characterized 
After reducing the amount of DNA and the concentration of antibiotic, the quality of the produced viral 
particles was characterized. We produced rAAV2 in the favorite HEK293-KARE1c clone. Cells were seeded 
on ten 100 mm dishes the day before transfection. Transfections were carried out using the previously 
adapted calcium-phosphate transfection protocol with a total plasmid DNA of 7.4 µg (2.5 pg per cell) and 
1:1 molar ratio of Rep2Cap2587wt to ITR-plasmid. Viral particles were purified using a standard iodixanol-
gradient ultracentrifugation protocol. The transducing titer was determined for a serial dilution of viral par-
ticles on HT 1080 cells. The ITR-delivered gene of interest coded for the fluorescent protein mVenus under 
the control of a CMV promoter and thus successful transduction resulted in yellow fluorescent cells, which 
were analyzed by fluorescence microscopy and flow cytometry. To calculate the transducing titer from flow 
cytometry data, the lowest serial dilution was used (Figure 5A) and the genomic titer was determined via 
qPCR. Both titers are presented in Figure 5B. The transducing titer is about 10-fold lower compared to the 
genomic titer which is in agreement with the literature [37]. The sample purified by ultracentrifugation was 
analyzed by atomic force microscopy (AFM) (Figure 5C). The calculated mean diameter of the marked par-
ticles is with 21.5 nm in the expected range of 20 to 24 nm (Figure 5D) [38]. 
 
Discussion 
The demand for an effective, safe rAAV production system is high. A well-known DNA contaminant in rAAV 
preparations is, beside others, DNA from the Helper plasmid. Depending on the rAAV purification method, 
0.01 % to 0.07 % contaminating Helper DNA has been found [33]. This can reduce vector potency and is 
therefore undesirable in rAAV preparations. Staying with the well-established production system in HEK293 
cells, we describe the generation and characterization of a new mammalian cell line providing all necessary 
adenoviral elements. By eliminating the need of transfecting the Helper plasmid and simultaneously reduc-
ing the DNA amount for successful rAAV production, this cell line offers a significant time and cost ad-
vantage compared to the use of the parental HEK293 cell line.  
rAAV production in HEK293 is classified as biosafety level 1 work in many countries. We assume that a stable 
HEK293-Ad-helper cell line does not change this assessment. The risk of the generation of a replicative ad-
enovirus or a replicative AAV is not altered whether the adenoviral helper genes are maintained on plasmids 
or within the genome. Late adenoviral genes required for adenovirus capsid assembly are nonexistent in 
either system and the risk of unintended recombination or contamination of the culture with other viruses 
remains at the same level. One could even speculate that recombination events are rarer due to the ge-
nomic fixation. Furthermore, the remaining two plasmid system is unchanged disallowing production of 
replication competent wtAAV, because ITRs and RepCap genes are separated.  
The HEK293-KARE1 cell line described here was generated using linear, dephosphorylated DNA. This al-
lowed for a random integration of the construct into the genome. Integration can cause dysregulation or 
impede the expression of endogenous genes leading to cell death. Surviving cells can show different levels 
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of the transgene product as the expression is strongly influenced by the surrounding genomic structure. A 
cell line that highly expresses adenoviral genes could show an inhibited cell growth or high mortality as seen 
for HEK293-KARE1d. These potential problems might also explain why a directed integration via 
CRISPR/Cas9 that we previously attempted at a predetermined locus did fail.  
Integration of adenoviral elements was proven by PCR for all clones. Analysis of cell growth and cell cycle 
progression revealed, that for all isolated clones the effect of transgene expression was not significant. The 
slower growth rate seen for HEK293-KARE1b in Figure 2C might be explained by the initial higher cell density 
limiting growth after 72 h or indeed by impeded growth. In comparison with the parental HEK293 cell line, 
growth characteristics of the other KARE clones were nearly equivalent suggesting that an adaptation to 
suspension and subsequent culturing without serum is possible. This would open new chances for a large-
scale production of rAAVs, e.g. in a bioreactor. 
The mRNA expression level of E2A and E4 was shown to be elevated compared to the parental HEK293 cell 
line. To our knowledge, the helper-gene dose required for highly efficient AAV production is not known. 
Expression of early adenoviral genes is controlled by several promoters starting from the E1A promoter. 
Upon E1A expression the promoters of E1B, E2, E3 and E4 become active [39]. The strength of the promoter 
and thus the transcription of mRNA can differ between adenoviral elements, even when all parts are inte-
grated at the same genomic site. The observed relative expression levels were expected, as high E2A ex-
pression would compromise cell growth. Previous work showed that a high level of E2A in presence of E1 
proteins can have toxic effects on cells [32].  
All HEK293-KARE1 clones were analyzed for their ability to produce virus in a two-plasmid system. Trans-
fecting a RepCap plasmid offers the opportunity to change parts of the capsid and the packaged DNA and 
thus provides the user with maximum flexibility. In comparison to the parental HEK293 cell line, all clones 
show a high capacity to produce rAAV. We observed during our experiments that the HEK293-KARE1 cell 
lines require more time to adapt to growth conditions after cryopreservation. For this reason, we believe 
that at later passages cells were better adapted and yielded in higher titer. To a lower extent we observed 
the influence on cell adaptation also for HEK293 cells. Adjusting transfection conditions and DNA ratios for 
HEK293-KARE1c increased the overall titer. These results demonstrate that the low mRNA levels of E2A and 
E4 support rAAV manufacturing. HEK293-KARE1c was chosen for a larger scale production with subsequent 
rAAV purification using a well-established purification protocol. These rAAV2 particles showed the expected 
ratio between genomic and transducing titer as it was known from the three-plasmid system [37]. The rAAV 
yield was in the range of 3.2×104 to 8.4×104 GC per cell (Fig. 4B). For similar small-scale experiments with 
HEK293 cells, albeit in a commercial context, a value of 8.3×104 GC per cell has been reported [40]. Other 
groups determined that the choice of primers and the reference material for qPCR (circular, linear DNA) 
have a tremendous effect on the genomic titers [41, 42].Specifically, ITR primers compared to primers bind-
ing the gene of interest yielded up to ten times higher genomic copies when plasmids were used as refer-
ence. We would like to mention that we used primers binding the hGHpA region whereas in literature pri-
mers binding the ITR region have been applied and both experiments used plasmid DNA as reference [40]. 
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Also size and shape of the produced viral particles, as detected by AFM, are in good agreement with tradi-
tionally produced rAAV. Hence, the quality of rAAVs produced using the novel cell line is equivalent.  
This cell line also opens up the new possibility for experiments that require a wild-type intermediate step, 
e.g. directed evolution of rAAV. Directed evolution requires the presence of either a wild-type rAAV or the 
helper genes to allow for amplification of the viral particles. The HEK293-KARE cell line facilitates this 
method, since neither wild type virus nor transfections have to be used. 
 
Conclusions 
For efficient AAV vector production a self-sufficient packaging cell line was created. Based on previous work 
by others the adenoviral genes VA RNA, E2A and E4orf6 were stably integrated in HEK293 cells in addition 
to the already present genes E1A and E1B19K. We demonstrated that the resulting HEK293-KARE1c cell line 
provides a cost-efficient production platform for rAAV2, because a helper plasmid is no longer required. 
This means not only higher safety, but also the necessity of their time-consuming production and purifica-
tion. It also offers a streamlined method for the directed evolution approaches. 
. The simplified production and the final quality of the preparations show the potential of stably transfected 
cell lines. We assume that our approach can be combined with other stable transfection strategies such as 
the integration of the ITR plasmid or the RepCap plasmid open up avenues for inexpensive and safe large 
scale rAAV production. An adaption to suspension will allow large scale production of rAAVs, e.g. in a bio-
reactor 
 
Methods 
Plasmids. The gene for blasticidin S deaminase of Aspergillus terreus was amplified from pcDNA6/myc-His 
(Thermo Fisher Scientific, Cat. No. V22120; sequence available from the vendor’s website), without desig-
nated promoter and poly(A) signal, using the primers bsd-SalI (5'-AAAAAAGTCG ACGTTTAAAC GGATCTGATC 
AGCACGTGTT-3') and bsd-NdeI (5'-AAAAAACATA TGATCTCGTA GCACGTGTCA GT-3'), which introduced the 
underlined SalI and NdeI restriction sites. For better comprehensibility the hydrizinding area is italicized. 
The digested insert was ligated to the likewise opened pHelper plasmid (GenBank: AF369965.1) resulting in 
pHelper-BSD (see Additional File). Successful cloning was confirmed by Sanger DNA sequencing (Sequencing 
Core Facility, CeBiTec, Bielefeld, Germany).  
Plasmids for viral particle production were based on a pSB1C3 backbone and were assembled using the 
iGEM RFC10 BioBrick assembly standard [43]. pZMB0216_Rep_VP123_453_587wt_p5tataless contains a 
genetically modified rep/cap similar to one encoded in pAAV-RC (Genbank Accession number: AF369963.1). 
In the ITR containing plasmid pZMB0522_ITR_EXS_CMV_mVenus_hGHpA, a CMV promoter expresses the 
fluorescent protein mVenus. Plasmids are described in detail by Feiner et. al [submitted 2019]. 
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Cell Culture. HEK293 (ACC-305, DSMZ) and HT-1080 (ACC-315, DSMZ) were cultured in DMEM (Sigma Al-
drich) supplemented with 10 % fetal calf serum (v/v) (FCS, Sigma Aldrich) and 1 % penicillin/streptomycin 
(v/v) (P/S, Sigma Aldrich) further called DMEM growth medium. The genomic profile of these cells was fre-
quently verified using STR analysis. 
HEK293-Ad-helper cell line generation. The pHelper-BSD plasmid was linearized with SalI and dephosphor-
ylated. 9×106 HEK293 cells were seeded on a 150 mm2 T-flask one day before transfection. A total of 45 µg 
plasmid DNA of pHelper-BSD was transfected using calcium phosphate. Three days after transfection 
10 µg/ml of the antibiotic blasticidin (BSD, Sigma Aldrich) was added for selective pressure. Culture medium 
(DMEM, 10 % FCS, 1% P/S, 10 µg/ml BSD) was changed every second day until cell growth was observable 
(approximately two weeks). Cells were trypsinized and subjected to limiting dilution on a 96-well plate. 
From this point on, cells were cultured in DMEM growth medium with 5 µg/ml BSD. Growth of single cell 
colonies was observed after about two additional weeks. Single cell colonies were subcultured and charac-
terized for the integration of the adenoviral elements. 
Analysis of genomic integration. Genomic DNA from subcultured monoclonal cell clones was isolated by 
Chelex 100 (Bio-Rad) extraction. 2.5×106 cells were centrifuged (1 min 10000×g) and washed with PBS. The 
pellet was resuspended in 100 µl Chelex suspension (5 % w/v), incubated for 30 min at 56 °C, vortexed for 
10 s and incubated for 8 min at 100 °C. The solution was centrifuged briefly at approx. 17,000×g and the 
supernatant was transferred to a new tube. The primer pairs Ad5-for (5'-CAACTCCATG CTTAACAGTC CCCA-
3')/Ad5-rev (5'-TCCAGTGCTG CAACCCTGTG TATC-3') and Bsd-for (5'-GGATCTGATC AGCACGTGTT-3')/Bsd-
rev (5'-ATCTCGTAGC ACGTGTCAGT-3') are binding on E2A- and bsd-gene, respectively (Figure 1 A) and were 
used for the PCR reaction. After successful detection of integration four clones were selected and name 
HEK293-KARE1a to HEK293-KARE1d. 
Growth curves. 1×105 cells of each clone were seeded in a 12-well plate and incubated under standard 
conditions. Cells were harvested by trypsinization and resuspended in 1 ml cell culture medium. Samples 
for viable cell density and viabilities were taken daily and analyzed using an automated cell counting system 
(CEDEX, Roche Diagnostics). Growth curves were analyzed by exponential fitting with Origin (OriginLab 
2018) and population doubling times were calculated.  
Cell cycle analysis. 2×106 cells were harvested by trypsinization and washed with ice-cold PBS. Briefly, cells 
were resuspended in 500 µl ice-cold PBS before 500 µl 2 % (w/v) paraformaldehyde was added to the solu-
tion. The mixture was stored 1 h on ice before washing with ice-cold PBS and resuspension in 1 ml ice-cold 
70 % ethanol. Samples were taken daily and stored at -20 °C for 5-7 days. After permeabilization cells to be 
analyzed by flow cytometry were washed with PBS before treatment with 1 ml staining solution (100 µg/ml 
RNase A (AppliChem) and 30 µg/ml propidium iodide (AppliChem)) in PBS at 37 °C for 30 min in the dark. 
Measurements of samples were performed on a Becton-Dickenson FACSCalibur. 10,000 counted events 
were analyzed with the software ModFit LT (Verity House Software). 
RNA isolation and quantitative RT-PCR. Total cellular RNA from HEK293 and HEK293-KARE1 clones was 
isolated using Trizol reagent (Invitrogen) according to the instructions by the manufacturer. 1 µg of RNA 
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was subsequently digested by 1 U DNase I (ThermoFisher Scientific) for 30 min at 37 °C. cDNA was synthe-
sized by oligo(dT)18 and Revert Aid M-MuLV reverse transcriptase (ThermoFisher Scientific). Quantitative 
real-time PCR using GoTaq® qPCR Master Mix (Promega) was performed with a LightCycler 480 II detection 
system (Roche) according to the manufacturer’s protocol. The following primer pairs were used at a 4 µM 
concentration to detect E1A (forward primer: 5’-AACCAGTTGC CGTGAGAGTTG-3’; reverse primer: 5’-
CTCGTTAAGC AAGTCCTCGA TACAT-3’), E2A (forward primer: 5’-TCAGGCACAA CCATCCGCGG-3’; reverse pri-
mer 5’-GGTCGGGCGC CGATATCTTGA-3’) and E4 (forward primer: 5’-GAACCCTAGT ATTCAACCTG CCAC-
CTCCC-3’; reverse primer: 5’- CCACACGGTT TCCTGTCGAGCC-3’). All samples were run in triplicate. Ct values 
of technical replicates were averaged and averages were used for further calculations. The relative 
expression ΔΔCt of E2A and E4 in HEK293-KARE1 cells was calculated from the differences in HEK293 and 
HEK293-KARE1a to HEK293-KARE1c after normalizing to E1A gene expression (ΔΔCt=Ct(GeneHEK293-KARE)-
Ct(E1AHEK293-KARE)-[Ct(GeneHEK293)-Ct(E1AHEK293)]). 
Viral particles production and purification. HEK293-KARE1 cells were seeded at a density of 3×106 cells per 
100 mm dish the day before transfection. On the day of transfection, a total amount of 15 µg DNA per 
100 mm dish of pSB1C3_001-RepCap587WT (pZMB0216) and pUC19bb-CMV_mVenus_hGH-pA (pZMB0522) 
was transfected using the calcium-phosphate method. The DNA was added to 0.5 ml 0.3 M CaCl2 and added 
dropwise to 0.5 ml of 2× HBS buffer (50 mM HEPES pH 7.05, 1.5 mM Na2HPO4, 280 mM NaCl). The transfec-
tion solution was mixed well and added immediately to the cells. After 72 h incubation at 37 °C the cells 
were harvested and separated from the medium by centrifugation (900×g, 5 min). The cell pellet was sub-
jected to three freeze-thaw cycles by alternating between liquid nitrogen and a 37 °C water bath. After 
Benzonase (50 U/ml, Sigma Aldrich) treatment at 37 °C for 30 min, the lysate was clarified via centrifugation 
at 3,000×g, 10 min. The crude lysate was added to a discontinuous iodixanol gradient (Progen Biotechnik 
GmbH) of 60 %, 40 %, 25 % and 15 % iodixanol in an open top polyallomer 16 × 76 mm tube (Science Ser-
vices) using a syringe equipped with a 23G x 3 1/8” injection needle as described in literature [44]. Tubes 
were sealed with cap assemblies and centrifuged in a T-880 rotor (Sorvall) at 340,000×g for 4 h at 18 °C. The 
fraction containing viral particles was collected with a 21G x 1 1/2” injection needle from the bottom of the 
tube and the buffer was exchanged to 1× HBSS (Sigma Aldrich) via an Amicon Ultra-4 100K ultrafiltration 
unit.  
Optimized viral particles production. HEK293-KARE1c cells were seeded as described before in DMEM with-
out BSD. On the day of transfection, a total amount of 7.4 µg DNA per 100 mm dish of pSB1C3_001-Rep-
Cap587WT (pZMB0216) and pUC19bb-CMV_mVenus_hGH-pA (pZMB0522) in a molar ratio of 1:1 was used. 
The DNA was added to 0.25 ml 0.3 M CaCl2 and added dropwise to 0.25 ml of 2× HBS buffer. The transfection 
solution was mixed well and added immediately to the cells. After a 72 h incubation at 37 °C cells were 
harvested and processed as described in viral particles production and purification. 
Determination of genomic titers. Genomic titers of viral particles were determined via quantitative real-
time PCR (qPCR). An aliquot of rAAV containing sample (5 µl) was incubated with 4 U DNase I (NEB) at 37 °C 
for 30 min followed by a 20 min heat inactivation at 75 °C. In the qPCR reaction 5 µl of a fivefold dilution of 
the DNase I digest was mixed with 5 µl primer-mix at a final concentration of 4 µM (qPCR-hGH-for: 5'-
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CTCCCCAGTG CCTCTCCT-3' / qPCR-hGH-rev: 5'-ACTTGCCCCT TGCTCCATAC-3') and 2x GoTaq qPCR Mas-
termix (Promega) to a final volume of 20 µl. The reaction was carried out as described by the manufacturers 
protocol using a LightCycler 480 II system (Roche Life Science). The genomic titer was calculated from a 
standard curve of 10 to 106 copies of the ITR plasmid (pZMB0522) with an efficiency between 90-110 % and 
an R value less than 0.1 (mean squared error of the single data points fit to the regression line). Genomic 
titers in crude lysates were estimated from a standard curve mixed with the same amount of a non-trans-
fected cell lysate. Since DNase I is partially inhibited in the presence of cell debris a small plasmid back-
ground can remain. All samples were processed identically in technical triplicates. 
Transduction assay. Functionality of purified rAAV2 preparations was analyzed by transduction of HT-1080 
cells with a vector plasmid coding for the fluorescence reporter mVenus (pZMB0522). 10,000 cells were 
seeded on a 12-well plate and after cells had settled a serial dilution of viral particles was applied to each 
well. Cells were detached by trypsinization for flow cytometry analysis. 10,000 events were counted using 
a Becton-Dickenson FACSCalibur instrument. Data sets were analyzed using Flowing Software 2.5.1. Positive 
cells were gated above the 99 % interval of the negative control.  
Atomic force microscopy. AFM measurements were performed on a Multimode 8 AFM (Bruker, Santa Bar-
bara, CA, USA) with Tap300Al-G cantilevers (BudgetSensors, Sofia, Bulgaria) in tapping mode in air.  2 µl 
sample of UC purified rAAV2 from HEK293-KARE1c was spotted onto freshly cleaved mica for 1 min before 
it was rinsed three times with distilled water and dried under a gentle nitrogen flow. Data analysis was 
performed with Gwyddion 2.48. Obtained images were treated with offset and plane correction algorithms 
and the size of visualized particles was measured at half maximum particle height. 
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Figures/Figure Legends 
 
Figure 1: Integration of adenoviral elements into HEK293. Scheme of the linearized helper plasmid after 
restriction digest with SalI. The blasticidin resistance gene bsd is located at the 5’-end. PCR primer positions 
are marked with green triangles.  
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Figure 2: Analysis of cell morphology and growth. (A, B) Comparison of cell morphology in bright field im-
ages of (A) HEK293-KARE1c and (B) HEK293. The morphology of HEK293-KARE1c looks similar to the one of 
the parental HEK293 cell line. (C) Growth curves of HEK293-KARE1 clones and HEK293 were recorded. Cells 
were seeded on a 12-well plate and harvested after the indicated incubation time. Viable cell density and 
viabilities were analyzed using an automated cell counting system (CEDEX, Roche Diagnostics). Doubling 
times td were calculated from an exponential fit with Origin 2018 (OriginLab) and are given in the inset of 
the graph. (D) Agarose gel of the PCR analysis of pHelper-BSD integration. Genomic DNA of the four clones 
HEK293-KARE1a to HEK293-KARE1d probed by PCR using the primer pairs given above each lane.  
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Figure 3: Analysis of adenoviral elements expression and their effect on the cell cycle of HEK293-KARE cell 
lines. (A) RNA was isolated from HEK293 and HEK293-KARE1 cells. The mRNA levels of E2A and E4 were 
determined by RT-qPCR, the error bars represent the standard deviation from three technical replicates. 
ΔΔCt values were calculated from the difference between expression in HEK293 and HEK293-KARE1 cells 
after normalizing to E1A gene expression. (B) Agarose gel from qPCR products for HEK293-KARE1-clones. 
(C, D) Effects of adenoviral early genes on cell cycle progression. (C) The DNA content of cells (exemplary 
for HEK293, HEK293-KARE1c) was measured after propidium iodide staining by flow cytometry at defined 
time points (24 h, 48 h, 72 h). In total 10,000 events were counted. (D) Percentage of cells in different cell 
cycle phases are presented for each cell line. HEK293 TF represent triple-transfected HEK293 cells for AAV 
production. Transfection was carried out 24 hours after seeding. This latter analysis was done based on cells 
gated for mVenus production present on the ITR plasmid. The flow cytometry data were analyzed with 
ModFit LT (Verity Software House). 
 
10 Appendix: Publications 
154 
 
 
Figure 4: Analysis of rAAV2 production in HEK293-KARE1 and HEK293 cells at passage three and nine after 
cryopreservation. (A) HEK293-KARE1 cells (1×100 mm dish) were transfected with ITR-plasmid and RepCap-
plasmid, for HEK293 the pHelper was included. Three days after transfection rAAV yield was determined 
from crude cell lysate after three freeze-thaw cycles by qPCR. A molar ratio of 1:1 of the plasmids Rep-
Cap:ITR was used during this experiment. For HEK293 cells experiments were performed also with a plasmid 
ratio of 1:1:1 for pHelper:RepCap:ITR. (B) Comparison of rAAV production in HEK293-KARE1c cells depend-
ing on15 µg transfection protocol and the optimized 7.4 µg transfection protocol. rAAV2 yield was quanti-
fied in crude lysates by qPCR. In general, RepCap and ITR plasmid were transfected in a molar 1:1 ratio.  
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Figure 5: Characterization of rAAV2. Viral particles were produced in the HEK293-KARE1c cell line seeded in 
ten 100 mm dishes and subsequently purified via iodixanol ultracentrifugation. (A) Determination of trans-
duction ability of rAAV (1:200 diluted sample) on HT-1080 cells using expression of the mVenus gene meas-
ured by flow cytometry of 10,000 cells in total. (B) The amount of DNase I-resistant particles was deter-
mined by qPCR from a standard curve of the ITR-plasmid. The total volume of the final viral sample was 2.5 
ml. The transducing titer was determined based on percent of fluorescent cells as depicted in panel A (see 
methods). (C, D) rAAV were visualized by atomic force microscopy and resulting particle height profiles were 
determined. A mean diameter of 21.5 ± 1.8 nm was measured at half maximum height of 8 particles.  
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HEK293-KARE1, a cell line with stably integrated adenovirus helper 
sequences simplifies rAAV production 
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SI Table 1: Raw data of E1A mRNA analysis from three independent qRT-PCR experiments. mRNA samples 
were isolated from cells directly before the experiment.  
 Ct (1) Ct (2) Ct (3) 
Kare1a 19.22 15.01 15.78 
Kare1b 18.98 14.55 15.80 
Kare1c 19.70 14.95 15.76 
HEK293 19.22 15.89 15.77 
 
 
Sequence information for pHelper-BSD 
        1 ggtacccaac tccatgctta acagtcccca ggtacagccc accctgcgtc gcaaccagga 
       61 acagctctac agcttcctgg agcgccactc gccctacttc cgcagccaca gtgcgcagat 
      121 taggagcgcc acttcttttt gtcacttgaa aaacatgtaa aaataatgta ctaggagaca 
      181 ctttcaataa aggcaaatgt ttttatttgt acactctcgg gtgattattt accccccacc 
      241 cttgccgtct gcgccgttta aaaatcaaag gggttctgcc gcgcatcgct atgcgccact 
      301 ggcagggaca cgttgcgata ctggtgttta gtgctccact taaactcagg cacaaccatc 
      361 cgcggcagct cggtgaagtt ttcactccac aggctgcgca ccatcaccaa cgcgtttagc 
      421 aggtcgggcg ccgatatctt gaagtcgcag ttggggcctc cgccctgcgc gcgcgagttg 
      481 cgatacacag ggttgcagca ctggaacact atcagcgccg ggtggtgcac gctggccagc 
      541 acgctcttgt cggagatcag atccgcgtcc aggtcctccg cgttgctcag ggcgaacgga 
      601 gtcaactttg gtagctgcct tcccaaaaag ggtgcatgcc caggctttga gttgcactcg 
      661 caccgtagtg gcatcagaag gtgaccgtgc ccggtctggg cgttaggata cagcgcctgc 
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      721 atgaaagcct tgatctgctt aaaagccacc tgagcctttg cgccttcaga gaagaacatg 
      781 ccgcaagact tgccggaaaa ctgattggcc ggacaggccg cgtcatgcac gcagcacctt 
      841 gcgtcggtgt tggagatctg caccacattt cggccccacc ggttcttcac gatcttggcc 
      901 ttgctagact gctccttcag cgcgcgctgc ccgttttcgc tcgtcacatc catttcaatc 
      961 acgtgctcct tatttatcat aatgctcccg tgtagacact taagctcgcc ttcgatctca 
     1021 gcgcagcggt gcagccacaa cgcgcagccc gtgggctcgt ggtgcttgta ggttacctct 
     1081 gcaaacgact gcaggtacgc ctgcaggaat cgccccatca tcgtcacaaa ggtcttgttg 
     1141 ctggtgaagg tcagctgcaa cccgcggtgc tcctcgttta gccaggtctt gcatacggcc 
     1201 gccagagctt ccacttggtc aggcagtagc ttgaagtttg cctttagatc gttatccacg 
     1261 tggtacttgt ccatcaacgc gcgcgcagcc tccatgccct tctcccacgc agacacgatc 
     1321 ggcaggctca gcgggtttat caccgtgctt tcactttccg cttcactgga ctcttccttt 
     1381 tcctcttgcg tccgcatacc ccgcgccact gggtcgtctt cattcagccg ccgcaccgtg 
     1441 cgcttacctc ccttgccgtg cttgattagc accggtgggt tgctgaaacc caccatttgt 
     1501 agcgccacat cttctctttc ttcctcgctg tccacgatca cctctgggga tggcgggcgc 
     1561 tcgggcttgg gagaggggcg cttctttttc tttttggacg caatggccaa atccgccgtc 
     1621 gaggtcgatg gccgcgggct gggtgtgcgc ggcaccagcg catcttgtga cgagtcttct 
     1681 tcgtcctcgg actcgagacg ccgcctcagc cgcttttttg ggggcgcgcg gggaggcggc 
     1741 ggcgacggcg acggggacga cacgtcctcc atggttggtg gacgtcgcgc cgcaccgcgt 
     1801 ccgcgctcgg gggtggtttc gcgctgctcc tcttcccgac tggccatttc cttctcctat 
     1861 aggcagaaaa agatcatgga gtcagtcgag aaggaggaca gcctaaccgc cccctttgag 
     1921 ttcgccacca ccgcctccac cgatgccgcc aacgcgccta ccaccttccc cgtcgaggca 
     1981 cccccgcttg aggaggagga agtgattatc gagcaggacc caggttttgt aagcgaagac 
     2041 gacgaggatc gctcagtacc aacagaggat aaaaagcaag accaggacga cgcagaggca 
     2101 aacgaggaac aagtcgggcg gggggaccaa aggcatggcg actacctaga tgtgggagac 
     2161 gacgtgctgt tgaagcatct gcagcgccag tgcgccatta tctgcgacgc gttgcaagag 
     2221 cgcagcgatg tgcccctcgc catagcggat gtcagccttg cctacgaacg ccacctgttc 
     2281 tcaccgcgcg taccccccaa acgccaagaa aacggcacat gcgagcccaa cccgcgcctc 
     2341 aacttctacc ccgtatttgc cgtgccagag gtgcttgcca cctatcacat ctttttccaa 
     2401 aactgcaaga tacccctatc ctgccgtgcc aaccgcagcc gagcggacaa gcagctggcc 
     2461 ttgcggcagg gcgctgtcat acctgatatc gcctcgctcg acgaagtgcc aaaaatcttt 
     2521 gagggtcttg gacgcgacga gaaacgcgcg gcaaacgctc tgcaacaaga aaacagcgaa 
     2581 aatgaaagtc actgtggagt gctggtggaa cttgagggtg acaacgcgcg cctagccgtg 
     2641 ctgaaacgca gcatcgaggt cacccacttt gcctacccgg cacttaacct accccccaag 
     2701 gttatgagca cagtcatgag cgagctgatc gtgcgccgtg cacgacccct ggagagggat 
     2761 gcaaacttgc aagaacaaac cgaggagggc ctacccgcag ttggcgatga gcagctggcg 
     2821 cgctggcttg agacgcgcga gcctgccgac ttggaggagc gacgcaagct aatgatggcc 
     2881 gcagtgcttg ttaccgtgga gcttgagtgc atgcagcggt tctttgctga cccggagatg 
     2941 cagcgcaagc tagaggaaac gttgcactac acctttcgcc agggctacgt gcgccaggcc 
     3001 tgcaaaattt ccaacgtgga gctctgcaac ctggtctcct accttggaat tttgcacgaa 
     3061 aaccgcctcg ggcaaaacgt gcttcattcc acgctcaagg gcgaggcgcg ccgcgactac 
     3121 gtccgcgact gcgtttactt atttctgtgc tacacctggc aaacggccat gggcgtgtgg 
     3181 cagcaatgcc tggaggagcg caacctaaag gagctgcaga agctgctaaa gcaaaacttg 
     3241 aaggacctat ggacggcctt caacgagcgc tccgtggccg cgcacctggc ggacattatc 
     3301 ttccccgaac gcctgcttaa aaccctgcaa cagggtctgc cagacttcac cagtcaaagc 
     3361 atgttgcaaa actttaggaa ctttatccta gagcgttcag gaattctgcc cgccacctgc 
     3421 tgtgcgcttc ctagcgactt tgtgcccatt aagtaccgtg aatgccctcc gccgctttgg 
     3481 ggtcactgct accttctgca gctagccaac taccttgcct accactccga catcatggaa 
     3541 gacgtgagcg gtgacggcct actggagtgt cactgtcgct gcaacctatg caccccgcac 
     3601 cgctccctgg tctgcaattc gcaactgctt agcgaaagtc aaattatcgg tacctttgag 
     3661 ctgcagggtc cctcgcctga cgaaaagtcc gcggctccgg ggttgaaact cactccgggg 
     3721 ctgtggacgt cggcttacct tcgcaaattt gtacctgagg actaccacgc ccacgagatt 
     3781 aggttctacg aagaccaatc ccgcccgcca aatgcggagc ttaccgcctg cgtcattacc 
     3841 cagggccaca tccttggcca attgcaagcc atcaacaaag cccgccaaga gtttctgcta 
     3901 cgaaagggac ggggggttta cctggacccc cagtccggcg aggagctcaa cccaatcccc 
     3961 ccgccgccgc agccctatca gcagccgcgg gcccttgctt cccaggatgg cacccaaaaa 
     4021 gaagctgcag ctgccgccgc cgccacccac ggacgaggag gaatactggg acagtcaggc 
     4081 agaggaggtt ttggacgagg aggaggagat gatggaagac tgggacagcc tagacgaagc 
     4141 ttccgaggcc gaagaggtgt cagacgaaac accgtcaccc tcggtcgcat tcccctcgcc 
     4201 ggcgccccag aaattggcaa ccgttcccag catcgctaca acctccgctc ctcaggcgcc 
     4261 gccggcactg cctgttcgcc gacccaaccg tagatgggac accactggaa ccagggccgg 
     4321 taagtctaag cagccgccgc cgttagccca agagcaacaa cagcgccaag gctaccgctc 
     4381 gtggcgcggg cacaagaacg ccatagttgc ttgcttgcaa gactgtgggg gcaacatctc 
     4441 cttcgcccgc cgctttcttc tctaccatca cggcgtggcc ttcccccgta acatcctgca 
     4501 ttactaccgt catctctaca gcccctactg caccggcggc agcggcagcg gcagcaacag 
     4561 cagcggtcac acagaagcaa aggcgaccgg atagcaagac tctgacaaag cccaagaaat 
     4621 ccacagcggc ggcagcagca ggaggaggag cgctgcgtct ggcgcccaac gaacccgtat 
     4681 cgacccgcga gcttagaaat aggatttttc ccactctgta tgctatattt caacaaagca 
     4741 ggggccaaga acaagagctg aaaataaaaa acaggtctct gcgctccctc acccgcagct 
     4801 gcctgtatca caaaagcgaa gatcagcttc ggcgcacgct ggaagacgcg gaggctctct 
     4861 tcagcaaata ctgcgcgctg actcttaagg actagtttcg cgccctttct caaatttaag 
     4921 cgcgaaaact acgtcatctc cagcggccac acccggcgcc agcacctgtc gtcagcgcca 
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     4981 ttatgagcaa ggaaattccc acgccctaca tgtggagtta ccagccacaa atgggacttg 
     5041 cggctggagc tgcccaagac tactcaaccc gaataaacta catgagcgcg ggaccccaca 
     5101 tgatatcccg ggtcaacgga atccgcgccc accgaaaccg aattctcctc gaacaggcgg 
     5161 ctattaccac cacacctcgt aataacctta atccccgtag ttggcccgct gccctggtgt 
     5221 accaggaaag tcccgctccc accactgtgg tacttcccag agacgcccag gccgaagttc 
     5281 agatgactaa ctcaggggcg cagcttgcgg gcggctttcg tcacagggtg cggtcgcccg 
     5341 ggcgttttag ggcggagtaa cttgcatgta ttgggaattg tagttttttt aaaatgggaa 
     5401 gtgacgtatc gtgggaaaac ggaagtgaag atttgaggaa gttgtgggtt ttttggcttt 
     5461 cgtttctggg cgtaggttcg cgtgcggttt tctgggtgtt ttttgtggac tttaaccgtt 
     5521 acgtcatttt ttagtcctat atatactcgc tctgtacttg gcccttttta cactgtgact 
     5581 gattgagctg gtgccgtgtc gagtggtgtt ttttaatagg tttttttact ggtaaggctg 
     5641 actgttatgg ctgccgctgt ggaagcgctg tatgttgttc tggagcggga gggtgctatt 
     5701 ttgcctaggc aggagggttt ttcaggtgtt tatgtgtttt tctctcctat taattttgtt 
     5761 atacctccta tgggggctgt aatgttgtct ctacgcctgc gggtatgtat tcccccgggc 
     5821 tatttcggtc gctttttagc actgaccgat gttaaccaac ctgatgtgtt taccgagtct 
     5881 tacattatga ctccggacat gaccgaggaa ctgtcggtgg tgctttttaa tcacggtgac 
     5941 cagttttttt acggtcacgc cggcatggcc gtagtccgtc ttatgcttat aagggttgtt 
     6001 tttcctgttg taagacaggc ttctaatgtt taaatgtttt tttttttgtt attttatttt 
     6061 gtgtttaatg caggaacccg cagacatgtt tgagagaaaa atggtgtctt tttctgtggt 
     6121 ggttccggaa cttacctgcc tttatctgca tgagcatgac tacgatgtgc ttgctttttt 
     6181 gcgcgaggct ttgcctgatt ttttgagcag caccttgcat tttatatcgc cgcccatgca 
     6241 acaagcttac ataggggcta cgctggttag catagctccg agtatgcgtg tcataatcag 
     6301 tgtgggttct tttgtcatgg ttcctggcgg ggaagtggcc gcgctggtcc gtgcagacct 
     6361 gcacgattat gttcagctgg ccctgcgaag ggacctacgg gatcgcggta tttttgttaa 
     6421 tgttccgctt ttgaatctta tacaggtctg tgaggaacct gaatttttgc aatcatgatt 
     6481 cgctgcttga ggctgaaggt ggagggcgct ctggagcaga tttttacaat ggccggactt 
     6541 aatattcggg atttgcttag agacatattg ataaggtggc gagatgaaaa ttatttgggc 
     6601 atggttgaag gtgctggaat gtttatagag gagattcacc ctgaagggtt tagcctttac 
     6661 gtccacttgg acgtgagggc agtttgcctt ttggaagcca ttgtgcaaca tcttacaaat 
     6721 gccattatct gttctttggc tgtagagttt gaccacgcca ccggagggga gcgcgttcac 
     6781 ttaatagatc ttcattttga ggttttggat aatcttttgg aataaaaaaa aaaaaacatg 
     6841 gttcttccag ctcttcccgc tcctcccgtg tgtgactcgc agaacgaatg tgtaggttgg 
     6901 ctgggtgtgg cttattctgc ggtggtggat gttatcaggg cagcggcgca tgaaggagtt 
     6961 tacatagaac ccgaagccag ggggcgcctg gatgctttga gagagtggat atactacaac 
     7021 tactacacag agcgagctaa gcgacgagac cggagacgca gatctgtttg tcacgcccgc 
     7081 acctggtttt gcttcaggaa atatgactac gtccggcgtt ccatttggca tgacactacg 
     7141 accaacacga tctcggttgt ctcggcgcac tccgtacagt agggatcgcc tacctccttt 
     7201 tgagacagag acccgcgcta ccatactgga ggatcatccg ctgctgcccg aatgtaacac 
     7261 tttgacaatg cacaacgtga gttacgtgcg aggtcttccc tgcagtgtgg gatttacgct 
     7321 gattcaggaa tgggttgttc cctgggatat ggttctgacg cgggaggagc ttgtaatcct 
     7381 gaggaagtgt atgcacgtgt gcctgtgttg tgccaacatt gatatcatga cgagcatgat 
     7441 gatccatggt tacgagtcct gggctctcca ctgtcattgt tccagtcccg gttccctgca 
     7501 gtgcatagcc ggcgggcagg ttttggccag ctggtttagg atggtggtgg atggcgccat 
     7561 gtttaatcag aggtttatat ggtaccggga ggtggtgaat tacaacatgc caaaagaggt 
     7621 aatgtttatg tccagcgtgt ttatgagggg tcgccactta atctacctgc gcttgtggta 
     7681 tgatggccac gtgggttctg tggtccccgc catgagcttt ggatacagcg ccttgcactg 
     7741 tgggattttg aacaatattg tggtgctgtg ctgcagttac tgtgctgatt taagtgagat 
     7801 cagggtgcgc tgctgtgccc ggaggacaag gcgtctcatg ctgcgggcgg tgcgaatcat 
     7861 cgctgaggag accactgcca tgttgtattc ctgcaggacg gagcggcggc ggcagcagtt 
     7921 tattcgcgcg ctgctgcagc accaccgccc tatcctgatg cacgattatg actctacccc 
     7981 catgtaggcg tggacttccc cttcgccgcc cgttgagcaa ccgcaagttg gacagcagcc 
     8041 tgtggctcag cagctggaca gcgacatgaa cttaagcgag ctgcccgggg agtttattaa 
     8101 tatcactgat gagcgtttgg ctcgacagga aaccgtgtgg aatataacac ctaagaatat 
     8161 gtctgttacc catgatatga tgctttttaa ggccagccgg ggagaaagga ctgtgtactc 
     8221 tgtgtgttgg gagggaggtg gcaggttgaa tactagggtt ctgtgagttt gattaaggta 
     8281 cggtgatcaa tataagctat gtggtggtgg ggctatacta ctgaatgaaa aatgacttga 
     8341 aattttctgc aattgaaaaa taaacacgtt gaaacataac atgcaacagg ttcacgattc 
     8401 tttattcctg ggcaatgtag gagaaggtgt aagagttggt agcaaaagtt tcagtggtgt 
     8461 attttccact ttcccaggac catgtaaaag acatagagta agtgcttacc tcgctagttt 
     8521 ctgtggattc actagaatcg atgtaggatg ttgcccctcc tgacgcggta ggagaagggg 
     8581 agggtgccct gcatgtctgc cgctgctctt gctcttgccg ctgctgagga ggggggcgca 
     8641 tctgccgcag caccggatgc atctgggaaa agcaaaaaag gggctcgtcc ctgtttccgg 
     8701 aggaatttgc aagcggggtc ttgcatgacg gggaggcaaa cccccgttcg ccgcagtccg 
     8761 gccggcccga gactcgaacc gggggtcctg cgactcaacc cttggaaaat aaccctccgg 
     8821 ctacagggag cgagccactt aatgctttcg ctttccagcc taaccgctta cgccgcgcgc 
     8881 ggccagtggc caaaaaagct agcgcagcag ccgccgcgcc tggaaggaag ccaaaaggag 
     8941 cgctcccccg ttgtctgacg tcgcacacct gggttcgaca cgcgggcggt aaccgcatgg 
     9001 atcacggcgg acggccggat ccggggttcg aaccccggtc gtccgccatg atacccttgc 
     9061 gaatttatcc accagaccac ggaagagtgc ccgcttacag gctctccttt tgcacggtct 
     9121 agagcgtcaa cgactgcgca cgcctcaccg gccagagcgt cccgaccatg gagcactttt 
     9181 tgccgctgcg caacatctgg aaccgcgtcc gcgactttcc gcgcgcctcc accaccgccg 
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     9241 ccggcatcac ctggatgtcc aggtacatct acggattacg tcgacgttta aacggatctg 
     9301 atcagcacgt gttgacaatt aatcatcggc atagtatatc ggcatagtat aatacgacaa 
     9361 ggtgaggaac taaaccatgg ccaagccttt gtctcaagaa gaatccaccc tcattgaaag 
     9421 agcaacggct acaatcaaca gcatccccat ctctgaagac tacagcgtcg ccagcgcagc 
     9481 tctctctagc gacggccgca tcttcactgg tgtcaatgta tatcatttta ctgggggacc 
     9541 ttgtgcagaa ctcgtggtgc tgggcactgc tgctgctgcg gcagctggca acctgacttg 
     9601 tatcgtcgcg atcggaaatg agaacagggg catcttgagc ccctgcggac ggtgccgaca 
     9661 ggtgcttctc gatctgcatc ctgggatcaa agccatagtg aaggacagtg atggacagcc 
     9721 gacggcagtt gggattcgtg aattgctgcc ctctggttat gtgtgggagg gctaagcact 
     9781 tcgtggccga ggagcaggac tgacacgtgc tacgagatca tatgatcagc tcactcaaag 
     9841 gcggtaatac ggttatccac agaatcaggg gataacgcag gaaagaacat gtgagcaaaa 
     9901 ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc 
     9961 cgcccccctg acgagcatca caaaaatcga cgctcaagtc agaggtggcg aaacccgaca 
    10021 ggactataaa gataccaggc gtttccccct ggaagctccc tcgtgcgctc tcctgttccg 
    10081 accctgccgc ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct 
    10141 catagctcac gctgtaggta tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt 
    10201 gtgcacgaac cccccgttca gcccgaccgc tgcgccttat ccggtaacta tcgtcttgag 
    10261 tccaacccgg taagacacga cttatcgcca ctggcagcag ccactggtaa caggattagc 
    10321 agagcgaggt atgtaggcgg tgctacagag ttcttgaagt ggtggcctaa ctacggctac 
    10381 actagaagaa cagtatttgg tatctgcgct ctgctgaagc cagttacctt cggaaaaaga 
    10441 gttggtagct cttgatccgg caaacaaacc accgctggta gcggtggttt ttttgtttgc 
    10501 aagcagcaga ttacgcgcag aaaaaaagga tctcaagaag atcctttgat cttttctacg 
    10561 gggtctgacg ctcagtggaa cgaaaactca cgttaaggga ttttggtcat gagattatca 
    10621 aaaaggatct tcacctagat ccttttaaat taaaaatgaa gttttaaatc aatctaaagt 
    10681 atatatgagt aaacttggtc tgacagttac caatgcttaa tcagtgaggc acctatctca 
    10741 gcgatctgtc tatttcgttc atccatagtt gcctgactcc ccgtcgtgta gataactacg 
    10801 atacgggagg gcttaccatc tggccccagt gctgcaatga taccgcgaga cccacgctca 
    10861 ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg cagaagtggt 
    10921 cctgcaactt tatccgcctc catccagtct attaattgtt gccgggaagc tagagtaagt 
    10981 agttcgccag ttaatagttt gcgcaacgtt gttgccattg ctacaggcat cgtggtgtca 
    11041 cgctcgtcgt ttggtatggc ttcattcagc tccggttccc aacgatcaag gcgagttaca 
    11101 tgatccccca tgttgtgcaa aaaagcggtt agctccttcg gtcctccgat cgttgtcaga 
    11161 agtaagttgg ccgcagtgtt atcactcatg gttatggcag cactgcataa ttctcttact 
    11221 gtcatgccat ccgtaagatg cttttctgtg actggtgagt actcaaccaa gtcattctga 
    11281 gaatagtgta tgcggcgacc gagttgctct tgcccggcgt caatacggga taataccgcg 
    11341 ccacatagca gaactttaaa agtgctcatc attggaaaac gttcttcggg gcgaaaactc 
    11401 tcaaggatct taccgctgtt gagatccagt tcgatgtaac ccactcgtgc acccaactga 
    11461 tcttcagcat cttttacttt caccagcgtt tctgggtgag caaaaacagg aaggcaaaat 
    11521 gccgcaaaaa agggaataag ggcgacacgg aaatgttgaa tactcatact cttccttttt 
    11581 caatattatt gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt 
    11641 atttagaaaa ataaacaaat aggggttccg cgcacatttc cccgaaaagt gccacctaaa 
    11701 ttgtaagcgt taatattttg ttaaaattcg cgttaaattt ttgttaaatc agctcatttt 
    11761 ttaaccaata ggccgaaatc ggcaaaatcc cttataaatc aaaagaatag accgagatag 
    11821 ggttgagtgt tgttccagtt tggaacaaga gtccactatt aaagaacgtg gactccaacg 
    11881 tcaaagggcg aaaaaccgtc tatcagggcg atggcccact acgtgaacca tcaccctaat 
    11941 caagtttttt ggggtcgagg tgccgtaaag cactaaatcg gaaccctaaa gggagccccc 
    12001 gatttagagc ttgacgggga aagccggcga acgtggcgag aaaggaaggg aagaaagcga 
    12061 aaggagcggg cgctagggcg ctggcaagtg tagcggtcac gctgcgcgta accaccacac 
    12121 ccgccgcgct taatgcgccg ctacagggcg cgatggatcc 
// 
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Abstract 
Background: Recombinant adeno associated virus (rAAV) gained an outstanding reputation in 
gene therapy. However, the prospective success of rAAV relies on efficient and cost-effective pu-
rification strategies which must be suitable for future up-scale requirements. Affinity chromatog-
raphy based on a relevant biological interaction allows for sufficient purity in one step and allows 
to simplify downstream processing of rAAV. 
Results: We generated an affinity chromatography resin based on the natural AAV receptor AAVR. 
Single polycystic kidney disease (PKD) domains were easily produced in E. coli as fusion proteins 
to maltose-binding protein (MBP). Cellulose was chosen as a suitable chromatography resin with 
advantageous properties such as low unspecific binding, low costs and ease of availability. Cova-
lent coupling of PKD2 to divinyl sulfone activated cellulose allowed for affinity purification of 
rAAV2 from crude cell extract. Purified samples showed superior purity and recovery rates com-
parable to other affinity purification strategies. Based on the established protocol for rAAV2 the 
process was successfully transferred to rAAV6 and rAAV9 purification and by this showed the uni-
versality of the novel affinity chromatography material. 
Conclusions: The results show that individual AAVR domains have the potential to reduce down-
stream costs while ensuring high purity rAAV manufacturing. 
Keywords: AAVR, recombinant adeno-associated virus, downstream processing, Gene therapy 
 
Background 
Recombinant Adeno-associated viruses (rAAV) are a rapidly expanding class of biologics for re-
search and therapy. They combine efficient gene delivery to dividing and non-dividing cells, long-
term gene expression and a high safety profile due to their inability to replicate autonomously 
without a helper virus 1,2. This market pull requires efficient and cost effective purification meth-
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ods, which is met with limited options. Despite several publications on the use of ultracentrifuga-
tion methods, classical chromatography methods such as ion-exchange 3 or semi specific materials 
such as heparin, affinity purification for AAV is very popular. Affinity chromatography materials 
are available from GE Healthcare, namely AVB Sepharose 4 based on an immobilized nanobody 
(cameloid VHH heavy chain only fragment)5 and from Thermo, namely AAV Capture select AAVX, 
AAV8, and AAV9 6, which are also based on nanobodies. The wide dependence of laboratories on 
the AVB sepharose material even prompted recent considerations to modify AAV capsids for im-
proved compatibility with the immobilized nanobody 7 as well as protein sequencing and reengi-
neering efforts of the immobilized nanobody 8. In a research publication, the monoclonal antibody 
A20 has been used for a purification  test 9, but this route has not been followed and no commer-
cial product has been developed. 
AAV typically engage a primary receptor for cell adhesion and then enter the cell while interacting 
with additional cellular components, of which some are described as secondary receptors. For 
many AAV serotypes the primary receptors are known. In the case of AAV2, the primary receptor 
is heparin sulfate proteoglycan (HSPG). According to a review by Srivastava 10, AAV1 interacts with 
α2-3 and α2-6 N-linked sialic acid (SIA); AAV2, AAV2, and AAV13 interact with HSPG, AAV4 and 
AAV5 interact with α2-3 O-linked and α2-3 N-linked SIAs; AAV6 interacts with HSPG and α2-3 and 
α2-6 N-linked SIA; AAV9 interacts with terminal N-linked galactose (GAL) of SIA; and the primary 
cellular receptors for AAV7, AAV8, AAV9, AAVrh10, AAV11, AAV12, and AAV13 remain unknown. 
The glycans are abundant on the cell surface of several cell types and they do also interact with 
other (i.e. non AAV) proteins. Hence, these molecules were not chosen for affinity purification.  
Next to the primary receptors several co-receptors have been identified. For AAV 2 these are 
αVβ5/α5β1 integrin, human fibroblast growth factor receptor 1 (FGFR1), hepatocyte growth fac-
tor receptor (HGFR) and laminin receptor (LamR) 11. These are potentially interesting candidates 
to derive an affinity ligand, yet according to the literature they merely support infection but are 
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expendable. Using one of these molecules for purification would pose an unnecessary limitation 
for the options for capsid modifications. 
In contrast, a protein named AAV-Receptor (AAVR) was recently described in detail based on a 
genetic screen as a protein with so far unknown function but high significance for the transduction 
ability of several AAV serotypes 12. This protein has a predicted molecular weight of 108 kDA and 
is the same as a previously described 150 kDa glycoprotein, which was discovered in a membrane 
assay.13 Even if in the absence of AAVR some basal transduction can occur 14, an interaction with 
this receptor seems important for clinical relevant transduction efficiencies for most AAV sero-
types. The extracellular part of AAVR is composed of a N-terminal MANEC domain followed by 
five PKD (polycystic kidney disease) domains named PKD1 to PKD5. Dominant interactions of cer-
tain domains with specific serotypes have been described and in general the most distal PKD do-
mains play the most prominent roles 15. Glycosylation is not required for interaction. 
PKD2 is important for AAV2 transduction and we chose this domain to demonstrate the genera-
tion of an affinity material based on a relevant biological interaction. In this study we could show 
that it is possible to bind rAAV2 particles very efficiently from HEK293 total cell extract. The pro-
tocol was then adopted for AAV6 and AAV9 purification. For AAV6, PKD3 and for AAV9 PKD5 was 
identified as promising interaction partners for affinity purification as so far the main interaction 
domains for these serotypes were not known. So generated AAV vectors show a higher purity, 
which was verified by SDS-PAGE using silver nitrate staining and Western blot. All in all, the costs 
for the purification could be reduced by a factor of more than ten with a reduced processing time 
from about two working days to about two to three hours. 
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Results 
Development of a PKD-based affinity chromatography material 
The aim of this study was to generate a scalable and low cost manufacturing process for the puri-
fication of rAAV from HEK293 crude cell lysate. In contrast to ultracentrifugation, affinity chroma-
tography offers the great advantage for scaling up. As an affinity ligand, PKD2 was chosen in the 
first step, as Pillay et al. published that AAVR PKD2 is critical for the interaction of AAV2 with 
AAVR.15 As a supporting material, cellulose was elected as a cost-effective material with advanta-
geous properties such as low unspecific binding and good physical and chemical resistance under 
selected process conditions. In order to avoid the clogging of a packed chromatography column 
by residues of the cell lysate, blotting paper was utilized, so that the incubation of cell lysate con-
taining rAAV was carried out in batch mode and not in the usual flow process of a packed column. 
An overview of the rAAV purification strategy is given in Figure 1. 
10 Appendix: Publications 
166 
 
 
Figure 1 Schematic representation of recombinant adeno-associated virus (rAAV) manufacturing technol-
ogy. (1) Adherent HEK293 cells are seeded and transfected with the three-plasmid system and harvested 
after 72 h. rAAVs were released from the cells by three freeze-thaw cycles and cell debris is pelleted by 
centrifugation (2) E. coli BL21(DE3) cells expressing PKD-MBP are cultivated in shaker flask for 4 h after 
induction with IPTG. The cell pellets are resuspended and then lysed using a french press. Lysate is clarified 
and loaded onto a AKTA FPLCand purified using IMAC. Blotting paper (BP) is activated by divinyl sulfone 
(DVS) and functionalized with purified PKD overnight. (3) rAAV containing clear lysate is incubated with 
functionalized BP and rAAV are eluted by transferring the BP to a spin tube and covering it with elution 
buffer. The rAAV containing elution is then dialyzed into the final storage buffer. 
 
Production and purification of PKD2 
For the expression of PKD2 as an affinity ligand, it was subcloned into a pET-24b expression vector 
from KIAA0319L full cDNA clone by PCR amplification of amino acid 405 to 502, which included 4 
amino acids to the left and to the right of the domain as proposed by Pillay et al. in order to ensure 
correct protein folding.12 To increase solubility the sequence of the maltose-binding protein was 
subjoined separated by a short glycine-serine linker at the 3'-end of PKD2. Here, subsequently a 
6x His-tag was introduced to allow purification of the fusion protein from E. coli production. A 
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theoretical sequence of the fusion protein is given in Figure 2A. The success of purification after 
Immobilized metal affinity chromatography (IMAC) is shown in Figure 2B. 
 
Figure 2: Construction and production of PKD2-MBP fusion protein. (A) Schematic representation of the 
basic components of the PKD2-MBP-fusion protein with its unique restriction sites for cloning and the 
position of GGSG linker sequences. (B) Coomassie-stained SDS PAGE protein analysis of PKD2-MBP puri-
fication steps. Cell extract, Ni-NTA column flow through and the wash fraction were diluted 1:2 in PBS 
buffer and elution fractions 1 to3 as well the combined and re buffered elution fraction was diluted 1:10 
with PBS before loading. 
 
Proof of binding of rAAV2 to PKD2-cellulose 
For covalent binding of PKD, divinyl sulfone (DVS) activation of the cellulose was chosen. Here, 
one of the vinyl groups reacts with a hydroxyl-group of the cellulose. The remaining vinyl group 
reacts with nucleophiles and by this covalently attaches biomolecules to the cellulose surface.16 
The binding of rAAV2 to PKD2 is known, but a negative influence of covalent coupling on PKD2 
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functionality by steric hindrance or coupling to the cellulose resin with important amino acids 
could not be excluded. Therefore, the binding of rAAV2 to the PKD2-blotting paper (PKD2-BP) was 
proven prior to the optimization of the purification strategy. 30 µg PKD2-MBP were coupled to 1 
cm2 DVS activated blotting paper and subsequently incubated with 5.7∙108 virus genomes (vg) of 
ultracentrifuge (UC) purified rAAV2 for 20 min, followed by two wash steps. The supernatant, 
PKD2-BP before and after the wash step and the wash fraction where analyzed by western blot 
analysis. As can be seen in Figure 3A, VP1, VP2 and VP3 were detected in the expected ratio on 
the PKD2-BP, with the washing procedure (BP-washed) had a low influence on signal strength. In 
the wash fraction no viral capsids were detected by western blot. The qPCR data where in accord-
ance with observed western blot data and calculated 78 % of rAAV2 were bound to the material, 
suggesting that the resin was saturated (Figure 3B).  
 
Figure 3: Characterization of rAAV2 binding to the PKD2-BP resin. (A) Western blot analysis of binding of 
UC purified rAAV2 to the PKD2-BP resin. (B) qPCR analysis of rAAV remaining in the respective fractions. 
Percentages were calculated by setting the genomic titer of starting material as 100 %. For each column, 
standard deviation was calculated between two technical replicates. 
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Optimization of PKD2 amount and elution conditions 
Since a huge amount of virus genomes of 22 % were still found in the supernatant after incubation 
of rAAV2 with PKD2-BP, varying amounts of coupled PKD2 where tested with 5.7∙108 vg, and non-
bound virus were detected by qPCR in the supernatant. As depicted in Table 1, no correlation 
between the amount of coupled PKD2 and rAAV2 in the supernatant was seen. Though, taking 
the excess of PKD2 towards rAAV2 into account no limitation was expected. 
Table 32: Relationship between amount of applied PKD2 to the amount of rAAV2 vg in the supernatant. 
Amount of PKD2 rAAV2 vg in supernatant in % PKD2 molecule number 
2 µM (12 µg) 7.8 ± 19.8 1.2∙1014 
5 µM (30 µg) 22.1 ± 0.98  3∙1014 
20 µM (120 µg) 6.0 ± 26.1  1.2∙1015 
 
Further experiments were carried out with 30 µg PKD2 and elution conditions were evaluated. 
Lowering the pH or increasing the ionic strength is well known for affinity purification procedures. 
Therefore, an elution buffer with 100 mM citric acid pH 2.5 and a 2.5 M magnesium chloride 
(MgCl2) buffer pH 7.0 were selected. Starting with UC purified rAAV2, only 0.2 % of the starting 
material were found in the pH elution sample, whereas for the MgCl2 elution a 33.5 % yield was 
reached. Subsequently, all following attempts were performed with 2.5 M MgCl2 50 mM Tris pH 
7.0.  
Description of the purification strategy from crude cell extract 
For purification of rAAV2, predetermined conditions were used with crude cell extract of rAAV2 
containing HEK293 cells. rAAV2, which carried the mVenus fluorescent protein as a transgene, 
were produced in HEK293 cells by triple plasmid transfection using calcium-phosphate. After 
three days, rAAV2-mVenus were released by three cycles of freeze-thaw and the clarified super-
natant of one 10 cm dish was incubated for 20 min with PKD2-BP while rotating on a roll-tumble 
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shaker. The resin was then washed rigorously with PBS-Tween until residual phenol red was un-
detectable. For elution, the resin was covered with 500 µl elution buffer in a spin tube for 5 min 
before it was centrifuged at 1000 × g for 2 min. After three cycles of elution, the fractions were 
combined and buffer exchange to HBSS was performed by ultra-centrifugal filters with a cut-off 
of 100´000 kDa. In qPCR, 41.5 % of vectors genomes were detected in the supernatant which was 
more than in previous trials with UC purified rAAV2. 24.6 % of total virus genomes were found in 
the combined elution fraction (Figure 4A). 
 
Figure 4: Characterization of rAAV2 binding to PKD2-BP from crude cell extract. (A) Distribution of rAAV2 
in the respective fractions. Percentages were calculated by setting the genomic titer of starting material 
as 100 %. Genomic titer was quantified in crude cell extract after three freeze-thaw cycles for start value 
and for supernatant value after incubation with PKD2-BP by qPCR. For each column, standard deviation 
was calculated between two technical replicates. (B) Silver-stained SDS PAGE analysis of rAAV2 sample 
purity after purification with PKD2-BP, POROS AAVX or UC. Viral particles were produced in HEK293 cells 
seeded in two 100 mm dishes for each purification method and subsequently purified via PKD2-BP, POROS 
AAVX or iodixanol ultracentrifugation. 
 
To compare the conventional UC method with a commercial affinity purification and the new 
PKD2 resin, two 10 cm dishes were purified either by PKD2, POROS CaptureSelect AAVX affinity 
resin (POROS AAVX) or UC, and the elution fractions were analyzed by qPCR (Table 2).  
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Table 33: Comparison of recovery rate for different purification approaches. 
 vg loaded in total vg recovered total Recovery rate in % 
PKD2 8.32∙1011 1.46∙1011 17.5 % 
POROS AAVX 8.32∙1011 1.12∙1011 13.4 % 
UC 8.32∙1011 3.2∙1011 38.0 % 
 
For UC purified rAAV2 the highest recovery rate was reached, whereas for PKD2 and POROS AAVX 
with 17.5 % and 13.4 %, respectively a similar yield was obtained. In a SDS-PAGE using silver ni-
trate staining (Figure 4B), many protein contaminants were observed for UC purified samples and, 
to a lower extent also for the POROS AAVX column material. Interestingly, the impurities in the 
POROS AAVX sample showed the same pattern as observed for the PKD2 sample. The most prom-
inent contaminant was detected with a molecular weight of approximately 60 kDa, which may 
potentially be residual BSA or VP3. For the PKD2-BP some other proteins were bound to the ma-
terial, indicating that a more rigid wash procedure may be necessary to diminish these. 
Biological characteristics of PKD2 purified rAAV2 
To analyze the biological activity of PKD2 purified rAAV2, a transducing titer assay on HT-1080 was 
performed and compared to UC purified rAAV2. Additionally, POROS AAVX was used in order to 
have a comparison to another affinity purification system. Here, 500 µl of slurry were used to 
purify rAAV2 from the clarified supernatant of a 10 cm dish, analogous to PKD2. Furthermore, the 
ratio of full to empty capsids was analyzed by a capsid ELISA. Therefore, a new capsid ELISA has 
been developed. While the standard capsid ELISA from PROGEN utilizes the A20 monoclonal an-
tibody (mAB) to capture fully assembled AAV capsids, PKD2 was coupled to the surface of a mi-
crotiter plate. For detection of captured viral capsids, a recombinant A20 single-chain variant (A20 
scFv-Fc) was cloned in our lab and produced in HEK-293 cells (for more details on this see Supple-
mentary Method 1 and SI Figure 1). 
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For UC purified rAAV2 with 0.27, the highest ratio of full to empty capsids was determined, 
whereas for PKD2 and POROS AAVX the ratio is roughly the same.  
Table 34: Biological characteristics of PKD2, POROS-AAVX and UC purified rAAV2 samples. 
 TU/ml Capsids/ gc full to empty ratio 
PKD2-BP 1.6∙108 7.07 0.14 
POROS AAVX n.D. 5.89 0.17 
UC 1.9∙108 3.63 0.27 
 
Transferring the method to AAV serotype 6 and 9 
The optimization of the purification method to increase the yield and purity is still necessary, but 
is sufficient to transfer it to other AAV serotypes. Therefore, PKD1, as well as PKD3-PKD5 were 
subcloned into pet-24b expression vector as a fusion to maltose-binding protein starting from full 
AAVR (KIAA0319) cDNA as for PKD2 before. Protein expression was performed by IPTG induction 
of E. coli BL21(DE3) transformed with the individual plasmids and subsequent purification by 
(IMAC) via His-tag. 
Individual PKD proteins were covalently coupled to blotting paper as before, and incubated with 
rAAV6 and rAAV9 containing HEK293 crude cell lysate from one 10 cm dish divided by five, so that 
for each domain the same amount of rAAV was secured. The elution fractions were then used for 
the determination of genomic titers by qPCR. rAAV6 showed a distinct affinity to PKD3 (Figure 5A), 
whereas for rAAV9, PKD2 and PKD5 gave a good result, with PKD5 giving a slightly higher genomic 
titer (Figure 5B). As before, purity of the samples from PKD3 for AAV6, respectively PKD5 for 
AAV9, was confirmed by SDS PAGE and subsequent Coomassie brilliant blue staining (Figure 5C). 
As concentrations of rAAV samples were too low to be detected by SDS PAGE analysis a western 
blot with B1 antibody was performed and confirmed the presence of VP3. The same samples were 
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also analyzed for the presence of PKD by anti-His-tag antibody to exclude leaching of PKD off BP 
during elution, but no PKD3, respectively PKD5 was observed in the elution fractions (Figure 5D). 
 
Figure 5: Summary of rAAV6 and rAAV9 purification. (A, B) Determination of suitable PKD domain for the 
purification of rAAV6 and rAAV9, respectively from crude cell extract by qPCR. For each column, standard 
deviation was calculated between two technical replicates. (C) Coomassie-stained SDS-PAGE protein 
analysis of PKD3 (rAAV6) or PKD5 (rAAV9) purified rAAV. (D) Western Blot analysis of rAAV6 and rAAV9 
elution fractions for detection of VP proteins by B1 antibody (two left panels) or for detection of PKD by 
Anti-His-tag antibody (two right panels). 
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Discussion 
As gene therapy utilizing AAV have become increasingly important with raising numbers of clinical 
trials worldwide, the demand for scalabale, user friendly purification strategies comes into fo-
cus.17 Standard processes, relying on a cesium chloride (CsCl) or an iodixanol gradient ultracen-
trifugation are restricted in their potential to scale up.18 Often, several chromatography steps are 
included into downstream processes like ion exchange, size exclusion and heparin column chro-
matography. These procedures are not only time intensive, but are accompanied by high costs 
and cumulative loss in yield. In this work a scalable affinity purification strategy, based on the 
natural AAV receptor AAVR, was developed which yields comparable rAAV titer as with commer-
cial affinity chromatography resins. In a first step the method was evaluated for rAAV2 as for this, 
the most important interacting domain of the AAVR, namely PKD2 is well-known.15 In order to 
avoid time-consuming and elaborate steps in the purification procedure, the method has been 
designed that it can be performed directly from the crude cell extract as concentration steps with 
ammonium sulfate or polyethylene glycol (PEG) precipitation interfere with upscaling due to the 
need for a centrifugation step.19 As depicted in Figure 1, in contrast to a packed column the chosen 
cellulose material in form of blotting paper allows for a batch process in where the rAAV contain-
ing suspension is either stirred or shaken with the PKD functionalized paper. Thereafter, the col-
umn material can be transferred into a spin tube and by this, separation of the column material 
from the elution can easily be executed. As for commercial POROS CaptureSelect AAVX or AVB 
Sepharose High Performance, batch processes can also be conducted, but separation of the ma-
terial from the sample is not easily realized as the small sized particles sticking to the vessels. PKD2 
can be produced in high concentrations and purity in E. coli when fused to MBP (Figure 2 B) and 
thus inexpensive supply of the affinity ligand is possible. Covalent binding of the fusion protein to 
blotting paper by DVS activation does not impair the functionality of PKD2, so that the binding of 
rAAV2 to the blotting paper was proven by western blot analysis (Figure 3 A). Interestingly an 
increase in the amount of applied PKD2 did not decrease the quantity of rAAV2 found in the su-
pernatant. Potentially, even if the amount of PKD2 was raised, no more functional protein was 
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covalently bound, as the method for coupling does not allow for quantification of bound protein 
as the blotting paper was just soaked with the protein without any protruding solution. After pro-
tein coupling SDS-PAGE analysis with subsequent determination of bound protein should be con-
sidered in the future. However, as the amount of affinity ligand exceeds applied viral capsids by 
far (Table 1), we hypothesize, that non bound rAAV2 may be in a structural conformation which 
does not allow for accurate binding and by this is not purified from crude cell lysate, but this 
hypothesis has yet to be substantiated. If this hypothesis could be confirmed, this method would 
primarily purify biologically relevant viruses and thus would have a substantial advantage over 
other systems. The purity of the samples was compared to ultracentrifugation and POROS Cap-
tureSelect AAVX purified rAAV2 samples (Figure 4B). Many impurities were detected for the UC 
purified sample. By selecting non-contaminated fractions using an additional SDS PAGE analysis, 
these could potentially be minimized but also leads to a reduction in yield. For PKD2 nearly no 
contaminations were detected. Interestingly, for POROS CaptureSelect AAVX the protein pattern 
looked similar to those obtained for PKD2 but with a higher intensity indicating a higher protein 
contamination. The most prominent band on the heights of about 60 kDa may refer residual BSA 
contaminants. With the best elution conditions 17.5 % to 24.5 % of applied genomic copies were 
recovered. The MgCl2 buffer does not only yielded the highest amount of rAAV but also offers the 
advantage of a neutral pH as other methods relying on elution conditions within a pH range of pH 
2.0 - 3.0. AAV undergoes autolytic proteolysis at low pH which results in a decrease in VP1 and 
VP2 and in an increase in lower-molecular-mass bands.20 For AAV serotype 8, amino acid side 
chain conformational rearrangements were observed at low pH values.21 However, effects on viral 
preparation potency still need to be investigated. As expected, separation of full and empty cap-
sids still needs a polishing step after affinity chromatography. Here, the UC purified rAAV sample 
showed highest proportion of full capsids with 27% in contrast to 14 % for PKD2-BP and 17 % for 
POROS CaptureSelect AAVX, respectively (Table 3). As empty capsids may cause serious side ef-
fects in patients, also for UC purified sample another polishing step is normally applied and by 
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this, UC offers only a slight advantage when used as a one-step purification strategy in the context 
of research, when the high purity of vector preparation is not needed. 
As the affinity chromatography was successfully implemented for AAV serotype 2, the aim was to 
transfer the conditions to the other serotypes commonly used in our lab. Therefore, the other 
PKD domains were cloned into pet-24b expression vector and purified via IMAC from E. coli ex-
pression. Combinations of the domains 1 to 5 with AAV serotype 6 and 9 with subsequent elution 
and qPCR analysis revealed a high affinity of rAAV6 to PKD3 and for rAAV9 towards PKD2 and 
PKD5. SDS PAGE analysis showed the high purity of the vector preparations. This gives rise to the 
assumption that a transfer of the method will be possible for other AAV serotypes and needs to 
be evaluated in the future. 
 
Conclusions 
An affinity chromatography procedure was established for efficient AAV post-processing. Based 
on the natural cellular receptor AAVR, we could show that the covalent coupling of single PKD 
domains to the surface of blotting paper did not significantly affect the functionality, allowing 
purification from raw cell extract without further processing steps such as concentration or ultra-
centrifugation. This means not only a reduction in processing steps, but also the potential for 
scaling up in the future. 
The simple production of the affinity ligand in E. coli as well as the easy accessibility of the carrier 
material in combination with the high purity of the end product shows the potential of the devel-
oped chromatography approach. We assume that this method can be adopted for other AAV sero-
types by searching for the corresponding PKD domain, which makes the presented strategy a uni-
versal approach for the purification of AAVs by affinity chromatography with superior purity of 
the final product. 
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Materials and Methods 
Construction of pET-24b_AAVR_PKDX-MBP-His6. The DNA sequence of individual PKD domains 
was amplified from a cDNA clone KIAA0319L (pCMV6_KIAA0319 (Myc_DDK-tagged, Origene). 
Starting from UniProt Q8IZA0 database, four amino acids to the left and to the right of the domain 
were included as proposed by Pillay et al. in order to ensure correct protein folding.12 The PKD2 
sequence was amplified with NdeI-PKD2-for (5'-AAAAACATAT GAATCGGCCC CCCATTGCTAT TG-
3'), which introduced the underlined NdeI restriction site and at the same time contained the ATG 
start codon and KpnI-linker-BamHI-PKD2-rev (5'-TTTTTGGTAC CACCGCCTGA ACCACCACCA 
GAGCCACCAC CGGATCCGGG GTAATCCACA GCTTTGTTCA C-3'). The MBP was amplified from 
pMAL™-c5X Vector (NEB) with primer BamHI-linker-MBP-for (5'-AAAAAGGATC CGGTGGTGGC 
TCTGGTGGTG GTTCAGGCGG TAAAATCGAA GAAGGTAAAC TGG-3') which contained the under-
lined BamHI restriction site and the glycine-serine-linker sequence with the hybridizing region 
marked italic, and KpnI-linker-MBP-rev (5'-TTTTTGGTAC CACCGCTACC GCCACCTGAA CCACCAC-
CGC TACCAGTCTG CGCGTCTTTC AG-3') with KpnI restriction site underlined and hybridizing region 
italicized. A third PCR was used to fuse PCR product 1 and 2 to KpnI-MBP-linker-BamHI-PKD2-
NdeI. The oligonucleotides KpnI-His6-tag-XhoI-for (5'-ACCCATCATC ACCATCATCA TTAACTCGA-3') 
and XhoI-His6-tag-KpnI-rev (5'-GTTAATGATG ATGGTGATGA TGG-3') were hybridized and ligated 
to the KpnI and NdeI digested PCR product in order to add the His6-tag and the XhoI restriction 
site. This product was then ligated into NdeI and XhoI opened pET-24b (+) (Novagen®).  
For PKD3 to PKD5 following primers were used to amplify respective DNA sequence from cDNA 
clone KIAA0319L. PKD3-NdeI-for (5'-ATATACATAT GTACCCCCCT GTGGCCAACG CAGG-3') and 
PKD3-BamHI-rev (5'-CACCGGATCC CTTATTGTTT TCAGGTTGCA CAATAACAGT CAC-3'); PKD4-NdeI-
for (5'-ATATACATAT GAATAAGCCT CCTCAGGCAG ATGCAGGC-3') and PKD4-BamHI-rev (5'-CACCG-
GATCC TTTGTTTATT TCTTCTTTGA CAATGACATT CACAGA-3'); PKD5-NdeI-for (5'-ATATACATAT 
GAAACCACCT ATAGCCAAGA TAACTGGGAA T-3') and PKD5-BamHI-rev (5'-CACCGGATCC 
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GTTTTTCCTG GGATCAGGTT TCACCTCCAC-3'). They introduced underlined NdeI and BamHI re-
striction sites and allowed for subsequent cloning into previous generated pET-24b vector by re-
moving PKD2 sequence via NdeI and BamHI. For PKD1 a second NdeI restriction site had to be 
removed before cloning into expression vector was performed. Therefore, the PCR product of 
PKD1-NdeI-for (5'-ATATACATAT GGTATCTGCT GGAGAGAGTG TC-3') and PKD1-Mut-rev (5'-
AACATAGGCA TTTAATTGAA CTTCATTCTT AGGCA-3') as well as the PCR product of PKD1-Mut-for 
(5'-AATGCCTATG TTCTCCAAGA ACCACCTAA-3') and PKD1-BamHI-rev (5'-CACCGGATCC AC-
GGGGCTCT GGCTTGACTG TCAC-3') were used in a third PCR. After digestion with NdeI and BamHI 
it was introduced into the likewise opened pET-24b expression vector by removing PKD2. In bold 
the nucleotide was changed from A to C and thus did not alter the amino acid sequence. The 
restriction sites of NdeI and BamHI were underlined. 
Plasmids for viral particle production. Plasmids were based on a pSB1C3 backbone and were as-
sembled using the iGEM RFC10 BioBrick assembly standard.22 
pZMB0216_Rep_VP123_453_587wt_p5tataless contains a genetically modified rep/cap similar to 
one encoded in pAAV-RC (Genbank Accession number: AF369963.1). In the ITR containing plasmid 
pZMB0522_ITR_EXS_CMV_mVenus_hGHpA, a CMV promoter expresses the fluorescent protein 
mVenus. Plasmids are described in detail by Feiner et. al [submitted 2019]. 
Cell Culture. HEK-293 and HT-1080 (DSMZ) cells were cultured in Dulbecco’s Modified Eagle Me-
dium supplemented 10% (v/v) fetal calf serum and 1% (v/v) penicillin/streptomycin (Sigma Al-
drich). Cells were maintained at 37 °C and 5% CO2. 
Viral particle production. HEK293 cells were seeded at a density of 3×106 cells per 100 mm dish 
the day before transfection. A total amount of 15 µg DNA per 100 mm dish was transfected using 
calcium phosphate. RepCap plasmid, ITR-containing plasmid and pHelper plasmid were used in a 
1:1:1 molar ratio23. After 72 h of incubation at 37 °C, cells were harvested and pelleted by centrif-
ugation (2000×g, 5 min). 
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Processing of viral particles for purification. Cells were resuspended in lysis buffer (50 mM Tris, 
150 mM NaCl, 2mM MgCl2, pH 7.5) and viral particles were released from cells with three freeze-
thaw cycles. Remaining DNA contamination was degraded by incubation with benzonase nuclease 
(final 100 U/ml, Sigma Aldrich) at 37 °C prior to addition of CHAPS (3-[(3-cholamidopropyl)dime-
thylammonio]-1-propanesulfonate, 0.5% w/v final). The crude lysate was cleared from cell debris 
by centrifugation (3,000×g, 10 min). The supernatant was added to the virus containing spent 
media which was then used for affinity chromatography. For ultracentrifugation, precipitation of 
viral particles from spent media, 3.13 g ammonium sulfate per 10 ml volume were dissolved and 
incubated for 30 min on ice. After centrifugation at 8300 x g, 10 min, 4 °C the resulting pellet was 
resuspended with the supernatant from cell lysis. This crude viral stock was further purified by 
ultracentrifugation.  
Purification by ultracentrifugation. The crude viral stock was used for a discontinuous iodixanol 
gradient24. Briefly, the lysate was transferred onto a gradient of 60%, 40%, 25% and 15% iodixanol 
in an open top polyallomer 16 x 76 mm tube (Science Services). Tubes were sealed and centrifuged 
in a T-880 rotor (Sorvall) at 340,000×g for 2 h at 18 °C. The rAAV containing fraction was collected 
with a 21G x 1 1/2” injection needle and the buffer was exchanged to 1× HBSS (Sigma Aldrich) via 
Amicon Ultra-4 100K centrifugal filter units (Merck Millipore). 
Purification of viral particles by POROS CaptureSelect AAVX. For affinity purification a 5 ml empty 
lab column with Luer-lock connections (MoBiTec S10131) was filled with 500 µl of the POROS 
CaptureSelect AAVX suspension and equilibrated with 10 column volumes of PBS. The sample was 
loaded with 1 ml per min with a syringe pump. After washing with 10 CV with PBS-T (PBS + 0.05 
% Tween20) rAAV2 were eluted three times with 250 µl 100 mM citric acid buffer pH 2.5 and 
neutralized with Tris-HCl pH 9.0. 
PKD expression and purification. An overnight preculture (37 °C, 180 rpm) of E. coli transformed 
with pET-24b expression vector was used to inoculate a culture in 0.5 L LB medium containing 50 
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μg/mL kanamycin. This culture was grown (37 °C, 180 rpm) up to an OD600 of 0.5. Protein expres-
sion was then induced with isopropyl-β-D-thiogalactopyranoside (IPTG) (1 mM) and the cells were 
cultivated at 37 °C, 180 rpm for 4 h. Afterwards, cells were harvested by centrifugation (6000 × g, 
4 °C, 15 min) and stored at -20 °C. For protein purification, cells from cultivation were thawed and 
suspended in 30 mL equilibration buffer (50 mM Na2HPO4, 300 NaCl, 10 mM imidazole pH 8). The 
cell membrane of bacteria was disrupted in three repeated French press cycles at a pressure of 
1000 psi. Cell debris was separated from soluble protein by centrifugation at 11.600 × g for 20 min 
at 4°C. The supernatant was filtered and applied to a Protino Ni-NTA column (Macherey-Nagel) 
for purification. After washing with 10 CV buffer containing 20 mM imidazole in equilibration 
buffer, the protein was eluted with 5 CV of an elution buffer containing 250 mM imidazole. Finally, 
the buffer was adjusted to 1 × PBS using an Amicon Ultra centrifugal filter unit (MWCO 30 kDa). 
Preparation of PKD affinity resin. Blotting paper (Rotilabo® Blotting Papers, Thickness 0.35 mm; 
Carl Roth) was cutted into 1 cm2 large pieces and incubated in 2 ml DVS buffer (0.1 M Na2CO3, 
pH11) with 10 % DVS (Sigma Aldrich) for 2 h. Then, the blotting paper was washed five times with 
10 ml MilliQ and dried for at least 2 h. Each blotting paper was incubated with 100 µl 5 µM PKD 
in PBS overnight in a water-saturated atmosphere. The remaining surface was blocked with 2 ml 
of PBS-T for 1 h before it was washed three times with PBS. Afterwards the material could be used 
for affinity purification or stored in PBS buffer at -20 °C. 
Purification of viral particles by PKD affinity chromatography. For affinity purification from crude 
cell lysate, it was incubated with one 1 cm2 of prepared PKD-blotting paper for 30 min in a suitable 
vessel under constant shaking. Afterwards the supernatant was removed and the resin was 
washed with PBS until no phenol red residues from the medium were seen (usually 5 to 6 wash 
steps with 10 ml PBS). Elution was performed by transferring the PKD-blotting paper into an 
empty spin column and adding 500 µl of elution buffer (2.5 M MgCl2, 50 mM Tris, pH 7.0 or 100 
mM citric acid pH 2.5). After 2 min incubation elution was performed by centrifugation (1000 × g, 
2 min). The elution fractions were combined and the buffer was exchanged to 1× HBSS (Sigma 
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Aldrich) via Amicon Ultra-4 100K centrifugal filter units (Merck Millipore). For purification from 
UC purified rAAV 20 µl of UC purified rAAV were diluted with PBS to 100 µl and afterwards pro-
cessed as for purification from cell lysate. 
SDS-PAGE and Western blot analysis. Cell pellets from rAAV production (1× 100 mm dish) were 
resuspended in 100 µl PBS and 5× SDS loading buffer. Samples were incubated at 95 °C for 10 min, 
centrifuged and 20 µl per lane were loaded on a 10% SDS-polyacrylamide gel (Hoefer SE260). 
Samples were blotted onto a 0.45 µm nitrocellulose membrane (Thermo Fisher Scientific) using 
semi-dry electrophoretic transfer (V20-SDB, Sci Plas). After blocking the membrane with 10% 
(w/v) non-fat milk in TBS, the membrane was incubated simultaneously for 1.5 h with the B1 an-
tibody (mouse monoclonal, supernatant, 1:100, Progen) and an anti β-Actin antibody (8H10D10, 
mouse monoclonal, 1:1000, Cell Signaling Technology). After incubation with an anti-mouse IgG, 
HRP-linked antibody (1:5000, Cell Signaling Technology), blots were imaged by luminescence de-
tection (Pierce ECL Western Blot Substrate, Thermo Fisher Scientific). 
Determination of genomic titers. Before determination of genomic titers via qPCR, samples were 
treated with 10 U DNase I (New England Biolabs) in 10× DNaseI buffer in a final volume of 50 µl at 
37 °C for 30 min before heat inactivation of the DNase I (75 °C, 20 min). Crude lysate samples were 
additionally incubated with 0.8 U Proteinase K (New England Biolabs) for 50 min at 37 °C before 
heat inactivation (95 °C, 10 min). Dilutions of the DNase I digest were used as template in the 
qPCR reaction. The sample was mixed with 2.5 µl primer qPCR-hGH-for (5'-CTCCCCAGTG 
CCTCTCCT-3') and 2.5 µl primer qPCR-hGH-rev (5´-ACTTGCCCCT TGCTCCATAC-3´), each at a stock 
concentration of 4 µM, and 10 µl of 2× GoTaq qPCR Mastermix (Promega). The qPCR reaction was 
carried out as described in the manual (TM318 6/14, Promega) with an increased time interval for 
the first denaturation step (95 °C, 10 min) using a LightCycler 480 II (Roche). The genomic titer 
was calculated from a standard curve of 10 to 106 copies of the ITR plasmid (pZMB0522) with an 
efficiency between 90-110% and an R value less than 0.1. Genomic titres in crude lysates were 
estimated from a standard curve mixed with the same amount of a non-transfected cell lysate. 
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Transducing titer assay. 10,000 cells per well were seeded in 500 µl of the corresponding media 
on a 12-well plate and settled for 1 h before application of rAAV preparations. After 12 h incuba-
tion 500 µl of fresh media was added to the cells. Cells were incubated at 37 °C for further 72 h 
before detaching with 0.25% Trypsin/EDTA, resuspension in PBS and analysis of 10,000 events 
using a FACSCalibur. All experiments were performed as biological duplicates. Data sets were an-
alyzed using FlowJo V10. Positive cells were gated above the 99 % interval of the negative control. 
AAV Capsid ELISA. For the determination of viral capsid titer, a96-well cell culture plate was incu-
bated overnight at 4 °C with purified PKD2 (200 ng in 100 µL per well) in 13 mM Na2CO3, 35 mM 
NaHCO3, pH 9.6. Afterwards, the plate was washed three times with PBS, 0.05% Tween-20 (wash 
buffer) and remaining sites were blocked with 200 µl blocking buffer (0.8 % BSA in PBS) per well 
for 1 h at RT. After three wash steps with wash buffer the A20 scFv was added with 100 ng per 
well in blocking buffer for 1 h at RT. The three times washed plate was then incubated with an 
anti-human IgG1 HRP antibody (AM08151HR-N, mouse monoclonal, 1:2000 in wash buffer with 
0.8 % BSA, Acris antibodies) for 1 h. The detection was started, after three wash steps with wash 
buffer, with 150 µl ABTS buffer (3.25 mM BH2NaO4, 40 mM citric acid monohydrate, 60 mM 
Na2HPO4, pH 4.5) with 1 g L-1 ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid). The 
absorbance was measured at 405 nm with a microplate spectrophotometer (PowerWave HT, Bi-
oTek) after 30 min. Calculation of capsids was performed by a standard curve of a serial dilution 
of a known capsid concentration (Kit control/Standard, Progen) 
List of abbreviation 
Abbreviation Meaning 
rAAV recombinant adeno-associated virus 
PKD1-5 polycystic kidney disease domain 1-5 
AAVR adeno-associated virus receptor 
AAV2 adeno-associated virus serotype 2 
  10 Appendix: Publications 
183 
 
ITR Inverted terminal repeat 
qPCR quantitative polymerase chain reaction 
 
Declarations 
Ethics approval and consent to participate 
Not applicable 
Consent for publication 
Not applicable 
Availability of data and material 
All data generated or analyzed during this study are included in this published article and its sup-
plementary information files.  
Competing interests 
The authors declare that they have no competing interests. 
 
 
Funding 
We acknowledge support of the publication fee by Deutsche Forschungsgemeinschaft and the 
Open Access Publication Funds of Bielefeld University. This work was supported by grants of Bie-
lefeld University.  
Authors' contributions 
All authors were involved in the design of this study. KT and JT planned and performed the exper-
iments to characterize the purification method for rAAV2. JT designed the plasmid construct and 
10 Appendix: Publications 
184 
 
optimized the protein production. KT optimized the protein binding to the column and purification 
parameters. ML performed the experiments to characterize the purification method for rAAV6 
and rAAV9. KT, JT and KM wrote the manuscript. All authors read and approved the final manu-
script. 
Acknowledgements 
We thank Philipp Borchert for experimental assistance.  
 
References 
1. Xiao, X., Li, J. & Samulski, R. J. Efficient long-term gene transfer into muscle tissue of 
immunocompetent mice by adeno-associated virus vector. J. Virol. 70, 8098–108 (1996). 
2. Russell, D. W., Miller, A. D. & Alexander, I. E. Adeno-associated virus vectors preferentially 
transduce cells in S phase. Proc. Natl. Acad. Sci. U. S. A. 91, 8915–9 (1994). 
3. Kaludov, N., Handelman, B. & Chiorini, J. A. Scalable Purification of Adeno-Associated Virus 
Type 2, 4, or 5 Using Ion-Exchange Chromatography. Hum. Gene Ther. 13, 1235–1243 
(2002). 
4. GE Healthcare. AVB SepharoseTM High Performance - Datafile 28-9207-54 AB. (2007). 
Available at: https://www.gelifesciences.co.jp/catalog/pdf/28920754ab.pdf. (Accessed: 
11th December 2018) 
5. Oranje, P. et al. Isolation of an Adeno-Associated Virus (AAV)-Specific Camelid-Derived 
Single Chain Antibody Fragment: A Novel Tool for Purification of AAV Vectors of Different 
Serotypes. Mol. Ther. 9, S162 (2004). 
6. Toueille, M. et al. Development of purification steps for several AAV serotypes using 
POROS CaptureSelect AAVX affinity chromatography. Cell Gene Ther. Insights 637–646 
(2017). doi:10.18609/cgti.2018.062 
  10 Appendix: Publications 
185 
 
7. Nass, S. A. et al. Universal Method for the Purification of Recombinant AAV Vectors of 
Differing Serotypes. Mol. Ther. - Methods Clin. Dev. 9, 33–46 (2018). 
8. Eichhoff, A. M. Nanobodies als Werkzeuge zur Optimierung Adeno-assoziierter Viren für 
die Gen- und Tumortherapie. (2018). 
9. Grimm, D., Kern, A., Rittner, K. & Kleinschmidt, J. A. Novel tools for production and 
purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 9, 2745–60 
(1998). 
10. Srivastava, A. In vivo tissue-tropism of adeno-associated viral vectors. Curr. Opin. Virol. 21, 
75–80 (2016). 
11. Herrmann, A. & Grimm, D. High-Throughput Dissection of AAV-Host Interactions: The Fast 
and the Curious. J. Mol. Biol. #pagerange# (2018). doi:10.1016/j.jmb.2018.05.022 
12. Pillay, S. et al. An essential receptor for adeno-associated virus infection. Nature 530, 108–
112 (2016). 
13. Mizukami, H., Young, N. S. & Brown, K. E. Adeno-associated virus type 2 binds to a 150-
kilodalton cell membrane glycoprotein. Virology 217, 124–130 (1996). 
14. Dudek, A. M. et al. An Alternate Route for Adeno-associated Virus (AAV) Entry Independent 
of AAV Receptor. J. Virol. 92, e02213-17 (2018). 
15. Pillay, S. et al. AAV serotypes have distinctive interactions with domains of the cellular 
receptor AAVR. J. Virol. 91, JVI.00391-17 (2017). 
16. Yu, A. et al. Biofunctional paper via the covalent modification of cellulose. Langmuir 28, 
11265–73 (2012). 
17. Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M. & Abedi, M. R. Gene therapy clinical 
trials worldwide to 2017: An update. J. Gene Med. 20, e3015 (2018). 
18. Clément, N. & Grieger, J. C. Manufacturing of recombinant adeno-associated viral vectors 
10 Appendix: Publications 
186 
 
for clinical trials. Mol. Ther. - Methods Clin. Dev. 3, 16002 (2016). 
19. Vandenberghe, L. H. et al. Efficient serotype-dependent release of functional vector into 
the culture medium during adeno-associated virus manufacturing. Hum. Gene Ther. 21, 
1251–7 (2010). 
20. Salganik, M. et al. Evidence for pH-Dependent Protease Activity in the Adeno-Associated 
Virus Capsid. J. Virol. 86, 11877–11885 (2012). 
21. Nam, H. et al. Structural Studies of Adeno-Associated Virus Serotype 8 Capsid Transitions 
Associated with Endosomal Trafficking ᰔ. 85, 11791–11799 (2011). 
22. Shetty, R. P., Endy, D. & Knight, T. F. Engineering BioBrick vectors from BioBrick parts. J. 
Biol. Eng. 2, 5 (2008). 
23. Agilent Technologies. AAV Helper-Free System Instruction Manual. Available at: 
https://www.agilent.com/cs/library/usermanuals/Public/240071.pdf. (Accessed: 13th 
August 2019) 
24. Zolotukhin, S. et al. Recombinant adeno-associated virus purification using novel methods 
improves infectious titer and yield. Gene Ther. 6, 973–85 (1999). 
 
  
  10 Appendix: Publications 
187 
 
Additional File 
Generating a quick, easy and low-cost affinity purification method 
for rAAV based on adeno-associated virus receptor’s PKD domain 
 
Rebecca C. Feiner1,†, Kathrin E. Teschner1,†,, Julian Teschner1,Kristian M. Müller1,*,  
† Both authors contributed equally to this work.  
1 Cellular and Molecular Biotechnology, Faculty of Technology, Bielefeld University, Bielefeld, Ger-
many 
 
*Corresponding author information (Address; Email; Phone) 
Kristian M. Müller, Cellular and Molecular Biotechnology, Faculty of Technology, Bielefeld Univer-
sity, Universitätsstraße 25, 33615 Bielefeld, Germany; Email: kristian@syntbio.net; Tel. +49-521-
106-6323 
  
10 Appendix: Publications 
188 
 
SI Method 1: 
On the basis of the Fab' fragment of the A20 antibody (PDB ID 3J1S), the A20 single chain variable 
fragment (scFv) was designed. For the light chain, all amino acids until position Lys107 were cho-
sen. For variable heavy chain, the amino acid sequence ended with Thr124. A (GGSG)4 linker was 
chosen to link the C-terminus of the light chain with the N-terminus of the heavy chain, where the 
last serine of the linker is also the first amino acid of the variable heavy chain. In order to enable 
secretory expression of the scFv, the protein construct was extended by the 22 amino acid long 
signal peptide sequence of the murine variants of the Ig-κ chain (UniProt: P01601) at its N-termi-
nus. At the C-terminus it was extended by the sequence of the human IgG1-Fc part (the 232 C-
terminal amino acids of the human Ig gamma-1 chain C region, including the hinge region and the 
CH2 and CH3 domains of the antibody (UniProt: P01857)) and a His6-tag sequence. As an expression 
vector, pcDNA5/FRT (ThermoFisher Scientific) was chosen. The sequence was ordered as a gene 
synthesis and inserted into pCDNA5/FRT via restriction digest with NheI and ApaI of the gene 
synthesis and the vector. The insert sequence is shown below. 
Sequence information for A20-scFv 
Restriction sites are underlined 
GCTAGCGCCACCATGGACATGAGAGTGCTGGCTCAGCTGCTGGGACTGCTGCTGTGTGTTTCCCTGGCGCTAGATGCGAC 
ATCCAGATGACCCAGTCCTCCTCCAGCTTCTCCGTGTCTCTGGGCGACAGAGTGACCATCACATGCAAGGCCTCCGAGGA 
CATCCACAACAGACTGGCCTGGTACAAGCAGAAGCCTGGCAACGCTCCCCGGCTGTTGATTTCTGGCGCTACCTCTCTGG 
AAACCGGCGTGCCCAGTAGATTCTCCGGCTCTGGCTCTGGCAAGGACTACACCCTGTCTATCACCAGCCTCCAGAACGAG 
GACGTGGCCACCTACTACTGCCAGCAGTATTGGATCGGCCCCTTCACCTTCGGCTCCGGCACCAACCTGGAAATCAAAGG 
CGGAGGATCTGGCGGAGGAAGCGGTGGCGGATCAGGTGGTGGATCTGATGTCCAGCTGCAAGAGTCTGGCCCCGACCTGG 
TTAAGCCCTCTCAGTCTCTGTCTCTGACCTGCACCGTGACCGGCTACTCTATCACCTCTGGCTACACCTGGCACTGGATC 
AGACAGTTCCCCGGCAACAAGCAAGAGTGGATGGGCTACATCCACTTCAGCGGCTACA CCAACTACAACCCCAGCCTGA 
AGTCCCGGGTGTCCATCACCAGAGATACCTCCAAGAACCAGTTCTTCCTGCACCTGAACTCCGTGACCACCGAGGATACC 
GCTACCTACTATTGCGCCAGAGGCGACTACGGCTACGAGTGGTTTACCTATTGGGGCCAGGGCACCCTGGTCACCGTGTC 
TGCTGCTAAAACAACCGGCGGTGGTAGTGGTGGTTCTGGTGGCGGAGGTACCGAACCTAAGTCTTGCGACAAGACCCACA 
CCTGTCCCCCCTGTCCTGCTCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTCCCCCCAAAGCCCAAGGACACCCTG 
ATGATCTCCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCAATTGGTA 
CGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTACAACTCCACCTACCGGGTGGTGTCCG 
TGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
ATCGAAAAGACCATCTCCAAGGCCAAGGGCCAGCCCCGGGAACCTCAGGTGTACACCCTGCCCCCTAGCAGGGACGAGCT 
GACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAGGGCTTCTACCCCTCCGACATTGCCGTGGAATGGGAGTCCAACG 
GCCAGCCTGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACTCCGACGGCTCATTCTTCCTGTACTCCAAGCTGACA 
GTGGACAAGTCCCGGTGGCAGCAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCA 
GAAGTCCCTGTCCCTGAGCCCCGGCAAGACCGGTCATCACCACCACCATCACTGAGGGCCC 
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SI Figure 6: Standard curve for the determination of capsid titer. The kit control from AAV2 titration ELISA 
(Progen) was diluted as recommended in the kit instruction. The particle titer was calculated by a 4 pa-
rameter logistic fit with OriginPro 2018 software. 
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Abstract 
Gene therapy for cancer offers the potential to of tailoring to specific cell types and thus overcome 
the lack of specificity of conventional non-invasive therapies. Targeting approaches limit the ex-
pression of a transgene to the tumor, thus avoiding normal tissue toxicity. This can be achieved at 
the transcriptional and translational level. Using recombinant adeno-associated virus (rAAV) for 
gene delivery in a virus-directed enzyme prodrug therapy (VDEPT), enables transcriptional control 
by tumor specific promoters and translational control mechanism by influencing the lifetime of 
mRNA transcripts. Here, we constructed rAAV2 vectors with thymidine-kinase (TK) under the 
control of survivin (SUR), cyclooxygenase-2 (COX-2) or the C-X-C motif chemokine receptor 4 
(CXCR-4) promoter. Tumor specificity was compared to the strong cytomegalovirus immediate 
early promoter (CMV) driven gene expression. For an additional layer of tumor-specificity the let-
7a microRNA (miRNA) target sequence was introduced into CMV- and SUR promoter driven ex-
pression cassettes. All promoters exhibited transcriptional activity in HT-1080, MDA-MB231, 
MDA-MB453 and A431 cancer cell lines as well as in primary HDFa and healthy M1FS fibroblast 
cells. In the presence of the prodrug ganciclovir (GCV) a cytotoxicity assay demonstrated dramatic 
repression of CMV promoter driven gene expression upon miRNA de-targeting, leading to the 
highest tumor-specificity among all investigated transgene expression cassettes. Contrary to expec-
tations the CMV promoter may be a good candidate for tumor specific gene expression when com-
bined with miRNA de-targeting strategies. 
Introduction 
Cancer is one of the leading causes of death in the world.1 The clinical effectiveness of conventional 
chemo- and radiotherapy is limited due to a lack of specificity, which causes serious side effects. 
Gene therapy offers the possibility to target a therapeutic transgene to tumor cells in order to avoid 
tissue toxicity. Virus-directed enzyme prodrug therapy (VDEPT) is an emerging strategy in the 
treatment of cancer. By delivering of an enzyme, a prodrug is activated into a cytotoxic compound 
that leads to apoptosis of the cancer cell.2 In this context, the herpes simplex virus type 1 thymidine 
kinase (HSV-tk) is most commonly used. By conversion of Ganciclovir (GCV) into the toxic me-
tabolite GCV-triphosphate in cells expressing HSV-tk, fast dividing cells undergo apotosis.3,4 To 
facilitate cell killing, a HSV-TK mutant (HSV-TK30) was developed which shows higher kinase 
activity and by this an increased GCV sensitivity 5. For activation of the non-toxic prodrug 
ganciclovir to ganciclovir triphosphate it passes three phosphorylation steps in which endogenous 
guanylate kinases (GMK) catalyze the phosphorylation of ganciclovir monophosphate (GCV-MP) 
to GCV diphosphate (GCV-DP). To overcome limitations in this intracellular conversion, a fusion 
gene consisting of mouse guanylate kinase (mGMK) and HSV-TK30 (mGMK-TK30) was incor-
porated into our suicide gene construct.6 
Recombinant adeno-associated viruses (rAAV) emerged as an outstanding option for gene therapy. 
rAAVs provide long-term target gene expression, are not associated with any disease and are unable 
to replicate autonomously resulting in a high safety profile. They transduce a wide range of dividing 
and non-dividing cells and are able to penetrate the stroma of solid tumors due to their small size, 
which ensures adequate distribution of the transgene throughout the tumor.7,8 Systemic application 
of rAAV allows targeting of the primary tumor and metastases but requires a strict control of gene 
expression to prevent harm to normal tissue.9 In general, tissue targeting with AAV can be attained 
by the use of different tissue specific serotypes. For example, AAV1 and AAV9 are able to trans-
duce skeletal and cardiac muscle cells, whereas AAV8 delivers genes effectively to the liver of 
rodents and non-human primates.10,11 By recombinant techniques, for instance directed evolution 
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or insertions of larger binding proteins, e.g. designed ankyrin repeat proteins (DARPins), variants 
of known AAV serotypes have been produced to ensure greater cell specificity.12,13 Transcriptional 
control of transgene expression can further increase targeting efficiency and will be an essential 
part of systemic cancer therapy.9,14 In the past a set of genes has been identified that are turned on 
or upregulated in certain types of tumors.15–17. The promoters of survivin (SUR), cyclooxygenase-
2 (COX-2) and the C-X-C motif chemokine receptor 4 (CXCR-4) are potential candidates for di-
rected cancer gene therapy. Survivin belongs to the inhibitor of apoptosis protein family (IAPs) 
with an important role in the regulation of apoptosis. It was found to be expressed in a variety of 
human cancers like brain, breast and ovarian tumors and to be absent in most normal tissue.18,19 
COX-2 expression is upregulated during inflammation and cancers like breast and colorectal can-
cer. It has been reported, that it is involved in tumor growth, invasion and metastasis and is rarely 
detected in most normal adult tissue.17,20 Overexpression of CXCR-4 gene is typical for ovarian 
and breast cancer, as well as for human melanoma.21,22 An additional layer of tumor specificity is 
advisable as residual activity of tumor-specific promoters in normal human cells was observed.23,24 
Post-transcriptional repression of transgene expression has been an emerging approach to improve 
vector targeting. MicroRNAs (miRNAs) are single-stranded, non-coding RNA molecules that an-
neal with complementary sequences in the 3`untranslated region (3'- UTR) of target mRNAs trig-
gering either translational repression or mRNA degradation.25  
The aim of this study was to develop a combined transcriptional and translational targeting strategy 
in for an increased tumor specificity in the context of VDEPT using rAAV serotype 2 (rAAV2). 
For this purpose, tumor-type specific promoters (TSPs) were used to drive the expression of the 
HSV-tk suicide gene rAAV2 upon transduction of various tumor cell lines. In the past, low pro-
moter activity and by this insufficient expression of target proteins was observed.14 Therefore, the 
tumor specific promotors (TSPs) were equipped with a strong Kozak sequence in front of the start 
codon. The Kozak consensus sequence 5'-GCCRCCATGG-3' (R = purine A or G), is known to 
enhance the initiation of translation by improving the recognition of the AUG start codon through 
the pre-initiation complex (PIC) and recruitment of the large ribosomal subunit.26,27 By this, poten-
tially low transcription rate of chosen promoters should be compensated by improved translation. 
The early immediate cytomegalovirus promoter (CMV) in contrast shows high expression levels in 
a variety of mammalian cells without tumor specificity and by this leads to off-target effects in 
normal human tissue. This promoter was chosen as a positive control for transfection efficiency as 
well as for comparison of achieved protection of non-tumor cells using TSP. Furthermore, transla-
tional control of gene expression by addition of a let7a miRNA target sequence at the 3`UTR was 
included.  
Results 
Ganciclovir influences cell viability in a dose dependent manner 
To determine the strength of TSPs, expression of HSV-TK was assessed by the conversion of GCV 
to GCV-TP. Previous data suggested, that a GCV concentration of 1 mM showed the greatest effect 
on cell viability after transduction of HT1080 cells with viral particles containing the mGMK-TK30 
transgene.28 Lower concentrations of GCV led to a weaker reduction in cell viability at a constant 
MOI. However higher concentrations were not tested in this previous study. To control whether 
even higher concentrations of ganciclovir were tolerated by the cells a cytotoxicity assay was per-
formed on HT1080 cells. In Fig. 1a, a major drop in cell viability caused by the increasing GCV 
concentration was observed which remained relatively constant up to a concentration of 1 mM. 
Since healthy cells should be studied, the high impact of GCV in the absence of thymidine-kinase 
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is untenable. Therefore, the concentration of 1 mM GCV was retained and the effect on all other 
cell lines used was investigated. The decline in cell viability relative to untreated cells is comparable 
between chosen cells lines ranging between 80 % for MDA-MB231 and 100 % for A431 (Fig. 1b). 
rAAV2 transduction with bicistronic vector constructs lead to limited fluorescence signals 
To correlate the effect of GCV on transduced cells with the transduction efficiency, the sequence 
of eGFP was introduced into the transgene expression cassette. However, flow cytometry analysis 
revealed, that the eGFP fluorescence signal was lower than expected, as at least for HT1080 trans-
duction efficiencies of more than 90 % are known for rAAV2 when using the CMV promoter.29 By 
this the eGFP fluorescence signal in the context of the bicistronic vector construct was not suitable 
for the determination of transduction efficiency (SI Fig. 1). The T2A site in the bicistronic vector 
should mediate 'cleavage' of polypeptides during translation. The underlying mechanism relies on 
a steric hindrance during translation and ribosome skipping leading to two 'cleaved' proteins. More 
2A sites exist, but T2A was reported to show the highest level of protein expression at the second 
gene position.30 However, a decrease of up to 70 % compared to the first gene in a bicistronic vector 
construct was observed.31 Additionally, it was found that cleavage efficiency differs widely be-
tween different cell lines.32 Therefore, a drop in eGFP expression was to be expected, although a 
decrease of the fluorescence signal below the detection limit was unpredictable. To determine the 
transduction efficiency of rAAV2 wt on the cell lines despite missing GFP fluorescence, cells were 
transduced with a CMV-mVenus (rAAV2_mVenus) vector construct. Here, fluorescence gene ex-
pression was directly driven by CMV promoter without being influenced by the bicistronic vector 
conditions. 
Successful transduction was detected by the expression of the delivered transgene mVenus using 
flow cytometry (SI Fig. 2). Transduction efficiency ranged from 59.5 % for HDFa to 98 % for 
HT1080 cells (Table 1). This proved the functionality of the rAAV2 wt on HDFa, M1FS, MDA-
MB453, MDA-MB231 and A431 cell lines and was therefore suitable as a test system for further 
investigations regarding the use of rAAV2 wt in combination with thymidine kinase to selectively 
kill tumor cells.  
The efficiency of de-targeting is dramatically increased using a translational control mechanism 
To access whether the chosen promoters are cancer-specific and to compare the cancer-specificity 
between the TSP and the commonly used CMV promoter, rAAV2 transduction with vector con-
structs listed in SI Table 1 were used to determine the activity of the promoters in cancer and 
normal cell lines. A schematic picture of the bicistronic expression cassette used is shown in Figure 
2a. As normal cell lines, HDFa and M1FS cells were chosen. HDFa are primary human dermal 
fibroblasts from adult skin. M1FS is a foreskin fibroblast culture from an apparently healthy indi-
vidual and by this, both are not tumor derived. Cells were transduced with a multiplicity of infection 
(MOI) of 10'000 and after 24 h, 1 mM GCV was added for another 72 h and a cytotoxicity assay 
(Alamar Blue Assay) was performed by adding resazurin. As reference (negative control), cells 
transduced with rAAV2_mVenus (Fig. 2b) were used which were also incubated with GCV to 
exclude effects on cell viability resulting from transduction. 
In Figure 3, results of the Alamar Blue assays for the two non-cancer cell lines HDFa and M1FS 
are shown. Additionally, the number of non-transduced cells is displayed via a horizontal line (Fig. 
3a, c). The conversion of GCV to its toxic metabolite was highest for the CXCR-4 promoter driven 
gene expression in HDFa (Fig. 3a, sixth column) and CMV promoter in M1FS cells (Fig. 3c, first 
column) indicated by the lowest relative fluorescence. The addition of the let-7a miRNA target 
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sequence (let-7aT) allowed for a strong protective effect for the CMV promoter construct, whereas 
the SUR promoter remained virtually unaffected by the translation control in both cell lines (Fig. 
3a, c columns with banded pattern). In Fig. 3b, d, only transduced cells were investigated and the 
proportion of dead cells in these populations were calculated from the relative fluorescence data. 
For HDFa and M1FS, the COX-2 promoter led to the lowest number of dead cells in the transduced 
population if only transcriptional targeting is considered. Overall, CMV promoter driven gene ex-
pression in combination with let-7aT, turned out to be the best combination for both non-cancer 
cell lines, and was able to rescue all transduced HDFa cells and only 12.8 % of M1FS cells died 
(Fig. 3b, d second columns). Interestingly, even if the highest expression rate was achieved under 
the CMV promoter, many of the transduced cells were still viable (~ 40 % HDFa, ~30 % M1FS). 
Since we observed doubling times of up to 48 h for both cell lines, a higher effect of GCV-treatment 
can probably be achieved by longer exposure times, as cytotoxicity of GCV-TP is induced by its 
incorporation into the DNA of replicating cells and by this inhibiting DNA synthesis.  
The results of the cytotoxicity assay for the four cancer cell lines were displayed in Fig. 4. On the 
left-hand side (Fig. 4a, c, e, g) an overview of the total transduced populations, and on the right-
hand side (Fig. 4b, d, f, h) only the percentage of dead cells in the transduced fraction were shown. 
In the transduced population, for HT1080, MDA-MB231 and A431 almost all cells died under 
CMV promoter driven suicide gene expression (Fig. 4b, d, h, first column). For MDA-MB453 
(Fig. 4f) the high percentage of viable cells is expected to be a result of observed doubling times 
of approximately 48 h as before for HDFa and M1FS cells. HT1080 cells strongly responded to the 
treatment with ganciclovir regardless of the promoter and let-7aT and by this HT1080 were not 
well suited as a control cell line, since differences in targeting efficiency were not discernible (Fig. 
4a, b). De-targeting with let-7aT led to an increase in the relative fluorescence for all tumor cells 
(Fig. 4a, c, e, g; columns with banded pattern) indicating that let-7a target sequence may not be the 
best-possible sequence for selected cell.  
De-targeting efficiency is highest for the CMV promoter in combination with the let-7a target 
sequence 
To determine the individual tumor specificity of the promoters used alone, or in combination with 
the let-7aT, the percentage of dead cells for the given promoter in HDFa (Fig. 5a) or M1FS (Fig. 
5b) cells was divided by the percentage of dead cells of the respective tumor cells with the corre-
sponding promoters. By this a heat map was generated indicating a ratio of zero in green and a ratio 
of one and more in read. Combinations with a value close to zero or zero, show the highest tumor 
specificity. Here, no or low numbers of the non-cancer cells and high proportions of the cancer 
cells died. At a value of one and more at least the same proportion of dead cells was found in the 
cancer and non-cancer cell lines. For both reference cell lines (HDFa, M1FS) the same pattern can 
be seen, with MDA-MB453 showing the only exception for CMV_let-7a. Across all other cell lines, 
the highest tumor specificity was achieved with the combination of the CMV promoter with the 
let7a target sequence. The CXCR-4 promoter showed low tumor specificity in the investigated cell 
lines. On the contrary, in A431 and MDA-MB453 even more non-tumor than tumor cells died. For 
breast cancer cell lines MDA-MB231 and MDA-MB453 previous data suggested high survivin 
promoter activity.33,34 At least for MDA-MB231 this was proven here as well. For MDA-MB453, 
both the COX-2 promoter and the SUR_let-7a combination achieve the highest tumor specificity.  
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Discussion 
rAAV emerged as an outstanding option for gene therapy and systemic application allows targeting 
of the primary tumor and metastases. In order to prevent healthy cells from expressing a suicide 
gene, the integration of several target layers promises targeted gene expression limited to cancer 
cells. This work provides insights in the possibility of de-targeting of non-cancer cells in rAAV 
VDEPT approaches. Bicistronic vectors, with the sequence of HSV-tk and eGFP were constructed 
to correlate the effect of GCV on transduced cells with the transduction efficiency. To obtain two 
proteins from one promoter a T2A site was introduced in between the two genes. Upon transduc-
tion, low fluorescence for CMV promoter-driven gene expression and almost no eGFP fluorescence 
was detectable for the tumor-specific promoters. (SI Fig. 1). The T2A site in the bicistronic vector 
should mediate 'cleavage' of polypeptides during translation. The underlying mechanism relies on 
a steric hindrance during translation and ribosome skipping leading to two 'cleaved' proteins. More 
2A sites exist, but T2A was reported to show the highest level of protein expression at the second 
gene position.30 However, a decrease of up to 70 % compared to the first gene in a bicistronic vector 
construct was observed.31 Additionally, it was found that cleavage efficiency differs widely be-
tween different cell lines.32 Therefore, a drop in eGFP expression was to be expected, although a 
decrease of the fluorescence signal near the detection limit was unpredictable. To determine the 
transduction efficiency of rAAV2 on the cell lines despite missing eGFP fluorescence, cells were 
transduced with rAAV2-CMV-mVenus and showed that rAAV2 represented a suitable vector for 
all investigated cell lines with transduction efficiencies ranging from 58.1 % for HDFa to 97.0 % 
for HT1080 (Table 1). It was assumed, that this transduction ability should remain if the transgene 
is changed, since the capsid remains the same. Admittedly, it has been reported that about 10 % of 
undissolved polypeptides are produced by ribosome read-through.31 This effect was not taken into 
account in the evaluations but should be aware, since individual activity of the two proteins in 
potentially present fusion proteins is unknown and may cause cells to show no thymidine kinase 
activity even though they were transduced.  
By a cytotoxicity assay, cancer specific expression of HSV-tk was shown for all TSPs to varying 
degrees depending on the cell line. HT1080 cells strongly responded to treatment with ganciclovir 
regardless of the promoter (Fig.4a, b) and are therefore not well suited as a control cell line since 
differences in promoter strength are not apparent. For surviving, over-expression is well known in 
most human tumor types, including colon, breast, lung and melanoma cancer. For breast cancer cell 
lines MDA-MB231 and MDA-MB453 increased SUR promoter activity was reported in plasmid 
transfection approaches 35 or detection of survivin protein levels by western blot.33 However, to our 
knowledge in the context of rAAV transduction, no data were available. This study demonstrates, 
that the survivin promoter in combination with a strong Kozak sequence can drive gene expression 
upon transduction in MDA-MB231 (Fig. 4c, d), but not in MDA-MB453 (Fig.4e, f), which was 
unexpected. The copy number of the transgene in plasmid transfection experiments is presumed to 
be much higher (up to 50,000 copies per nucleus) than in transduction approaches and by this may 
lead to this unsuspected result.36 For MDA-MB453, both the COX-2 promoter and the SUR_let-7a 
combination achieve the highest tumor specificity. For the CXCR-4 promoter, high activity was 
detected in the two non-cancer cell lines and appears not to be an option in the context of rAAV2 
based suicide gene therapy. 
Surprisingly, the highest tumor-specific gene expression was reached with the CMV promoter 
driven gene expression in combination with let-7a miRNA translational repression. However, a 
reduced HSV-tk activity was observed in non-cancer as well as in cancer cells upon addition of the 
miRNA target sequence, indicating that even though aberrant miRNA expression is well known for 
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cancer cells,37–39 a general statement about the expression profile cannot be made. For MDA-
MB231 and MDA-MB453 cells, a high let-7a expression level was detected in miRNA microar-
rays, which fits to obtained results.38 Though, for A431 and HT1080 no published data were found, 
but the experimental findings indicate that let-7a miRNA is also expressed in this both cell lines. 
To optimize the regulation of protein translation, other miRNA target sequences are possible or 
even the use of different targets in one transgene expression cassette to de-target various cells.24  
In the HSV-tk/GCV prodrug system the occurrence of a bystander effect was frequently ob-
served.40–42 A drop of the relative fluorescence below the number of transduced cells (horizontal 
line in Fig. 3a, c and 4a, c, e, g) may provide a good indicator for this effect, but was not observed 
in any investigated cell line. In previous in vitro studies, it was found that cell-cell contact is essen-
tial for most cell lines for an efficient bystander effect.43,44 In this study low plating densities were 
used in order to circumvent an overgrowing of the culture during the four day long cultivation in 
96-well plates which underlines this assumption. 
In summary these results suggest, that no general statement can be made about the functionality of 
the individual promoters. Also, for let-7a upregulation rather than downregulation of the miRNA 
was reported for several types of cancer.45 Regarding the bystander effect, higher plating densities 
could potentially lead to an increased killing and needs to be further evaluated. The addition of 
translational control by the introduction of miRNA target sequences showed to be a powerful tool. 
The most promising combination of the strong CMV promoter with the let-7a miRNA target se-
quence can serve as a good starting point for further optimization e.g. with other or even a combi-
nation of several miRNA target sequences in one transgene expression cassette. One optimal pro-
moter and one miRNA target sequence for all types of cancer is unrealistic and a patient-specific 
adaptation of the transgene expression cassette is probably inevitable. 
 
Methods 
Construction of plasmids. Six different plasmids were constructed, harboring the bicistronic ex-
pression cassette (in parentheses the respective promotors): pZMB0588 (CMV); pZMB0589 (COX-
2); pZMB0590 (SUR); pZMB0591 (CXCR-4); pZMB0639 (CMV_let-7a); pZMB0640 (SUR_let-7a). 
For the expression of the thymidine-kinase under the control of tumor-specific promoters, survivin 
(Sur), cyclooxygenase 2 (COX-2) and chemokine receptor type 4 (CXCR-4) gene syntheses (Ge-
neArt, Thermo Fischer Scientific) were constructed. For human survivin promoter a 521-base-pair 
(bp) long fragment (nucleotides 2283 to 2804, GenBank Accession number U75285.1), for COX-
2 a 904 bp (nucleotides 6249 to 7152, GenBank Accession Number AF044206.1) and for CXCR-
4 a 936 bp (nucleotides 1165 to 2100, GenBank Accession Number AY728138.1) fragment was 
designed for idempotent cloning strategy according to  RFC[10].46 The CMV, hGHpA and mGMK-
TK30 containing plasmids were from the iGEM parts registry (parts.igem.org). AAV plasmids 
listed in SI Table 2 were cloned as described in SI Method 1. Resulting vectors were analyzed for 
their correctness by Sanger DNA-sequencing (Sequencing Core Facility, CeBiTec, Bielefeld, Ger-
many). 
Cell Culture. HDFa (Thermo Fisher Scientific), M1FS (HDZ), HT1080 and HEK293 (DSMZ) cells 
were cultured in Dulbecco’s Modified Eagle Medium supplemented 10% (v/v) fetal calf serum and 
1% (v/v) penicillin/streptomycin (Sigma Aldrich). A431, MDA-MB231 and MDA-MB-453 
(DSMZ) were cultured in RPMI supplemented 10% (v/v) fetal calf serum and 1% (v/v) penicil-
lin/streptomycin. Cells were maintained at 37°C and 5% CO2.  
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Viral particle production. HEK293 cells were seeded at a density of 9×106 cells per 150 mm dish 
the day before transfection. A total amount of 30 µg DNA per 150 mm dish was transfected using 
calcium phosphate. RepCap (pZMB0216), ITR (pZMB0522) and pHelper (pZMB0088) plasmid 
were used in a 1:1:1 molar ratio.47 After 72 h of incubation at 37 °C, cells were harvested and 
pelleted by centrifugation (2000×g, 5 min). 
Purification of viral particles. Cells were resuspended in lysis buffer (50 mM Tris, 150 mM NaCl, 
2 mM MgCl2, pH 7.5) and viral particles were released from cells with three freeze-thaw cycles. 
Remaining DNA contamination was degraded by incubation with benzonase nuclease (final 100 
U/ml, Sigma Aldrich) at 37 °C prior to addition of CHAPS (3-[(3-cholamidopropyl)dime-
thylammonio]-1-propanesulfonate, 0.5% w/v final). The crude lysate was cleared from cell debris 
by centrifugation (3,000×g, 10 min). This crude viral stock was further purified with a discontinu-
ous iodixanol gradient48. Briefly, the lysate was transferred onto a gradient of 60%, 40%, 25% and 
15% iodixanol in an open top polyallomer 16 x 76 mm tube (Science Services). Tubes were sealed 
and centrifuged in a T-880 rotor (Sorvall) at 340,000×g for 2 h at 18 °C. The rAAV containing 
fraction was collected with a 21G x 1 1/2” injection needle and the buffer was exchanged to 1× 
PBS (137 mM NaCl, 2.6 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.2) via Amicon Ultra-
4 100K centrifugal filter units (Merck Millipore). 
Determination of genomic titers. Before determination of genomic titers via qPCR, samples were 
treated with 10 U DNase I (New England Biolabs) in 10× DNaseI buffer in a final volume of 50 µl 
at 37 °C for 30 min before heat inactivation of the DNase I (75 °C, 20 min). 50-fold dilutions of 
the DNase I digest were used as template in the qPCR reaction. Samples were mixed with 2.5 µl 
primer qPCR-hGH-for (5'-CTCCCCAGTG CCTCTCCT-3') and 2.5 µl primer qPCR-hGH-rev (5´-
ACTTGCCCCT TGCTCCATAC-3´), each at a stock concentration of 4 µM, and 10 µl of 2× 
GoTaq qPCR Mastermix (Promega). The qPCR reaction was carried out as described in the manual 
(TM318 6/14, Promega) with an increased time interval for the first denaturation step (95 °C, 10 
min) using a LightCycler 480 II (Roche). The genomic titer was calculated from a standard curve 
of 102 to 107 copies of the ITR plasmid (CMV-mVenus) with an efficiency between 90-110% and 
an R value less than 0.1.  
Transduction assay. The transducibility of the cell lines was analyzed by transduction of respective 
cells with a vector plasmid coding for the fluorescence reporter mVenus. 10ʹ000 cells were seeded 
in biological duplicates on a 12-well plate and after cells had settled, they were transduced with a 
MOI of 10,000. After three days, cells were detached by trypsinization for flow cytometry analysis. 
10ʹ000 events were counted using a Becton-Dickenson FACSCalibur instrument. Data sets were 
analyzed using FlowJo V10. Positive cells were calculated by Overton cumulative histogram sub-
traction. 
Alamar Blue Assay. Cell viability was assessed by a cytotoxicity assay. In case of transduction 
experiments, 10,000 cells with a cell density of 1,000 cells ml-1 of respective cell lines were mixed 
with rAAV_promoter_mGMK-TK30_T2A_eGFP were the expression is driven by different pro-
moters. CMV, COX-2, Survivin and CXCR-4 were chosen and used with a MOI of 10ʹ000 in bio-
logical duplicates. After careful mixing, 100 µl of the cell suspension was dispensed in 6-fold rep-
licates in a 96-well plate. After 24 h, 1 mM ganciclovir (Sigma Aldrich) was added for another 72 
h. After the incubation period, resazurin was added at a final concentration of 0.05 g L-1. The plates 
were placed in an incubator at 37 °C, 5 % CO2 and fluorescence intensity was measured at regular 
intervals in a PowerWave HT (BioTek) plate reader with an excitation wavelength of 545/30 nm 
and an 590/20 emission filter. Fluorescence data were normalized to the fluorescence signal of cells 
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transduced with rAAV2_mVenus with added ganciclovir. To study the effect of different GCV 
concentration on non-transduced cells, 1,000 HT1080 cells in 100 µl growth medium were seeded 
in 6-fold replicates in a 96-well plate and 0, 0.5, 1, 2 and 4 mM GCV was added. After 72 h Alamar 
Blue Assay was performed. The relative fluorescence of the samples was calculated by setting the 
fluorescence signal of cells without GCV as 100 % viable. For the other cell lines, only the working 
concentration of 1 mM GCV was tested as described.  
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Figures/ Figure Legends 
 
Figure 1: Effect of Ganciclovir on non-transduced cells. (a) Analysis of the effect of increasing GCV 
concentrations on the viability of HT1080 cells. Relative viability was determined to non-incubated 
HT1080 cells in biological duplicates and 6-fold technical replicates. For each spot, SD was calculated 
between biological samples. (b) Cytotoxicity assay to study the effect of 1 mM GCV on the cell viability 
of HDFa, M1FS, HT1080, MDA-MB231, MDA-MB453 and A431 cells. Relative viability was deter-
mined to non-incubated cells in biological duplicates and 6-fold technical replicates. For each column, 
SD was calculated between biological samples. 
 
Figure 2: Schematic overview of the rAAV transgene expression cassettes. a) Vector plasmid for 
transcriptional targeting of cancer cells, with promoter as placeholder for CMV, COX-2, SUR or 
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CXCR-4 promoter, respectively. b) CMV_mVenus vector plasmid used as transduction control for 
the determination of transduction efficiency of rAAV2 and as negative control for the calculation 
of relative fluorescence. c and d) Vector plasmid for translational targeting of cancer cells, where 
transgene expression is driven by CMV and SUR promoter, respectively. In the 3' UTR of the 
transgene, a let-7a target sequence (let-7aT) was introduced.  
 
Figure 3: Alamar Blue Assay for determination of thymidine kinase activity in the context of TSPs. 
The transcriptional activity of CMV, COX-2, SUR and CXCR-4 promoters, driving the transgene 
expression upon rAAV transduction, was measured in the two non-cancer cell lines HDFa (a, b) 
and M1FS (c, c). Cells were transduced with a MOI of 10ʹ000 and after 24 h treated with 1 mM 
GCV for another 72 h before performing the Alamar blue assay. Negative reference cells were 
transduced with rAAV2_mVenus and treated with 1 mM GCV. (a, c) Calculation of relative fluo-
rescence was performed by normalization of the fluorescence for the different viral vectors to the 
fluorescence obtained from the rAAV-mVenus transduced reference (negative). The number of 
non-transduced cells is given as a horizontal line. (b, d) The proportion of dead cells in the trans-
duced population was calculated from the relative fluorescence data and the transduction efficiency 
determined by rAAV_mVenus transduction of the respective cells. The data shown are the means 
of two biological duplicates with six technical replicates, with error bars indicating the standard 
deviation.  
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Figure 4: Alamar Blue Assay for determination of thymidine kinase activity in the context of TSPs. 
The transcriptional activity of CMV, COX-2, SUR and CXCR-4 promoters, driving the transgene 
expression upon rAAV transduction, was measured in two normal (a, b) and four cancer (c-f) cell 
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lines. As reference, respective cells were transduced with rAAV2_mVenus (negative). The data 
shown are the means of two biological duplicates with six technical replicates, with error bars in-
dicating the standard deviation. 
 
 
 
Figure 5: Alamar Blue Assay for determination of thymidine kinase activity in the context of TSPs. 
The transcriptional activity of CMV, COX-2, SUR and CXCR-4 promoters, driving the transgene 
expression upon rAAV transduction, was measured in four cancer cell lines HT1080 (a, b), MDA-
MB231 (c, d), MDA-MB453 (e, f) and A431 (g, h). Cells were transduced with a MOI of 10ʹ000 
and after 24 h treated with 1 mM GCV for another 72 h before performing the Alamar blue assay. 
Negative reference cells were transduced with rAAV2_mVenus and treated with 1 mM GCV. (a, 
c, e, g) Calculation of relative fluorescence was per-formed by normalization of the fluorescence 
for the different viral vectors to the fluorescence obtained from the rAAV-mVenus transduced ref-
erence (negative). The number of non-transduced cells is given as a horizontal line. (b, d, f, h). The 
proportion of dead cells in the transduced population was calculated from the relative fluorescence 
data and the transduction efficiency determined by rAAV_mVenus transduction of the respective 
cells. The data shown are the means of two biological duplicates with six technical replicates, with 
error bars indicating the standard deviation. 
 
Tables 
Table 35. Transduction efficiencies of rAAV2 with CMV_mVenus as reporter of different cell lines transduced with a 
MOI of 10.000. Mean and standard deviation (SD) of two biological duplicates are shown. 
Cell line Transduction efficiency in % 
HDFa 58.1 ± 1.5 
M1FS 73.5 ± 1.4 
HT1080 97.0 ± 1.0 
MDA-MB231 64.5 ± 2.6 
MDA-MB453 59.3 ± 2.3 
A431 77.1 ± 2.3 
 
HDFa A431 MDA-MB231 MDA-MB453 HT-1080
CMV 0.59 0.51 0.97 0.70
CMV_let7 0.00 0.00 2.65 0.00
COX2 0.67 0.55 0.40 0.24
SUR 0.84 0.69 4.46 0.58
SUR_let7 1.38 0.51 0.00 0.48
CXCR4 2.51 0.92 2.96 0.79
M1FS A431 MDA-MB231 MDA-MB453 HT-1080
CMV 0.71 0.61 1.17 0.84
CMV_let7 0.39 0.61 0.00 0.19
COX2 0.98 0.80 0.58 0.35
SUR 0.46 0.38 2.46 0.32
SUR_let7 1.32 0.48 0.00 0.46
CXCR4 1.47 0.54 1.73 0.46
a
b
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Supplementary information 
 
Comparison of viral mediated suicide gene therapy targeting 
by promoters and de-targeting by miRNA in tumor and pri-
mary cells 
Kathrin E. Teschner1, Julian Teschner1, Kristian M. Müller1* 
 
1   Methods 
1.1   SI Method 1. Plasmid construction 
1.1.1   Plasmids constructed for transcriptional targeting 
 
pZMB0441_mGMK-TK30_T2A_eGFP_hGHpA. This plasmid was generated as a preconstruct, 
where in following steps all promotors could be inserted via RFC[10]. The coding sequence of 
mGMK-TK30 and eGFP were amplified via PCR. The oligonucleotide primers provided overhang-
ing ends with RFC[10] restriction sites (lacking NotI) and overlapping nucleotides of the T2A site. 
The sequences of the primers for mGMK_TK30 amplification are as follows: mGMK-
TK30_RFC10_for_new (5´-TGGAATTCTT CTAGATGGCC GGCGCAGGAC CTA) and 
mGMK-TK30_2A_rev (5´-CCTCTGCCCT CTCCACTGCC ACCGGTGTTA GCCTCCCCCA 
T). The coding sequence of eGFP was amplified from pSB1C3_001_eGFP (pZMB0398) which 
was a gene synthesis based on the pEGFP-C1 cloning vector (GenBank entry ACD99686.1) with 
primers T2A_eGFP_for_ new (5´-GGCAGTGGAG AGGGCAGAGG AAGTCTGCTA 
ACATGCGGTG ACGTCGAGGA GAATCCTGGC CCAATGGTGT CCAAGGGCGA GG and 
eGFP_RFC10_rev_new (5´-GGCATGGACG AGCTGTACAA GTAATACTAG 
TAGCGGCCGC TGCAGAAA). These two PCR products were used in a megaprimer PCR to 
generate mGMK-TK30_T2A_eGFP which subsequently was cloned into pSB1C3_001_hGHpA 
(pZMB0135). This plasmid was finally ligated with the different promoters using EcoRI, SpeI and 
XbaI, with CMV promoter coming from iGEM parts registry. The TSPs were planned as gene 
synthesis with overhangs according to RFC[10]. 
 
pZMB0588_ITR_EXS_CMV_Kozak_mGMK-TK30_T2A_eGFP_hGHpA. This vector was 
constructed in two steps, starting from pZMB0442_CMV_mGMK-TK30_T2A_eGFP_hGHpA. 
With primers Pr-for_CMV_MluI (5´-CCAGATATACGCGTTGACATTG) and Pr-
rev_Kozak_CMV (5´-GGTGGCCTAG TAATTTCGAT AAGCCAGTAA GC) a part of the CMV 
promoter was amplified with the Kozak sequence as a 3´ extension. Pr-for_CMV_Kozak (5´-
GAAATTACTA GGCCACCATG GCCGGCGCAG G) and Pr-rev_TK30_SalI (5´-CCTT-
GTAGGT CGACATCTAG CAC) amplified a part of the mGMK-TK30 with the Kozak sequence 
as a 5´ extension. This to fragments were used in a megaprimer PCR and was finally ligated into 
the starting vector after restriction digest with MluI and SalI and by this generated 
pZMB0584_CMV_Kozak_mGMK-TK30_T2A_eGFP_hGHpA. In a second step, the insert se-
quence was introduced into pZMB0522_ITR_EXS_CMV_mVenus_hGHpA by restriction digest 
with EcoRI and SpeI. 
 
pZMB0589_ITR_EXS_COX-2_Kozak_mGMK-TK30_T2A_eGFP_hGHpA. The Kozak se-
quence was introduced by hybridization of oligonucleotides COX-2-MfeI_Kozak-AvrII_for (5´-
AATTGTCATA CTAGAGCCAC CATGGCCGGC GCAGGAC) and COX-2-MfeI_Kozak-Av-
rII_rev (5´-CTAGGTCCTGC GCCGGCCATG GTGGCTCTAG TATGAC) and ligation into 
pZMB0443_COX-2_mGMK-TK30_T2A_eGFP_hGHpA by restriction digest with MfeI. In a sec-
ond step, this sequence was introduced into pZMB0522_ITR_EXS_CMV_mVenus_hGHpA by 
restriction digest with EcoRI and SpeI. 
 
pZMB0590_ITR_EXS_SUR_Kozak_mGMK-TK30_T2A_eGFP_hGHpA. This vector was 
constructed in two steps, starting from pZMB0444_SUR_mGMK-TK30_T2A_eGFP_hGHpA. 
With primers Pr-for_Sur_MluI (5´-CTGCACGCGTTCTTTGAAA) and Pr-rev_Sur_Kozak (5´-
GGTGGCCTAGTAGCCGCCACCTCTG) a part of the SUR promoter was amplified with the 
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Kozak sequence as a 3´ extension. Pr-for_Sur_Kozak (5´-GCGGCTACTAGGCCAC-
CATGGCCGGCGCAGG) and Pr-rev_TK30_SalI (5´-CCTTGTAGGT CGACATCTAG CAC) 
amplified a part of the mGMK-TK30 with the Kozak sequence as a 5´ extension. This to fragments 
were used in a megaprimer PCR and was finally ligated into the starting vector after restriction 
digest with MluI and SalI and by this generated pZMB0586_SUR_Kozak_mGMK-
TK30_T2A_eGFP_hGHpA. In a second step, the insert sequence was introduced into 
pZMB0522_ITR_EXS_CMV_mVenus_hGHpA by restriction digest with EcoRI and SpeI. 
 
pZMB0591_ITR_EXS_CXCR-4_Kozak_mGMK-TK30_T2A_eGFP_hGHpA. This vector 
was constructed in two steps, starting from pZMB0474_CXCR-4_mGMK-
TK30_T2A_eGFP_hGHpA. With primers Pr-for_MluI_CXCR-4 (5´-CACAGAGAGA 
CGCGTTCCTA G) and Pr-rev_CXCR-4_Kozak (5´-GGTGGCCTAG TAGACAAAGC AGGTT-
GAAAC TG) a part of the CXCR-4 promoter was amplified with the Kozak sequence as a 3´ ex-
tension. Pr-for_CXCR-4_Kozak (5´-CTTTGTCTAC TAGGCCACCA TGGCCGGCGC AGG) 
and Pr-rev_TK30_SalI (5´-CCTTGTAGGT CGACATCTAG CAC) amplified a part of the 
mGMK-TK30 with the Kozak sequence as a 5´ extension. This to fragments were used in a mega-
primer PCR and was finally ligated into the starting vector after restriction digest with MluI and 
SalI and by this generated pZMB0587_CXCR-4_Kozak_mGMK-TK30_T2A_eGFP_hGHpA. In a 
second step, the insert sequence was introduced into pZMB0522_ITR_EXS_CMV_mVe-
nus_hGHpA by restriction digest with EcoRI and SpeI. 
 
 
1.1.2   Plasmids constructed for translational targeting 
 
For translational targeting a let-7a target sequence was introduced to plasmids 
pZMB0584_CMV_Kozak_mGMK-TK30_T2A_eGFP_hGHpA and 
pZMB0586_SUR_Kozak_mGMK-TK30_T2A_eGFP_hGHpA. Therefore, eGFP was amplified 
with following oligonucleotide primers: eGFP_ENX_for (5´-AAAGAATTCG CGGCCCTTCT 
AGATGGTGTC CAAGGGCGAG) and eGFP_let-7a_SNP_rev (5´-AAACTGCAGC GGCCGC-
TACT AGTATGAGGT AGTAGGTTGT ATAGTTTACT TGTACAGCTC GTCCATGCC) 
which was cloned into pSB1C3_001 hGHpA. By restriction digest with SpeI and NdeI the sequence 
was introduced into mGMK-TK30_T2A_eGFP_hGHpA to generate pSB1C3_001_mGMK-
TK30_T2A_eGFP_1xlet7a_hGHpA (pZMB0638). By restriction digest of pZMB0638, 
pZMB0588 and pZMB0590 with SalI and SpeI and subsequent ligation, CMV_mGMK-
TK30_T2A_eGFP1xlet7a_hGHpA and SUR_mGMK-TK30_T2A_eGFP_1xlet7a_hGHpA where 
generated. For AAV production all constructs where transferred into 
(pZMB0522_ITR_EXS_CMV_mVenus_hGHpA), which serves as a final destination plasmid. By 
this, pZMB639_ITR_EXS_CMV_Kozak_mGMK-TK30_T2A_eGFP1xlet7a_hGHpA and 
pZMB0640_ITR_EXS_SUR_ Kozak_mGMK-TK30_T2A_eGFP1xlet7a_hGHpA were created. 
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1   Supplementary Information Figures 
1.1   SI Figure 1 
 
SI Figure 1. Flow cytometry data for rAAV transduction in comparison the negative buffer control. Cells 
were transduced with rAAV_CMV_Kozak_mGMK-TK30_T2A_eGFP_hGHpA at a MOI of 10,000 and an-
alyzed via flow cytometry after incubation in biological duplicates. Data analysis was performed using 
FlowJo. A gate of 1% false positive cells was selected in the sample of the negative control. This gate is 
visualized in each diagram. Overlay histograms for the wild-type rAAV2 for a), HT1080 b) HDFa c) M1FS 
d) MDA-MB453 e) MDA-MB231 f) A431 are shown. 
  
a b c 
d e f 
M1FS 
rAAV2_CMV_TK_eGFP 
M1FS negative 
HDFa 
rAAV2_CMV_TK_eGFP 
HDFa negative 
HT-1080 
rAAV2_CMV_TK_eGFP 
HT1080 negative 
MDA-MB231 
rAAV2_CMV_TK_eGFP 
MDA-MB231 negative 
MDA-MB453 
rAAV2_CMV_TK_eGFP 
MDA-MB453 negative 
A431 
rAAV2_CMV_TK_eGFP 
A431 negative 
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1.2   SI Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
SI Figure 2. Flow cytometry data for rAAV variants in comparison the negative buffer control. Cells were 
transduced with rAAV2_mVenus at a MOI of 10,000 and analyzed via flow cytometry after incubation in bio-
logical duplicates. Data analysis was performed using FlowJo. A gate of 1% false positive cells was selected in 
the sample of the negative control. This gate is visualized in each diagram. Since the transduction efficiency 
was thus underestimated, the Overton algorhythm was used for the calculation in a subsequent step. Overlay 
histograms for the wild-type rAAV2 for a) HDFa b) M1FS c) HT1080 d) MDA-MB231 e) MDA-MB453 f) 
A431 are shown. 
HT1080 rAAV2_mVenus 
HT1080 negative 
A431 rAAV2_mVenus 
A431 negative 
MDA-MB231 
rAAV2_mVenus 
MDA-MB231 negative 
MDA-MB453 
rAAV2_mVenus 
MDA-MB453 negative 
M1FS rAAV2_mVenus 
M1FS negative 
HDFa rAAV2_mVenus 
HDFa negative 
a b c 
d e f 
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SI Table 1: Overview of plasmid vector constructs used as GOI for rAAV2 production 
Plasmid name with description Length 
pZMB0522_ITR_EXS_CMV_mVenus_hGHpA 
AAV2 ITR flanking a CMV promoter expressing the fluorescent protein mVenus 
4014 bp 
pZMB0588_ITR_EXS_CMV_Kozak_mGMK-TK30_T2A_eGFP_hGHpA 
AAV2 ITR flanking a CMV promoter expressing the protein mGMK-TK30 and the 
fluorescent protein eGFP 
5780 bp 
pZMB0589_ITR_EXS_COX-2_Kozak_mGMK-TK30_T2A_eGFP_hGHpA 
AAV2 ITR flanking a COX-2 promoter expressing the protein mGMK-TK30 and 
the fluorescent protein eGFP 
6027 bp 
pZMB0590_ITR_EXS_SUR_Kozak_mGMK-TK30_T2A_eGFP_hGHpA 
AAV2 ITR flanking a SUR promoter expressing the protein mGMK-TK30 and the 
fluorescent protein eGFP 
5647 bp 
pZMB0591_ITR_EXS_CXCR-4_Kozak_mGMK-TK30_T2A_eGFP_hGHpA 
AAV2 ITR flanking a CXCR-4 promoter expressing the protein mGMK-TK30 
and the fluorescent protein eGFP 
6053 bp 
pZMB0639_ITR_EXS_CMV_Kozak_mGMK-
TK30_T2A_eGFP_1xlet7a_hGHpA 
AAV2 ITR flanking a CMV promoter expressing the protein mGMK-TK30 and 
the fluorescent protein eGFP with a 3'-let7a target sequence after the stop codon 
of the eGFP coding sequence 
5801 bp 
pZMB0640_ITR_EXS_SUR_Kozak_mGMK-
TK30_T2A_eGFP_1xlet7a_hGHpA 
AAV2 ITR flanking a SUR promoter expressing the protein mGMK-TK30 and 
the fluorescent protein eGFP with a 3'-let7a target sequence after the stop codon 
of the eGFP coding sequence 
5668 bp 
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AAV production in suspension: Evaluation of different cell culture media and scale-up 
potential 
 
Rebecca C Feiner1, Kathrin Teschner1, Irina Schierbaum1, Julian Teschner1, Kristian M Müller1* 
1 Cellular and Molecular Biotechnology, Bielefeld University, 33602 Bielefeld, Germany 
 
*Email address of corresponding author: kristian@syntbio.net  
 
Background  
Recombinant adeno-associated virus (rAAV) approaches have an outstanding reputation in gene 
therapy and are evaluated for cancer therapy [1]. Advantages include long-term gene expression, 
targeting of dividing and non-dividing cells, and low immunogenicity. Established rAAV production 
utilizes triple transfection of adherent HEK 293 cells, which hardly meets product yield requirements 
for clinical applications. We transferred the AAV production system to HEK 293-F suspension cells. 
This process is scalable and uses serum-free media streamlining downstream procedures. After 
optimization of transfection efficiencies and shaker cultivations, we produced titers of 1×105 viral 
genomes per cell in a 2 l bioreactor. 
 
Materials and methods 
The suspension adapted HEK-FreeStyle 293-F cell line was used for the experiments in chemically 
defined animal component free media (HEK-TF, HEK-GM (Xell AG), Freestyle F17 (Thermo Fisher 
Scientific)). Samples for viable cell density and viabilities were taken daily and analyzed using an 
automated cell counting system (CEDEX, Roche Diagnostics). Transient transfection of 3×106 
cells/ml was carried out with polyethylenimine Max in a 1:4 DNA-PEI ratio (w/w) with 2 µg DNA. 
Three plasmids (pGOI, pRepCap, pHelper) were applied in a molar 1:1:1 ratio (Figure 1 A). Pretests 
were performed in orbital shaking tube spin bioreactors. For scale-up, batch processes were carried 
out in 125 ml shake flasks as well as in 2 l stirred bioreactors at 30% air saturation and pH 7.1. 
Transfection efficiencies and rAAV production were quantified by flow cytometry using a GOI cod-
ing for a fluorescent protein and qPCR of genomic copies, respectively. 
 
Results 
 
Figure 7: (A) Schematic overview of rAAV production in HEK293 cells with triple-transfection system. (B) Viable cell 
densities (VCD), viabilities and genomic copies per ml (GC) of a rAAV production with 293-F batch cultivations in shaker 
flasks. Genomic copies per ml refer to the titer determined in 1 ml culture volume. Error bars represent biological and 
technical duplicate measurements of samples. (C) Viable cell densities and genomic copies per cell of a rAAV production 
with 293-F batch cultivation in a 2 l bioreactor. For reasons of comparability between shaker and bioreactor data ge-
nomic copies are given per cell. Error bars represent technical duplicate measurements of samples. 
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By optimizing the DNA amount for transfection of 293-F cells more than 90 % of the cells were 
reproducibly transfected. Batch cultivations in shaker flasks revealed that rAAV were produced in 
the first 24-96 h after transfection. Figure 1 B shows viable cell densities and viabilities in relation 
to the genomic titer. Genomic titers were determined from raw cell extracts and up to 109 copies/ml 
were repetitively achievable. A decrease in viability marked the decline in genomic copies per ml 
showing that a prolongation of the process e.g. by addition of a feed would probably not increase 
yield. In a first scale-up, the rAAV production was transferred to a 2 l bioreactor (Figure 1 C). Trans-
fection efficiencies in bioreactors of up to 55% were comparable to that obtained in a simultaneous 
shaker flask experiment. Transfection efficiencies were lower compared to prior experiments due 
to controlled conditions in the bioreactor. Nonetheless the titer with up to 1×105 genomic copies per 
cell was elevated compared to that of shaker flasks.  
 
Conclusions 
First experiments with 293-F cells in HEK TF medium showed promising results of transferring 
rAAV production from the adherent system to suspension. After improvement of transfections by 
the adjustment of DNA amounts in small scale experiments, AAV production was analyzed in 
shaker flasks. The batch process showed an expected increase in cell density with low variability 
between biological replicates (Figure 1 B). The genomic titer increased according to the viable cell 
density until day four where a sudden drop started. This observation was made for AAV productions 
in HEK-TF, HEK-GM and Freestyle F17 medium. For optimal yields, we assume that a slight de-
crease in viability marks the point in time for harvest. From optimized protocols, a batch process in 
a 2 l bioreactor was carried out. Interestingly the bioreactor cultivation resulted in lower overall 
viable cell densities but in higher genomic copies per cell compared to shaker flasks (Figure 1 C). 
These results are comparable to already published data for suspension cells [2]. Subsequent opti-
mization of the bioreactor protocol will lead to further increase in rAAV yield. 
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